 UTILITY PATENT APPLICATION TRANSMITTAL (Only for new nonprovisional applications under 37 CFR 1.53(b)) Altomey Docket No. OPSMULATION (Only for new nonprovisional applications under 37 CFR 1.53(b)) (Only for new nonprovisional applications under 37 CFR 1.53(b)) APPLICATION ELEMENTS Sow MEPC inhapter 500 concerning utility platent polication contents. APPLICATION ELEMENTS Sow MEPC inhapter 500 concerning utility platent polication contents. APPLICATION ELEMENTS Sow MEPC inhapter 500 concerning utility platent application contents. APPLICATION PLEMENTS Sow MEPC inhapter 500 concerning utility platent contents. APPLICATION PLEMENTS Sow MEPC inhapter 500 concerning utility platent application contents. APPLICATION PLEMENTS Sow MEPC inhapter 500 concerning utility platent application contents. Applicant claims and aberrat mast stat and an ever page metal inhometation of Crist Poges 23 11 Both the claims and aberrat mast stat an ever page metal inhometation of Crist Poges 23 12 I Coll Stock C 1133 [Crist Sheets 1 1] Contention (Crist Poges 23 CFR 1.76 Coll Crist Poges 1 Crist Poges 20 CFR 1.52(b) Decloration of Crist Poges 20 CFR 1.52(b) Decloration of the deplication, see 37 CFR 1.56(d) Decloration bats Sheet. See 37 CFR 1.76 Coll Crist Poges 1 Crist Poges 20 CFR 1.52(b) Element 2 Poges 20 CFR 1.52(c) Decloration of address and states 20 CFR 1.52(c) Computer Redable Form (CRF) Specification Sequence Listing on: Conputer Redable Form (CRF) <li< th=""><th>Under the Paperwork Reduction Act of 1995, no persons are required to res</th><th></th><th>proved for use through 06/30/2010. OMB 0651-0032 emark Office. U.S. DEPARTMENT OF COMMERCE ation unless it displays a valid OMB control number.</th></li<>	Under the Paperwork Reduction Act of 1995, no persons are required to res		proved for use through 06/30/2010. OMB 0651-0032 emark Office. U.S. DEPARTMENT OF COMMERCE ation unless it displays a valid OMB control number.					
PATENT APPLICATION TRANSMITTAL John R. Evans (Interpretation of the properties of	S S							
TRANSMITTAL Title FORMULATION (Only for new nonprovisional applications under 37 CFR 1.53(b)) Title FORMULATION APPLICATION ELEMENTS ADDRESS TO: P.0. Box 1450 Alexandria VA 22313-1450 1 Fee Transmittal Form (e.g., PTO/SB/17) ACCOMPANYING APPLICATION PARTS 2 Applicationis small entity status. So 37 CFR 127. 3 Specification Total Pages 23 1 Drawing(s) (35 U.S. C. 17) (Total Pages 23 1 Drawing(s) (35 U.S. C. 17) (Total Sheets 1 5 Oath or Declaration (Total Sheets 1 1 1 Drawing(s) (35 U.S. C. 17) (Total Sheets 1 1 1 1 1 1 Power of Altorney 1		First Inventor	John R. Evans					
Commissioner for Patents See MPEP chapter 800 concerning utility patent application contents. ADDRESS TO: Commissioner for Patents Commissioner for Patents ADDRESS TO: P.O.Box 1450 ADDRESS TO: P.O.Box 1450 ADDRESS TO: P.O.Box 1450 ADDRESS TO: P.O.Box 1450 ACCOMPANYING APPLICATION PARTS See 37 CFR 1.77. So that of calcuments on the patent application (37 CFR 1.33(d)) Dowingly (35 U.S. C. 173) [Total Sheets1] Dowingly (35 U.S. C. 173) [Total Sheets1] Accomplexition, 37 CFR 1.33(d)) (Information Disclosure Statement (Provem of a target deleng invento(s)) Descinction Data Sheet See 37 CFR 1.76 C. CoROM or CD-R in duplicate, large table or Camputer Program (Appendix) (Sould be spontare ware page: a statement (PTO/SB00 or PTO-1449) (Lor Confuration Data Sheet See 37 CFR 1.76 C. Statement verifying identity of above copies I. Conputer Readable Form (CRF) b. Specification Squaree Listing on: List accomparity as bianed form CRF) Listatement verifying identity of above c	• • • • • • • • • • • • • • • • • • • •	Title	FORMULATION					
APPLICATION ELEMENTS ADDRESS TO: P.O. Box 1450 Alexandria VA 22313-1450 1: Fee Transmittal Form (e.g., PTO/SB/17) AccomPANYING APPLICATION PARTS 2: Applicant claims small entity status. See 37 CFR 1.27. Assignment Papers (cover sheet & document(s)) 3: Specification (for athrous on the petition and abstract must stat on a new page (for othrous) on the petition and abstract must stat on a new page (for othrous) on the petition and abstract must stat on a new page (for othrous) on the petition and abstract must stat on a new page (for othrous) on the petition and abstract must stat on a new page (for othrous) on the petition and abstract must stat on a new page (for othrous) on the petition and abstract must stat on a new page (for othrous) on the petition and abstract must stat on a new page (for othrous) on the petition application (37 CFR 1.63(u)) 0: Daving(b) (35 U S C .17) (Fold Sheets) 0: Daving(b) (35 U S C .17) (Fold Sheets) 1: English Translation Document (if applicable) (for onthuethoris) and abstract. See 37 CFR 1.5(d)) 1: ELETION OF INVENTOR(S) (Signed statement statched deling inventors) (and computer Program (Appendix) (Landcape Table on CD 2: Information Acid Sequence Submission (fi applicable, items a - c. are required) a	(Only for new nonprovisional applications under 37 CFR 1.53(b))	Express Mail Label No.	· · · · ·					
2. Applicant claims small entity status. See 37 CFR 127. 9. Assignment Papers (cover sheet & document(s)) 3. Specification (for information on the application of a new page (for information on the application) 10. 37 CFR 3.73(b) Statement (when there is an assignee) Power of Attorney 4. Drawing(s) (35 U.S.C. 113) [Total Sheets _ 1_] 10. 37 CFR 3.73(b) Statement (when there is an assignee) Power of Attorney 5. Oath or Declaration (for continuation/divisional with Box 18 completed) (for continuation divisional methor pairs and assignee) 10. 6. Application Data Sheet. Sea 37 CFR 1.76 13. Preliminary Amendment 7. CD-ROM or CD-Ri dupleted lealing new torks (for forign priority is claimed) 11. Centribut Coupy of Priority Document(s) (ff foreign priority is claimed) 8. Mucleable, form (CRP) (ff applicable, items a a: are required) (ff foreign priority is claimed) 15. Centribut Coupy of	•	ADDRESS TO:	P.O. Box 1450					
2. Applicant claims small entity status. 9. Assignment Papers (cover sheet & document(s)) 3. Specification and subject status on a new page of the dams and subject status on a new page of the dams and subject status on a new page of the dams and subject status on a new page of the dams and subject status on a new page of the dams and subject status on a new page of the dams and subject status on a new page of the dams and subject status on a new page of the dams and subject status on a new page of the dams and subject status on a new page of the dams and subject status on a new page of the dams and subject status on a new page of the dams and subject status on a new page of the dams and subject status on a new page of the dams and subject status on a new page of the dams and subject status on a new page of the dams and subject status on a new page of the dams and subject status on a new page of the dams and subject status on a new page of the dams and subject status of the page of the dams and subject status of the dams	1 Fee Transmittal Form (e.g., PTO/SB/17)	ACCOMPAN	YING APPLICATION PARTS					
3. Specification Chain and subtract must start on sev page 1 for information on the preferred management, see WPEP 680 (rig) Name of Assignee 4. Drawing(s) (35 U.S.C. 113) [Total Sheets 1_1] Name of Assignee Name of Assignee a. Newly executed (original or copy) 10. 37 CFR 3.73(b) Statement (if applicable) Attorney b. A copy from a prior application (37 CFR 1.63(d)) (when there is an assignee) Name of Assignee 10. 37 CFR 3.73(b) Statement (if applicable) 11. English Translation Document (if applicable) 11. Betternon Version application, 137 CFR 1.63(d)) 10. 37 CFR 3.73(b) Statement (PTO/SBIOB or PTO-1449) 11. Benglish Translation Document (if applicable) 11. Compare application, see 37 CFR 1.76 7. Co-ROM or CD-R in duplicate, large table or Computer Redable Form (Appendix) 13. Preliminary Amendment 14. Bepticable, items a c. are required) 15. Certified Copy of Priority Document(s) (if foreign priority is claimed) 8. Nucleotide andor Amino Acid Sequence Submission (i application Request under 35 U.S.C. 122(b)(2)(b)(h). Application form PTO/SB/35 or equivalent. 17. Determinary Amendment 14. Return Receipt Postard (MPEP 503) 18. Continuition Divisional active torus and table form (CRF) 16. Nonopublication Request under 35 U.S.C. 122(b)(2)	— ,,							
a. Newly executed (original or copy) Number application (37 CFR 1.63(d)) (when there is an assignee) Attorney b. DelLETION OF INVENTORIS Signed stalement attached deleting inventor(s) Image: an assignee) Attorney 1. DelLETION OF INVENTORIS Signed stalement attached deleting inventor(s) Image: an assignee) Attorney 1. DelLETION OF INVENTORIS Signed stalement attached deleting inventor(s) Image: an assignee) Attorney 1. DelLETION OF INVENTORIS Signed stalement attached deleting inventor(s) Image: an assignee) Attorney 1. DelLETION OF INVENTORIS Image: an assignee) Image: an assignee) Attorney 1. DelLETION OF INVENTORIS Image: an assignee) Image: an assignee) Attorney 1. DelLETION OF INVENTORIS Image: an assignee) Image: an assignee) Image: an assignee) Image: an assignee) Attorney 1. DelLETION OF INVENTORIS Image: an assignee) Image: an assignee) Image: an assignee) Image: an assignee) Attorney 1. DeltETION OF Invention Image: an assignee) Image: an assignee) Image: an assignee) Image: an assignee) Image:	3. Specification [Total Pages 23] Both the claims and abstract must start on a new page (For information on the preferred arrangement, see MPEP 608.01(a))	Name of Assi	ignee					
(for continuation/divisional with Box 18 completed) 11. □ English Translation Document (if applicable) 11. □ DELETION OF INVENTORS) Signed statement attached deleting inventor(s) rane in the prior application, see 37 CFR 16. □ Application Data Sheet. See 37 CFR 1.76 13. □ Preliminary Amendment 7. □ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 14. □ Return Receipt Postcard (MPEP 503) (Should be specifically iternized) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, items a c. are required) 15. □ Certified Copy of Priority Document(s) (if foreign priorily is claimed) 9. □ Computer Program (Appendix) 16. □ Nonpublication Request under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attached 18. □ CD-ROM or CD-R (2 copies); or ii. □ Paper 17. □ Other:	5. Oath or Declaration [Total Sheets 1] a. Newly executed (original or copy)		· · · · · · · · · · · · · · · · · · ·					
Signed statement attached deleting inventor(s) name in the pior application, see 37 CFR 1.63(d)(2) and 1.33(b). 12 lnformation Disclosure Statement (PTO/SB/08 or PTO-1449) Copies of citations attached 6. Application Data Sheet. See 37 CFR 1.76 13. Preliminary Amendment 7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) Landscape Table on CD 13. Preliminary Amendment 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, items a. – c. are required) a. 14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, items a. – c. are required) a. 15. Certified Copy of Priority Document(s) (if foreign priority is claimed) 8. Mucleotide and/or Amino Acid Sequence Submission (if applicable, items a. – c. are required) 16. Nonpublication Request under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or equivalent. 1. CD-ROM or CD-R (2 copies); or ii. 17. Other: 17. Other: 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification information: Examiner San Ming R. Hui Art Unit: 1617 Prior application information: Visite information: OR Correspondence address below Name 09629 OR Co	(for continuation/divisional with Box 18 completed)	11. 🔲 English Trans	lation Document (if applicable)					
7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 14. Return Receipt Postcard (MPEP 503) 8. Nucleotide and/or Amino Acid Sequence Submission (If applicable, items a c. are required) 15. Certified Copy of Priority Document(s) a. Computer Readable Form (CRF) b. Specification Sequence Listing on: 15. Certified Copy of Priority Document(s) b. Specification Sequence Listing on: 16. Nonpublication Request under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or equivalent. 17. Other: 17. c. Statements verifying identity of above copies 17. Other: 17. 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76: 19. CORRESPONDENCE ADDRESS If a endress associated with Customer Number: 09629 OR Correspondence address below Name 21/2 State Zip Code 21/2 City State Zip Code Email	Signed statement attached deleting inventor(s) name in the prior application, see 37 CFR	12. Information Di	isclosure Statement (PTO/SB/08 or PTO-1449) s of citations attached					
Computer Program (Appendix) 14Return Receipt Posteard (MPEP 503) S. Nucleotide and/or Amino Acid Sequence Submission (if applicable, items a. c. are required) 15Centified Copy of Priority Document(s) aComputer Readable Form (CRF) bSpecification Sequence Listing on: 15Centified Copy of Priority Document(s) iCD-ROM or CD-R (2 copies); or 16Nonpublication Request under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or equivalent. 17Other:	6. Application Data Sheet. See 37 CFR 1.76	13. 🗹 Preliminary A	mendment					
(if applicable, items a c. are required) (if foreign priority is claimed) a. Computer Readable Form (CRF) b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or ii. Paper c: Statements verifying identity of above copies 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76: Image: Continuation Divisional Continuation Divisional Continuation Divisional Continuation Divisional Continuation Divisional Contribution Opican 19. CORRESPONDENCE ADDRESS Image: Address associated with Customer Number: 09629 OR Correspondence address below Name Address City State Zip Code City State Zip Code	Computer Program (Appendix)							
b. Specification Sequence Listing on: Interpret in the second sequence Listing on: Interpret interpr	(if applicable, items a. – c. are required)	(if foreign priority is claimed)						
i. CD-ROM or CD-R (2 copies); or ii. Paper c. Statements verifying identity of above copies 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76: Image: Continuation Divisional Image: Continuation Divisional Image: Continuation information: Examiner San Ming R. Hui Art Unit: 1617 19. CORRESPONDENCE ADDRESS Image: Correspondence address below Name Address City State City State State Zip Code Contry State								
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76:								
specification following the title, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-part (CIP) of prior application No.: 10/872,784 Prior application information: Examiner San Ming R. Hui Art Unit: 1617 19. CORRESPONDENCE ADDRESS Image: Continuation of the address associated with Customer Number: 09629 OR Correspondence address below Name Address City State Country State Zip Code Email	c. Statements verifying identity of above copies							
Prior application information: Examiner_San Ming R. Hui Art Unit: 1617 19. CORRESPONDENCE ADDRESS Image: The address associated with Customer Number: 09629 OR Correspondence address below Name Address City State Zip Code Country Telephone Email	18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the							
19. CORRESPONDENCE ADDRESS Image: The address associated with Customer Number: 09629 OR Correspondence address below Name Address Correspondence address below Correspondence address below City State Zip Code Country Celephone Email	Continuation Divisional Continua	ation-in-part (CIP) of prior application No.: 10/872.784						
Image: The address associated with Customer Number: 09629 OR Correspondence address below Name	Prior application information: Examiner San Ming R. Hui Art Unit: 1617							
Name OK Conrespondence address delow Address City State Zip Code Country Selephone Email	19. CORRESPONDENCE ADDRESS							
Address City State Zip Code Country Eelephone Email	The address associated with Customer Number:	0629 OR Correspondence address below						
City State Zip Code Country Eelephone Email	Name							
Country Email	Address							
			Email					

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

...

10

FORMULATION

The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound

5 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol, more particularly to a formulation adapted for administration by injection containing the compound 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a nonaqueous ester solvent which is miscible in the ricinoleate vehicle.

Oestrogen deprivation is fundamental to the treatment of many benign and malignant diseases of the breast and reproductive tract. In premenopausal women, this is achieved by the ablation of ovarian function through surgical, radiotherapeutic, or medical means, and, in postmenopausal women, by the use of aromatase inhibitors.

An alternative approach to oestrogen withdrawal is to antagonise oestrogens with 15 antioestrogens. These are drugs that bind to and compete for oestrogen receptors (ER) present in the nuclei of oestrogen-responsive tissue. Conventional nonsteroidal antioestrogens, such as tamoxifen, compete efficiently for ER binding but their effectiveness is often limited by the partial agonism they display, which results in an incomplete blockade of oestrogen-mediated activity (Furr and Jordan 1984, May and Westley 1987).

20 The potential for nonsteroidal antioestrogens to display agonistic properties prompted the search for novel compounds that would bind ER with high affinity without activating any of the normal transcriptional hormone responses and consequent manifestations of oestrogens. Such molecules would be "pure" antioestrogens, clearly distinguished from tamoxifen-like ligands and capable of eliciting complete ablation of the trophic effects of oestrogens. Such 25 compounds are referred to as Estrogen Receptor-Downregulators (E.R.D.). The rationale for

the design and testing of novel, pure antioestrogens has been described in: Bowler et al 1989, Wakeling 1990a, 1990b, 1990c. Wakeling and Bowler 1987, 1988.

Steroidal analogues of oestradiol, with an alkylsulphinyl side chain in the 7α position, provided the first examples of compounds devoid of oestrogenic activity (Bowler et al 1989).
One of these, 7α-[9-(4,4,5,5,5-pentafluoropentyl sulphinyl)nonyl]oestra-1,3,5-(10)triene-3,17β-diol was selected for intensive study on the basis of its pure oestrogen antagonist

activity and significantly increased antioestrogenic potency over other available

5

antioestrogens. In vitro findings and early clinical experience with 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3-5(10)-triene-3,17 β -diol have

promoted interest in the development of the drug as a therapeutic agent for oestrogendependent indications such as breast cancer and certain benign gynaecological conditions.

-2-

 7α -[9-(4,4,5,5,5-Pentafluoropentylsulphinyl)nonyl]oestra-1,3-5(10)-triene-3,17 β -diol, or ICI 182,780, has been allocated the international non-proprietary name fulvestrant, which is used hereinafter. When referring to fulvestrant we include pharmaceutically-acceptable salts thereof and any possible solvates of either thereof.

Fulvestrant binds to ER with an affinity similar to that of oestradiol and completely blocks the growth stimulatory action of oestradiol on human breast cancer cells *in vitro*; it is more potent and more effective than tamoxifen in this respect. Fulvestrant blocks completely the uterotrophic action of oestradiol in rats, mice and monkeys, and also blocks the uterotrophic activity of tamoxifen.

Because fulvestrant has none of the oestrogen-like stimulatory activity that is 15 characteristic of clinically available antioestrogens such as tamoxifen or toremifene, it may offer improved therapeutic activity characterised by more rapid, complete, or longer-lasting tumour regression; a lower incidence or rate of development of resistance to treatment; and a reduction of tumour invasiveness.

In intact adult rats, fulvestrant achieves maximum regression of the uterus at a dose 20 which does not adversely affect bone density or lead to increased gonadotrophin secretion. If also true in humans, these findings could be of extreme importance clinically. Reduced bone density limits the duration of oestrogen-ablative treatment for endometriosis. Fulvestrant does not block hypothalamic ER. Oestrogen ablation also causes or exacerbates hot flushes and other menopausal symptoms; fulvestrant will not cause such effects because it does not cross 25 the blood-brain barrier.

European Patent Application No. 0 138 504 discloses that certain steroid derivatives are effective antioestrogenic agents. The disclosure includes information relating to the preparation of the steroid derivatives. In particular there is the disclosure within Example 35 of the compound 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-

30 1,3,5(10)-triene-3,17β-diol, which compound is specifically named in Claim 4. It is also disclosed that the compounds of that invention may be provided for use in the form of a pharmaceutical composition comprising a steroid derivative of the invention together with a

pharmaceutically-acceptable diluent or carrier. It is stated therein that the composition can be in a form suitable for oral or parenteral administration.

- 3 -

Fulvestrant shows, along with other steroidal based compounds, certain physical properties which make formulation of these compounds difficult. Fulvestrant is a particularly

5 lipophilic molecule, even when compared with other steroidal compounds, and its aqueous solubility is extremely low at around 10 ngml⁻¹ (this is an estimate from a water/solvent mixture solute since measurements this low could not be achieved in a water only solute).

Currently there are a number of sustained release injectable steroidal formulations which have been commercialised. Commonly these formulations use oil as a solvent and wherein additional excipients may be present. Below in Table 1 are described a few commercialised sustained release injectable formulations.

In the formulations within Table 1 a number of different oils are used to solubilise the compound and additional excipients such as benzyl benzoate, benzyl alcohol and ethanol have been used. Volumes of oil needed to solubilise the steroid active ingredient are low. Extended 15 release is achievable for periods from 1 to 8 weeks.

20

25

CTIONS		
LAR INJE		
ING INTRAMUSCULAR INJECTIONS	-	
ACTING INT		
D LONG-A		
ole 1 - OIL BASED LONG-ACTING		
Table 1		

			·	•	د				
DOSING	3 weeks		1 week	< 1 week	15 to 30 days	8 weeks	1 week	l week	1 - 2 weeks
DOSE	lml		l or 2ml	2ml	lml	lml	1ml	l or	2ml 2ml
EtOH								•	
BzOH	0.1ml		•						
BzBz			up to 46%	*40%	45%	YES		YES	YES
<u>IIO</u>	Arachis	•.	Castor	Ethyl	Olive	Castor	Arachis	Castor	Castor
SOURCE	ABPI Data Sheet	Comp.1999	ABPI Data Sheet	Comp.1999 Dict. Vidal 1999	Dict. Vidal 1997	ABPI Data Sheet	Comp.1999 Dict. Vidal 1998	Dict. Vidal	Dict. Vidal 1995
COMP'.	Organon		Schering HC	Theramax	Theramax	Schering HC	Roussel	Pharlon.	Schering HC
TYPE	Androgen		Progestogen	Progestogen	Mixed	Contraceptive	Estradiol	Progestogen	Mixed
DOSE	30mg 60mg	60mg	100mg 250mgml ⁻¹	200mg	50mg 250mg 1.3mg 50mg 80mg	200mg	Smg	.250mgml ⁻¹	5mgml ⁻¹ 250mgml ⁻¹
<u>STEROID</u>	Testosterone proprionate Testosterone	Testosterone isocaproate	I estosterone decanoate Hydroxy progesterone hexanoate	Hydroxy progesterone enantate	Progesterone α-Tocopherol Estrapronicate Nandrolone undecanoate Hydroxyprogesterone	heptanoate Norethisterone oenanthoate	Estradiol hexahydrobenzoate	Hydroxy progesterone caproate	Estradiol 17-β-valerate Hydroxyprogesterone caproate
PRODUCT NAME	SUSTANON 100		PROLUTON DEPOT	TOCOGESTAN	TROPHOBOLENE	NORISTERAT	BENZO- GYNOESTRYL	PROGESTERONE -RETARD	GRAVIBINAN

÷

MYLAN PHARMS. INC. EXHIBIT 1002 PAGE 5

Ċ

Arachis	Castor	Castor	
Dict. Vidal 1997	J.Pharm. Sci	(1964) 53(8) 891 J.Pharm. Sci.(1964)	53(8) 891
Negma	BMS	SMG	
Androgen	Estradiol.	Progestrogen	
76mg	20mgml ⁻¹ 40meml ⁻¹	250mgml ⁻¹	
		· ·	
Trenbolone	Estradiol valerate	17-Hydroxy progesterone	• -
PARABOLAN	DELESTROGEN	DELALUTIN	

45mg 1.5ml 2 weeks

75mg

2% 2%

20% 40%

78% 58%

BzBz = benzylbenzoate BzOH = benzylalcohol EtOH = ethanol Dict. Vidal = Dictionnaire Vidal 5 % are w/v and * approximate as measured directly from a single sample

 \bigcirc

up to 2%

YES

YES

Ċ

described which comprises 50mg of fulvestrant, 400mg of benzyl alcohol and sufficient castor oil to bring the solution to a volume of 1 ml. Manufacture at a commercial scale of a formulation as described in US 5,183,814 will be complicated by the high alcohol concentration. Therefore, there is a need to lower the alcohol concentration in fulvestrant
formulations whilst preventing precipitation of fulvestrant from the formulation.

- 6 -

Table 2 shows the solubility of fulvestrant in a number of different solvents.

Table 2 - SOLUBILITY OF FULVESTRANT

	•
SOLVENT	SOLUBILITY
	(mgml ⁻¹ at 25°C)
Water	0.001
Arachis oil	0.45
Sesame oil	0.58
Castor oil	20
Miglyol 810	3.06
Miglyol 812	2.72
Ethyl oleate	1.25
Benzyl benzoate	6.15
Isopropyl myristate	0.80
Span 85 (surfactant)	3.79
Ethanol	>200
Benzyl Alcohol	>200

10

As can be seen fulvestrant is significantly more soluble in castor oil than any of the other oils tested. The greater solvating ability of castor oil for steroidal compounds is known and is attributed to the high number of hydroxy groups of ricinoleic acid, which is the major constituent of the fatty acids within the triglycerides present in castor oil - see (Riffkin et.al. J. Pharm. Sci., (1964), 53, 891).

However, even when using the best oil based solvent, castor oil, we have found that it is not possible to dissolve fulvestrant in an oil based solvent alone so as to achieve a high enough concentration to dose a patient in a low volume injection and achieve a therapeutically

significant release rate. To achieve a therapeutically significant release rate the amount of fulvestrant needed would require the formulation volume to be large, at least 10 ml. This requires the doctor to inject an excessively large volume of formulation to administer a dose significantly high enough for human therapy.

5

25

Currently guidelines recommend that no more than 5mls of liquid is injected intramuscularly in a single injection. Pharmacologically active doses required for a 1 month long acting depot formulation of fulvestrant is around 250mg. Therefore, when dissolved in just castor oil, fulvestrant would need to be administered in at least 10ml of castor oil.

The addition of organic solvents in which fulvestrant is freely soluble, and which are 10 miscible with castor oil, may be used, such as an alcohol. With the addition of high concentrations of an alcohol concentrations of >50mgml⁻¹ of fulvestrant in a castor oil formulation is achievable, thereby giving an injection volumes of <5ml - see Table 3 below. We have surprisingly found that the introduction of a non-aqueous ester solvent which is miscible in the castor oil and an alcohol surprisingly eases the solubilisation of fulvestrant into 15 a concentration of at least 50 mgml⁻¹ - see Table 3 below. The finding is surprising since the solubility of fulvestrant in non-aqueous ester solvents - see Table 2 above - is significantly lower than the solubility of fulvestrant in an alcohol. The solubility of fulvestrant is also lower

in non-aqueous ester solvents than is the solubility of fulvestrant in castor oil.
Therefore, we present as a feature of the invention a pharmaceutical formulation
comprising fulvestrant (preferably fulvestrant is present at 3-10%w/v, 4-9%w/v, 4-8%w/v, 4-7%w/v, 4-6%w/v and most preferably at about 5%w/v) in a ricinoleate vehicle, a
pharmaceutically acceptable non-aqueous ester solvent, and a pharmaceutically acceptable

alcohol wherein the formulation is adapted for intramuscular administration and attaining a therapeutically significant blood plasma fulvestrant concentration for at least 2 weeks.

Another feature of the invention is a pharmaceutical formulation comprising fulvestrant in which the formulation is adapted for intra-muscular injection into a human and which is capable after injection of attaining a therapeutically significant blood plasma fulvestrant concentration for at least 2 weeks.

Further features of the invention include a pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 30% or less weight of a pharmaceuticallyacceptable alcohol per volume of formulation, at least 1% weight of a pharmaceuticallyacceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of

formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation which is capable after injection of attaining a therapeutically significant blood plasma fulvestrant concentration for at least 2 weeks.

- 8 -

- Further features of the invention include a pharmaceutical formulation adapted for
 intra-muscular injection comprising fulvestrant; 35% (preferably 30% and ideally 25%) or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% (preferably at least 5% or ideally 10%) weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible within a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml⁻¹ of
 fulvestrant.
- For the avoidance of any doubt when using the term % weight per volume of formulation for the constituents of the formulation we mean that within a unit volume of the formulation a certain percentage of the constituent by weight will be present, for example a 1% weight per volume formulation will contain within a 100ml volume of formulation 1g of 15 the constituent. By way of further illustration

% of x by weight per volume of formulation	weight of x in 1ml of formulation
30%	300mg
20%	200mg
10%	100mg
5%	50mg
1%	10mg

Preferred pharmaceutical formulations of the invention are as described above

wherein:

20 1. The total volume of the formulation is 6ml, or less, and the concentration of fulvestrant is at least 45mgml⁻¹.

2. The total amount of fulvestrant in the formulation is 250mg, or more, and the total volume of the formulation is 6ml, or less.

3. The total amount of fulvestrant in the formulation is 250mg and the total volume of 25 the formulation is 5-5.25ml.

It is appreciated that in the formulation an excess of formulation may be included to allow the attendant physician or care giver to be able to deliver the required dose. Therefore, when a 5ml dose is required it would be appreciated that an excess of up to 0.25ml, preferably up to 0.15ml will also be present in the formulation. Typically the formulation will be 5 presented in a vial or a prefilled syringe, preferably a prefilled syringe, containing a unit dosage of the formulation as described herein, these being further features of the invention.

- 9 -

Preferred concentrations of a pharmaceutically-acceptable alcohol present in any of the above formulations are; at least 3%w/v, at least 5%w/v, at least 7%w/v, at least 10% w/v, at least 11% w/v, at least 12% w/v, at least 13% w/v, at least 14% w/v, at least 15% w/v and,
preferably, at least 16% w/v. Preferred maximal concentrations of pharmaceutically-acceptable alcohol present in the formulation are ;28% w/v or less, 22% w/v or less and 20% w/v or less.. Preferred ranges of pharmaceutically-acceptable alcohol present in any of the above formulations are selected from any minimum or maximum value described above and preferably are; 3-35%w/v, 4-35%w/v, 5-35%w/v, 5-32%w/v, 7-32%w/v, 10-30%w/v, 12-15 28%w/v, 15-25%w/v, 17-23%w/v, 18-22%w/v and ideally 19-21%w/v.

The pharmaceutically-acceptable alcohol may consist of one alcohol or a mixture of two or more alcohols, preferably a mixture of two alcohols. Preferred pharmaceutically-acceptable alcohols for parenteral administration are ethanol, benzyl alcohol or a mixture of both ethanol and benzyl alcohol, preferably the ethanol and benzyl alcohol are present in the formulation in the same w/v amounts. Preferably the formulation alcohol contains 10% w/v ethanol and 10% w/v benzyl alcohol.

The pharmaceutically-acceptable non-aqueous ester solvent may consist of one or a mixture of two or more pharmaceutically-acceptable non-aqueous ester solvents, preferably just one. A preferred pharmaceutically-acceptable non-aqueous ester solvent for parenteral administration is selected from benzyl benzoate, ethyl oleate, isopropyl myristate, isopropyl palmitate or a mixture of any thereof.

The ricinoleate vehicle should preferably be present in the formulation in a proportion of at least 30% weight per volume of the formulation, ideally at least 40% or at least 50% weight per volume of formulation.

30

It will be understood by the skilled person that the pharmaceutically-acceptable alcohol will be of a quality such that it will meet pharmacopoeial standards (such as are described in the US, British, European and Japanese pharmacopoeias) and as such will contain

some water and possibly other organic solvents, for example ethanol in the US Pharmacopeia contains not less than 94.9% by volume and not more than 96.0% by volume of ethanol when measured at 15.56°C. Dehydrated alcohol in the US Pharmacopeia contains not less than 99.5% ethanol by volume when measured at 15.56°C.

- 10 -

- ⁵ Preferred concentrations of the pharmaceutically-acceptable non-aqueous ester solvent present in any of the above formulations are; at least 5% w/v, at least 8% w/v, at least 10% w/v, at least 11% w/v, at least 12% w/v, at least 13% w/v, at least 15% w/v, at least 16% w/v, at least 17% w/v, at least 18% w/v, at least 19% w/v and at least 20% w/v. Preferred maximal concentrations of the pharmaceutically-acceptable non-aqueous ester solvent are; 60% w/v or
- 10 less, 50%w/v or less, 45% w/v or less, 40% w/v or less, 35% w/v or less, 30% w/v or less and 25% w/v or less. A preferred concentration is 15% w/v. Preferred ranges of pharmaceutically-acceptable non-aqueous ester solvent present in any of the above formulations are selected from any minimum or maximum value described above and preferably are; 5-60%w/v, 7-55%w/v, 8-50%w/v, 10-50%w/v, 10-45%w/v, 10-40%w/v, 10-35%w/v, 10-30%w/v, 10-
- 15 25%w/v, 12-25%w/v, 12-22%w/v, 12-20%w/v, 12-18%w/v, 13-17%w/v and ideally 14 16%w/v. Preferably the ester solvent is benzyl benzoate, most preferably at about 15%w/v.

It will be understood by the skilled person that the pharmaceutically-acceptable nonaqueous ester solvent will be of a quality that it will meet pharmacopoeial standards (such as described in the US, British, European and Japanese pharmacopoeias).

20

Preferred combinations of pharmaceutically-acceptable alcohol and pharmaceuticallyacceptable non-aqueous ester solvent in the formulation are set out below:

Pharmaceutically-acceptable	Pharmaceutically-acceptable non-aqueous				
alcohol(%w/v)	ester (%w/v)				
10-30	5-60, 7-55, 8-50, 10-50, 10-45, 10-40, 10-35, 10-				
	30, 10-25, 12-25, 12-22, 12-20, 12-18, 13-17 and				
	ideally 14-16.				

17-23	5-60, 7-55, 8-50, 10-50, 10-45, 10-40, 10-35, 10-
1	30, 10-25, 12-25, 12-22, 12-20, 12-18, 13-17 and
	ideally 14-16.
3-35, 4-35, 5-35, 5-32, 7-32, 10-30, 12-	10-35
28, 15-25, 17-23, 18-22 and ideally 19-	
3-35, 4-35, 5-35, 5-32, 7-32, 10-30, 12-	12-18
28, 15-25, 17-23, 18-22 and ideally 19-	•
21.	
ethanol and benzyl alcohol, most	benzyl benzoate, most preferably at about 15%
preferably each at about 10%	

By the use of the term ricinoleate vehicle we mean an oil which has as a proportion (at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% w/v) of its composition as triglycerides of ricinoleic acid. The ricinoleate vehicle may be a synthetic oil or conveniently

is castor oil, ideally of pharmacopoeial standards, as described above.

We have surprisingly found that the above formulations of the invention provide, after intra-muscular injection, satisfactory release of fulvestrant over an extended period of time.

This finding is indeed surprising for the following reasons.

10 1. Previously tested by the applicants have been intra-muscular injections of fulvestrant in the form of an aqueous suspension. We have found extensive local tissue irritation at the injection site as well as a poor release profile. It is believed that the tissue

irritation/inflammation was due to the presence of fulvestrant in the form of solid particles.
The release profile appeared to be determined by the extent of inflammation/irritation present
at the injection site and this was variable and difficult to control. Also the fulvestrant release
rate was not sufficiently high to be clinically significant.

2. Our findings from studies using ¹⁴C labelled benzyl alcohol show that it dissipates rapidly from the injection site and is removed from the body within 24 hours of administration.

20

It would be expected that ethanol will dissipate at least as quickly, if not more rapidly, from the injection site.

MYLAN PHARMS. INC. EXHIBIT 1002 PAGE 12

- 11 -

It is known that benzyl benzoate is metabolised by conjugation to glycine to form hippuric acid by the human liver and excreted into the urine - Martindale: The Extra Pharmacopoeia 32nd edition page 1103, and, therefore, it is unlikely that benzyl benzoate, when used, is present at the injection site during the whole of the extended release period.

- 12 -

We have found that despite the rapid elimination of the additional solubilising excipients, i.e. the alcohol and pharmaceutically-acceptable non-aqueous ester solvent, from the formulation vehicle and the site of injection after injection of the formulation, extended release at therapeutically significant levels of fulvestrant over an extended period can still achieved by the formulation of the invention.

By use of the term "therapeutically significant levels" we mean that blood plasma concentrations of at least 2.5 ngml⁻¹, ideally at least 3 ngml⁻¹, at least 8.5 ngml⁻¹, and up to 12 ngml⁻¹ of fulvestrant are achieved in the patient. Preferably blood plasma levels should be less than 15 ngml⁻¹.

By use of the term "extended release" we mean at least two weeks, at least three 15 weeks, and, preferably at least four weeks of continuous release of fulvestrant is achieved. In a preferred feature extended release is achieved for 36 days. Preferably extended release of fulvestrant is for at least 2- 5 weeks and more preferably for the following periods (weeks) 2.5-5, 2.5-4, 3-4, 3.5-4 and most preferably for at least about 4 weeks.

It will be understood that the attendant physician may wish to administer the intramuscular injection as a divided dose, i.e. a 5ml formulation is sequentially administered in two separate injections of 2.5ml, this is a further feature of the invention

Simply solubilising fulvestrant in an oil based liquid formulation is not predictive of a good release profile or lack of precipitation of drug after injection at the injection site.

Table 3 shows the solubility of fulvestrant in a castor oil vehicle additionally containing alcohols ethanol and benzyl alcohol with or without benzyl benzoate. The results clearly show the positive effect of benzyl benzoate on fulvestrant solubility in castor oil, despite fulvestrant having a lower solubility in benzyl benzoate than in either alcohol or castor oil.

30

10

Table 3

Table 3 - EFFECT OF BENZYL BENZOATE ON FULVESTRANT SOLUBILITY IN CASTOR OIL AT 25⁰C

				√/M %				
Ethanol	S	S	10	10 .	10	10	15	15
(%96)				÷				
Benzyl	5	5	.	S	10	10	15	15
Alcohol						•	·	
Benzyl		15		15		15		15
Benzoate								
Castor Oil	to 100	to100	to 100	to 100	to 100	to 100	to 100	to 100
Fulvestrant	27	36	46	54	45	65	76	102
Solubility			•					
[mgml ⁻¹]								

MYLAN PHARMS. INC. EXHIBIT 1002 PAGE 14

(. .

The following Table 4 shows the solubility of fulvestrant in a range of oil based formulations which contain the same amounts of alcohol and benzyl benzoate but in which the oil is changed. The data also shows solubility of fulvestrant after removal of the alcohols. Table 4

- 14 -

5 Solubility comparisons of fulvestrant in oil based formulations with and without alcohols

		Fulvestrant Solu	bility mg ml ⁻¹ @ 25°C
10	Formulation ^(a)	Complete vehicle	Vehicle minus alcohols
	Castor oil based	81.2	12.6
15	Miglyol 812-N based	86.8	1.7
	Sesame seed/Castor oil (1:1) based	70.1	4.4
•••	Sesame seed oil based	45.7	0.7
20	Arachis oil based	40.2	< 0.2

Complete Vehicle Formulations comprised ethanol [96%](10%), benzyl alcohol (10%) and benzyl benzoate (a) 25 (15%) made to volume with the stated oil. Excess fulvestrant was added to each solvent mixture and solubility determined.

Effect of formulation on precipitation of fulvestrant at the injection site

30	· ·			······	Days			
	Formulation ^a	2	3	4	7	10	30	51
35	Formulation F1 castor oil based	0	0	0	0	0	0	0
	Formulation F2 Miglyol 812-N based	++ ^b	+++	+++	+++	+++	++	0
.40	Formulation F3 sesame seed oil/castor oil based	+ ^c	++	++	***	++	· +	+

0, +, ++, +++ = Degree of precipitation (None detected, Mild, Moderate, Severe)

45 ^a Formulations comprised fulvestrant (5%), ethanol [96%] (10%), benzyl alcohol (10%) and benzyl benzoate (15%) made to volume with the stated oil.

Mainly large needle shaped crystals

^c Small needles and/or sheafs of crystals

- 15 -

Precipitation of fulvestrant and the release profile was determined with the above formulations in an *in vivo* rabbit study.

Figure 1 shows the release profile *in vivo* of the four formulations from the second part of Table 4 and shows the effect of the fixed oil component on fulvestrant plasma profile over
5 five days following intramuscular administration in rabbits (data normalised to 50mg per 3kg; mean given; number of animals per timepoint = 8, plasma samples assayed for fulvestrant content using lc-ms/ms detection following solvent extraction). As can be seen the castor oil formulation showed a particularly even release profile with no evidence of precipitation of fulvestrant at the injection site.

Therefore we present as a further feature of the invention an extended release pharmaceutical formulation adapted for intramuscular injection comprising fulvestrant; 35% (preferably 30% or ideally 25%) or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% (preferably at least 5% or ideally 10%) weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per

15 volume of formulation and sufficient amount of a ricinoleate vehicle, taking into account the addition of any further optional pharmaceutically-acceptable excipients, so as to prepare a formulation of at least 45mgml⁻¹ of fulvestrant.

A further feature of the invention is a pharmaceutical formulation adapted for intramuscular injection, as defined above, for use in medical therapy.

A further feature of the invention is a method of treating a benign or malignant diseases of the breast or reproductive tract, preferably treating breast cancer, by administration to a human in need of such treatment by intramuscular injection an extended release ricinoleate vehicle based pharmaceutical formulation comprising at least 45mgml⁻¹ of fulvestrant; 35% (preferably 30% or ideally 25%) or less weight of a pharmaceuticallyacceptable alcohol per volume of formulation, at least 1% (preferably at least 5% or ideally 10%) weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation.

Preferably 5ml of the intramuscular injection is administered.

A further feature of the invention is use of fulvestrant in the preparation of a 30 pharmaceutical formulation as describe hereinabove, for the treatment of a benign or malignant disease of the breast or reproductive tract, preferably treating breast cancer.

MYLAN PHARMS. INC. EXHIBIT 1002 PAGE 16

20

10

Additional excipients commonly used in the formulation field including, for example, an antioxidant preservative, a colorant or a surfactant may be used. A preferred optional excipient is a surfactant.

- 16 -

As described above fulvestrant is useful in the treatment of oestrogen-dependent 5 indications such as breast cancer and gynaecological conditions, such as endometriosis.

- In addition to fulvestrant another similar type of molecule is currently under clinical investigation. SH-646 (11β-fluoro- 7α-(14,14,15,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl)estra-1,3,5(10)-triene-3,17β-diol) is also putatively a compound with the same mode of action as fulvestrant and has a very similar chemical
 structure. It is believed that the compound will also share with fulvestrant similar physical
- properties and therefore the current invention will also have application with this compound. A further feature of the invention is a pharmaceutical formulation adapted for

intra-muscular injection comprising 11 β -fluoro- 7 α -(14,14,15,15,15-pentafluoro-6methyl-10-thia-6-azapentadecyl)estra-1,3,5(10)-triene-3,17 β -diol; 35% or less weight of a

15 pharmaceutically-acceptable alcohol per volume of formulation, at least 1% weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible within a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml⁻¹ of 11β-fluoro- 7α-(14,14,15,15,15-pentafluoro-6methyl-10-thia-6-azapentadecyl)estra-1,3,5(10)-triene-3,17β-diol.

20

Further features of the invention are those as described above but in which SH-646 is substituted for fulvestrant.

Formulation Example

25

Fulvestrant is mixed with alcohol and benzyl alcohol, stirring until completely dissolved. Benzyl benzoate is added and the solution is made to final weight with castor oil and stirred, (for convenience weight is used rather than volume by using the weight to volume ratio). The bulk solution is overlaid with Nitrogen. The solution is sterilised by filtration using one or two filters of $0.2\mu m$ porosity. The sterile filtrate is kept under a nitrogen overlay

30 as it is filled under aseptic conditions into washed and depyrogenised, sterile primary containers, for example vials or pre-filled syringes. An overage is included in the primary

5

pack to facilitate removal of the dose volume. The primary packs are overlaid with sterile nitrogen, before aseptically sealing.

- 17 -

See also process flow diagram below

Quantities of each component of the formulation is chosen according to the required formulation specification, examples are described above. For example quantities are added of each component to prepare a formulation which contains

10% weight per volume of benzyl alcohol

10 10% weight per volume of ethanol


15% weight per volume of benzyl benzoate

250mg of fulvestrant for each 5ml of finished formulation

and the remaining amount as castor oil

- 18 -

FLOW DIAGRAM OF MANUFACTURING



STAGE 4: STERILE FILTRATION (0.2µm) INTO BULK RECEIVING VESSEL

STAGE 5: STERILE (0.2µm) IN-LINE FILTRATION

STAGE 6: ASEPTIC FILLING, AND STOPPERING

STAGE 7: VISUAL **INSPECTION**

References

1. Bowler J, Lilley TJ, Pittam JD, Wakeling AE. Novel steroidal pure antioestrogens. Steroids 989; 5471-99.

5 2. Wakeling AE. Novel pure antioestrogens: mode of action and therapeutic prospects. American New York Academy Science 1990a; 595: 348-56.

3. Wakeling AE. Steroidal pure antioestrogens. In Lippman M, Dickson R, editors. Regulatory mechanisms in breast cancer. Boston: Kluwer Academic, 1990b: 239-57.

10

4. Wakeling AE. Therapeutic potential of pure antioestrogens in the treatment of breast cancer. Journal Steroid Biochemistry 1990c; 37: 771-5.

5. Wakeling AE, Bowler J. Steroidal pure antioestrogens. Journal Endocrinology 1987; 112:15 R7-10.

6. Wakeling AE, Bowler J. Biology and mode of action of pure antioestrogens. Journal Steroid Biochemistry 1988; 3: 141-7.

Claims

1. A pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 30% or less weight of a pharmaceutically-acceptable alcohol per volume of

⁵ formulation, at least 1% weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation which is capable after injection of attaining a therapeutically significant blood plasma fulvestrant concentration of at least 2.5ngml⁻¹ for at least 2 weeks.

10 2. A pharmaceutical formulation as claimed in claim 1 wherein the blood plasma fulvestrant concentration is attained for at least 4 weeks.

3. A pharmaceutical formulation as claimed in claim 1 wherein the blood plasma fulvestrant concentration is attained for 2 to 5 weeks.

A pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 30% or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml⁻¹ of fulvestrant.

5. A pharmaceutical formulation as claimed in claim 1 to 4 which contains 25% w/v or less of a pharmaceutically-acceptable alcohol.

6. A pharmaceutical formulation as claimed in claim 5 which contains 20% w/v or less of 25 a pharmaceutically-acceptable alcohol.

7. A pharmaceutical formulation as claimed in any claim from 1 to 6 which contains 60% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

30 8. A pharmaceutical formulation as claimed in claim 7 which contains 50%w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

10 .

9. A pharmaceutical formulation as claimed in claim 7 which contains 45% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

5 10. A pharmaceutical formulation as claimed in claim 7 which contains 40% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

11. A pharmaceutical formulation as claimed in claim 7 which contains 35% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

12. A pharmaceutical formulation as claimed in claim 7 which contains 30% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

13. A pharmaceutical formulation as claimed in claim 7 which contains 25% w/v or less
15 of a pharmaceutically-acceptable non-aqueous ester solvent.

14. A pharmaceutical formulation as claimed in any claim from 1 to 13 wherein the pharmaceutically-acceptable alcohol is a mixture of ethanol and benzyl alcohol.

20 15. A pharmaceutical formulation as claimed in any claim from 1 to 14 wherein the pharmaceutically-acceptable non-aqueous ester solvent is selected from benzyl benzoate, ethyl oleate, isopropyl myristate, isopropyl palmitate or a mixture of any thereof.

16. A pharmaceutical formulation as claimed in any claim from 1 to 15 wherein the 25 pharmaceutically-acceptable non-aqueous ester solvent is benzyl benzoate.

17. A pharmaceutical formulation as claimed in any claim from 1 to 16 wherein the total volume of the formulation is 6ml, or less, and the concentration of fulvestrant is at least 45mgml⁻¹.

30

20

18. A pharmaceutical formulation as claimed in any claim from 1 to 13 wherein the total amount of fulvestrant in the formulation is 250mg, or more, and the total volume of the formulation is 6ml, or less.

- 22 -

5 19. A pharmaceutical formulation as claimed in claim 18 wherein the total amount of fulvestrant in the formulation is 250mg and the total volume of the formulation is 5 to 5.25ml.

20. A pharmaceutical formulation as claimed in any of claims 1-19 wherein the pharmaceutically-acceptable alcohol is a mixture of 10% weight of ethanol per volume of
10 formulation, 10% weight of benzyl alcohol per volume of formulation and 15% weight of benzyl benzoate per volume of formulation and the ricinoleate vehicle is castor oil.

21. A method of treating a benign or malignant diseases of the breast or reproductive tract by administration to a human in need of such treatment by intramuscular a pharmaceutical
15 formulation as claimed in claims 1 to 19.

22. A method as claimed in claim 21 for treating breast cancer.

23. A syringe or vial containing a pharmaceutical formulation as defined in claim 20.

<u>ABSTRACT</u> <u>TITLE: Formulation</u>

- 23 -

The invention relates to a novel sustained release pharmaceutical formulation adapted 5 for administration by injection containing the compound

7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17β-diol, more particularly to a formulation adapted for administration by injection containing the compound 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17β-diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a nonaqueous ester solvent which is miscible in the ricinoleate vehicle.




Figure 1

MYLAN PHARMS. INC. EXHIBIT 1002 PAGE 25

Z70635

CIP/PCT NAT ORIGINAL/SUBSTIT		MENTAL		RULE 63 (37 C RATION AND POV FOR PATENT AP STATES PATENT	NEI)\'(PLICATION	DRNEY MARK OFFIC	F	n & S Orm
As a below named inven believe I am the original, below) of the subject ma FORMULATION	first and sole in Iter which is claim	ventor (if only one med and for which	name is listed a patent is sou	below) or an original,	first and joint in	ed below next to ventor (if plural r	my name, a names are lis	and I sted
X A. ☐ is atta BOX(FS) → B. ☐ y	ched hereto. vas filed on	<u>HECK</u> applicable	•	as U.S. Application N	lo. <u>/</u>			
C. C. And (if applicable to U.S.) I hereby state that I have rev above. I acknowledge the differeign priority benefits under Application which designated certificate, or PCT Internation the application on which prior	or PCT applicat iewed and unders uty to disclose all l r 35 U.S.C. 119(a) i at least one othe asl Application file	tand the contents of nformation known to H(d) or 365(b) of any r country than the Ut rd by me or my assio	d on the above identifi me to be materia foreign application ited States, listed mee disclosing th	ed specification, includir I to patentability as defin n(s) for patent or invent I below and have also id a subject matter claimed	ng the claims, as a ned in 37 C.F.R. 1. or's certificate, or 3 lentified below any l in this application	56. Except as note 365(a) of any PCT foreign application	ed below, I he International 1 for patent or	reby claim
PRIOR FOREIGN APPL Number <u>C</u>	ICATION(S) ountry	Day/MONTH/	Year Filed	<u>Date first Laid-</u> open or Publi		Patented Granted P	riority NOT	Claimed
	GB GB	10 Janu 12 Apri	ary 2000 1 2000		••••		•	
		· .			а . .	-	• ,	-
PCT international application application is in addition to ff defined in 37 C.F.R. 1.56 wh application: <u>PRIOR U.S. PROVISION</u> <u>Application No. (series</u>	nat disclosed in su ich became availa IAL, NONPROV	ch prior applications, ble between the filin /ISIONAL AND/OI	I acknowledge th g date of each su	e duty to disclose all info ch prior application and the second s	ormation known to	me to be material T international filing	to patentabilit	y as
I hereby declare that all state further that these statements Section 1001 of Title 18 of th And I hereby appoint Pillsbur telephone number (202) 861 attorneys to prosecute this a authorize them to delete nam persor/assignee/attomey/fin	were made with the United States C ry Madison & Sutra -3000 (to whom all pplication and to the restrumbers below	he knowledge that w ode and that such w o LLP, Intellectual Pr I communications an ansact all business i w of persons no long whether linest sands/s	ultul taise stateme operty Group, 11(e to be directed), in the Patent and er with their firm a ent this case to th	ants and the tike so mad ants may jeopardize the DO New York Avenue, N and the below-named p Trademark Office conne Ind to act and rety on ins wern and by whom/which	e are punishable c validity of the app .W., Ninth Floor, E ersons (of the sam cted therewith and structions from and	ny time or imprisonn lication or any pate ast Tower, Washin e address) individu I with the resulting I communicate dire	nent, or both, i nt issued then gton, D.C. 200 Jally and colle- patent, and I ctfv with the	under eon. 005-3918, ctively my hereby
to be represented unless/uni Paul N. Kokulis Raymond F. Lippitt G. Lloyd Knight	Il linstruct the abo 16773 Dat 17519 Par	we Firm and/or a bel le S. Lazar ul E. White, Jr. un J. Perry	ow attorney in wit 28872 32011 28458	iting to the contrary. Mark G. Paulson Stephen C. Glazier Paul F. McQuade	30793 31361 31542	Michael R. Dz W. Patrick Ber Jack S. Barufi	wonczyk ngtsson	36787 32456. 37087
Carl G. Love Kevin E. Joyce George M. Sirilla Donald J. Bird Peter W. Gowdey	18781 Ker 20508 G. 18221 Lyr 25323 Tim	ndrew H. Colton Paul Edgell In E. Eccleston Nothy J. Klima Vid A. Jakopin	30368 24238 35861 34852 32995	Ruth N. Morduch Richard H. Zaitlen Roger R. Wise Jay M. Finkelstein Anita M. Kirkpatrick	31044 27248 31204 21082 32617	Adam R. Hes	S	41835
(1) INVENTOR'S SIGNA		Dri K	<u>reer</u>		Date: 2512	Janny	2001	
Joł			R Middle Initial	EVANS		unity Name		
Residence Maco	First lesfield.	Cheshire	Unite	d Kingdom		British		
I HACL	City	THE SHILP		State/Foreign Country			of Citizenship	
Post Office Address	A	lderley Par	k. Maccle	sfield Ches	hire, SK1	0 4TG, Uni	ted King	gdom
(include Zip Code)		K10 4TG						
(2) INVENTOR'S SIGNA	the second s	alind_	a G	rendig GRUN	Date: 2.5th	Januar	1-2051	
RC	SALIND		U Middle Initial			unity Name		
Residence Maco	First lesfield,	Cheshire	Unit	ed Kingdom	<u>F</u>	British		
Residence Maco	City	SHOULL C		State/Foreign Country	<u></u>		of Citizenship	: · <u>.</u>
Post Office Address		narter Way,	Macclesf	ield, Cheshi	re, SK10 2		d Kingdo	
(include Zip Code)		SKIO 2NA]					
FOR ADDITIONAL	INVENTORS	, "X[■] box □ a es on attached	nd proceed page (incon	porated herein by	bage to list ea reference). Ity. Dkt. No.		l inventor.	

(M#)	
• •	

. :

PAT-116 11/99(*

PATENT Attorney Docket 056291-5004-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

))

In re <u>Continuation</u> Application of: John R. Evans *et. al* Continuation of Application No. 10/872,784 Application No. Not Assigned Filed: October 15, 2008 Group Art Unit: Not Assigned

Examiner: Not Assigned

For: FORUMLATION

Date: October 15, 2008

PRELIMINARY AMENDMENT

Prior to examination on the merits, please amend the above-referenced application as follows:

Amendments to the Specification begin on page 2 of this paper. Remarks begin on page 3 of this paper.

Attorney Docket **056291-5004-02** New Continuation of U.S. Patent Application No. **10/872,784** Page 2

Amendments to the Specification:

On page 1, please after the title, please insert the following paragraph:

This application is a Continuation Application of copending U.S. Patent Application No. 10/872,784, filed June 22, 2004, which claims benefit of U.S. Patent Application No. 09/756,291, filed January 9, 2001 which claims the benefit of Great Britain Application No. 0008837.7 filed April 12, 2000 and Great Britain Application No. 0000313.7, filed January 10, 2000, all of which are incorporated herein by reference in their entireties.

Attorney Docket 056291-5004-02

New Continuation of U.S. Patent Application No. 10/872,784 Page 3

REMARKS

The specification has been amended to update the priority data. Applicants submit that the amendments to the specification do not introduce prohibited new matter.

Dated: October 15, 2008

Morgan, Lewis & Bockius LLP Customer No. **09629** 1111 Pennsylvania Avenue, N.W. Washington, D.C. 20004 Tel: 202-739-3000 Fax: 202-739-3001

Respectfully submitted Morgan, Lewis & Bockius ALP

Donald J. Bird Registration No. 25,323

PTO/SB/06 (12-04)

Approved for use through 7/31/2006. OMB 0651-0032 Filing Date: 10/15/08 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application or Docket Number PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875 12/285.887 **APPLICATION AS FILED – PART I** OTHER THAN OR SMALL ENTITY SMALL ENTITY (Column 1) (Column 2) FEE (\$) RATE (\$) FEE (\$) FOR NUMBER FILED NUMBER EXTRA RATE (\$) BASIC FEE 330 N/A N/A N/A ·N/A (37 CFR 1.16(a), (b), or (c)) SEARCH FEE N/A 540 N/A N/A N/A (37 CFR 1.16(k), (i), or (m)) EXAMINATION FEE 220 N/A N/A N/A N/A (37 CFR 1.16(o), (p), or (q)) TOTAL CLAIMS 23 3 156 x\$26 x\$52 (37 CFR 1.16(i)) minus 20 OR INDEPENDENT CLAIMS 2 x\$220 x\$110 (37 CFR 1.16(h)) minus 3 If the specification and drawings exceed 100 APPLICATION SIZE sheets of paper, the application size fee due is \$270 (\$135 for small entity) for each additional FEE 50 sheets or fraction thereof. See (37 CFR 1.16(s)) 35 U.S.C. 41(a)(1)(G) and 37 CFR 195 390 MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j)) TOTAL TOTAL 1246 If the difference in column 1 is less than zero, enter "0" in column 2. **APPLICATION AS AMENDED – PART II** OTHER THAN SMALL ENTITY OR (Column 1) (Column 2) (Column 3) SMALL ENTITY CLAIMS HIGHEST ADDI-ADDI-PRESENT REMAINING NUMBER RATE (\$) TIONAL RATE (\$) TIONAL ∢ AFTER PREVIOUSLY EXTRA FEE (\$) FEE (\$) AMENDMENT AMENDMENT PAID FOR Total OR Minus = = = х х (37 CFR 1.16(i)) Independent ** Minus = = = х х (37 CFR 1.16(h)) OR Application Size Fee (37 CFR 1.16(s)) FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j)) N/A OR N/A TOTAL TOTAL OR ADD'T FEE ADD'T FEE (Column 1) (Column 2) (Column 3) OR CLAIMS HIGHEST ADDI-ADDI-REMAINING NUMBER PRESENT TIONAL RATE (\$) TIONAL RATE (\$) m PREVIOUSLY EXTRA AFTER FEE (\$) FEE (\$) AMENDMENT PAID FOR AMENDMENT OR Total Minus = = х = х (37 CFR 1.16(i)) Independent Minus = = = х х (37 CFR 1.16(h)) OR Application Size Fee (37 CFR 1.16(s)) FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j)) N/A OR N/A TOTAL TOTAL OR ADD'T FEE ADD'T FEE * If the entry in column 1 is less than the entry in column 2, write "0" in column 3. ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter *20". If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3". The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1. This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the

USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Paten and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. ADDRESS.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Best Available Copy

PTO/SB/07 (07-06) Approved for use through 1/31/2007. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number Filing Date **MULTIPLE DEPENDENT CLAIM** 12/285,887 10/15/2008 **FEE CALCULATION SHEET** Substitute for Form PTO-1360 Applicant(s) (For use with Form PTO/SB/06) * May be used for additional claims or amendments AFTER SECOND CLAIMS AS FILED AFTER FIRST AS FILED AFTER FIRST AFTER SECOND AMENDMENT AMENDMENT AMENDMENT AMENDMENT Indep Depend Indep Depend Indep Depend Indep Depend Indep Depend Indep Depend 51 1 1 2 1 52 3 1 53 4 1 54 5 2 55 6 2 56 7 2 67 8 2 58 9 2 59 10 2 60 11 2 61 12 2 62 13 2 63 14 2 64 15 2 65 16 2 66 17 2 67 18 2 68 19 2 69 20 70

21 2 71 71 22 2 72 72 72	╂───┨
23 2 73 73	
24 74 74	
25 75 75	
27 77 77 77 77 77 77 77 77 77 77 77 77 7	
29 79 79	
30 80 80	
31 81 81	
32 82	
33 83 83	
34 84 84	
35 85 85	
36 86 9	
37 87 87	
38 88 88	
39 89 89	
40 90 90 90	
41 91 91 91	
	T
43 93 93 93	
<u>47</u> <u>97</u> <u>97</u> <u>97</u> <u>97</u> <u>97</u> <u>97</u> <u>97</u> <u>97</u> <u>97</u> <u>9</u>	
48 98 98 98 98 98 98 98 98 98 98 98 98 98	
49 99 99 99 99 99 99 99 99 99 99 99 99 9	
<u>50</u> 100 100 100 100 100 100 100 100 100 1	
Total Total	
Indep 2	
Total Total	-
Depend 40	
Total 19	
Claims 42	

his collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to mplete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Y comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Year, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR YPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

MYLAN PHARMS. INC. EXHIBIT 1002 PAGE 31

I

UNITED STATES PATENT AND TRADEMARK OFFICE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS PO Box 1450 Alexandria, Virginia 22313-1450 www.uspicagov					
APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS IND CLAIMS
12/285,887	10/15/2008	1617	0.00	056291-5004-02	23 2
					CONFIRMATION NO. 1199
9629				FILING F	RECEIPT
MORGAN LEWIS & BOCKIUS LLP			_LP		
1111 PENNSYLVANIA AVENUE NW					*OC000000032935419*
WASHINGTON, DC 20004 *********************************					*000000032935419*

Date Mailed: 11/04/2008

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections

Applicant(s)

John R. Evans, Macclesfield, UNITED KINGDOM; Rosalind U. Grundy, Macclesfield, UNITED KINGDOM;

Power of Attorney: None

Domestic Priority data as claimed by applicant This application is a CON of 10/872,784 06/22/2004

Foreign Applications

UNITED KINGDOM 0008837.7 04/12/2000 UNITED KINGDOM 0000313.7 01/10/2000

If Required, Foreign Filing License Granted: 11/03/2008

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 12/285,887**

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

page 1 of 3

Title

Formulation

Preliminary Class

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

<u>GRANTED</u>

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as

page 2 of 3

set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

page 3 of 3

UNITED STA	ates Patent and Tradem	ARK OFFICE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS PC. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov		
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE	
12/285,887	10/15/2008	John R. Evans	056291-5004-02	
			CONFIRMATION NO. 1199	
9629		FORMALITIES LETTER		
MORGAN LEWIS & BOCK	(IUS LLP			
1111 PENNSYLVANIA AV		*OC00000032935420*		
WASHINGTON, DC 20004	1		000000032933420	
			Date Mailed: 11/04/2008	

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

Items Required To Avoid Abandonment:

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The statutory basic filing fee is missing.
- Applicant must submit \$330 to complete the basic filing fee for a non-small entity. If appropriate, applicant may make a written assertion of entitlement to small entity status and pay the small entity filing fee (37 CFR 1.27).

The application is informal since it does not comply with the regulations for the reason(s) indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- A substitute specification in compliance with 37 CFR 1.52, 1.121(b)(3), and 1.125, is required. The substitute specification must be submitted with markings and be accompanied by a clean version (without markings) as set forth in 37 CFR 1.125(c) and a statement that the substitute specification contains no new matter (see 37 CFR 1.125(b)). The specification, claims, and/or abstract page(s) submitted is not acceptable and cannot be scanned or properly stored because:
 - The application contains drawings, but the specification does not contain a brief description of the several views of the drawings as required by 37 CFR 1.74 and 37 CFR 1.77(b)(7).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

The applicant needs to satisfy supplemental fees problems indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

• Additional claim fees of \$156 as a non-small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.

page 1 of 2

• To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.16(f) of \$130 for a non-small entity, must be submitted with the missing items identified in this notice.

SUMMARY OF FEES DUE:

Total additional fee(s) required for this application is \$1376 for a non-small entity

- \$330 Statutory basic filing fee.
- \$130 Surcharge.
- The application search fee has not been paid. Applicant must submit \$540 to complete the search fee.
- The application examination fee has not been paid. Applicant must submit \$220 to complete the examination fee for a non-small entity.
- Total additional claim fee(s) for this application is \$156
 - \$156 for 3 total claims over 20.

Replies should be mailed to:

Mail Stop Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. <u>https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html</u>

For more information about EFS-Web please call the USPTO Electronic Business Center at **1-866-217-9197** or visit our website at <u>http://www.uspto.gov/ebc.</u>

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

/tnguyen/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

page 2 of 2

UNITED ST	ates Patent and Tradem	UNITED STAT United States Address: COMMIS P.O. Box I	, Virginia 22313-1450
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
12/285,887	10/15/2008	John R. Evans	056291-5004-02
			CONFIRMATION NO. 1199
9629		IMPROPER	R CPOA LETTER
MORGAN LEWIS & BOC 1111 PENNSYLVANIA AV WASHINGTON, DC 2000	VENUE NW		DC000000032935459*
- ,			Date Mailed: 11/04/2008

NOTICE REGARDING POWER OF ATTORNEY

This is in response to the Power of Attorney filed 10/15/2008. The Power of Attorney in this application is not accepted for the reason(s) listed below:

• The Power of Attorney you provided did not comply with the new Power of Attorney rules that became effective on June 25, 2004. See 37 CFR 1.32.

/tnguyen/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

page 1 of 1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:) Confirmation No. 1199
John R. EVANS <i>et al.</i>	
Application No.: 12/285,887) Group Art Unit: 1617
Filed: October 15, 2008) Prior Examiner: San-Ming R. Hui
FOR: FORMULATION) Date: June 4, 2009

SECOND PRELIMINARY AMENDMENT

Prior to calculation of the excess claims fee and examination on the merits, please amend the claims of the above-referenced application as follows:

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 6 of this paper.

IN THE CLAIMS:

This listing of claims will replace all prior versions and listing of claims in this application.

Listing of the claims:

Claim 1 (**original**): A pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 30% or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation which is capable after injection of attaining a therapeutically significant blood plasma fulvestrant concentration of at least 2.5ngml⁻¹ for at least 2 weeks.

Claim 2 (**original**): A pharmaceutical formulation as claimed in claim 1 wherein the blood plasma fulvestrant concentration is attained for at least 4 weeks.

Claim 3 (**original**): A pharmaceutical formulation as claimed in claim 1 wherein the blood plasma fulvestrant concentration is attained for 2 to 5 weeks.

Claim 4 (**original**): A pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 30% or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml⁻¹ of fulvestrant.

Claim 5 (**currently amended**): A pharmaceutical formulation as claimed in claim 1 or claim <u>4</u>-to-4 which contains 25% w/v or less of a pharmaceutically-acceptable alcohol.

Claim 6 (**original**): A pharmaceutical formulation as claimed in claim 5 which contains 20% w/v or less of a pharmaceutically-acceptable alcohol.

Claim 7 (**currently amended**): A pharmaceutical formulation as claimed in <u>claim 1 or claim</u> <u>4 any claim from 1 to 6</u> which contains 60% w/v or less of a pharmaceutically-acceptable nonaqueous ester solvent.

Claim 8 (**original**): A pharmaceutical formulation as claimed in claim 7 which contains 50%w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent .

Claim 9 (**original**): A pharmaceutical formulation as claimed in claim 7 which contains 45% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

Claim 10 (**original**): A pharmaceutical formulation as claimed in claim 7 which contains 40% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

Claim 11 (**original**): A pharmaceutical formulation as claimed in claim 7 which contains 35% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

Claim 12 (**original**): A pharmaceutical formulation as claimed in claim 7 which contains 30% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

Claim 13 (**original**): A pharmaceutical formulation as claimed in claim 7 which contains 25% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

Claim 14 (**currently amended**): A pharmaceutical formulation as claimed in <u>claim 1 or</u> <u>claim 4 any claim from 1 to 13</u> wherein the pharmaceutically-acceptable alcohol is a mixture of ethanol and benzyl alcohol.

Claim 15 (**currently amended**): A pharmaceutical formulation as claimed in <u>claim 1 or</u> <u>claim 4 any claim from 1 to 14</u> wherein the pharmaceutically-acceptable non-aqueous ester solvent

is selected from benzyl benzoate, ethyl oleate, isopropyl myristate, isopropyl palmitate or a mixture of any thereof.

Claim 16 (**currently amended**): A pharmaceutical formulation as claimed in <u>claim 1 or</u> <u>claim 4 any claim from 1 to 15</u> wherein the pharmaceutically-acceptable non-aqueous ester solvent is benzyl benzoate.

Claim 17 (**currently amended**): A pharmaceutical formulation as claimed in <u>claim 1 or</u> <u>claim 4 any claim from 1 to 16</u> wherein the total volume of the formulation is 6ml, or less, and the concentration of fulvestrant is at least 45mgml⁻¹.

Claim 18 (**currently amended**): A pharmaceutical formulation as claimed in <u>claim 1 or</u> <u>claim 4 any claim from 1 to 13</u> wherein the total amount of fulvestrant in the formulation is 250mg, or more, and the total volume of the formulation is 6ml, or less.

Claim 19 (**currently amended**): A pharmaceutical formulation as claimed in <u>claim 1 or</u> <u>claim 4-elaim 18</u> wherein the total amount of fulvestrant in the formulation is 250mg and the total volume of the formulation is 5 to 5.25ml.

Claim 20 (**currently amended**): A pharmaceutical formulation as claimed in <u>claim 1 or</u> <u>claim 4 any of claims 1-19</u> wherein the pharmaceutically-acceptable alcohol is a mixture of 10% weight of ethanol per volume of formulation, 10% weight of benzyl alcohol per volume of formulation and 15% weight of benzyl benzoate per volume of formulation and the ricinoleate vehicle is castor oil.

Claim 21 (**currently amended**): A method of treating a benign or malignant diseases of the breast or reproductive tract by administration to a human in need of such treatment by intramuscular a pharmaceutical formulation as claimed in <u>claim 1 or claim 4 elaims 1 to 19</u>.

Claim 22 (original): A method as claimed in claim 21 for treating breast cancer.

Claim 23 (**original**): A syringe or vial containing a pharmaceutical formulation as defined in claim 20.

Attorney Docket No.: **056291-5004-02** Application No. **12/285,887** Page 6

REMARKS

Claim Amendments

The claims have been amended to remove improper multiple dependencies.

These amendments have been made without waiver or prejudice to Applicants' right to prosecute any subject matter deleted thereby in one or more continuing applications. Following entry of these amendments, claims 1-23 remain pending in this application.

EXCEPT for issue fees payable under 37 C.F.R. § 1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully Submitted, Morgan Lewis & Bockius LLP

Date: June 4, 2009 Morgan Lewis & Bockius LLP Customer No. **09629** 1111 Pennsylvania Avenue, N.W. Washington, D.C. 20004 Tel. No.: 202-739-3000 DJB: /Donald Bird/

By:

Donald J. Bird Registration No. 25,323 Tel. No.: (202) 739-5320 Fax No.: (202) 739-3001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:) Confirmation No. 1199
John R. EVANS <i>et al.</i>	
Application No.: 12/285,887) Group Art Unit: 1617
Filed: October 15, 2008) Prior Examiner: San-Ming R. Hui
FOR: FORMULATION) Date: June 4, 2009

STATEMENT ACCOMPANYING SUBSTITUTE SPECIFICATION

In response to the Notice to File Missing Requirements, attached are a clean copy and a marked up copy of the substitute specification in which headings have been inserted. Both copies contain the amendments that are set forth in the Preliminary Amendment filed on October 15, 2008. The attached copies of the substitute specification do not include prohibited new matter. In particular, referring to the "marked up" copy:

- At page 1, the text under CROSS-REFERENCE TO RELATED APPLICATIONS was previously inserted by the Preliminary Amendment of October 15, 2008.
- At page 1, the deleted text under "Field of the Invention" has been copied to page 6 under SUMMARY OF THE INVENTION.
- At page 6, the text under SUMMARY OF THE INVENTION is copied from the original specification at page 1, lines 3-9.
- At page 6, the text under BRIEF DESCRIPTION OF THE DRAWING is copied from the original specification at page 15, lines 3-5.
- The claims in this substitute specification are as originally presented. However, the Examiner's attention is drawn to the accompanying Second Preliminary Amendment wherein the claims are amended to remove improper multiple dependencies.

If there are any additional fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 50-0310. If a fee is required for an extension of time

under 37 C.F.R. §1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

By:

Respectfully Submitted, Morgan Lewis & Bockius LLP

Date: June 4, 2009 Morgan Lewis & Bockius LLP Customer No. 09629 1111 Pennsylvania Avenue, N.W. Washington, D.C. 20004 Tel. No.: 202-739-3000 /Donald Bird/ Donald J. Bird Registration No.25,323 Tel. No.: (202) 739-5320 Fax No.: (202) 739-3001

FORMULATION

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a Continuation Application of copending U.S. Patent Application 5 No. 10/872,784, filed June 22, 2004, which claims benefit of U.S. Patent Application No. 09/756,291, filed January 9, 2001 which claims the benefit of Great Britain Application No. 0008837.7 filed April 12, 2000 and Great Britain Application No. 0000313.7, filed January 10, 2000, all of which are incorporated herein by reference in their entireties.

10 BACKGROUND OF THE INVENTION

Field of the Invention

The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound

 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol.

15

Description of the Related Art

Oestrogen deprivation is fundamental to the treatment of many benign and malignant diseases of the breast and reproductive tract. In premenopausal women, this is achieved by the ablation of ovarian function through surgical, radiotherapeutic, or medical means, and, in 20 postmenopausal women, by the use of aromatase inhibitors.

An alternative approach to oestrogen withdrawal is to antagonise oestrogens with antioestrogens. These are drugs that bind to and compete for oestrogen receptors (ER) present in the nuclei of oestrogen-responsive tissue. Conventional nonsteroidal antioestrogens, such as tamoxifen, compete efficiently for ER binding but their effectiveness is often limited by the

25 partial agonism they display, which results in an incomplete blockade of oestrogen-mediated activity (Furr and Jordan 1984, May and Westley 1987).

The potential for nonsteroidal antioestrogens to display agonistic properties prompted the search for novel compounds that would bind ER with high affinity without activating any of the normal transcriptional hormone responses and consequent manifestations of oestrogens.

30 Such molecules would be "pure" antioestrogens, clearly distinguished from tamoxifen-like ligands and capable of eliciting complete ablation of the trophic effects of oestrogens. Such compounds are referred to as Estrogen Receptor-Downregulators (E.R.D.). The rationale for

the design and testing of novel, pure antioestrogens has been described in: Bowler et al 1989, Wakeling 1990a, 1990b, 1990c. Wakeling and Bowler 1987, 1988.

Steroidal analogues of oestradiol, with an alkylsulphinyl side chain in the 7α position, provided the first examples of compounds devoid of oestrogenic activity (Bowler et al 1989).

- 5 One of these, 7α -[9-(4,4,5,5,5-pentafluoropentyl sulphinyl)nonyl]oestra-1,3,5-(10)triene-3,17 β -diol was selected for intensive study on the basis of its pure oestrogen antagonist activity and significantly increased antioestrogenic potency over other available antioestrogens. *In vitro* findings and early clinical experience with
- 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3-5(10)-triene-3,17β-diol have
 promoted interest in the development of the drug as a therapeutic agent for oestrogendependent indications such as breast cancer and certain benign gynaecological conditions.

7α-[9-(4,4,5,5,5-Pentafluoropentylsulphinyl)nonyl]oestra-1,3-5(10)-triene-3,17β-diol, or ICI 182,780, has been allocated the international non-proprietary name fulvestrant, which is used hereinafter. When referring to fulvestrant we include pharmaceutically-acceptable salts
15 thereof and any possible solvates of either thereof.

Fulvestrant binds to ER with an affinity similar to that of oestradiol and completely blocks the growth stimulatory action of oestradiol on human breast cancer cells *in vitro*; it is more potent and more effective than tamoxifen in this respect. Fulvestrant blocks completely the uterotrophic action of oestradiol in rats, mice and monkeys, and also blocks the uterotrophic activity of tamoxifen.

Because fulvestrant has none of the oestrogen-like stimulatory activity that is characteristic of clinically available antioestrogens such as tamoxifen or toremifene, it may offer improved therapeutic activity characterised by more rapid, complete, or longer-lasting tumour regression; a lower incidence or rate of development of resistance to treatment; and a 25 reduction of tumour invasiveness.

In intact adult rats, fulvestrant achieves maximum regression of the uterus at a dose which does not adversely affect bone density or lead to increased gonadotrophin secretion. If also true in humans, these findings could be of extreme importance clinically. Reduced bone density limits the duration of oestrogen-ablative treatment for endometriosis. Fulvestrant does

30 not block hypothalamic ER. Oestrogen ablation also causes or exacerbates hot flushes and other menopausal symptoms; fulvestrant will not cause such effects because it does not cross the blood-brain barrier.

MYLAN PHARMS. INC. EXHIBIT 1002 PAGE 47

- 2 -

European Patent Application No. 0 138 504 discloses that certain steroid derivatives are effective antioestrogenic agents. The disclosure includes information relating to the preparation of the steroid derivatives. In particular there is the disclosure within Example 35 of the compound 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-

5 1,3,5(10)-triene-3,17β-diol, which compound is specifically named in Claim 4. It is also disclosed that the compounds of that invention may be provided for use in the form of a pharmaceutical composition comprising a steroid derivative of the invention together with a pharmaceutically-acceptable diluent or carrier. It is stated therein that the composition can be in a form suitable for oral or parenteral administration.

10 Fulvestrant shows, along with other steroidal based compounds, certain physical properties which make formulation of these compounds difficult. Fulvestrant is a particularly lipophilic molecule, even when compared with other steroidal compounds, and its aqueous solubility is extremely low at around 10 ngml⁻¹ (this is an estimate from a water/solvent mixture solute since measurements this low could not be achieved in a water only solute).

- 15 Currently there are a number of sustained release injectable steroidal formulations which have been commercialised. Commonly these formulations use oil as a solvent and wherein additional excipients may be present. Below in Table 1 are described a few commercialised sustained release injectable formulations.
- In the formulations within Table 1 a number of different oils are used to solubilise the compound and additional excipients such as benzyl benzoate, benzyl alcohol and ethanol have been used. Volumes of oil needed to solubilise the steroid active ingredient are low. Extended release is achievable for periods from 1 to 8 weeks.

25

	lable I -	UIL BASEI	UIL BASED LUNG-ACTING IN I KAMUSCULAK IN JECTIONS	INI SNIT	KAMUSCI	JLAK IN	JECH				
PRODUCT NAME	<u>STEROID</u>	DOSE	TYPE	COMP'.	SOURCE	<u>OIT</u>	BzBz	BzOH	EtOH	DOSE	DOSING
SUSTANON 100	Testosterone proprionate Testosterone phenylproprionate Testosterone isocaproate Testosterone decanoate	30mg 60mg 60mg 100mg	Androgen	Organon	ABPI Data Sheet Comp.1999	Arachis		0.1ml		lml	3 weeks
PROLUTON DEPOT	Hydroxy progesterone hexanoate	250mgml ⁻¹	Progestogen	Schering HC	ABPI Data Sheet Comp.1999	Castor	up to 46%			1 or 2ml	1 week
TOCOGESTAN	Hydroxy progesterone enantate Progesterone α-Tocopherol	200mg 50mg 250mg	Progestogen	Theramax	Dict. Vidal 1999	Ethyl oleate	*40%			2ml	< 1 week
TROPHOBOLENE	Estrapronicate Nandrolone undecanoate Hydroxyprogesterone heptanoate	1.3mg 50mg 80mg	Mixed	Theramax	Dict. Vidal 1997	Olive	45%			lml	15 to 30 days
NORISTERAT	Norethisterone oenanthoate	200mg	Contraceptive	Schering HC	ABPI Data Sheet Comp.1999	Castor	YES			lml	8 weeks
BENZO- GYNOESTRYL	Estradiol hexahvdrobenzoate	5mg	Estradiol	Roussel	Dict. Vidal 1998	Arachis				lml	1 week
PROGESTERONE -RETARD	Hydroxy progesterone caproate	250mgml ⁻¹	Progestogen	Pharlon	Dict. Vidal 1999	Castor	YES			1 or 2ml	1 week
GRAVIBINAN	Estradiol 17-β-valerate Hydroxyprogesterone caproate	5mgml ⁻¹ 250mgml ⁻¹	Mixed	Schering HC	Dict. Vidal 1995	Castor	YES			1 or 2ml	1 - 2 weeks

Table 1 - OIL BASED LONG-ACTING INTRAMUSCULAR INJECTIONS

Z70635

5
3
2
2

2 weeks		
1.5ml		
45mg	2% 2%	up to 2%
75mg	20% 40%	YES
	78% 58%	YES
Arachis	Castor	Castor
Dict. Vidal 1997	J.Pharm. Sci (1964)	53(8) 891 J.Pharm. Sci.(1964) 53(8) 891
Negma	BMS	DMS
Androgen	Estradiol	Progestrogen
76mg	20mgml ⁻¹ 40mgml ⁻¹	250mgml ⁻¹
Trenbolone	Estradiol valerate	17-Hydroxy progesterone
PARABOLAN	DELESTROGEN	DELALUTIN

BzBz = benzylbenzoateBzOH = benzylalcoholEtOH = ethanolDict. Vidal = Dictionnaire Vidal5 % are w/v and * approximate as measured directly from a single sample

described which comprises 50mg of fulvestrant, 400mg of benzyl alcohol and sufficient castor oil to bring the solution to a volume of 1 ml. Manufacture at a commercial scale of a formulation as described in US 5,183,814 will be complicated by the high alcohol concentration. Therefore, there is a need to lower the alcohol concentration in fulvestrant

5 formulations whilst preventing precipitation of fulvestrant from the formulation.

SUMMARY OF THE INVENTION

The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound

10 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol, more particularly to a formulation adapted for administration by injection containing the compound 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a nonaqueous ester solvent which is miscible in the ricinoleate vehicle.

15

BRIEF DESCRIPTION OF THE DRAWING

Figure 1 shows the release profile *in vivo* of the four formulations from the second part of Table 4 below, and shows the effect of the fixed oil component on fulvestrant plasma profile over five days following intramuscular administration in rabbits.

20

DETAILED DESCRIPTION OF THE INVENTION

Table 2 shows the solubility of fulvestrant in a number of different solvents.

Table 2 - SOLUBILITY OF FULVESTRANT

2	5
4	J

SOLVENT	SOLUBILITY
	(mgml ⁻¹ at 25°C)
Water	0.001
Arachis oil	0.45
Sesame oil	0.58
Castor oil	20
Miglyol 810	3.06

MYLAN PHARMS. INC. EXHIBIT 1002 PAGE 51

- 6 -

- 7 -

Miglyol 812	2.72
Ethyl oleate	1.25
Benzyl benzoate	6.15
Isopropyl myristate	0.80
Span 85 (surfactant)	3.79
Ethanol	>200
Benzyl Alcohol	>200

As can be seen fulvestrant is significantly more soluble in castor oil than any of the other oils tested. The greater solvating ability of castor oil for steroidal compounds is known and is attributed to the high number of hydroxy groups of ricinoleic acid, which is the major

5 constituent of the fatty acids within the triglycerides present in castor oil - see (Riffkin et.al. J. Pharm. Sci., (1964), 53, 891).

However, even when using the best oil based solvent, castor oil, we have found that it is not possible to dissolve fulvestrant in an oil based solvent alone so as to achieve a high enough concentration to dose a patient in a low volume injection and achieve a therapeutically

10 significant release rate. To achieve a therapeutically significant release rate the amount of fulvestrant needed would require the formulation volume to be large, at least 10 ml. This requires the doctor to inject an excessively large volume of formulation to administer a dose significantly high enough for human therapy.

Currently guidelines recommend that no more than 5mls of liquid is injected intramuscularly in a single injection. Pharmacologically active doses required for a 1 month long acting depot formulation of fulvestrant is around 250mg. Therefore, when dissolved in just castor oil, fulvestrant would need to be administered in at least 10ml of castor oil.

The addition of organic solvents in which fulvestrant is freely soluble, and which are miscible with castor oil, may be used, such as an alcohol. With the addition of high

concentrations of an alcohol concentrations of >50mgml⁻¹ of fulvestrant in a castor oil formulation is achievable, thereby giving an injection volumes of <5ml - see Table 3 below. We have surprisingly found that the introduction of a non-aqueous ester solvent which is miscible in the castor oil and an alcohol surprisingly eases the solubilisation of fulvestrant into a concentration of at least 50 mgml⁻¹ - see Table 3 below. The finding is surprising since the

25 solubility of fulvestrant in non-aqueous ester solvents - see Table 2 above - is significantly

lower than the solubility of fulvestrant in an alcohol. The solubility of fulvestrant is also lower in non-aqueous ester solvents than is the solubility of fulvestrant in castor oil.

Therefore, we present as a feature of the invention a pharmaceutical formulation comprising fulvestrant (preferably fulvestrant is present at 3-10%w/v, 4-9%w/v, 4-8%w/v,

5 4-7%w/v, 4-6%w/v and most preferably at about 5%w/v) in a ricinoleate vehicle, a pharmaceutically acceptable non-aqueous ester solvent, and a pharmaceutically acceptable alcohol wherein the formulation is adapted for intramuscular administration and attaining a therapeutically significant blood plasma fulvestrant concentration for at least 2 weeks.

Another feature of the invention is a pharmaceutical formulation comprising 10 fulvestrant in which the formulation is adapted for intra-muscular injection into a human and which is capable after injection of attaining a therapeutically significant blood plasma fulvestrant concentration for at least 2 weeks.

Further features of the invention include a pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 30% or less weight of a pharmaceutically-

- 15 acceptable alcohol per volume of formulation, at least 1% weight of a pharmaceuticallyacceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation which is capable after injection of attaining a therapeutically significant blood plasma fulvestrant concentration for at least 2 weeks.
- Further features of the invention include a pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant; 35% (preferably 30% and ideally 25%) or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% (preferably at least 5% or ideally 10%) weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible within a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml⁻¹ of

fulvestrant.

For the avoidance of any doubt when using the term % weight per volume of formulation for the constituents of the formulation we mean that within a unit volume of the formulation a certain percentage of the constituent by weight will be present, for example a

30 1% weight per volume formulation will contain within a 100ml volume of formulation 1g of the constituent. By way of further illustration

MYLAN PHARMS. INC. EXHIBIT 1002 PAGE 53

- 8 -

% of x by weight per volume of formulation	weight of x in 1ml of formulation
30%	300mg
20%	200mg
10%	100mg
5%	50mg
1%	10mg

Preferred pharmaceutical formulations of the invention are as described above 5 wherein:

1. The total volume of the formulation is 6ml, or less, and the concentration of fulvestrant is at least 45mgml⁻¹.

2. The total amount of fulvestrant in the formulation is 250mg, or more, and the total volume of the formulation is 6ml, or less.

10 3. The total amount of fulvestrant in the formulation is 250mg and the total volume of the formulation is 5-5.25ml.

It is appreciated that in the formulation an excess of formulation may be included to allow the attendant physician or care giver to be able to deliver the required dose. Therefore, when a 5ml dose is required it would be appreciated that an excess of up to 0.25ml, preferably

15 up to 0.15ml will also be present in the formulation. Typically the formulation will be presented in a vial or a prefilled syringe, preferably a prefilled syringe, containing a unit dosage of the formulation as described herein, these being further features of the invention.

Preferred concentrations of a pharmaceutically-acceptable alcohol present in any of the above formulations are; at least 3%w/v, at least 5%w/v, at least 7%w/v, at least 10% w/v, at

- 20 least 11% w/v, at least 12% w/v, at least 13% w/v, at least 14% w/v, at least 15% w/v and, preferably, at least 16% w/v. Preferred maximal concentrations of pharmaceutically-acceptable alcohol present in the formulation are ;28% w/v or less, 22% w/v or less and 20% w/v or less.. Preferred ranges of pharmaceutically-acceptable alcohol present in any of the above formulations are selected from any minimum or maximum value described above and
- 25 preferably are; 3-35%w/v, 4-35%w/v, 5-35%w/v, 5-32%w/v, 7-32%w/v, 10-30%w/v, 12-28%w/v, 15-25%w/v, 17-23%w/v, 18-22%w/v and ideally 19-21%w/v.

The pharmaceutically-acceptable alcohol may consist of one alcohol or a mixture of two or more alcohols, preferably a mixture of two alcohols. Preferred pharmaceuticallyacceptable alcohols for parenteral administration are ethanol, benzyl alcohol or a mixture of both ethanol and benzyl alcohol, preferably the ethanol and benzyl alcohol are present in the

5 formulation in the same w/v amounts. Preferably the formulation alcohol contains 10% w/v ethanol and 10% w/v benzyl alcohol.

The pharmaceutically-acceptable non-aqueous ester solvent may consist of one or a mixture of two or more pharmaceutically-acceptable non-aqueous ester solvents, preferably just one. A preferred pharmaceutically-acceptable non-aqueous ester solvent for parenteral administration is selected from benzyl benzoate, ethyl oleate, isopropyl myristate, isopropyl palmitate or a mixture of any thereof.

The ricinoleate vehicle should preferably be present in the formulation in a proportion of at least 30% weight per volume of the formulation, ideally at least 40% or at least 50% weight per volume of formulation.

It will be understood by the skilled person that the pharmaceutically-acceptable alcohol will be of a quality such that it will meet pharmacopoeial standards (such as are described in the US, British, European and Japanese pharmacopoeias) and as such will contain some water and possibly other organic solvents, for example ethanol in the US Pharmacopeia contains not less than 94.9% by volume and not more than 96.0% by volume of ethanol when measured at 15.56°C. Dehydrated alcohol in the US Pharmacopeia contains not less than

99.5% ethanol by volume when measured at 15.56°C.

Preferred concentrations of the pharmaceutically-acceptable non-aqueous ester solvent present in any of the above formulations are; at least 5% w/v, at least 8% w/v, at least 10% w/v, at least 11% w/v, at least 12% w/v, at least 13% w/v, at least 15% w/v, at least 16% w/v,

at least 17% w/v, at least 18% w/v, at least 19% w/v and at least 20% w/v. Preferred maximal concentrations of the pharmaceutically-acceptable non-aqueous ester solvent are; 60% w/v or less, 50% w/v or less, 45% w/v or less, 40% w/v or less, 35% w/v or less, 30% w/v or less and 25% w/v or less. A preferred concentration is 15% w/v. Preferred ranges of pharmaceutically-acceptable non-aqueous ester solvent present in any of the above formulations are selected

30 from any minimum or maximum value described above and preferably are; 5-60%w/v, 7-55%w/v, 8-50%w/v, 10-50%w/v, 10-45%w/v, 10-40%w/v, 10-35%w/v, 10-30%w/v, 10-

25%w/v, 12-25%w/v, 12-22%w/v, 12-20%w/v, 12-18%w/v, 13-17%w/v and ideally 14-

16%w/v. Preferably the ester solvent is benzyl benzoate, most preferably at about 15%w/v.

It will be understood by the skilled person that the pharmaceutically-acceptable nonaqueous ester solvent will be of a quality that it will meet pharmacopoeial standards (such as 5 described in the US, British, European and Japanese pharmacopoeias).

Preferred combinations of pharmaceutically-acceptable alcohol and pharmaceuticallyacceptable non-aqueous ester solvent in the formulation are set out below:

Pharmaceutically-acceptable	Pharmaceutically-acceptable non-aqueous
alcohol(%w/v)	ester (%w/v)
10-30	5-60, 7-55, 8-50, 10-50, 10-45, 10-40, 10-35, 10-
	30, 10-25, 12-25, 12-22, 12-20, 12-18, 13-17 and
	ideally 14-16.
17-23	5-60, 7-55, 8-50, 10-50, 10-45, 10-40, 10-35, 10-
	30, 10-25, 12-25, 12-22, 12-20, 12-18, 13-17 and
	ideally 14-16.
3-35, 4-35, 5-35, 5-32, 7-32, 10-30, 12-	10-35
28, 15-25, 17-23, 18-22 and ideally 19-	
3-35, 4-35, 5-35, 5-32, 7-32, 10-30, 12-	12-18
28, 15-25, 17-23, 18-22 and ideally 19-	
21.	
ethanol and benzyl alcohol, most	benzyl benzoate, most preferably at about 15%
preferably each at about 10%	

By the use of the term ricinoleate vehicle we mean an oil which has as a proportion (at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% w/v) of its composition as triglycerides of ricinoleic acid. The ricinoleate vehicle may be a synthetic oil or conveniently is castor oil, ideally of pharmacopoeial standards, as described above.

We have surprisingly found that the above formulations of the invention provide, after 15 intra-muscular injection, satisfactory release of fulvestrant over an extended period of time. This finding is indeed surprising for the following reasons.

Z70635

1. Previously tested by the applicants have been intra-muscular injections of fulvestrant in the form of an aqueous suspension. We have found extensive local tissue irritation at the injection site as well as a poor release profile. It is believed that the tissue irritation/inflammation was due to the presence of fulvestrant in the form of solid particles.

⁵ The release profile appeared to be determined by the extent of inflammation/irritation present at the injection site and this was variable and difficult to control. Also the fulvestrant release rate was not sufficiently high to be clinically significant.

Our findings from studies using ¹⁴C labelled benzyl alcohol show that it dissipates rapidly from the injection site and is removed from the body within 24 hours of
 administration.

It would be expected that ethanol will dissipate at least as quickly, if not more rapidly, from the injection site.

It is known that benzyl benzoate is metabolised by conjugation to glycine to form hippuric acid by the human liver and excreted into the urine - Martindale: The Extra 15 Pharmacopoeia 32nd edition page 1103, and, therefore, it is unlikely that benzyl benzoate,

We have found that despite the rapid elimination of the additional solubilising excipients, i.e. the alcohol and pharmaceutically-acceptable non-aqueous ester solvent, from the formulation vehicle and the site of injection after injection of the formulation, extended

when used, is present at the injection site during the whole of the extended release period.

20 release at therapeutically significant levels of fulvestrant over an extended period can still achieved by the formulation of the invention.

By use of the term "therapeutically significant levels" we mean that blood plasma concentrations of at least 2.5 ngml⁻¹, ideally at least 3 ngml⁻¹, at least 8.5 ngml⁻¹, and up to 12 ngml⁻¹ of fulvestrant are achieved in the patient. Preferably blood plasma levels should be less 25 than 15 ngml⁻¹.

By use of the term "extended release" we mean at least two weeks, at least three weeks, and, preferably at least four weeks of continuous release of fulvestrant is achieved. In a preferred feature extended release is achieved for 36 days. Preferably extended release of fulvestrant is for at least 2- 5 weeks and more preferably for the following periods (weeks)
2.5-5, 2.5-4, 3-4, 3.5-4 and most preferably for at least about 4 weeks.

MYLAN PHARMS. INC. EXHIBIT 1002 PAGE 57

- 12 -

It will be understood that the attendant physician may wish to administer the intramuscular injection as a divided dose, i.e. a 5ml formulation is sequentially administered in two separate injections of 2.5ml, this is a further feature of the invention

Simply solubilising fulvestrant in an oil based liquid formulation is not predictive of a 5 good release profile or lack of precipitation of drug after injection at the injection site.

Table 3 shows the solubility of fulvestrant in a castor oil vehicle additionally containing alcohols ethanol and benzyl alcohol with or without benzyl benzoate. The results clearly show the positive effect of benzyl benzoate on fulvestrant solubility in castor oil, despite fulvestrant having a lower solubility in benzyl benzoate than in either alcohol or castor 10 oil.

Z70635

- 14 -

<u>Table 3</u>

Table 3 - EFFECT OF BENZYL BENZOATE ON FULVESTRANT SOLUBILITY IN CASTOR OIL AT 25⁰C

Ethanol (96%) Benzyl	vo vo	vy vy	5 10	% w/v 10 5	10	10 10	15 15	15 15
Alcohol								
Benzyl		15		15		15		15
Benzoate								
Castor Oil	to 100	to100	to 100	to 100	to 100	to 100	to 100	to 100
Fulvestrant	27	36	46	54	45	65	76	102
Solubility								
[mgml ⁻¹]								

Ś

The following Table 4 shows the solubility of fulvestrant in a range of oil based formulations which contain the same amounts of alcohol and benzyl benzoate but in which the oil is changed. The data also shows solubility of fulvestrant after removal of the alcohols.

Table 4

5	Solubility comparisons of fulvestrant in oil based formulations with and without
	alcohols

10	Fulvestrant Solubility mg ml ⁻¹ @ 25°C						
10	Formulation ^(a)	Complete vehicle	Vehicle minus alcohols				
	Castor oil based	81.2	12.6				
15	Miglyol 812-N based	86.8	1.7				
	Sesame seed/Castor oil (1:1) based	70.1	4.4				
20	Sesame seed oil based	45.7	0.7				
20	Arachis oil based	40.2	< 0.2				

(a) Complete Vehicle Formulations comprised ethanol [96%](10%), benzyl alcohol (10%) and benzyl benzoate 25 (15%) made to volume with the stated oil. Excess fulvestrant was added to each solvent mixture and solubility determined.

30					Days			
	Formulation ^a	2	3	4	7	10	30	51
35	Formulation F1 castor oil based	0	0	0	0	0	0	0
	Formulation F2 Miglyol 812-N based	++ ^b	+++	+++	+++	+++	++	0
40	Formulation F3 sesame seed oil/castor oil based	+ ^c	++	++	+++	++	+	+

Effect of formulation on precipitation of fulvestrant at the injection site

 $\overline{0, +, ++, +++}$ = Degree of precipitation (None detected, Mild, Moderate, Severe)

45 ^a Formulations comprised fulvestrant (5%), ethanol [96%] (10%), benzyl alcohol (10%) and benzyl benzoate (15%) made to volume with the stated oil. ^b Mainly large needle shaped crystals

^c Small needles and/or sheafs of crystals

Precipitation of fulvestrant and the release profile was determined with the above formulations in an *in vivo* rabbit study.

Figure 1 shows the release profile *in vivo* of the four formulations from the second part of Table 4 and shows the effect of the fixed oil component on fulvestrant plasma profile over

- 5 five days following intramuscular administration in rabbits (data normalised to 50mg per 3kg; mean given; number of animals per timepoint = 8, plasma samples assayed for fulvestrant content using lc-ms/ms detection following solvent extraction). As can be seen the castor oil formulation showed a particularly even release profile with no evidence of precipitation of fulvestrant at the injection site.
- 10 Therefore we present as a further feature of the invention an extended release pharmaceutical formulation adapted for intramuscular injection comprising fulvestrant; 35% (preferably 30% or ideally 25%) or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% (preferably at least 5% or ideally 10%) weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per
- 15 volume of formulation and sufficient amount of a ricinoleate vehicle, taking into account the addition of any further optional pharmaceutically-acceptable excipients, so as to prepare a formulation of at least 45mgml⁻¹ of fulvestrant.

A further feature of the invention is a pharmaceutical formulation adapted for intramuscular injection, as defined above, for use in medical therapy.

- A further feature of the invention is a method of treating a benign or malignant diseases of the breast or reproductive tract, preferably treating breast cancer, by administration to a human in need of such treatment by intramuscular injection an extended release ricinoleate vehicle based pharmaceutical formulation comprising at least 45mgml⁻¹ of fulvestrant; 35% (preferably 30% or ideally 25%) or less weight of a pharmaceutically-
- 25 acceptable alcohol per volume of formulation, at least 1% (preferably at least 5% or ideally 10%) weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation.

Preferably 5ml of the intramuscular injection is administered.

A further feature of the invention is use of fulvestrant in the preparation of a 30 pharmaceutical formulation as describe hereinabove, for the treatment of a benign or malignant disease of the breast or reproductive tract, preferably treating breast cancer.

Additional excipients commonly used in the formulation field including, for example, an antioxidant preservative, a colorant or a surfactant may be used. A preferred optional excipient is a surfactant.

As described above fulvestrant is useful in the treatment of oestrogen-dependent 5 indications such as breast cancer and gynaecological conditions, such as endometriosis.

In addition to fulvestrant another similar type of molecule is currently under clinical investigation. SH-646 (11 β -fluoro- 7 α -(14,14,15,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl)estra-1,3,5(10)-triene-3,17 β -diol) is also putatively a compound with the same mode of action as fulvestrant and has a very similar chemical

10 structure. It is believed that the compound will also share with fulvestrant similar physical properties and therefore the current invention will also have application with this compound.

A further feature of the invention is a pharmaceutical formulation adapted for intra-muscular injection comprising 11 β -fluoro- 7 α -(14,14,15,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl)estra-1,3,5(10)-triene-3,17 β -diol; 35% or less weight of a

- 15 pharmaceutically-acceptable alcohol per volume of formulation, at least 1% weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible within a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml⁻¹ of 11β-fluoro- 7α -(14,14,15,15,15-pentafluoro-6methyl-10-thia-6-azapentadecyl)estra-1,3,5(10)-triene-3,17β-diol.
- 20 Further features of the invention are those as described above but in which SH-646 is substituted for fulvestrant.

Formulation Example

- 25 Fulvestrant is mixed with alcohol and benzyl alcohol, stirring until completely dissolved. Benzyl benzoate is added and the solution is made to final weight with castor oil and stirred, (for convenience weight is used rather than volume by using the weight to volume ratio). The bulk solution is overlaid with Nitrogen. The solution is sterilised by filtration using one or two filters of 0.2µm porosity. The sterile filtrate is kept under a nitrogen overlay
- 30 as it is filled under aseptic conditions into washed and depyrogenised, sterile primary containers, for example vials or pre-filled syringes. An overage is included in the primary

pack to facilitate removal of the dose volume. The primary packs are overlaid with sterile nitrogen, before aseptically sealing.


See also process flow diagram below

5

Quantities of each component of the formulation is chosen according to the required formulation specification, examples are described above. For example quantities are added of each component to prepare a formulation which contains 10% weight per volume of benzyl alcohol

10 10% weight per volume of ethanol
15% weight per volume of benzyl benzoate
250mg of fulvestrant for each 5ml of finished formulation
and the remaining amount as castor oil

FLOW DIAGRAM OF MANUFACTURING



References

1. Bowler J, Lilley TJ, Pittam JD, Wakeling AE. Novel steroidal pure antioestrogens. Steroids 989; 5471-99.

5 2. Wakeling AE. Novel pure antioestrogens: mode of action and therapeutic prospects. American New York Academy Science 1990a; 595: 348-56.

3. Wakeling AE. Steroidal pure antioestrogens. In Lippman M, Dickson R, editors. Regulatory mechanisms in breast cancer. Boston: Kluwer Academic, 1990b: 239-57.

10

4. Wakeling AE. Therapeutic potential of pure antioestrogens in the treatment of breast cancer. Journal Steroid Biochemistry 1990c; 37: 771-5.

5. Wakeling AE, Bowler J. Steroidal pure antioestrogens. Journal Endocrinology 1987; 112:15 R7-10.

6. Wakeling AE, Bowler J. Biology and mode of action of pure antioestrogens. Journal Steroid Biochemistry 1988; 3: 141-7.

Claims

1. A pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 30% or less weight of a pharmaceutically-acceptable alcohol per volume of

- ⁵ formulation, at least 1% weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation which is capable after injection of attaining a therapeutically significant blood plasma fulvestrant concentration of at least 2.5ngml⁻¹ for at least 2 weeks.
- 10 2. A pharmaceutical formulation as claimed in claim 1 wherein the blood plasma fulvestrant concentration is attained for at least 4 weeks.
 - 3. A pharmaceutical formulation as claimed in claim 1 wherein the blood plasma fulvestrant concentration is attained for 2 to 5 weeks.
- 15 4. A pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 30% or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml⁻¹ of fulvestrant.

20

5. A pharmaceutical formulation as claimed in claim 1 to 4 which contains 25% w/v or less of a pharmaceutically-acceptable alcohol.

A pharmaceutical formulation as claimed in claim 5 which contains 20% w/v or less of
 a pharmaceutically-acceptable alcohol.

7. A pharmaceutical formulation as claimed in any claim from 1 to 6 which contains 60% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

30 8. A pharmaceutical formulation as claimed in claim 7 which contains 50%w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent .

9. A pharmaceutical formulation as claimed in claim 7 which contains 45% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

5 10. A pharmaceutical formulation as claimed in claim 7 which contains 40% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

11. A pharmaceutical formulation as claimed in claim 7 which contains 35% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

10

12. A pharmaceutical formulation as claimed in claim 7 which contains 30% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

13. A pharmaceutical formulation as claimed in claim 7 which contains 25% w/v or less
15 of a pharmaceutically-acceptable non-aqueous ester solvent.

14. A pharmaceutical formulation as claimed in any claim from 1 to 13 wherein the pharmaceutically-acceptable alcohol is a mixture of ethanol and benzyl alcohol.

20 15. A pharmaceutical formulation as claimed in any claim from 1 to 14 wherein the pharmaceutically-acceptable non-aqueous ester solvent is selected from benzyl benzoate, ethyl oleate, isopropyl myristate, isopropyl palmitate or a mixture of any thereof.

16. A pharmaceutical formulation as claimed in any claim from 1 to 15 wherein the25 pharmaceutically-acceptable non-aqueous ester solvent is benzyl benzoate.

17. A pharmaceutical formulation as claimed in any claim from 1 to 16 wherein the total volume of the formulation is 6ml, or less, and the concentration of fulvestrant is at least 45mgml⁻¹.

30

18. A pharmaceutical formulation as claimed in any claim from 1 to 13 wherein the total amount of fulvestrant in the formulation is 250mg, or more, and the total volume of the formulation is 6ml, or less.

5 19. A pharmaceutical formulation as claimed in claim 18 wherein the total amount of fulvestrant in the formulation is 250mg and the total volume of the formulation is 5 to 5.25ml.

20. A pharmaceutical formulation as claimed in any of claims 1-19 wherein the pharmaceutically-acceptable alcohol is a mixture of 10% weight of ethanol per volume of

10 formulation, 10% weight of benzyl alcohol per volume of formulation and 15% weight of benzyl benzoate per volume of formulation and the ricinoleate vehicle is castor oil.

21. A method of treating a benign or malignant diseases of the breast or reproductive tract by administration to a human in need of such treatment by intramuscular a pharmaceutical
15 formulation as claimed in claims 1 to 19.

22. A method as claimed in claim 21 for treating breast cancer.

23. A syringe or vial containing a pharmaceutical formulation as defined in claim 20.

ABSTRACT OF THE DISCLOSURE

The invention relates to a novel sustained release pharmaceutical formulation adapted 5 for administration by injection containing the compound

- 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol, more particularly to a formulation adapted for administration by injection containing the compound 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-
- 10 aqueous ester solvent which is miscible in the ricinoleate vehicle.




Figure 1

Electronic Patent Application Fee Transmittal						
Application Number:	12	285887				
Filing Date:	15-	-Oct-2008				
Title of Invention:	Formulation					
First Named Inventor/Applicant Name:	Joł	John R. Evans				
Filer:	Do	Donald J. Bird				
Attorney Docket Number:	050	056291-5004-02				
Filed as Large Entity						
Utility under 35 USC 111(a) Filing Fees						
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)	
Basic Filing:						
Utility application filing		1011	1	330	330	
Utility Search Fee		1111	1	540	540	
Utility Examination Fee		1311	1	220	220	
Pages:						
Claims:						
Claims in excess of 20		1202	22	52	1144	
Independent claims in excess of 3		1201	2	220	440	
Multiple dependent claims		1203	1	390	390	

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)				
Miscellaneous-Filing:								
Late filing fee for oath or declaration	1051	1	130	130				
Petition:								
Patent-Appeals-and-Interference:								
Post-Allowance-and-Post-Issuance:								
Extension-of-Time:								
Extension - 5 months with \$0 paid	1255	1	2350	2350				
Miscellaneous:								
	Total in USD (\$)			5544				

Electronic Acknowledgement Receipt					
EFS ID:	5447464				
Application Number:	12285887				
International Application Number:					
Confirmation Number:	1199				
Title of Invention:	Formulation				
First Named Inventor/Applicant Name:	John R. Evans				
Customer Number:	09629				
Filer:	Donald J. Bird				
Filer Authorized By:					
Attorney Docket Number:	056291-5004-02				
Receipt Date:	04-JUN-2009				
Filing Date:	15-OCT-2008				
Time Stamp:	14:01:06				
Application Type:	Utility under 35 USC 111(a)				

Payment information:

Submitted with Payment	yes				
Payment Type	Deposit Account				
Payment was successfully received in RAM	\$5544				
RAM confirmation Number	215				
Deposit Account	500310				
Authorized User					
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:					
Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)					
Charge any Additional Fees required under 37 C.F.F	8. Section 1.17 (Patent application and reexamination processing fees)				

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Transmittal Letter	056291-5004-02-IDS-First.pdf	81302	no	2
·		030231 3004 02 123 1 13t.pdf	eade4c534e276bda9fa6f9e5b4e8332d914 2e0aa	110	2
Warnings:					
Information:					
2	Information Disclosure Statement (IDS)	056291-5004-02-1449-First.pdf	116751	no	3
	Filed (SB/08)	e6838			
Warnings:					
Information:					
This is not an US	5PTO supplied IDS fillable form				
3	Foreign Reference			no	30
-			17eb0e2105e6de09d3b59735d456b173d1 5d799f		
Warnings:					
Information:					
4	NPL Documents	PharmaceuticalDosageForms.	321460	no	5
		pdf	39ff9c71d0af795f5437c1a25f3481319563e 66f		
Warnings:					
Information:					
5 Transmittal Letter		056291-5004-02-IDS-Second.	81796	no	2
		pdf	fd36687d33e20f7fd5ff580e7099a596bc134 16e		
Warnings:					
Information:					
6	Information Disclosure Statement (IDS)	IDSonControlledConfidentialN	792753	no	19
	Filed (SB/08)	onCommercialTesting.pdf	cb3373ff7c2ce4bc041ffd0dad5f368f09c2c5 90		
Warnings:					
Information:					
This is not an US	5PTO supplied IDS fillable form				
7	Transmittal Letter	056291-5004-02-IDS-Third.pdf	82365	no	2
			d9be9d39c492d49ab6b6d49daa15f9c47d9 49b80		2
Warnings:					
Information:					
			113011		
8	Information Disclosure Statement (IDS) Filed (SB/08) 056291-5004-02-1449-Third.pdf				1

Claims 2 5	Information:					
9 Foreign Reference Attachment 1_EP125013881. pdf indication (Construction to the description of the descript	This is not an US	PTO supplied IDS fillable form				
Information: 10 Foreign Reference Attachment, 2, EP1250138B1- Opposition, pdf 13564969 no 10 Foreign Reference Attachment, 2, EP1250138B1- Opposition, pdf 13564969 no 11 Foreign Reference Attachment, 2, EP3260248B1- Opposition, pdf 302425 no 11 Foreign Reference Attachment, 2, EP3260402- pdf 302425 no 11 Foreign Reference Attachment, 2, EP3260402- PreliminaryAmendment, pdf 93701 yes 12 055291-5004-02- PreliminaryAmendment, pdf 93701 yes yes 12 Obscarige to prescription/PDF files in .zip description Start Er 13 Applicant Arguments/Remarks Made in an Amendment 6 0 13 Applicant Response to Pre-Exam Formalities Notice 255291-5004-02- StatementAccompanying- SubstituteSpecification, pdf 2562979 no 14 055291-5004-02- SubstituteSpecification, pdf 109710 yes 2565291-5004-02- StatementAccompanying- SubstituteSpecification, pdf 100 109710 yes	9	Foreign Reference		1033234	no	22
Information: Third-IDS- Attachment, 2, EP125013B1- Opposition,pdf 13564969 no 10 Foreign Reference Attachment, 2, EP125013B1- Opposition,pdf 13564969 no Warnings: Information: 11 Foreign Reference Attachment, 3, EPS earch Report pdf 302425 no Mutipart Poscar Colspan="2">Colspan="2"Colspan			pdf			
10 Foreign Reference Third-IDS: Attachment_2_EP1250138B1- Opposition.pdf 11564969 no Warnings: Information: 11 Foreign Reference Third-IDS: Attachment_3_EPSearChReport .pdf 302425 no Warnings: Information: 12 PreliminaryAmendment.pdf 9701 yes Multipart Description/PDF files in .zip description Document Description/PDF files in .zip description Qarnings: Information: Colspan="2">Qarnings: Information: 12 056291-5004-02- PreliminaryAmendment.pdf 9701 yes Qarnings: Information: Qarnings: Information: 11 Occument Description/PDF files in .zip description Qarnings: Information: 13 Applicant Arguments/Remarks Made in an Amendment Formalities Notice 056291-5004-02- StatementAccompanying- SubstituteSpecification.pdf 92679 2072 no 11 11 Applicant Response to Pre-Exam Formalities Notice 056291-5004-02- StatementAccompanying- SubstituteSpecification.pdf 92679 2072 no 11 Applicant Response to Pre-Exam Formalities Notice 056291-5004-02- StatementAccompanying- SubstituteSpecification.pdf	Warnings:					
10 Foreign Reference Attachment_2_EP125013881- Opposition.pdf Ino Warnings: 11 Foreign Reference Attachment_3_EPSeerChReport .pdf 302425 .002425 no 11 Foreign Reference Attachment_3_EPSeerChReport .pdf 302425 .002425 no Warnings: 12 055291-5004-02- PreliminaryAmendment.pdf 93701 .0056291-5004-02- PreliminaryAmendment.pdf yes Multipart Description/PDF files in .zip description Concertification .zip description Claims Start Claims Information: Claims Start Opticant Arguments/Remarks Made in an Amendment 10 Applicant Arguments/Remarks Made in an Amendment 6 Claims 10 Applicant Response to Pre-Exam Formalities Notice StatementAccompanying- StatementAccompanying- SubstituteSpecification.pdf 92679 .20040000000000000000000000000000000000	Information:					
Warnings: Information: 11 Foreign Reference Attachment_3_EPSearch Report 302425 no 11 Foreign Reference Attachment_3_EPSearch Report 302425 no 12 Information: 93701 yes 12 PreliminaryAmendment.pdf 93701 yes 12 Multipart Description/PDF files in .zip description yes Information: Information: Information: Information: 12 Osciption/PDF files in .zip description yes Information: Information: Information: Information: Information: Information: Informatides informatides information: Information:	10	Foreign Reference	Attachment_2_EP1250138B1-	nt_2_EP1250138B1- position.pdf 40565840d23255482e222a3baf07ab64d13		323
Information: 11 Foreign Reference Attachment_3_EPSearchReport_apdf 302425 no Warnings:	Warnings:			d70a3		
11 Foreign Reference Attachment_3_EPSearchReport no Warnings: Information:						
Information:	11			50	10	
Information: 93701 yes 12 PreliminaryAmendment.pdf 93701 yes multipart Description/PDF files in .zip description Start Er Preliminary Amendment 1 1 1 Claims 2 5 Applicant Arguments/Remarks Made in an Amendment 6 6 Warnings: 1 1 1 13 Applicant Response to Pre-Exam Formalities Notice 056291-5004-02- StatementAccompanying- SubstituteSpecification.pdf 92679 no 14 056291-5004-02- SubstituteSpecification- CleanCopy.pdf 109710 substituteSpecification- 20056291-5004-02- substituteSpecification- CleanCopy.pdf 109710 substituteSpecification- attri yes		roleighneierence		dca31854f20a13359152eac5a9511c65b2d	110	10
12 93701 yes 12 Multipart Description/PDF files in .zip description Multipart Description Start 1 1 <	Warnings:		,	ı – – – – – – – – – – – – – – – – – – –		
12 $056291-5004-02-$ PreliminaryAmendment.pdfyesMultipart Description/PDF files in .zip descriptionDocument DescriptionStartPreliminary Amendment111Claims2Applicant Arguments/Remarks Made in an Amendment6Warnings:056291-5004-02- SubstituteSpecification.pdf13Applicant Response to Pre-Exam Formalities Notice056291-5004-02- StatementAccompanying- SubstituteSpecification.pdf13Applicant Response to Pre-Exam Formalities Notice056291-5004-02- StatementAccompanying- SubstituteSpecification.pdf92679 2990balan07220047000tcaeM 320014Multipart Description/PDF files in .zip descriptionyes	Information:					
PreliminaryAmendment.pd ordext332741exedutationed ordext332741exedutationed Multipart Description/PDF files in .zip description Free Document Description Start Er PreliminaryAmendment 1 1 1 1 1 Claims 2 5 Applicant Arguments/Remarks Made in an Amendment 6 6 Warnings: Disclament Companying-SubstituteSpecification.pdf 92679 no 13 Applicant Response to Pre-Exam Formalities Notice 056291-5004-02-StatementAccompanying-SubstituteSpecification.pdf 92679 no 14 056291-5004-02-StatementAccompanying-SubstituteSpecification.pdf 109710 yes yes 14 056291-5004-02-SubstituteSpecification-CleanCopy.pdf 109710 yes yes	12			93701	Ves	6
Image: constraint of the second state of the second st			PreliminaryAmendment.pdf		,	
$\frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ \frac{ }{ } \\ $		Multip	oart Description/PDF files in	zip description		
$\frac{ }{ } $		Document De	Start	E	nd	
$\frac{ }{Applicant Arguments/Remarks Made in an Amendment} = 6$ $\frac{Applicant Arguments/Remarks Made in an Amendment} = 6$ $\frac{Warnings:}{Information:}$ $\frac{13}{Pormalities Notice} = \frac{056291-5004-02-}{StatementAccompanying-SubstituteSpecification.pdf} = \frac{92679}{332b0} \xrightarrow{no} $ $\frac{14}{Portunation} = \frac{056291-5004-02-}{SubstituteSpecification} = \frac{109710}{SubstituteSpecification}} \xrightarrow{109710} yes$		Preliminary Am	1	1		
Warnings: Information: 13 Applicant Response to Pre-Exam Formalities Notice 056291-5004-02-StatementAccompanying-SubstituteSpecification.pdf 92679 no Warnings: 2995beba00152b5b15cbb47600c4cce460 no no Warnings: 056291-5004-02-StatementAccompanying-SubstituteSpecification.pdf 92679 no Warnings: 14 056291-5004-02-StatementAccompanying-SubstituteSpecification-CleanCopy.pdf 109710 yes 14 056291-5004-02-StatementAccompanying-SubstituteSpecification-CleanCopy.pdf 109710 yes 14 056291-5004-02-StatementAccompanying-SubstituteSpecification-CleanCopy.pdf 109710 yes 14 056291-5004-02-StatementAccompanying-Statement		Claims	2	5		
Information: 13 Applicant Response to Pre-Exam Formalities Notice 056291-5004-02- StatementAccompanying-StatementAccompanying-SubstituteSpecification.pdf 92679 no Warnings: 2993beba00152b5b15cbb47600c4cea46 332b0 no no Information: 056291-5004-02- StatementAccompanying-SubstituteSpecification.pdf 92679 no 14 056291-5004-02- SubstituteSpecification-CleanCopy.pdf 109710 yes 14 056291-5004-02- SubstituteSpecification-CleanCopy.pdf 109710 yes 14 0110000000000000000000000000000000000		Applicant Arguments/Remarks	Made in an Amendment	6	6	
13 Applicant Response to Pre-Exam Formalities Notice 056291-5004-02-StatementAccompanying-SubstituteSpecification.pdf 92679 no 20073beba00152b5b15cbb47600c4cea46 332b0 no no Warnings: Information: 14 056291-5004-02-SubstituteSpecification-CleanCopy.pdf 109710 yes	Warnings:			1		
13 Applicant Response to Pre-Exam Formalities Notice StatementAccompanying-StatementAccompanying-StatementAccompanying-SubstituteSpecification.pdf no Warnings: Information: 22993beba00152b5b15cbb47600c4cea46 332b0 no 14 056291-5004-02-SubstituteSpecification-CleanCopy.pdf 109710 setd509a92td52412d6fa8ccd3b6124be3d a91f yes Multipart Description/PDF files in .zip description	Information:					
Formalities Notice SubstituteSpecification.pdf 2293beba00152b5b15cbb47600c4cea46 Warnings: Information: 14 056291-5004-02- SubstituteSpecification- CleanCopy.pdf 109710 setd509a92fd52412d6fa8ccd3b6124be3d a911f yes Multipart Description/PDF files in .zip description	13			92679	no	2
Information: 056291-5004-02- SubstituteSpecification- CleanCopy.pdf 109710 setds09a92/d52412/d6fa8ccd3b6124be3d a911f yes Multipart Description/PDF files in .zip description 056291-5004-02- Setds09a92/d52412/d6fa8ccd3b6124be3d 109710		Formalities Notice				
14 056291-5004-02- SubstituteSpecification- CleanCopy.pdf 109710 setd509a92fd52412d6fa8ccd3b6124be3d af91f yes Multipart Description/PDF files in .zip description	Warnings:					
14 SubstituteSpecification- CleanCopy.pdf yes SubstituteSpecification- Seid509a92fd52412d6fa8ccd3b6124be3d af91f yes	Information:					
Multipart Description/PDF files in .zip description	14		SubstituteSpecification-		yes	25
				af91f		
Document Description Start Er	-	-	-		F	
	-	Document De	scription	Start	E	na
Specification 1 2		Specificat	tion	1	2	20

Claims	21		23				
Abstrac	t	24		24			
Drawings-only black and v	white line drawings	25		25			
:							
Specification	056291-5004-02- SubstituteSpecification-	111551	no	25			
	MarkedCopy.pdf	eaca016da35e65b59d55b4252f29a81707b 065b5					
		·		•			
:							
Fee Worksheet (PTO-875)	heet (PTO-875) fee-info.pdf		no	2			
		cd28591b73ad539e0e4d6b6b16512f68460 b0231					
I	I	1		1			
:							
	Total Files Size (in bytes)	181	42062				
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. New Applications Under 35 U.S.C. 111 If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. New International Application is being filed and the international application includes the necessary components for an international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.							
	Abstract Drawings-only black and v Specification Specification Fee Worksheet (PTO-875) See Worksheet (PTO-875) See Worksheet (PTO-875) See Worksheet (PTO-875) See Worksheet (PTO-875) Second Second S	Abstract Drawings-only black and white line drawings Drawings-only black and white line drawings Specification Specification Specification Specification SubstituteSpecification- MarkedCopy.pdf Fee Worksheet (PTO-875) fee-info.pdf Image: Specification is being filed and the application includes the necessary of a described in MPEP 503. tions Under 35 U.S.C. 111 lication is being filed and the application includes the necessary of a MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due to the application. ge of an International Application under 35 U.S.C. 371 ubmission to enter the national stage of an international application to the application is being filed and the issued in addition to the tional Application Filed with the USPTO as a Receiving Office rnational application is being filed and the international application to the international filing Date (Form PCT/RO/105) will be issued in due to the application is being filed and the international application to the international application is being filed and the international application to the international filing Date (Form PCT/RO/105) will be issued in due to the application is being filed and the international application to the international filing Date (Form PCT/RO/105) will be issued in due conternational application and the international filed and the international application is being filed and th	Abstract 24 Drawings-only black and white line drawings 25 Drawings-only black and white line drawings 25 Specification 056291-5004-02- SubstituteSpecification- MarkedCopy.pdf 111551 Fee Worksheet (PTO-875) fee-info.pdf 42584 Fee Worksheet (PTO-875) fee-info.pdf 42584 Image: Specification in the noted date by the USPTO of the indicated build be the specification is being filed and the application includes the necessary components for a filing nd MPEP 503. 18 Itions Under 35 U.S.C. 111 Ilication is being filed and the application includes the necessary components for a filing nd MPEP 503. 11 Itions to enter the national stage of an international application is compliant with and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the ge submission to enter the national stage of an international application includes the necessary components for a filing fining acceptance of the ge submission under 35 U.S.C. 371 ubmission to enter the national stage of an international application is compliant with and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the ge submission under 35 U.S.C. 371 ubmission to enter the national stage of an international application includes the necessary complication includes the necessary complement filing date (see PCT Article 11 and MPEP 1810), a Notification includes the necessary complement of the international application of the international application of the international application of the	Abstract 24 Drawings-only black and white line drawings 25 Drawings-only black and white line drawings 25 Specification 056291-5004-02- SubstituteSpecification- MarkedCopy.pdf 111551 Specification 111551 no Specification 42584 no Fee Worksheet (PTO-875) fee-info.pdf 42594 no Image: Specification and the application the noted date by the USPTO of the indicated document boots 18142062 Image: Specification and including page counts, where applicable. It serves as evidence of receipt is a described in MPEP 503. 18142062 Itions Under 35 U.S.C. 111 Image: Specification includes the necessary components for a filing date (see nd MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on the memert Receipt will establish the filing date of the application. ge of an International Application under 35 U.S.C. 371 Ibmission to enter the national stage of an international application is compliant with the condition of a the application is compliant with the coundition ge submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. tional Application Filed with the USPTO as a Receiving Office Image: Specification includes the necessary component filing date (see runding application includes the necessary component filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application o			

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:) Confirmation No. 1199
John R. EVANS <i>et al.</i>))
Application No.: 12/285,887) Group Art Unit: 1617
Filed: October 15, 2008) Examiner: Unassigned
FOR: FORMULATION)) Date: June 4, 2009

FIRST INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants request that the Examiner consider this Information Disclosure Statement and the documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-referenced application. Accordingly, Applicants do not believe that a fee is due for filing this Information Disclosure Statement.

With the exception of documents 38 and 65, copies of the listed documents were previously submitted or cited by the Examiner in parent Application No. 10/872,784. A copy of each of documents 38 and 65 are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required,

DB1/63061204.1

including any required extension of time fees, or credit any overpayment to Deposit Account No.

50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR**

By:

EXTENSION OF TIME in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted, Morgan Lewis & Bockius LLP

Date: June 4, 2009 Morgan Lewis & Bockius LLP Customer No. 09629 1111 Pennsylvania Avenue, N.W. Washington, D.C. 20004 Tel. No.: 202-739-3000 /Donald Bird/ Donald J. Bird

Registration No. 25,323 Tel. No.: (202) 739-5320 Fax No.: (202) 739-3001

	, , ,	Pro-
SEP 1 3 2002 3		ATTORNEY DOCKET NO.: 96291-5004
		PATENT AND TRADEMARK OFFICE
re P.	ATENT APPLICATION of:	
) Group Art Unit: 1617
EVAN	S et al.	
DVIII) Examiner: Hui, San-ming
. 1	N 00/75/ 001) Examiner. Hui, San-Ining
Appln.	No.: 09/756,291)
)
Filed:	January 9, 2001	
	•	
FOR:	FORMULATION)
FOR.	TORMOLATION) Soutombon 12, 2002
		September 13, 2002
Commi	issioner of Patents	
Washir	ngton, D.C. 20231	

Sir:

1 .

SECOND INFORMATION DISCLOSURE STATEMENT

Applicant wishes to make of record the following circumstances regarding the controlled, confidential and non-commercial testing of compositions meeting the definition of "pharmaceutical formulation", as used in the present method of treatment claims, which was carried out in the United States more than one year before the filing date of the present application in preparation for and during the testing (IND) phase of the regulatory review of such formulation by the FDA.

 The elected invention as presently claimed is directed toward a method for treating a benign or malignant disease of the breast or reproductive tract of a human by intramuscular injection of a particular pharmaceutical formulation comprising the active drug fulvestrant in a vehicle comprising ricinoleate, a pharmaceutically-acceptable alcohol, and a pharmaceutically-acceptable non-aqueous ester solvent miscible in ricinoleate, as detailed in the claims.

03/16/2002 BABRAHA1 00000047 500310 09756291 05 FD:126 180.00 CH

 Fulvestrant is the international non-proprietary (generic) name for the compound 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]estra-1,3-5(10)-triene-3,17-betadiol, which compound is encompassed by claims of U.S. Patent No. 4,659,516 issued to Bowler *et al.* in 1987 (hereinafter the "Bowler '516 patent").

· · · ,

. .

- 3. The present specification acknowledges that fulvestrant is included among the steroid derivatives disclosed in European Patent Application No. 0 138 504 (corresponding to the Bowler '516 patent) as being effective antioestrogenic agents. The Bowler '516 patent notes at the bottom of column 7 that compositions of the disclosed steroid derivatives may be in a form suitable for oral or parenteral administration, and that compounds having antioestrogenic effect may have value in the treatment of, *e.g.*, anovulatory infertility, breast tumors and menstrual disorders.
- 4. However, certain characteristics of fulvestrant make it very difficult to formulate a pharmaceutically acceptable and effective composition for administration to humans. In particular, fulvestrant is an extremely lipophilic molecule, even when compared with other steroidal compounds, and its aqueous solubility is extremely low, placing severe limitations on the manner and mechanism by which it can be administered.
- 5. Subsequent to grant of the Bowler '516 patent, applicants developed an injectable extended release formulation of fulvestrant by which it became feasible to effectively utilize the known pharmacological properties of fulvestrant in the treatment of benign or malignant diseases of the breast or reproductive tract in humans, as presently claimed. This injectable extended release formulation of fulvestrant was subjected to extensive *in*

vitro and *in vivo* testing in animals, and eventually in clinical trials as detailed below, leading up to the first FDA approval of this formulation in April 2002.

• • • •

· .

- 6. In brief chronology, fulvestrant was initially put into development by Imperial Chemical Industries PLC (hereinafter "ICI"), under the product designation ICI 182,780. Development of fulvestrant was continued by Zeneca Limited (formed from ICI in 1993) under the product designation ZD9238. By December 6, 1996, preliminary testing of an injectable formulation containing fulvestrant as active ingredient had progressed to the point that an IND (Investigational New Drug) application was filed with the FDA for FASLODEX[®] (fulvestrant) Injection. As of the January 5, 1997 effective date of the IND application, clinical testing could, for the first time, commence in human subjects in the United States.
- 7. Clinical testing under the IND continued on behalf of AstraZeneca (formed by merger in 1999) until it was believed that sufficient evidence of safety and efficacy of the formulation had been obtained, and on March 28, 2001 an NDA (New Drug Application) was submitted to the FDA. Meanwhile, the subject application for patent, Application No. 09/756,291, was filed in the United States on January 9, 2001, claiming priority from GB Application 0000313.7, filed January 10, 2000, and GB Application 0008837.7, filed April 12, 2000. Thereafter, on April 25, 2002, the NDA for the Faslodex (injectable fulvestrant formulation) was approved by the FDA, whereupon Faslodex was approved for commercial marketing for the treatment of certain breast cancers.
- 8. The injectable fulvestrant formulation constituting Faslodex comes within the definition of "pharmaceutical formulation" as used in the method of treatment claims presently

pending in this application. The April 25, 2002 approval date constitutes the earliest possible date for commercial marketing in the United States of a formulation for use in accordance with the present claims.

9. This FDA approval came after the present application was filed, and was the culmination of many years of testing and gathering of data on the injectable formulation of fulvestrant (ICI 182,780 or ZD9238), both in the United States and abroad, in animals and eventually in human clinical trials. As will be evident below, all such testing in the United States more than one year before this application was filed was carried out under agreements which imposed obligations of confidentiality on the involved institutions and/or investigators, gave AstraZeneca strict control over the permitted use and disposition of the test samples of formulation, and provided that AstraZeneca was entitled to all information or data derived from the testing.¹ Moreover, all persons enrolled in the clinical trials were advised of the experimental nature of the formulation, and acknowledged this in signed informed consent forms as a precondition to their enrollment. AstraZeneca received no payment for the samples, and was not otherwise compensated for the use of these samples in the clinical trials. Under these conditions and the applicable case law discussed later below, these tests of the fulvestrant formulation in the United States did not constitute a "public use" under 35 U.S.C. § 102(b) of the present invention because the tests were carried out under strict obligations of confidentiality, and the tests and the use and disposition of the formulation, remained

¹ Reference to AstraZeneca hereinafter should be understood to refer to AstraZeneca and/or its predecessors in interest, ICI and Zeneca, unless the context indicates otherwise.

under the control of AstraZeneca throughout the entire period. These tests did not place the formulation in the public domain or cause the public to believe that the formulation of the invention was freely available, and certainly did not constitute a commercial exploitation of the invention more than one year before this application was filed.

- 10. Prior to the January 5, 1997 effective date of the IND application, all testing of fulvestrant formulation in the United States was necessarily carried out *in vitro* or in animals, and therefore cannot come within the scope of the present method of treatment claims. Nevertheless, it should be noted that all such testing was carried out under strict conditions of confidentiality and limitations of use imposed by a Statement of Proposed Investigation (SOPI) form that each investigator was required to sign as a condition to receiving samples of fulvestrant formulation.
- 11. The SOPI forms used by ICI in the early 1990s required a statement of proposed use of the material (necessarily not including any use in humans) that had to be approved by ICI, and stated just above the required signature of the investigator:

"If samples are supplied, I undertake:-

· · · ·

• •

- 1. to make available all results to ICI;
- that the results will not be submitted for publication or disclosed in any other way prior to disclosure to ICI;
- 3. to use the samples only for the purposes described above and not to pass the samples or any portion thereof to any investigators for any other purpose;
- 4. not to use the samples for any commercial purpose or for any study requested by a commercial organization."

12. The SOPI forms used by Zeneca and AstraZeneca (even after the effective date of the IND, for any samples provided to investigators outside of formal protocols for clinical or compassionate use trials discussed below) similarly required a statement of proposed use of the material that had to be approved by Zeneca or AstraZeneca, and explicitly stated, "Laboratory studies/tests on animals only. (Not for human use)." Again, just above the signature of the investigator, the following undertaking was printed on each form:

• • •

• •

- "1. All results acquired as a direct result of the use of the sample(s) will be promptly furnished to AstraZeneca.
- 2. The results will not be submitted for publication or disclosed in any other way without prior consent from AstraZeneca, which will not be unreasonably withheld.
- 3. The sample(s) will only be used for the purpose described above and shall not be passed to a third party. Any unused material will be returned to AstraZeneca.
- The sample(s) will not be used to support the development of any commercial product containing the compound(s) supplied by AstraZeneca.
- 5. AstraZeneca shall be granted first option of a license to all rights in any discoveries or inventions made as a direct result of the investigations described above (whether patentable or not). In particular, the option will include an option for a license under any patents and patent applications relating to the use of the sample(s).
- 6. AstraZeneca requires assurance from all external investigators that all studies carried out on behalf of AstraZeneca and/or involving AstraZeneca compounds are carried out in compliance with all animal welfare legislation, regulations and policies applicable in that country/state. Please let us have your confirmation in writing that this is the case. We would also like to receive any additional

information on your in-house animal welfare arrangements which you are able to provide."

13. It is understood that no investigator receiving fulvestrant formulation pursuant to a SOPI, at least in the United States and prior to the filing of the present application for patent, was informed of the components and/or proportions thereof constituting the injectable vehicle in which the fulvestrant was carried, and that no investigator publication of results approved by AstraZeneca included such a disclosure.

· · · ·

. .

- 14. Two clinical studies involving Faslodex were carried out at least in part in the United States prior to the filing date of the present application for patent.
 - Clinical Study 9238IL/0021 began, in the United States, in April 1997 and extended to June 2000; was carried out in 69 centers involving 414 patients; and had the objective of comparing the effect, in terms of time to progression, of two doses of Faslodex (125 and 250 mg) with one dose of Arimidex (1 mg) in postmenopausal women with advanced breast cancer.
 - Clinical Study 9238IL/0025 began, in the United States, in November 1998 and extended to July 2001; was carried out in 32 centers involving 51 patients; and had the objective of comparing the effect, in terms of time to progression, of Faslodex (250 mg) with Nolvadex (20 mg) as first-line therapy in postmenopausal women with advanced breast cancer.
- 15. Each clinical study was carried out under a Clinical Study Agreement entered into by each Institution and Investigator taking part in the study.

16. A representative Clinical Study Agreement for Clinical Study 9238IL/0021 provided in relevant part:

• • •

÷.

"The clinical Study to be performed pursuant to this Agreement shall be that set forth in the Protocol entitled "A Double-blind, Randomized, Multicenter Trial comparing the Efficacy and Tolerability of 125 and 250 mg of FASLODEXTM (Long-acting ICI 182,780) With 1 mg ARIMIDEXTM (Anastrozole) in Postmenopausal Women With Advanced Breast Cancer" (hereinafter referred to as "Protocol"). Institution shall use its best efforts to ensure that the work required under the Protocol is properly performed in accordance therewith."

* * * * *

"ZENECA reserves the right to terminate this Agreement and Study at any time in its sole discretion upon thirty (30) days prior written notice. However, ZENECA may terminate this agreement upon five (5) days written notice for safety, regulatory or ethical reasons. In the event of termination, all unused Study materials shall be returned to ZENECA and ZENECA shall reimburse Institution for all actual costs reasonably incurred up until the effective termination date."

* * * * *

"All rights to all data, inventions or discoveries Institution may make or conceive in the course of their work for ZENECA in their performance under this Agreement and using product in accordance with the detailed protocol provided by ZENECA will be the property of ZENECA and will be assigned to ZENECA, and Institution will assist ZENECA, at ZENECA's expense, by executing rightful papers for obtaining proper patent protection in such inventions or discoveries in any country which ZENECA at ZENECA's option, desires to obtain patent protection. All control of and decisions regarding such patent filings and prosecution, whether U.S. or foreign, and all costs and fees associated therewith, shall be exercised and/or borne by ZENECA."

* * * * *

"It may be necessary for Zeneca to disclose to Institution certain information considered proprietary or confidential (hereinafter 'Confidential Information') to aid Institution in effecting or completing their performance under this Agreement. Institution agrees to maintain in confidence all Confidential Information Institution obtains from ZENECA relating to this Agreement and not to disclose any of said Confidential Information to a third party for a period of three (3) years after the termination of this Agreement without the prior written consent of ZENECA. Notwithstanding the foregoing, it is understood that Confidential Information shall not include the following: (i) information that is now publicly available, (ii) information that later becomes publicly available, after it has become publicly available, (iii) information which Institution obtain from some third party not under any obligation to ZENECA with respect to such information, or (iv) information which Institution already have in their possession, prior to any disclosure by ZENECA, as evidenced by written records, (v) is independently developed by Institution or (vi) is required by law or regulation to be disclosed, provided, however, that Institution notifies and consults with Zeneca prior to such disclosure.

"Subject to the provisions of confidentiality set forth in Section 6(d) above, ZENECA agrees to grant Institution the right to publish its findings in the scientific literature, provided that ZENECA shall have the right to review, at least 30 days prior to submission for publication, copies of any and all final draft manuscripts which are authored or co-authored by Institution or by anyone in their research group and which are based in whole or in part on research conducted under this Agreement. Upon request by ZENECA, in order to protect intellectual property rights, Institution agrees to delay submission of such final draft manuscripts for publication for a period not exceeding six (6) months from the date on which ZENECA receives such final draft manuscripts. Institution agrees to implement any reasonable suggestions made to preserve ZENECA's right in its Confidential Information before any disclosure for publication or presentation; Investigator and Institution agrees to take appropriate cognizance of any other suggestions by ZENECA before any disclosure for publication or presentation."

17. A representative Clinical Study Agreement for Clinical Study 9238IL/0025 similarly provided in relevant part:

• • • •

· .

"The clinical Study to be performed pursuant to this Agreement shall be that set forth in the Protocol which is attached hereto as Exhibit A and incorporated herein by reference. Institution and Investigator shall use their best efforts to ensure that the work required under the Protocol is properly performed in accordance therewith."

* * * * *

"Zeneca reserves the right to terminate this Agreement and Study at any time in its sole discretion upon five (5) days prior written notice. In the event of termination, all unused Study materials shall be returned to Zeneca and Zeneca shall reimburse Institution and Investigator for all actual costs reasonably incurred up until the effective termination date."

* * * * *

"All rights to all data, inventions or discoveries Institution and Investigator may make or conceive in the course of their work for Zeneca in their performance under this Agreement will be the property of Zeneca and will be assigned to Zeneca, and Institution and Investigator will assist Zeneca, at Zeneca's expense, by executing rightful papers for obtaining proper patent protection in such inventions or discoveries."

* * * * *

"It may be necessary for Zeneca to disclose to Investigator and Institution certain information considered proprietary or confidential (hereinafter "Confidential

ATTORNEY DOCKET NO. : 056291-5004 Application No.: 09/756,291 Page 11

Information") to aid Investigator and Institution in effecting or completing their performance under this Agreement. Confidential Information shall also include Study data; however, Investigator's and Institution's right to publish pursuant to Section (d) below^{*} shall not be affected by this provision. Investigator and Institution agree to maintain in confidence all Confidential Information Investigator and Institution obtain from Zeneca relating to this Agreement and not to disclose any of said Confidential Information to a third party without the prior written consent of Zeneca. Notwithstanding the foregoing, it is understood that Confidential Information shall not include the following: (i) information that is now publicly available, (ii) information that later becomes publicly available, after it has become publicly available, (iii) information which Investigator and Institution obtain from some third party not under any obligation to Zeneca with respect to such information, or (iv) information which Investigator and Institution already have in their possession, prior to any disclosure by Zeneca, as evidenced by written records.

· · ·

۰.

"Nothing herein shall prevent Investigator and Institution from complying with the legal obligation to disclose Confidential Information so long as Investigator and Institution (i) provide Zeneca prompt notice of its intent to disclose (or to resist disclosure) (ii) take reasonable steps to require the recipient to preserve the confidential nature of the information once disclosed and (iii) afford Zeneca the opportunity to attempt to prevent the disclosure (whether or not Investigator and Institution have sought to resist disclosure) or obtain protection for the information disclosed."

* * * * *

*[(d)] "Subject to the provisions of confidentiality set forth in Section 6(c) above, Zeneca agrees to grant Investigator and Institution the right to publish their findings in the scientific literature, provided that Zeneca shall have the right to review, at least 30 days prior to submission for publication, copies of any and all final draft manuscripts which are authored or co-authored by Investigator and

ATTORNEY DOCKET NO. : 056291-5004 Application No.: 09/756,291 Page 12

Institution or by anyone in their research group and which are based in whole or in part on research conducted under this Agreement. In the event it is necessary for Zeneca to prepare a patent application(s) and other documentation, and upon request by Zeneca, Investigator and Institution agree to delay submission of such final draft manuscripts for publication for a period not exceeding six (6) months from the date on which Zeneca receives such final draft manuscripts. Investigator and Institution agree to implement any reasonable suggestions made to preserve Zeneca's right in its Confidential Information before any disclosure for publication or presentation; Investigator and Institution agree to take appropriate cognizance of any other suggestions by Zeneca before any disclosure for publication or presentation."

* * * * *

"Zeneca shall be entitled to make copies, at Zeneca's expense, of any and all documents and data generated from the Study. In addition, Institution and Investigator agree to allow Zeneca to audit the Study records (including administrative files and source documents such as hospital charts, office records and written results of laboratory and diagnostic tests) of Institution and Investigator at mutually convenient times.

18. An additional clinical study involving Faslodex was commenced in the United States more than one year prior to the filing date of the present application for patent, being Clinical Study 9238IL/0037, a compassionate-use trial under a protocol initially entitled "An Open-label, Treatment-use Protocol of 250 mg of FASLODEXTM (Long-acting ICI 182,780) in Postmenopausal Women With Advanced Breast Cancer." It is understood that as of one year prior to the filing date of this application, seven subjects had been enrolled in Clinical Study 9238IL/0037.

19. A "Confidentiality and Proprietary Rights Agreement" was entered into by each Investigator prior to his involvement in Clinical Study 9238IL/0037, in which the Investigator acknowledged that "he will have access to and obtain knowledge of certain proprietary and confidential Information of Zeneca and that as a condition of receiving such information" the parties agreed, in part as here relevant:

"1. 'Confidential Information' shall mean all information (a) disclosed by Zeneca to Investigator, either orally or in writing or (b) obtained by the Investigator from a third party or any other source, regarding the protocol entitled 'An Open-label, Treatment-use Protocol of 250 mg of FASLODEXTM (Long-acting ICI 182,780) in Postmenopausal Women With Advanced Breast Cancer, Study No. 9238IL/0037' ('Study')

"Confidential Information shall not include information that: (i) was already in the possession of Investigator before disclosure thereof by Zeneca to Investigator as evidenced by Investigator's written records (ii) is independently developed by Investigator as evidenced by Investigator's written records, (iii) is or becomes publicly available through no fault of Investigator, or (iv) is obtained by Investigator from a third party under no obligation not to disclose same.

"Nothing herein shall prevent Investigator from complying with a legal obligation to disclose Confidential Information so long as Investigator (i) provides Zeneca prompt notice of its intent to disclose (or to resist disclosure) (ii) takes reasonable steps to require the recipient to preserve the confidential nature of the information once disclosed and (iii) affords Zeneca the opportunity to attempt to prevent the disclosure (whether or not Investigator has sought to resist disclosure) or obtain protection for the Information disclosed.

"2. The purpose of the disclosure of Confidential Information is to allow Investigator to participate in the Treatment-use Protocol.

ATTORNEY DOCKET NO.: 056291-5004 Application No.: 09/756,291 Page 14

"3. Investigator agrees to maintain in strictest confidence and to take all reasonable steps to maintain the confidentiality of the Confidential Information. Investigator also agrees not to disclose Confidential Information to any third party, and to use Confidential Information only for the purposes stated in paragraph 2 of this Agreement.

"4. Investigator recognizes that all documents and records received by Investigator from Zeneca and all copies of such records and documents shall be Zeneca's property exclusively. The Investigator shall at all times keep all such documents, records and copies of documents and records in Investigator's custody and subject to Investigator's control and shall surrender the same upon request by Zeneca.

"5. Investigator shall not disclose any Confidential Information to any of its employees, except employees of Investigator who have a need to know the Confidential Information for the purposes stated in paragraph 2 of this Agreement and who have assumed an obligation to maintain Zeneca's Confidential Information in confidence at least to the extent that Investigator is bound hereunder. Investigator shall advise each such employee of the confidential nature of the Confidential Information received from Zeneca and the existence and importance of the confidentiality provisions of this Agreement and shall be responsible for ensuring that such employees maintain the Confidential Information in confidence in accordance with the terms of this Agreement.

"6. Because of the unique nature of the Confidential Information, Investigator understands and agrees that Zeneca will suffer irreparable harm in the event that Investigator fails to comply with any of its obligations contained hereinabove and that monetary damages will be inadequate to compensate Zeneca for such breach. Accordingly, Investigator agrees that Zeneca shall have the right to seek immediate injunctive relief to enforce the confidentiality obligations contained herein.

"7. All rights to all data, inventions or discoveries Investigator may make or conceive in the course of Investigator participation in the Study will be the property of Zeneca and will be assigned to Zeneca, and Investigator will assist Zeneca, at Zeneca's expense, by executing rightful papers for obtaining proper patent protection in such inventions or discoveries. Investigator agrees to make no claim which will restrict the rights of Zeneca to use and disclose to others any information, knowledge, and ideas which are disclosed to Zeneca by Investigator in the course of performance of the Study.

"8. Subject to the provisions of confidentiality set forth herein, Zeneca agrees to grant Investigator the right to publish his findings in the scientific literature, provided that Zeneca shall have the right to review, at least 30 days prior to submission for publication, copies of any and all final draft manuscripts which are authored by Investigator or by anyone in his research group and which are based in whole or in part on research conducted pursuant to this Study. In the event it is necessary for Zeneca to prepare a patent application(s) and other documentation, and upon request by Zeneca, Investigator agrees to delay submission of such final draft manuscripts for publication for a period not exceeding six (6) months from the date on which Zeneca receives such final draft manuscripts. Investigator agrees to implement any reasonable suggestions made to preserve Zeneca's right in its Confidential Information before any disclosure for publication or presentation; Investigator agrees to take appropriate cognizance of any other suggestions by Zeneca before any disclosure for publication or presentation."

- 20. The Protocols referenced with respect to the above-noted Studies No. 9238IL/0021, No. 9238IL/0025 and No. 9238IL/0037 provided details of, *inter alia*, the:
 - criteria for the selection and screening for eligibility of subjects for entry into the trial, as well as exclusion criteria;

- route, dose and regimen for administration of the respective drugs to individual subjects;
- procedures for drug accountability, including maintenance of accurate records on receipt and disposition of investigational materials, and return or destruction of any unused drug;
- frequency and procedures for clinical and laboratory evaluations;

• • • •

- regular recordation of data on case report forms, record retention and submission of records to AstraZeneca; and
- trial monitoring and data verification by representatives of AstraZeneca.
- 21. These Protocols furthermore required that each subject be given appropriate information on the treatment prior to its commencement, including the experimental aspects of the treatment and the risks involved, and sign an informed consent form approved by AstraZeneca, and conforming to the requirements of 21 C.F.R. 50.20 *et seq.*, which requires as a basic element of informed consent, that each subject be provided with, *inter alia*, a "statement that the study involves research, an explanation of the purposes of the research and the expected duration of the subject's participation, a description of the procedures to be followed, and identification of any procedures which are experimental." 21 C.F.R. 50.25(a)(1).

In evaluating the above circumstances in context of 35 U.S.C. § 102(b), the Examiner's attention is called to MPEP ¶ 2133.03 "Rejections Based on 'Public Use' or 'On Sale', and particularly MPEP ¶ 2133.03(a) "Public Use", section *B*. headed "*Use by Third*

Parties Deriving the Invention from Applicant." It is respectfully submitted that the above circumstances do not constitute a "public use" of the presently claimed invention under the criteria set forth in the MPEP, and as established by decisions of the Federal Circuit, because of the strict confidentiality and control imposed and maintained by AstraZeneca throughout the relevant trial periods. MPEP $\[12133.03(a)B.$ provides:

An Invention Is in Public Use If the Inventor Allows Another To Use the Invention Without Restriction or Obligation of Secrecy

"Public use" of a claimed invention under 35 U.S.C. 102(b) occurs when the inventor allows another person to use the invention without limitation, restriction or obligation of secrecy to the inventor." In re Smith, 714 F.2d 1127, 1134, 218 USPQ 976, 983 (Fed. Cir. 1983). The presence or absence of a confidentiality agreement is not itself determinative of the public use issue, but is one factor to be considered along with the time, place, and circumstances of the use which show the amount of control the inventor retained over the invention. Moleculon Research Corp. v. CBS, Inc., 793 F.2d 1261, 1265, 229 USPQ 805, 809 (Fed. Cir. 1986). See *Ex parte C*, 27 USPQ2d 1492, 1499 (Bd. Pat. App. & Inter. 1992) (Inventor sold inventive soybean seeds to growers who contracted and were paid to plant the seeds to increase stock for later sale. The commercial nature of the use of the seed coupled with the "on-sale" aspects of the contract and apparent lack of confidentiality requirements rose to the level of a "public use" bar.); Egbert v. Lippmann, 104 U.S. 333, 336 (1881) (Public use found where inventor allowed another to use inventive corset insert, though hidden from view during use, because he did not impose an obligation of secrecy or restrictions on its use.).

The samples of fulvestrant formulation provided under the SOPI forms was not for

human use, and therefore outside of the scope of the present method of use claims.

Nevertheless, the tests conducted on these samples by the third party Investigators did not

constitute a "public use". Through the SOPI forms, AstraZeneca maintained strict

confidentiality over the samples and tests conducted therewith, maintained control over the

use and disposition of the samples, and was entitled to all data developed in the course of the

tests. (¶¶ 10-13, *supra*). Moreover, AstraZeneca received no payment or other commercial benefit from providing these samples

Similarly, the three clinical trials or studies conducted in human subjects did not constitute a "public use" under the definition thereof set out in the MPEP as developed by the courts. Prior to the release of any materials or formulations on which to carry out these studies, the institutions and/or investigators involved were required to sign an agreement whereunder strict confidentiality was required, and all information provided to or developed by the institution/investigator during the course of such studies remained or became the property of AstraZeneca. (¶ 16, 17 and 19, supra). Through the Clinical Study Agreements, and the Protocols under which all three studies were conducted, AstraZeneca maintained full control over the use and disposition of the study materials or formulation that it provided to the institutions/investigators throughout the course of these studies, and the right to receive the data and records that were produced. (¶¶ 16, 17 and 20, supra). Moreover, each subject of these studies was fully informed of the experimental nature of the formulation and its use, as acknowledged in signed informed consent forms, and clearly did not have any basis to believe that the formulation or its use in the treatments was in the public domain or otherwise freely available. (¶ 21, supra). Again, AstraZeneca received no payment for the formulation used in these studies, and these studies did not constitute a commercial exploitation of the formulation.

Therefore, under the case law as developed by the courts, and its application by the Patent and Trademark Office as set out in the above-quoted paragraph from the MPEP, it is

ATTORNEY DOCKET NO. : 056291-5004 Application No.: 09/756,291 Page 19

respectfully submitted that the foregoing circumstances do not constitute a "public use"

By:

under 35 U.S.C. § 102(b).

Respectfully Submitted, Morgan Lewis & Bocking LLP Donald J. Bird

3

September 13, 2002 Morgan Lewis & Bockius LLP Customer No. **009629** 1111 Pennsylvania Avenue, N.W. Washington, D.C. 20004 Tel. No.: 202-739-3000 DJB:

Registration No. 25,323 Tel. No.: (202) 739-5320 Fax No.: (202) 739-3001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:) Confirmation No. 1199
John R. EVANS <i>et al.</i>	
Application No.: 12/285,887) Group Art Unit: 1617
Filed: October 15, 2008) Examiner: Unassigned
FOR: FORMULATION) Date: June 4, 2009

<u>THIRD INFORMATION DISCLOSURE STATEMENT</u> <u>UNDER 37 C.F.R. § 1.97(b)</u>

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants request that the Examiner consider this Information Disclosure Statement and the documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-referenced application. Accordingly, Applicants do not believe that a fee is due for filing this Information Disclosure Statement.

Copies of the listed documents were previously submitted or cited by the Examiner in parent Application No. 10/872,784. Accordingly, no copies of the listed documents are provided herewith. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

Also submitted with this Information Disclosure Statement as Attachments I to III are the following documents: <u>Attachment I</u>: A copy of EP 1250138B1, which is the European Patent that granted on the European counterpart of the subject Application; <u>Attachment II</u>: A copy of documents from the EPO file relating to the European Opposition pending against EP 1250138B1; and <u>Attachment III</u>: A copy the Supplementary European Search Report received by Applicant in European Application 05016921.8, which is a divisional of the application from which EP 1250138B1 granted.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or

constitute "prior art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted, Morgan Lewis & Bockius LLP

Date: June 4, 2009 Morgan Lewis & Bockius LLP Customer No. 09629 1111 Pennsylvania Avenue, N.W. Washington, D.C. 20004 Tel. No.: 202-739-3000 /Donald Bird/

By:


Donald J. Bird Registration No. 25,323 Tel. No.: (202) 739-5320 Fax No.: (202) 739-3001

INFORMATION DISCLOSURE CITATION		Attorney Docket No. Application No. 056291-5004-02 12/285,887							
	(Use several sheets if necessary)			Applicants: John R. EVANS et al.					
		PTO Form 1449 June 4, 2009		Filing Date: October 15, 2	2008	Group	9 Art Unit: 1617		
			U.S. PA	TENT DOCUMENTS					
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date		
	1.	US 3,164,520	January 5, 1965	Huber					
	2.	US 4,212,863	July 15, 1980	Cornelius					
	3.	US 4,388,307	June 14, 1983	Cavanak					
			FODELCN	DATENT DOCUMENTS					
		Document No.	Date	PATENT DOCUMENTS Country	Class	Sub-Class	Translation		
	4.	EP 0310542A1	April 5, 1989	EPO	01400	0 40 01400	Yes		
			F , · · ·						
		OTHER DO	OCUMENTS (Inclue	ling Author, Title, Date, Per	tinent Pa	ges, etc.)			
	5. P.K. Gupta and G.A. Brazeau (eds). <i>Injectable Drug Development:Techniques to Reduce Pain and Irritation</i> . Chapters 11 & 17 Interpharm Press, Denver, Colorado (1999)								
	6.	P.V. Lopatin, V. P. Safonov, T. P. Litvinova and L. M. Yakimenko. Use of nonaqueous solvents to prepare injection solutions. <i>Pharm. Chem. J.</i> 6 :724-733 (1972)							
	7.	S. Nema, R.J. Washku 51:166-71 (1997)	hn, and R.J. Brendel.	Excipients and their use in inj	ectable pr	oducts. PDA	J. Pharm. Sci. Technol.		
	8.	Physicians' Desk Refer NJ (1973)	rence (27th edition).	1277-1278, 1350-1354, 1391-1	1392 Med	ical Econom	ics Company, Oradell,		
	9.	M. F. Powell, T. Nguy Technol. 52 :238–311 [-	compendium of excipients for pled] (1998)	parenteral	formulations	s. PDA J. Pharm. Sci.		
	10.	R. G. Strickley. Parente J. Pharm. Sci. Technol		small molecule therapeutics ma	arketed in	the United S	tates (1999) -Part I. PDA		
	11.	R. G. Strickley. Parent PDA J. Pharm. Sci. Te		small molecule therapeutics mail molecule therapeutics mailed	arketed in	the United S	tates (1999) - Part II		
	12.	R. G. Strickley. Parent PDA J. Pharm. Sci. Te		small molecule therapeutics ma	arketed in	the United S	tates (1999) - Part III.		
	13.	Y.C. J. Wang and R. R. Kowal. Review of excipients and pH's for parenteral products used in the United States. <i>J. Parenteral Drug Assoc.</i> 34 :452–462 (1980).							
Examiner	1	1	Date C	Considered					
F	. т . ч.	1.0 0	1 1 41 4 1	, · · · · · · · · · · · · · · · · · · ·		1 1' 4	1 4 4 10 4 1		
				tion is in conformance with M ith next communication to app		araw line thr	ougn citation if not in		

Page 1 of 1

Third IDS

Attachment I



1 250 138 B1 Ы

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Printed by Jouve, 75001 PARIS (FR)

Description

40

- 5 ol, more particularly to a formulation adapted for administration by injection containing the compound 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-aqueous ester solvent which is miscible in the ricinoleate vehicle.
- [0002] Oestrogen deprivation is fundamental to the treatment of many benign and malignant diseases of the breast
 and reproductive tract. In premenopausal women, this is achieved by the ablation of ovarian function through surgical,
 radiotherapeutic, or medical means, and, in postmenopausal women, by the use of aromatase inhibitors.
- [0003] An alternative approach to oestrogen withdrawal is to antagonise oestrogens with antioestrogens. These are drugs that bind to and compete for oestrogen receptors (ER) present in the nuclei of oestrogen-responsive tissue. Conventional nonsteroidal antioestrogens, such as tamoxifen, compete efficiently for ER binding but their effectiveness is often limited by the partial agonism they display, which results in an incomplete blockade of oestrogen-mediated
- is often limited by the partial agonism they display, which results in an incomplete blockade of oestrogen-mediated activity (Furr and Jordan 1984, May and Westley 1987).
 [0004] The potential for nonsteroidal antioestrogens to display agonistic properties prompted the search for novel compounds that would bind ER with high affinity without activating any of the normal transcriptional hormone responses and consequent manifestations of oestrogens. Such molecules would be "pure" antioestrogens, clearly distinguished
- from tamoxifen-like ligands and capable of eliciting complete ablation of the trophic effects of oestrogens. Such compounds are referred to as Estrogen Receptor-Downregulators (E.R.D.). The rationale for the design and testing of novel, pure antioestrogens has been described in: Bowler et al 1989, Wakeling 1990a, 1990b, 1990c. Wakeling and Bowler 1987, 1988.
- **[0005]** Steroidal analogues of oestradiol, with an alkylsulphinyl side chain in the 7 α position, provided the first examples of compounds devoid of oestrogenic activity (Bowler et al 1989). One of these, 7 α -[9-(4,4,5,5,5-pentafluoropentyl sulphinyl)nonyl]oestra-1,3,5-(10)triene-3,17 β -diol was selected for intensive study on the basis of its pure oestrogen antagonist activity and significantly increased antioestrogenic potency over other available antioestrogens. *In vitro* findings and early clinical experience with 7 α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3-5(10)triene-3,17 β -diol have promoted interest in the development of the drug as a therapeutic agent for oestrogen-dependent indications such as breast cancer and certain benign gynaecological conditions.
- **[0006]** 7α -[9-(4,4,5,5,5-Pentafluoropentylsulphinyl)nonyl]oestra-1,3-5(10)-triene-3,17 β -diol, or ICI 182,780, has been allocated the international non-proprietary name fulvestrant, which is used hereinafter. When referring to fulvestrant we include pharmaceutically-acceptable salts thereof and any possible solvates of either thereof.
- [0007] Fulvestrant binds to ER with an affinity similar to that of oestradiol and completely blocks the growth stimulatory action of oestradiol on human breast cancer cells *in vitro*; it is more potent and more effective than tamoxifen in this respect. Fulvestrant blocks completely the uterotrophic action of oestradiol in rats, mice and monkeys, and also blocks the uterotrophic activity of tamoxifen.

[0008] Because fulvestrant has none of the oestrogen-like stimulatory activity that is characteristic of clinically available antioestrogens such as tamoxifen or toremifene, it may offer improved therapeutic activity characterised by more rapid, complete, or longer-lasting tumour regression; a lower incidence or rate of development of resistance to treat-

ment; and a reduction of tumour invasiveness.
 [0009] In intact adult rats, fulvestrant achieves maximum regression of the uterus at a dose which does not adversely affect bone density or lead to increased gonadotrophin secretion. If also true in humans, these findings could be of extreme importance clinically. Reduced bone density limits the duration of oestrogen-ablative treatment for endome-

- triosis. Fulvestrant does not block hypothalamic ER. Oestrogen ablation also causes or exacerbates hot flushes and other menopausal symptoms; fulvestrant will not cause such effects because it does not cross the blood-brain barrier.
 [0010] European Patent Application No. 0 138 504 discloses that certain steroid derivatives are effective antioestrogenic agents. The disclosure includes information relating to the preparation of the steroid derivatives. In particular there is the disclosure within Example 35 of the compound 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-
- 50 1,3,5(10)-triene-3,17β-diol, which compound is specifically named in Claim 4. It is also disclosed that the compounds of that invention may be provided for use in the form of a pharmaceutical composition comprising a steroid derivative of the invention together with a pharmaceutically-acceptable diluent or carrier. It is stated therein that the composition can be in a form suitable for oral or parenteral administration.
- **[0011]** Fulvestrant shows, along with other steroidal based compounds, certain physical properties which make formulation of these compounds difficult. Fulvestrant is a particularly lipophilic molecule, even when compared with other steroidal compounds, and its aqueous solubility is extremely low at around 10 ngml⁻¹ (this is an estimate from a water/ solvent mixture solute since measurements this low could not be achieved in a water only solute).

[0012] Currently there are a number of sustained release injectable steroidal formulations which have been com-

EP 1 250 138 B1

mercialised. Commonly these formulations use oil as a solvent and wherein additional excipients may be present. Below in Table 1 are described a few commercialised sustained release injectable formulations.

[0013] In the formulations within Table 1 a number of different oils are used to solubilise the compound and additional excipients such as benzyl benzoate, benzyl alcohol and ethanol have been used. Volumes of oil needed to solubilise the steroid active ingredient are low. Extended release is achievable for periods from 1 to 8 weeks.

10			
15			
20			
25			
30			
35			
40			
45			
50			
55			

	DOSING	3 weeks	1 week	< 1week	15 to 30 days	8 weeks	I week	1 week	1 - 2 weeks
	DOSE	Iml	1 or 2ml	2mJ	1mi	lml	Iml	1 or 2ml	l or 2ml
	HOIE								
SNO	BzOH	0.1ml							
UECTI	BzBz		up to 46%	*40%	45%	YES		YES	YES
ULAR IN	ΠO	Arachis	Castor	Ethyl oleate	Olive	Castor	Arachis	Castor	Castor
FRAMUSCI	SOURCE	ABPI Data Sheet Comp.1999	ABPI Data Sheet Comp.1999	Dict. Vidal 1999	Dict. Vidal 1997	ABPI Data Sheet Comp. 1999	Dict. Vidal 1998	Dict. Vidal 1999	Dict. Vidal 1995
INI ĐNILO	COMP.	Organon	Schering HC	Theramax	Theramax	Schering HC	Roussel	Pharlon	Schering HC
Table 1 - OIL BASED LONG-ACTING INTRAMUSCULAR INJECTIONS	TYPE	Androgen	Progestogen	Progestogen	Mixed	Contraceptive	Estradiol	Progestogen	Mixed
OIL BASE	DOSE	30mg 60mg 60mg 100mg	250mgml ^{.1}	200mg 50mg 250me	1.3mg 50mg 80mg	200mg	Smg	250mgml ⁻¹	5mgml ^{-l} 250mgml ^{-l}
Table 1 -	STEROID	Testosterone proprionate Testosterone phenylproprionate Testosterone isocaproate Testosterone decanoate	Hydroxy progesterone hexanoate	Hydroxy progesterone enantate Progesterone α-Tocopheroi	Estrapronicate Nandrolone undecanoate Hydroxyprogesterone hepianoate	Norethisterone oenanthoate	Estradiol hexahydrobenzoate	Hydroxy progesterone caproate	Estradiol 17-β-valerate Hydroxyprogesterone caproate
	PRODUCT NAME	SUSTANON 100	PROLUTON DEPOT	TOCOGESTAN	TROPHOBOLENE	NORISTERAT	BENZO- GYNOESTRYL	PROGESTERONE -RETARD	GRAVIBINAN

EP 1 250 138 B1

	2 weeks			
5	1.5ml			
10	45mg	2% 2%	up to 2%	
	75mg	20% 40%	YES	
15		78% 58%	YES	
20	Arachis	Castor	Castor	
25	Dict. Vidal	1997 J.Pharm. Sci (1964)	53(8) 891 J.Pharm. Sci.(1964) 53(8) 891	iomaire Vidal
	Negma	BMS	SMG	Vidal = Dict
30	76mg Androgen	Estradiol	Progestrogen	EtOH ≂ ethanol Dict. Vidal = Dictionnaire Vidal com a single sample
35	76mg	20mgml ⁻ⁱ 40mgml ⁻ⁱ	250mgml ⁻ⁱ	EtOH = ly from a single
40			ر م	benzylalcohol teasured direct
45	Trenbolone	Estradiol valerate	l 7-Hydroxy progesterone	oate BzOH=1 proximate as m
50	PARABOLAN	DELESTROGEN	DELALUTIN	BzBz = benzylbenzoate BzOH = benzylalcohol EtOH = ethanol % are w/v and * approximate as measured directly from a single sample
55	PA	DE	DEI	BzE % aı

5

EP 1 250 138 B1

[0014] In US 5,183,814 Example 3 an oil based injection formulation of fulvestrant is described which comprises 50mg of fulvestrant, 400mg of benzyl alcohol and sufficient castor oil to bring the solution to a volume of 1 ml. Manufacture at a commercial scale of a formulation as described in US 5,183,814 will be complicated by the high alcohol concentration. Therefore, there is a need to lower the alcohol concentration in fulvestrant formulations whilst preventing precipitation of fulvestrant from the formulation.

[0015] Table 2 shows the solubility of fulvestrant in a number of different solvents.

Table 2 -	
SOLUBILITY OF FULVESTRANT	
SOLVENT	SOLUBILITY
	(mgml ⁻¹ at 25°C)
Water	0.001
Arachis oil	0.45
Sesame oil	0.58
Castor oil	20
Miglyol 810	3.06
Miglyol 812	2.72
Ethyl oleate	1.25
Benzyl benzoate	6.15
lsopropyl myristate	0.80
Span 85 (surfactant)	3.79
Ethanol	>200
Benzyl Alcohol	>200

[0016] As can be seen fulvestrant is significantly more soluble in castor oil than any of the other oils tested. The greater solvating ability of castor oil for steroidal compounds is known and is attributed to the high number of hydroxy groups of ricinoleic acid, which is the major constituent of the fatty acids within the triglycerides present in castor oil - see (Biffkin et al., L. Pharm, Sci., (1964), 53, 891)

30

40

25

5

10

15

20

see (Riffkin et.al. J. Pharm. Sci., (1964), 53, 891). [0017] However, even when using the best oil based solvent, castor oil, we have found that it is not possible to dissolve fulvestrant in an oil based solvent alone so as to achieve a high enough concentration to dose a patient in a low volume injection and achieve a therapeutically significant release rate. To achieve a therapeutically significant

release rate the amount of fulvestrant needed would require the formulation volume to be large, at least 10 ml. This requires the doctor to inject an excessively large volume of formulation to administer a dose significantly high enough for human therapy.

[0018] Currently guidelines recommend that no more than 5mls of liquid is injected intramuscularly in a single injection. Pharmacologically active doses required for a 1 month long acting depot formulation of fulvestrant is around 250mg. Therefore, when dissolved in just castor oil, fulvestrant would need to be administered in at least 10ml of castor oil.

[0019] The addition of organic solvents in which fulvestrant is freely soluble, and which are miscible with castor oil, may be used, such as an alcohol. With the addition of high concentrations of an alcohol concentrations of >50mgml⁻¹ of fulvestrant in a castor oil formulation is achievable, thereby giving an injection volumes of <5ml - see Table 3 below.

- 45 We have surprisingly found that the introduction of a non-aqueous ester solvent which is miscible in the castor oil and an alcohol surprisingly eases the solubilisation of fulvestrant into a concentration of at least 50 mgml⁻¹ - see Table 3 below. The finding is surprising since the solubility of fulvestrant in non-aqueous ester solvents - see Table 2 above is significantly lower than the solubility of fulvestrant in an alcohol. The solubility of fulvestrant is also lower in nonaqueous ester solvents than is the solubility of fulvestrant in castor oil.
- 50 [0020] Therefore, we present as a feature of the invention a pharmaceutical formulation comprising fulvestrant (preferably fulvestrant is present at 3-10%w/v, 4-9%w/v, 4-8%w/v, 4-7%w/v, 4-6%w/v and most preferably at about 5%w/v) in a ricinoleate vehicle, a pharmaceutically acceptable non-aqueous ester solvent, and a pharmaceutically acceptable alcohol wherein the formulation is adapted for intramuscular administration and attaining a therapeutically significant blood plasma fulvestrant concentration for at least 2 weeks.
- 55 **[0021]** Another feature of the invention is a pharmaceutical formulation comprising fulvestrant in which the formulation is adapted for intra-muscular injection into a human and which is capable after injection of attaining a therapeutically significant blood plasma fulvestrant concentration for at least 2 weeks.

[0022] Further features of the invention include a pharmaceutical formulation adapted for intra-muscular injection

EP 1 250 138 B1

comprising fulvestrant, 30% or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation which is capable after injection of attaining a therapeutically significant blood plasma fulvestrant concentration for at least 2 weeks.

- 5 [0023] Further features of the invention include a pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant; 35% (preferably 30% and ideally 25%) or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% (preferably at least 5% or ideally 10%) weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible within a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml⁻¹ of fulvestrant.
- 10 **[0024]** For the avoidance of any doubt when using the term % weight per volume of formulation for the constituents of the formulation we mean that within a unit volume of the formulation a certain percentage of the constituent by weight will be present, for example a 1% weight per volume formulation will contain within a 100ml volume of formulation 1g of the constituent. By way of further illustration

% of x by weight per volume of formulation	weight of x in 1ml of formulation
30%	300mg
20%	200mg
10%	100mg
5%	50mg
1%	10mg

15

20

25

50

[0025] Preferred pharmaceutical formulations of the invention are as described above wherein:

The total volume of the formulation is 6ml, or less, and the concentration of fulvestrant is at least 45mgml⁻¹.
 The total amount of fulvestrant in the formulation is 250mg, or more, and the total volume of the formulation is 6ml, or less.

3. The total amount of fulvestrant in the formulation is 250mg and the total volume of the formulation is 5-5.25ml.

- ³⁰ **[0026]** It is appreciated that in the formulation an excess of formulation may be included to allow the attendant physician or care giver to be able to deliver the required dose. Therefore, when a 5ml dose is required it would be appreciated that an excess of up to 0.25ml, preferably up to 0.15ml will also be present in the formulation. Typically the formulation will be presented in a vial or a prefilled syringe, preferably a prefilled syringe, containing a unit dosage of the formulation as described herein, these being further features of the invention.
- ³⁵ [0027] Preferred concentrations of a pharmaceutically-acceptable alcohol present in any of the above formulations are; at least 3%w/v, at least 5%w/v, at least 7%w/v, at least 10% w/v, at least 11% w/v, at least 12% w/v, at least 13% w/v, at least 14% w/v, at least 15% w/v and, preferably, at least 16% w/v. Preferred maximal concentrations of pharmaceutically-acceptable alcohol present in the formulation are ;28% w/v or less, 22% w/v or less and 20% w/v or less. Preferred ranges of pharmaceutically-acceptable alcohol present in any of the above formulations are selected from
- any minimum or maximum value described above and preferably are; 3-35%w/v, 4-35%w/v, 5-35%w/v, 5-32%w/v, 7-32%w/v, 10-30%w/v, 12-28%w/v, 15-25%w/v, 17-23%w/v, 18-22%w/v and ideally 19-21%w/v.
 [0028] The pharmaceutically-acceptable alcohol may consist of one alcohol or a mixture of two or more alcohols, preferably a mixture of two alcohols. Preferred pharmaceutically-acceptable alcohols for parenteral administration are ethanol, benzyl alcohol or a mixture of both ethanol and benzyl alcohol, preferably the ethanol and benzyl alcohol are
- ⁴⁵ present in the formulation in the same w/v amounts. Preferably the formulation alcohol contains 10% w/v ethanol and 10% w/v benzyl alcohol.

[0029] The pharmaceutically-acceptable non-aqueous ester solvent may consist of one or a mixture of two or more pharmaceutically-acceptable non-aqueous ester solvents, preferably just one. A preferred pharmaceutically-acceptable non-aqueous ester solvent for parenteral administration is selected from benzyl benzoate, ethyl oleate, isopropyl myristate, isopropyl palmitate or a mixture of any thereof.

[0030] The ricinoleate vehicle should preferably be present in the formulation in a proportion of at least 30% weight per volume of the formulation, ideally at least 40% or at least 50% weight per volume of formulation.

[0031] It will be understood by the skilled person that the pharmaceutically-acceptable alcohol will be of a quality such that it will meet pharmacopoeial standards (such as are described in the US, British, European and Japanese pharmacopoeias) and as such will contain some water and possibly other organic solvents, tor example ethanol in the US Pharmacopeia contains not less than 94.9% by volume and not more than 96.0% by volume of ethanol when measured at 15.56°C. Dehydrated alcohol in the US Pharmacopeia contains not less than 94.9% by volume acceptable alcohol solvents.

7

when measured at 15.56°C.

[0032] Preferred concentrations of the pharmaceutically-acceptable non-aqueous ester solvent present in any of the above formulations are; at least 5% w/v, at least 8% w/v, at least 10% w/v, at least 11% w/v, at least 12% w/v, at least 13% w/v, at least 15% w/v, at least 16% w/v, at least 17% w/v, at least 18% w/v, at least 19% w/v and at least 20% w/

- v. Preferred maximal concentrations of the pharmaceutically-acceptable non-aqueous ester solvent are; 60% w/v or less, 50% w/v or less, 45% w/v or less, 40% w/v or less, 35% w/v or less, 30% w/v or less and 25% w/v or less. A preferred concentration is 15% w/v. Preferred ranges of pharmaceutically-acceptable non-aqueous ester solvent present in any of the above formulations are selected from any minimum or maximum value described above and preferably are; 5-60% w/v, 7-55% w/v, 8-50% w/v, 10-50% w/v, 10-45% w/v, 10-40% w/v, 10-35% w/v, 10-30% w/v,
- 10-25% w/v, 12-25% w/v, 12-22% w/v, 12-20% w/v, 12-18% w/v, 13-17% w/v and ideally 14-16% w/v. Preferably the ester solvent is benzyl benzoate, most preferably at about 15% w/v.
 [0033] It will be understood by the skilled person that the pharmaceutically-acceptable non-aqueous ester solvent will be of a quality that it will meet pharmacopoeial standards (such as described in the US, British, European and Japanese pharmacopoeias).
- ¹⁵ **[0034]** Preferred combinations of pharmaceutically-acceptable alcohol and pharmaceutically-acceptable non-aqueous ester solvent in the formulation are set out below:

	Pharmaceutically-acceptable alcohol(%w/v)	Pharmaceutically-acceptable non-aqueous ester (%w/v)
20	10-30	5-60, 7-55, 8-50, 10-50, 10-45, 10-40, 10-35, 10-30, 10-25, 12-25, 12-22, 12-20, 12-18, 13-17 and ideally 14-16.
25	17-23	5-60, 7-55, 8-50, 10-50, 10-45, 10-40, 10-35, 10-30, 10-25, 12-25, 12-22, 12-20, 12-18, 13-17 and ideally 14-16.
	3-35, 4-35, 5-35, 5-32, 7-32, 10-30, 12-28, 15-25, 17-23, 18-22 and ideally 19-	10-35
30	3-35, 4-35, 5-35, 5-32, 7-32, 10-30, 12-28, 15-25, 17-23, 18-22 and ideally 19-21.	12-18
	ethanol and benzyl alcohol, most preferably each at about 10%	benzyl benzoate, most preferably at about 15%

35

40

45

[0035] By the use of the term ricinoleate vehicle we mean an oil which has as a proportion (at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% w/v) of its composition as triglycerides of ricinoleic acid. The ricinoleate vehicle may be a synthetic oil or conveniently is castor oil, ideally of pharmacopoeial standards, as described above.

[0036] We have surprisingly found that the above formulations of the invention provide, after intra-muscular injection, satisfactory release of fulvestrant over an extended period of time.

[0037] This finding is indeed surprising for the following reasons.

1. Previously tested by the applicants have been intra-muscular injections of fulvestrant in the form of an aqueous suspension. We have found extensive local tissue irritation at the injection site as well as a poor release profile. It is believed that the tissue irritation/inflammation was due to the presence of fulvestrant in the form of solid particles.

The release profile appeared to be determined by the extent of inflammation/irritation present at the injection site and this was variable and diffcult to control. Also the fulvestrant release rate was not sufficiently high to be clinically significant.

2. Our findings from studies using ¹⁴C labelled benzyl alcohol show that it dissipates rapidly from the injection site and is removed from the body within 24 hours of administration.

50

[0038] It would be expected that ethanol will dissipate at least as quickly, if not more rapidly, from the injection site. **[0039]** It is known that benzyl benzoate is metabolised by conjugation to glycine to form hippuric acid by the human liver and excreted into the urine - Martindale: The Extra Pharmacopoeia 32nd edition page 1103, and, therefore, it is unlikely that benzyl benzoate, when used, is present at the injection site during the whole of the extended release period.

55 [0040] We have found that despite the rapid elimination of the additional solubilising excipients, i.e. the alcohol and pharmaceutically-acceptable non-aqueous ester solvent, from the formulation vehicle and the site of injection after injection of the formulation, extended release at therapeutically significant levels of fulvestrant over an extended period

can still achieved by the formulation of the invention.

[0041] By use of the term "therapeutically significant levels" we mean that blood plasma concentrations of at least 2.5 ngml⁻¹, ideally at least 3 ngml⁻¹, at least 8.5 ngml⁻¹, and up to 12 ngml⁻¹ of fulvestrant are achieved in the patient. Preferably blood plasma levels should be less than 15 ngml⁻¹.

- ⁵ **[0042]** By use of the term "extended release" we mean at least two weeks, at least three weeks, and, preferably at least four weeks of continuous release of fulvestrant is achieved. In a preferred feature extended release is achieved for 36 days. Preferably extended release of fulvestrant is for at least 2- 5 weeks and more preferably for the following periods (weeks) 2.5-5, 2.5-4, 3-4, 3.5-4 and most preferably for at least about 4 weeks.
- [0043] It will be understood that the attendant physician may wish to administer the intramuscular injection as a
 divided dose, i.e. a 5ml formulation is sequentially administered in two separate injections of 2.5ml, this is a further feature of the invention

[0044] Simply solubilising fulvestrant in an oil based liquid formulation is not predictive of a good release profile or lack of precipitation of drug after injection at the injection site.

[0045] Table 3 shows the solubility of fulvestrant in a castor oil vehicle additionally containing alcohols ethanol and benzyl alcohol with or without benzyl benzoate. The results clearly show the positive effect of benzyl benzoate on fulvestrant solubility in castor oil, despite fulvestrant having a lower solubility in benzyl benzoate than in either alcohol or castor oil.

20			
25			
30			
35			
40			
45			
50			
55			

5	ر ¢۲۵		15		15		15		to 100	102			
10	STOR OIL AT		15		15				to 100	76			
15	<u>Table 3 - EFFECT OF BENZYL BENZOATE ON FULVESTRANT SOLUBILITY IN CASTOR OIL AT 35⁰C</u>		10		10		15		to 100	65			
20	ANT SOLUBI		10		10				to 100	45			
25	<u>Table 3</u> FULVESTR/	2											
30	<u>T</u> TE ON FU	∧/m %	10		5		15		to 100	54			
35	YL BENZOA		10		5				to 100	46			
40	T OF BENZ		\$		5		15		to100	36			
45	3 - EFFEC				٠				00				
50	Table		S		Ś				l to 100	nt 27	_		
55			Ethanol	(%96)	Benzyl	Alcohol	Benzyl	Benzoate	Castor Oil	Fulvestrant	Solubility	[mgm] ⁻¹]	

MYLAN PHARMS. INC. EXHIBIT 1002 PAGE 111

10

[0046] The following Table 4 shows the solubility of fulvestrant in a range of oil based formulations which contain the same amounts of alcohol and benzyl benzoate but in which the oil is changed. The data also shows solubility of fulvestrant after removal of the alcohols.

Table 4

5

10

15

Solubility comparisons of fulve	estrant in oil based formulations v	with and without alcohols				
	Fulvestrant Solubility mg ml ⁻¹ @ 25°C					
Formulation ^(a)	Complete vehicle	Vehicle minus alcohols				
Castor oil based	81.2	12.6				
Miglyol 812-N based	86.8	1.7				
Sesame seed/Castor oil (1:1) based	70.1	4.4				
Sesame seed oil based	45.7	0.7				
Arachis oil based	40.2	< 0.2				

(a) Complete Vehicle Formulations comprised ethanol [96%](10%), benzyl alcohol (10%) and benzyl benzoate (15%) made to volume with the stated oil. Excess fulvestrant was added to each solvent mixture and solubility determined.

20

25

	Days						
Formulation ^a	2	3	4	7	10	30	51
Formulation F1 castor oil based	0	0	0	0	0	0	0
Formulation F2 Miglyol 812-N based	++ b	+++	+++	+++	+++	++	0
Formulation F3 sesame seed oil/castor oil based	+ c	++	++	+++	++	+	+

30

^a Formulations comprised fulvestrant (5%), ethanol [96%] (10%), benzyl alcohol (10%) and benzyl benzoate (15%) made to volume with the stated oil. ^b Mainly large needle shaped crystals

^C Small needles and/or sheafs of crystals

³⁵ [0047] Precipitation of fulvestrant and the release profile was determined with the above formulations in an *in vivo* rabbit study.

[0048] Figure 1 shows the release profile *in vivo* of the four formulations from the second part of Table 4 and shows the effect of the fixed oil component on fulvestrant plasma profile over five days following intramuscular administration in rabbits (data normalised to 50mg per 3kg; mean given; number of animals per timepoint = 8, plasma samples assayed for fulvestrant content using lc-ms/ms detection following solvent extraction). As can be seen the castor oil formulation

- ⁴⁰ showed a particularly even release profile with no evidence of precipitation of fulvestrant at the injection site.
 [0049] Therefore we present as a further feature of the invention an extended release pharmaceutical formulation adapted for intramuscular injection comprising fulvestrant; 35% (preferably 30% or ideally 25%) or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% (preferably at least 5% or ideally 10%)
- weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and sufficient amount of a ricinoleate vehicle, taking into account the addition of any further optional pharmaceutically-acceptable excipients, so as to prepare a formulation of at least 45mgml⁻¹ of fulvestrant.
 [0050] A further feature of the invention is a pharmaceutical formulation adapted for intramuscular injection, as defined above, for use in medical therapy.
- 50 [0051] A further feature of the invention is the treatment of a benign or malignant diseases of the breast or reproductive tract, preferably treating breast cancer, by administration to a human in need of such treatment by intramuscular injection an extended release ricinoleate vehicle based pharmaceutical formulation comprising at least 45mgml⁻¹ of fulvestrant; 35% (preferably 30% or ideally 25%) or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% (preferably at least 5% or ideally 10%) weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation.

[0052] Preferably 5ml of the intramuscular injection is administered.

[0053] A further feature of the invention is use of fulvestrant in the preparation of a pharmaceutical formulation as describe hereinabove, for the treatment of a benign or malignant disease of the breast or reproductive tract, preferably

treating breast cancer.

5

[0054] Additional excipients commonly used in the formulation field including, for example, an antioxidant preservative, a colorant or a surfactant may be used. A preferred optional excipient is a surfactant.

[0055] As described above fulvestrant is useful in the treatment of oestrogen-dependent indications such as breast cancer and gynaecological conditions, such as endometriosis.

[0056] In addition to fulvestrant another similar type of molecule is currently under clinical investigation. SH-646 (11β-fluoro-7α-(14,14,15,15,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl)estra-1,3,5(10)-triene-3,17β-diol) is also putatively a compound with the same mode of action as fulvestrant and has a very similar chemical structure. It is believed that the compound will also share with fulvestrant similar physical properties and therefore the current invention will also have application with this compound.

[0057] A further feature of the invention is a pharmaceutical formulation adapted for intra-muscular injection comprising 11β -fluoro- 7α -(14,14,15,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl)estra-1,3,5(10)-triene-3,17 β -diol; 35% or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible within a ricinoleate vehicle per volume of formulation

 and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml⁻¹ of 11β-fluoro-7α-(14,14,15,15,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl)estra-1,3,5(10)-triene-3,17β-diol.
 [0058] Further features of the invention are those as described above but in which SH-646 is substituted for fulvestrant.

20 Formulation Example

[0059] Fulvestrant is mixed with alcohol and benzyl alcohol, stirring until completely dissolved. Benzyl benzoate is added and the solution is made to final weight with castor oil and stirred, (for convenience weight is used rather than volume by using the weight to volume ratio). The bulk solution is overlaid with Nitrogen. The solution is sterilised by filtration using one or two filtrates of 0.2 up perception.

- filtration using one or two filters of 0.2µm porosity. The sterile filtrate is kept under a nitrogen overlay as it is filled under aseptic conditions into washed and depyrogenised, sterile primary containers, for example vials or pre-filled syringes. An overage is included in the primary pack to facilitate removal of the dose volume. The primary packs are overlaid with sterile nitrogen, before aseptically sealing.
- 30 See also process flow diagram below

[0060] Quantities of each component of the formulation is chosen according to the required formulation specification, examples are described above. For example quantities are added of each component to prepare a formulation which contains


10% weight per volume of benzyl alcohol
10% weight per volume of ethanol
15% weight per volume of benzyl benzoate
250mg of fulvestrant for each 5ml of finished formulation and the remaining amount as castor oil

40

4	5

50

55



FLOW DIAGRAM OF MANUFACTURING

6. Wakeling AE, Bowler J. Biology and mode of action of pure antioestrogens. Journal Steroid Biochemistry 1988;

3: 141-7.

Claims

1. A pharmaceutical formulation comprising fulvestrant in a ricinoleate vehicle, a pharmaceutically acceptable nonaqueous ester solvent, and a pharmaceutically acceptable alcohol wherein the formulation is adapted for intramuscular administration and attaining a therapeutically significant blood plasma fulvestrant concentration for at least 2 weeks.

10

15

5

- 2. A pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 30% or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation which is capable after injection of attaining a therapeutically significant blood plasma fulvestrant concentration for at least 2 weeks.
 - **3.** A pharmaceutical formulation as claimed in claim 1 or 2 wherein the blood plasma fulvestrant concentration attained is at least 2.5ngml⁻¹ for at least 2 weeks..
- 4. A pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 30% or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml⁻¹ of fulvestrant.
- A pharmaceutical formulation as claimed in claim 1 to 4 which contains 25% w/v or less of a pharmaceuticallyacceptable alcohol.
 - 6. A pharmaceutical formulation as claimed in claim 5 which contains 20% w/v or less of a pharmaceutically-acceptable alcohol.
- 30
- 7. A pharmaceutical formulation as claimed in claim 5 which contains 15-25% w/v of a pharmaceutically acceptable alcohol.
- 8. A pharmaceutical formulation as claimed in claim 5 which contains 17-23% w/v of a pharmaceutically acceptable
 alcohol.
 - 9. A pharmaceutical formulation as claimed in any claim from 1 to 8 which contains 60% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.
- 40 **10.** A pharmaceutical formulation as claimed in claim 9 which contains 50%w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.
 - **11.** A pharmaceutical formulation as claimed in claim 9 which contains 45% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

45

50

- **12.** A pharmaceutical formulation as claimed in claim 9 which contains 40% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.
- **13.** A pharmaceutical formulation as claimed in claim 9 which contains 35% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.
- 14. A pharmaceutical formulation as claimed in claim 9 which contains 30% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.
- **15.** A pharmaceutical formulation as claimed in claim 9 which contains 25% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.
 - 16. A pharmaceutical formulation as claimed in claim 9 which contains 10-25% w/v of a pharmaceutically acceptable

non-aqueous ester solvent.

- **17.** A pharmaceutical formulation as claimed in claim 9 which contains 12-18% w/v of a pharmaceutically acceptable non-aqueous ester solvent.
- 5
- **18.** A pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 15-25% weight of a pharmaceutically-acceptable alcohol per volume of formulation, 10-25% weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml⁻¹ of fulvestrant.
- 10
- 19. A pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 17-23% weight of a pharmaceutically-acceptable alcohol per volume of formulation, 12-18 % weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml⁻¹ of fulvestrant.
- 15
- **20.** A pharmaceutical formulation as claimed in any claim from 1 to 19 wherein the pharmaceutically-acceptable alcohol is a mixture of ethanol and benzyl alcohol.
- 21. A pharmaceutical formulation as claimed in any claim from 1 to 20 wherein the pharmaceutically-acceptable non-aqueous ester solvent is selected from benzyl benzoate, ethyl oleate, isopropyl myristate, isopropyl palmitate or a mixture of any thereof.
 - **22.** A pharmaceutical formulation as claimed in any claim from 1 to 21 wherein the pharmaceutically-acceptable non-aqueous ester solvent is benzyl benzoate.
- 25
- 23. A pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 15-25% weight of a pharmaceutically-acceptable alcohol per volume of formulation, 10-25 % weight of benzyl benzoate in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml⁻¹ of fulvestrant.
- 30
- 24. A pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 17-23% weight of a pharmaceutically-acceptable alcohol per volume of formulation, 12-18 % weight of benzylbenzoate in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml⁻¹ of fulvestrant.
- 35
- **25.** A pharmaceutical formulation according to claim 23 or 24 wherein the pharmaceutically-acceptable alcohol is a mixture of ethanol and benzyl alcohol.
- 26. A pharmaceutical formulation according to claim 25 wherein the ethanol and benzyl alcohol are present at aboutequal % weight per volume of formulation.
 - **27.** A pharmaceutical formulation as claimed in any claim from 1 to 26 wherein the total volume of the formulation is 6ml, or less, and the concentration of fulvestrant is at least 45mgml⁻¹.
- 45 28. A pharmaceutical formulation as claimed in any claim from 1 to 27 wherein the total amount of fulvestrant in the formulation is 250mg, or more, and the total volume of the formulation is 6ml, or less.
 - **29.** A pharmaceutical formulation as claimed in claim 28 wherein the total amount of fulvestrant in the formulation is 250mg and the total volume of the formulation is 5 to 5.25ml.
- 50
- **30.** A pharmaceutical formulation as claimed in any of claims 1-29 wherein the pharmaceutically-acceptable alcohol is a mixture of 10% weight of ethanol per volume of formulation, 10% weight of benzyl alcohol per volume of formulation, and the formulation contains 15% weight of benzyl benzoate per volume of formulation and the ricinoleate vehicle is castor oil.
- 55
- **31.** A pharmaceutical formulation adapted for intramuscular injection, as defined in any claim from 1 to 30, for use in medical therapy.

- **32.** Use of fulvestrant in the preparation of a pharmaceutical formulation, as defined in any claim from 1 to 30, for the treatment of a benign or malignant disease of the breast or reproductive tract.
- **33.** A syringe or vial containing a pharmaceutical formulation as defined in claim 30.

5

Patentansprüche

- Pharmazeutische Formulierung, enthaltend Fulvestrant in einer Ricinoleat-Trägersubstanz, ein pharmazeutisch annehmbares nichtwässriges Esterlösungsmittel und einen pharmazeutisch annehmbaren Alkohol, wobei die Formulierung zur intramuskulären Anwendung und Erzielung einer mindestens 2 Wochen anhaltenden, therapeutisch signifikanten Fulvestrantkonzentration im Blutplasma geeignet ist.
- Pharmazeutische Formulierung zur intramuskulären Injektion, enthaltend Fulvestrant, jeweils bezogen auf das Volumen der Formulierung 30 Gew.-% oder weniger eines pharmazeutisch annehmbaren Alkohols und mindestens 1 Gew.-% eines in einer Ricinoleat-Trägersubstanz mischbaren, pharmazeutisch annehmbaren nichtwässrigen Esterlösungsmittels, sowie eine zur Herstellung einer nach Injektion zur Erzielung einer mindestens 2 Wochen anhaltenden, therapeutisch signifikanten Fulvestrantkonzentration im Blutplasma geeigneten Formulierung ausreichende Menge einer Ricinoleat-Trägersubstanz.
- 20

25

- **3.** Pharmazeutische Formulierung nach Anspruch 1 oder 2, bei der die im Blutplasma erzielte Fulvestrantkonzentration mindestens 2 Wochen lang mindestens 2,5 ngml⁻¹ beträgt.
- Pharmazeutische Formulierung zur intramuskulären Injektion, enthaltend Fulvestrant, jeweils bezogen auf das Volumen der Formulierung 30 Gew.-% oder weniger eines pharmazeutisch annehmbaren Alkohols und mindestens 1 Gew.-% eines in einer Ricinoleat-Trägersubstanz mischbaren, pharmazeutisch annehmbaren nichtwässrigen Esterlösungsmittels, sowie eine zur Herstellung einer Formulierung mit mindestens 45 mgml⁻¹ Fulvestrant ausreichende Menge einer Ricinoleat-Trägersubstanz.
- Pharmazeutische Formulierung nach Anspruch 1 bis 4, die 25% w/v oder weniger eines pharmazeutisch annehmbaren Alkohols enthält.
 - 6. Pharmazeutische Formulierung nach Anspruch 5, die 20% w/v oder weniger eines pharmazeutisch annehmbaren Alkohols enthält.

35

- 7. Pharmazeutische Formulierung nach Anspruch 5, die 15-25% w/v eines pharmazeutisch annehmbaren Alkohols enthält.
- 8. Pharmazeutische Formulierung nach Anspruch 5, die 17-23% w/v eines pharmazeutisch annehmbaren Alkohols
 40 enthält.
 - **9.** Pharmazeutische Formulierung nach einem der Ansprüche 1 bis 8, die 60% w/v oder weniger eines pharmazeutisch annehmbaren nichtwässrigen Esterlösungsmittels enthält.
- 45 10. Pharmazeutische Formulierung nach Anspruch 9, die 50% w/v oder weniger eines pharmazeutisch annehmbaren nichtwässrigen Esterlösungsmittels enthält.
 - **11.** Pharmazeutische Formulierung nach Anspruch 9, die 45% w/v oder weniger eines pharmazeutisch annehmbaren nichtwässrigen Esterlösungsmittels enthält.
- 50

55

- **12.** Pharmazeutische Formulierung nach Anspruch 9, die 40% w/v oder weniger eines pharmazeutisch annehmbaren nichtwässrigen Esterlösungsmittels enthält.
- **13.** Pharmazeutische Formulierung nach Anspruch 9, die 35% w/v oder weniger eines pharmazeutisch annehmbaren nichtwässrigen Esterlösungsmittels enthält.
 - 14. Pharmazeutische Formulierung nach Anspruch 9, die 30% w/v oder weniger eines pharmazeutisch annehmbaren nichtwässrigen Esterlösungsmittels enthält.

- **15.** Pharmazeutische Formulierung nach Anspruch 9, die 25% w/v oder weniger eines pharmazeutisch annehmbaren nichtwässrigen Esterlösungsmittels enthält.
- 16. Pharmazeutische Formulierung nach Anspruch 9, die 10-25% w/v eines pharmazeutisch annehmbaren nichtwässrigen Esterlösungsmittels enthält.
- 17. Pharmazeutische Formulierung nach Anspruch 9, die 12-18% w/v eines pharmazeutisch annehmbaren nichtwässrigen Esterlösungsmittels enthält.
- 10 18. Pharmazeutische Formulierung zur intramuskulären Injektion, enthaltend Fulvestrant, jeweils bezogen auf das Volumen der Formulierung 15-25 Gew.-% eines pharmazeutisch annehmbaren Alkohols und 10-25 Gew.-% eines in einer Ricinoleat-Trägersubstanz mischbaren, pharmazeutisch annehmbaren nichtwässrigen Esterlösungsmittels, sowie eine zur Herstellung einer Formulierung mit mindestens 45 mgml⁻¹ Fulvestrant ausreichende Menge einer Ricinoleat-Trägersubstanz.
- 15

20

30

35

40

5

- 19. Pharmazeutische Formulierung zur intramuskulären Injektion, enthaltend Fulvestrant, jeweils bezogen auf das Volumen der Formulierung 17-23 Gew.-% eines pharmazeutisch annehmbaren Alkohols und 12-18 Gew.-% eines in einer Ricinoleat-Trägersubstanz mischbaren, pharmazeutisch annehmbaren nichtwässrigen Esterlösungsmittels, sowie eine zur Herstellung einer Formulierung mit mindestens 45 mgml⁻¹ Fulvestrant ausreichende Menge einer Ricinoleat-Trägersubstanz.
- 20. Pharmazeutische Formulierung nach einem der Ansprüche 1 bis 19, bei der es sich bei dem pharmazeutisch annehmbaren Alkohol um ein Gemisch aus Ethanol und Benzylalkohol handelt.
- 25 21. Pharmazeutische Formulierung nach einem der Ansprüche 1 bis 20, bei der das pharmazeutisch annehmbare nichtwässrige Esterlösungsmittel unter Benzylbenzoat, Ethyloleat, Isopropylmyristat, Isopropylpalmitat oder einem beliebigen Gemisch davon ausgewählt ist.
 - **22.** Pharmazeutische Formulierung nach einem der Ansprüche 1 bis 21, bei der es sich bei dem pharmazeutisch annehmbaren nichtwässrigen Esterlösungsmittel um Benzylbenzoat handelt.
 - **23.** Pharmazeutische Formulierung zur intramuskulären Injektion, enthaltend Fulvestrant, jeweils bezogen auf das Volumen der Formulierung 15-25 Gew.-% eines pharmazeutisch annehmbaren Alkohols und 10-25 Gew.-% Benzylbenzoat in einer Ricinoleat-Trägersubstanz, sowie eine zur Herstellung einer Formulierung mit mindestens 45 mgml⁻¹ Fulvestrant ausreichende Menge einer Ricinoleat-Trägersubstanz.
 - 24. Pharmazeutische Formulierung zur intramuskulären Injektion, enthaltend Fulvestrant, jeweils bezogen auf das Volumen der Formulierung 17-23 Gew.-% eines pharmazeutisch annehmbaren Alkohols und 12-18 Gew.-% Benzylbenzoat in einer Ricinoleat-Trägersubstanz, sowie eine zur Herstellung einer Formulierung mit mindestens 45 mgml⁻¹ Fulvestrant ausreichende Menge einer Ricinoleat-Trägersubstanz.
 - **25.** Pharmazeutische Formulierung nach Anspruch 23 oder 24, bei der es sich bei dem pharmazeutisch annehmbaren Alkohol um ein Gemisch aus Ethanol und Benzylalkohol handelt.
- 45 26. Pharmazeutische Formulierung nach Anspruch 25, bei der der gew.-%ige Anteil an Ethanol und Benzylalkohol pro Volumen Formulierung jeweils etwa gleich ist.
 - **27.** Pharmazeutische Formulierung nach einem der Ansprüche 1 bis 26, bei der das Gesamtvolumen der Formulierung 6 ml oder weniger und die Fulvestrantkonzentration mindestens 45 mgml⁻¹ ausmachen.
- 50

55

- **28.** Pharmazeutische Formulierung nach einem der Ansprüche 1 bis 27, bei der die Gesamtmenge an Fulvestrant in der Formulierung 250 mg oder mehr und das Gesamtvolumen der Formulierung 6 ml oder weniger ausmachen.
- **29.** Pharmazeutische Formulierung nach Anspruch 28, bei der die Gesamtmenge an Fulvestrant in der Formulierung 250 mg und das Gesamtvolumen der Formulierung 5 bis 5,25 ml ausmachen.
 - **30.** Pharmazeutische Formulierung nach einem der Ansprüche 1 bis 29, bei der es sich bei dem pharmazeutisch annehmbaren Alkohol um ein Gemisch von, jeweils bezogen auf das Volumen der Formulierung, 10 Gew.-% Etha-

nol und 10 Gew.-% Benzylalkohol handelt, und die Formulierung pro Volumen 15 Gew.-% Benzylbenzoat enthält, und es sich bei der Ricinoleat-Trägersubstanz um Rizinusöl handelt.

- **31.** Pharmazeutische Formulierung zur intramuskulären Injektion gemäß Definition eines der Ansprüche 1 bis 30 zur Verwendung in der medizinischen Therapie.
 - **32.** Verwendung von Fulvestrant bei der Herstellung einer wie in einem der Ansprüche 1 bis 30 definierten pharmazeutischen Formulierung zur Behandlung gutartiger oder bösartiger Erkrankungen der Brust oder des Reproduktionstrakts.

10

5

33. Spritze oder Fläschchen, enthaltend eine wie in Anspruch 30 definierte pharmazeutische Formulierung.

Revendications

- 15
- 1. Préparation pharmaceutique comprenant du fulvestrant dans un véhicule de ricinoléate, un solvant d'ester non aqueux acceptable d'un point de vue pharmaceutique et un alcool acceptable d'un point de vue pharmaceutique, dans laquelle la préparation est adaptée à une administration intramusculaire et atteint une concentration en fulvestrant dans le plasma sanguin significative d'un point de vue thérapeutique pendant au moins 2 semaines.
- 20
- 2. Préparation pharmaceutique adaptée à une injection intramusculaire comprenant du fulvestrant, 30% ou moins en poids d'un alcool, acceptable d'un point de vue pharmaceutique, par volume de préparation, au moins 1% en poids d'un solvant d'ester non aqueux, acceptable d'un point de vue pharmaceutique et miscible dans un véhicule de ricinoléate, par volume de préparation et une quantité suffisante d'un véhicule de ricinoléate, de sorte à élaborer une préparation qui soit capable, après injection, d'atteindre une concentration en fulvestrant dans le plasma sanguin significative d'un point de vue thérapeutique pendant au moins 2 semaines.
- **3.** Préparation pharmaceutique selon la revendication 1 ou 2, dans laquelle la concentration en fulvestrant dans le plasma sanguin atteinte est de 2,5 ng.ml⁻¹ au moins pendant 2 semaines au moins.
- 30

35

25

4. Préparation pharmaceutique adaptée à une injection intramusculaire comprenant du fulvestrant, 30% ou moins en poids d'un alcool, acceptable d'un point de vue pharmaceutique, par volume de préparation, au moins 1% en poids d'un solvant d'ester non aqueux, acceptable d'un point de vue pharmaceutique et miscible dans un véhicule de ricinoléate, par volume de préparation et une quantité suffisante d'un véhicule de ricinoléate, de sorte à élaborer une préparation à 45 mg.ml⁻¹ au moins de fulvestrant.

- 5. Préparation pharmaceutique, selon les revendications 1 à 4, qui contient 25% p/v ou moins d'un alcool acceptable d'un point de vue pharmaceutique.
- 40 6. Préparation pharmaceutique, selon la revendication 5, qui contient 20% p/v ou moins d'un alcool acceptable d'un point de vue pharmaceutique.
 - 7. Préparation pharmaceutique, selon la revendication 5, qui contient de 15 à 25% p/v d'un alcool acceptable d'un point de vue pharmaceutique.
- 45

50

- **8.** Préparation pharmaceutique, selon la revendication 5, qui contient de 17 à 23% p/v d'un alcool acceptable d'un point de vue pharmaceutique.
- 9. Préparation pharmaceutique, selon l'une quelconque des revendications 1 à 8, qui contient 60% p/v ou moins d'un solvant d'ester non aqueux acceptable d'un point de vue pharmaceutique.
 - **10.** Préparation pharmaceutique, selon la revendication 9, qui contient 50% p/v ou moins d'un solvant d'ester non aqueux acceptable d'un point de vue pharmaceutique.
- 55 11. Préparation pharmaceutique, selon la revendication 9, qui contient 45% p/v ou moins d'un solvant d'ester non aqueux acceptable d'un point de vue pharmaceutique.
 - 12. Préparation pharmaceutique, selon la revendication 9, qui contient 40% p/v ou moins d'un solvant d'ester non

aqueux acceptable d'un point de vue pharmaceutique.

- **13.** Préparation pharmaceutique, selon la revendication 9, qui contient 35% p/v ou moins d'un solvant d'ester non aqueux acceptable d'un point de vue pharmaceutique.
- **14.** Préparation pharmaceutique, selon la revendication 9, qui contient 30% p/v ou moins d'un solvant d'ester non aqueux acceptable d'un point de vue pharmaceutique.
- 15. Préparation pharmaceutique, selon la revendication 9, qui contient 25% p/v ou moins d'un solvant d'ester non aqueux acceptable d'un point de vue pharmaceutique.
 - **16.** Préparation pharmaceutique, selon la revendication 9, qui contient de 10 à 25% p/v d'un solvant d'ester non aqueux acceptable d'un point de vue pharmaceutique.
- 15 **17.** Préparation pharmaceutique, selon la revendication 9, qui contient de 12 à 18% p/v d'un solvant d'ester non aqueux acceptable d'un point de vue pharmaceutique.
 - 18. Préparation pharmaceutique adaptée à une injection intramusculaire comprenant du fulvestrant, 15 à 25% en poids d'un alcool, acceptable d'un point de vue pharmaceutique, par volume de préparation, 10 à 25% en poids d'un solvant d'ester non aqueux, acceptable d'un point de vue pharmaceutique et miscible dans un véhicule de
- 20 d'un solvant d'ester non aqueux, acceptable d'un point de vue pharmaceutique et miscible dans un véhicule de ricinoléate, par volume de préparation et une quantité suffisante d'un véhicule de ricinoléate, de sorte à élaborer une préparation à 45 mg.ml⁻¹ au moins de fulvestrant.
- 19. Préparation pharmaceutique adaptée à une injection intramusculaire comprenant du fulvestrant, 17 à 23% en poids d'un alcool, acceptable d'un point de vue pharmaceutique, par volume de préparation, 12 à 18% en poids d'un solvant d'ester non aqueux, acceptable d'un point de vue pharmaceutique et miscible dans un véhicule de ricinoléate, par volume de préparation et une quantité suffisante d'un véhicule de ricinoléate, de sorte à élaborer une préparation à 45 mg.ml⁻¹ au moins de fulvestrant.
- 30 20. Préparation pharmaceutique selon l'une quelconque des revendications 1 à 19, dans laquelle l'alcool acceptable d'un point de vue pharmaceutique est un mélange d'éthanol et d'alcool benzylique.
 - 21. Préparation pharmaceutique selon l'une quelconque des revendications 1 à 20, dans laquelle le solvant d'ester non aqueux, acceptable d'un point de vue pharmaceutique, est choisi parmi : le benzoate de benzyle ; l'oléate d'éthyle ; le myristate d'isopropyle ; le palmitate d'isopropyle ; ou un mélange de n'importe lesquels d'entre eux.
 - **22.** Préparation pharmaceutique selon l'une quelconque des revendications 1 à 21, dans laquelle le solvant d'ester non aqueux, acceptable d'un point de vue pharmaceutique, est le benzoate de benzyle.
- 23. Préparation pharmaceutique adaptée à une injection intramusculaire comprenant du fulvestrant, 15 à 25% en poids d'un alcool, acceptable d'un point de vue pharmaceutique, par volume de préparation, 10 à 25% en poids de benzoate de benzyle, dans un véhicule de ricinoléate, par volume de préparation et une quantité suffisante d'un véhicule de ricinoléate, de sorte à élaborer une préparation à 45 mg.ml⁻¹ au moins de fulvestrant.
- 45 24. Préparation pharmaceutique adaptée à une injection intramusculaire comprenant du fulvestrant, 17 à 23% en poids d'un alcool, acceptable d'un point de vue pharmaceutique, par volume de préparation, 12 à 18% en poids de benzoate de benzyle, dans un véhicule de ricinoléate, par volume de préparation et une quantité suffisante d'un véhicule de ricinoléate, de sorte à élaborer une préparation à 45 mg.ml⁻¹ au moins de fulvestrant.
- 50 25. Préparation pharmaceutique selon la revendication 23 ou 24, dans laquelle l'alcool, acceptable d'un point de vue pharmaceutique, est un mélange d'éthanol et d'alcool benzylique.
 - **26.** Préparation pharmaceutique selon la revendication 25, dans laquelle l'éthanol et l'alcool benzylique sont présents avec des % en poids environ égaux par volume de préparation.
- 55

35

5

27. Préparation pharmaceutique selon l'une quelconque des revendications 1 à 26, dans laquelle le volume total de la préparation est de 6 ml ou moins et la concentration en fulvestrant est de 45 mg.ml⁻¹ au moins.

- **28.** Préparation pharmaceutique selon l'une quelconque des revendications 1 à 27, dans laquelle la quantité totale de fulvestrant dans la préparation est de 250 mg ou plus et le volume total de la préparation est de 6 ml ou moins.
- **29.** Préparation pharmaceutique selon la revendication 28, dans laquelle la quantité totale de fulvestrant dans la préparation est de 250 mg et le volume total de la préparation est de 5 à 5,25 ml.
 - **30.** Préparation pharmaceutique selon l'une quelconque des revendications 1 à 29, dans laquelle l'alcool, acceptable d'un point de vue pharmaceutique, est un mélange de 10% en poids d'éthanol par volume de préparation, de 10% en poids d'alcool benzylique par volume de préparation, la préparation contient 15% en poids de benzoate de benzyle par volume de préparation et le véhicule de ricinoléate est de l'huile de castor.
- **31.** Préparation pharmaceutique adaptée à une injection intramusculaire, selon l'une quelconque des revendications 1 à 30, à utiliser dans une thérapie médicale.
- 32. Utilisation de fulvestrant dans l'élaboration d'une préparation pharmaceutique, selon l'une quelconque des revendications 1 à 30, destinée au traitement d'une maladie bénigne ou maligne du sein ou de l'appareil reproducteur.
 - 33. Seringue ou flacon contenant une préparation pharmaceutique, selon la revendication 30.

5

10

25

30


35

40

45

50

55



21

INFORMATION DISCLOSURE CITATION				Attorney Docket No. 056291-5004-02			Application No. 12/285,887			
	(Us	e several sheets if nec	essary)	Ap	Applicants: John R. EVANS et al.					
	PTO Form 1449 June 4, 2009				iling Date: October 15, 2	2008	Group Art Unit: 1617			
			U.S. PA'	TEN	T DOCUMENTS					
Initial		Document No.	Date		Name	Class	Sub-Class	Filing Date		
	1.	2,822,316	February 4, 1958	3	Richter et al.					
	2.	2,983,649	May 9, 1961		Ercoli et al.					
	3.	3,541,209	November 17, 197		Neumann et al.					
	4.	RE 28,690	January 20, 1976		Lehmann et al.					
	5.	4,048,309	September 13, 197		Chen et al.					
	6.	4,048,310	September 13, 197	77	Chen et al.					
	7.	4,659,516	April 21, 1987		Bowler et al.					
	8.	4,888,331	December 19, 198		Elger et al.					
	9.	5,095,129	March 10, 1992		Ottow et al.					
	10.	5,183,814	February 2, 1993		Dukes		+			
	11.	5,484,801	January 16, 1996		Al-Razzak et al.		+			
	12.	5,733,902	March 31, 1998		Schneider					
	13.	<u>5,929,030</u> 20010006963	July 27, 1999		Hamied et al.		+			
	14.	20010006965	July 5, 2001		Lachnit-Fixson et al.		+			
			FORFICN	PAT	ENT DOCUMENTS					
		Document No.	Date		Country	Class	Sub-Class	Translation		
	15.	EP 0138504	Apr., 1985		EP	01435		1 i unsiution		
	16.	EP 0346014	Dec., 1989		EP					
	17.	EP 0819431	Mar., 1999		EP					
	18.	EP 0905143	Mar., 1999		EP					
	19.	FR 6241	Sep., 1968		France			Abstract		
	20.	GB 817241	Jul., 1959		GB					
	21.	GB 1126892	Sep., 1968		GB					
	22.	GB 1207571	Oct., 1970		GB					
	23.	GB 1569286	Jun., 1980		GB					
	24.	JP 43-27327	Nov., 1992		Japan					
	25.	JP 09-208496	Dec., 1997		Japan			Abstract		
	26.	JP 10-203982	Apr., 1998		Japan					
	27.	JP 10-152438	Jun., 1998		Japan	ļ	<u> </u>	Abstract		
	28.	JP 11-501649	Feb., 1999		Japan					
	29.	JP 11-158200	Jun., 1999		Japan			A 1 / /		
	30.	SU 549118	Mar., 1977		Soviet Union		+	Abstract		
	31.	SU 676284	Jul., 1979		Soviet Union			Abstract		
	32.	WO 95/12383	May., 1995		WIPO		+	Abstract		
		OTHER DO	OCUMENTS (Includ	ding A	Author, Title, Date, Per	tinent Pa	ges, etc.)			
Examiner	II		Date C	Consid	lered					
Examiner	• Initial	if reference considere	d whether or not cita:	ition i	s in conformance with M	[PEP 609	draw line the	rough citation if not in		
					ext communication to app					

INFORMATION DISCLOSURE CITATION				Attorney Docket No 056291-5004-02	•	Application No. 12/285,887					
	(U	se several sheets if nece	ssary)	Applicants: John R. EVANS et al.							
		PTO Form 1449 June 4, 2009]	Filing Date: October 15,	2008	Group Art Unit: 1617				
			U.S. PA	ATENT DOCUMENTS							
Initial		Document No.	Date		Name	Class	Sub-Class	Filing Date			
		1		РАТ	CENT DOCUMENTS						
		Document No.	Date		Country	Class	Sub-Class	Translation			
	33.	WO 96/19997	Jul., 1996		WIPO			Abstract			
	34.	WO 97/21440	Jun., 1997		WIPO						
	35.	WO 97/37653	Oct., 1997		WIPO			Abstract			
	36.	WO 97/40823	Nov., 1997		WIPO						
	37.	WO 98/11902	Mar., 1998		WIPO			Abstract			
	38.	WO 99/27906	Jun., 1999		WIPO						
	39.	ZA 681014	Feb., 1968		South Africa						
	40.	ZA 682530	Apr., 1968		South Africa						
		OTHER DO	CUMENTS (Inclué	ling	Author, Title, Date, Pe	rtinent Pa	oes. etc.)				
	41.				in Injektionen", Pharm,			a) nn 781-787			
	42. Davis et al., "17-Alpha-Hydroxyprogestero										
		And Metabolism, 1955			aproate		, sectore ,	b. chin Endourmon			
	43.			phic effects of pure antioestrogen. ICI 182,780, the uterus in ovariectomized monkeys							
		Endocrinology, 1992, V	Vol. 135, pp. 239-24	7	-						
	44.				re antioestrogen ICI 182,	780qu	antitative mag	gnetic resonance			
		imaging"; J. Endocrino	ology, 1992, Vol. 138	3, pp.	203-209						
	45.				cal and anti-tumour effec			estrogen ICI 182780 in			
					urnal of Cancer, 1996, V						
	46.			estro	gen (ICI 182780) in tame	oxifen-resi	stant breast c	ancer", The Lancet,			
	4.5	Jan. 7, 1995, pp. 29-30					1 * 1 * 1	D 1 1 1			
	47.			r mje	ections of testosterone es	ter in oil v	ehicle", Hum	an Reproduction, vol.			
	40	10, no. 4, pp, 869-865,			1 D 1000 1000	1101					
	48.				al Press, 1999, pp. 1099-		000 1100	1104			
	49.				Alcohol"; Pharmaceutic			2-1104			
	50.				harmaceutical Press, 199			A 1			
	51.				oate Used as a Vehicle fo	or Antiand	rogens on the	Adrenal Cortex",			
	52	Archives of Andrology			Duna Stanaidal Antiagtura	on With T	hass of Tame	wifen in a Madal of			
	52.				Pure Steroidal Antiestrog						
	53				Cancer, May 1995, Vol.						
	 53. Pellegrino, "Use of 17 α Hydroxyprogesterone Caproate in Threatened Abortion", Current Therapeutic Research, V 4, No. 6, June, 1962, pp. 301-305 54. Piver et al., "Medroxyprogesterone Acetate (Depo-Provera) vs Women with Metastatic Endometrial 						apeune Research, voi.				
							ometrial				
Adenocarcinoma", Cancer, Vol. 45, American Cancer Society, 1980, pp. 268-272						ometriar					
	55.	Remington's Pharmace				200 212					
			sector Serences, 10th								
Examiner		1	Date C	Consi	dered						
					is in conformance with M		draw line the	rough citation if not in			
conforman	ice and	l not considered. Include	copy of this form w	rith n	ext communication to ap	plicant.					

INFORMATION DISCLOSURE CITATION			Attorney Docket No. 056291-5004-02			Application No. 12/285,887			
	(U	se several sheets if nece	essary)	Applicants: John R. EVANS et al.					
		PTO Form 1449 June 4, 2009		F	iling Date: October 15, 2	2008	Group	9 Art Unit: 1617	
			U.S. PA	TEN	T DOCUMENTS				
Initial		Document No.	Date		Name	Class	Sub-Class	Filing Date	
			FOREIGN	РАТ	ENT DOCUMENTS				
	Document No. Date				Country	Class	Sub-Class	Translation	
		OTHER DO	CUMENTS (Includ	ding 4	Author, Title, Date, Pert	inent Pa	ges, etc.)		
	56.	Riffkin et al., "Castor	Oil as a Vehicle for P	Parent	eral Administration of Sto			rnal of Pharmaceutical	
	57	Sciences, Vol. 53, No.				•			
	57.				multicentre study compar ICI 182,780 with tamoxifi				
					d Annual San Antonio Bro				
		San Antonio, Breast C	ancer Research and T	Freatr	nent 1999; 57 (1; special :	issue); p.	31		
	58.				H82,780 Exacerbates Iscl	hemic Inj	ury in Femal	e Mouse", Journal of	
	59.	Vidal, Le Dictionnaire			No. 1, 2000, pp. 112-118. rd" 1998 pg 201				
	60.	Vidal, Le Dictionnaire							
	61.	Vidal, Le Dictionnaire	, "Parabolan", 1997,	pg. 11	245				
	62.	Vidal, Le Dictionnaire							
	63.	3867-3873	-		rogen with Clinical Poten				
	64.	182,780"; Laboratory .	Animal Science, 1993	3, Vo	gtailed MonkeyTreated 1. 43, No. 3, 1993, pp. 24'	7-251		-	
	65.	"Pharmaceutical dosag Lachman, 1992	ge forms: Parenteral n	nedic	ations, Volume 1", 2nd e	dition, ed	ited by Avis,	Lieberman and	
Examiner	I	I	Date C	Consid	lered				
	• Initio	1 if reference considere	d whether or not gits	tioni	s in conformance with M	<u>ΡΕΡ ΚΛΟ·</u>	draw line th	rough citation if not in	
					ext communication to app			iougn chanon it not in	



WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :		(11) International Publication Number: WO 99/27906
A61K 9/08, 47/14, 47/44, 31/70, 31/365	A1	(43) International Publication Date: 10 June 1999 (10.06.99)
 (21) International Application Number: PCT/US (22) International Filing Date: 14 September 1998 ((30) Priority Data: 	14.09.9	 CA, CN, CU, CZ, ÉE, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY,
60/067,3743 December 1997 (03.12.97)9809792.67 May 1998 (07.05.98)	/	 KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
 (71) Applicants (for all designated States except US): MI CO., INC. [US/US]; 126 East Lincoln Avenue, Rai 07065 (US). MERIAL LLC [US/US]; 2100 Rons ISD – 200F, Iselin, NJ 08830–3077 (US). 	hway, I	LI I
 (72) Inventors; and (75) Inventors/Applicants (for US only): WILLIAMS, J [US/US]; 126 East Lincoln Avenue, Rahway, N (US). CHERN, Rey, T. [US/US]; 126 East Lincoln Rahway, NJ 07065 (US). 	VJ 0700	55
(74) Common Representative: MERCK & CO., INC.; Lincoln Avenue, Rahway, NJ 07065 (US).	126 Ea	ist

(54) Title: LONG ACTING INJECTABLE FORMULATIONS CONTAINING HYDROGENATED CASTOR OIL

(57) Abstract

This invention relates to novel, long-acting injectable formulations. These formulations comprise: (a) a therapeutic agent selected from the group consisting of, e.g., insecticides, acaricides, parasiticides, growth enhancers and oil-soluble NASIDS; (b) hydrogenated castor oil and (c) a hydrophobic carrier comprising: (i) triacetin, benzyl benzoate or ethyl oleate or a combination thereof; and (ii) acylated monoglycerides, propyl dicaprylates/dicaprates or caprylic/capric acid triglycerides or a combination thereof. Also provided herein is a method for the treatment or prevention of various disease states by the parental administration of the invention formulations.

FOR THE PURPOSES OF INFORMATION ONLY

.

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	тт	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	МХ	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Кепуа	NL	Netherlands	YU	Yugoslavia
СН	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
СМ	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	РТ	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TITLE OF THE INVENTION LONG ACTING INJECTABLE FORMULATIONS CONTAINING HYDROGENATED CASTOR OIL

5 CROSS REFERENCE TO RELATED APPLICATIONS

Reference is made to provisional U.S. application Serial No. 60/067,374, filed on December 3, 1997. That application, as well as all documents cited herein and all documents cited in documents cited herein, are hereby incorporated by reference.

10

SUMMARY OF THE INVENTION

This invention is concerned with the unexpectedly long duration of activity which is observed when injectable formulations containing certain therapeutic agents are prepared using hydrogenated

- 15 castor oil and a combination of hydrophobic or water immiscible carriers. Thus, it is an object of this invention to provide such a prolonged therapeutic effect. An additional object is to describe the therapeutic agents which may be employed in the long acting formulations. A still further object is to provide additional components
- 20 which may be employed in the formulations. Additional objects will become apparent from a reading of the following description.

BACKGROUND OF THE INVENTION

- The therapeutic agents which are used in the inventive formulations are well known to the practitioner to which this invention pertains. Classes of therapeutic agents contemplated by the inventive formulations include insecticides, acaricides, parasiticides, growth enhancers, and oil-soluble, nonsteroidal anti-inflammatory drugs (NSAIDS). Specific classes of compounds which fall within these
- 30 classes include, for example, avermectins, milbemycins, nodulisporic acid and its derivatives, estrogens, progestins, androgens, substituted pyridylmethyl derivatives, phenylpyrazoles, and COX-2 inhibitors.

- 1 -

PCT/US98/19016

WO 99/27906

.

The avermectin and milbemycin series of compounds are potent anthelmintic and antiparasitic agents against a wide range of internal and external parasites. The compounds which belong to this series are either natural products or are semi-synthetic derivatives

- 5 thereof. The structure of these two series of compounds are closely related and they both share a complex 16-membered macrocyclic lactone ring; however, the milbemycins do not contain the disaccharide substitutent in the 13-position of the lactone ring. The natural product avermectins are disclosed in U.S. Patent 4,310,519 to Albers-Schonberg,
- 10 et al., and the 22, 23-dihydro avermectin compounds are disclosed in Chabala, et al., U.S. Patent 4,199,569. For a general discussion of avermectins, which include a discussion of their uses in humans and animals, see "Ivermectin and Abamectin," W.C. Campbell, ed., Springer-Verlag, New York (1989). Naturally occurring milbemycins
- 15 are described in Aoki et al., U.S. Patent 3,950,360 as well as in the various references cited in "The Merck Index" 12th ed., S. Budavari, Ed., Merck & Co., Inc. Whitehouse Station, New Jersey (1996). Semisynthetic derivatives of these classes of compounds are well known in the art and are described, for example, in U.S. Patent 5,077,308, U.S. Patent
- 4,859,657, U.S. Patent 4,963,582, U.S. Patent 4,855,317, U.S. Patent 4,871,719, U.S. Patent 4,874,749, U.S. Patent 4,427,663, U.S. Patent 4,310,519, U.S. Patent 4,199,569, U.S. Patent 5,055,596, U.S. Patent 4,973,711, U.S. Patent 4,978,677, and U.S. Patent 4,920,148.
- European Patent Application 413,538 relates to an injectable formulation containing an avermectin compound and triacetin. European Patent Application 535,734 relates to an injectable formulation containing an avermectin compound and hydrogenated castor oil in a hydrophobic carrier such as triacetin. The formulations in both European Patent Applications are said to provide efficacy against
- 30 external and internal parasites in animals only for up to 42 days. Neither of these applications suggests or teaches how to manipulate the composition of the formulation in order to achieve efficacy beyond 42 days.

- 2 -

5

Nodulisporic acid and its derivatives are a class of acaricidal, antiparasitic, insecticidal and anthelminitic agents known to a practitioner of the art. These compounds are used to treat or prevent infections in humans and animals. These compounds are described, for example, in U.S. Patent 5,399,582 and WO 96/29073. Additionally, the

- compounds can be administered in combination with other insecticides, parasiticides, and acaricides. Such combinations include anthelminitic agents, such as those discussed above which include ivermectin, avermectin, and emamectin, as well as other agents such as
- 10 thiabendazole, febantel or morantel; phenylpyrazoles such as fipronil; and insect growth regulators such as lufenuron. Such combinations are also contemplated in the present invention.

Generally, all classes of insecticides are provided for in this invention. One example of this class include substituted pyridylmethyl derivatives such as imidacloprid. Agents of this class are described, for example, in U.S. Patent 4,742,060 or in EP 892,060. It would be well within the skill level of the practitioner to decide which individual compound can be used in the inventive formulation to treat a particular infection of an insect.

20 Phenylpyrazoles are another class of insecticides which possess excellent insecticidal activity against all insect pests including blood-sucking pests such as ticks, fleas etc., which are parasites on animals. This class of agents kills insects by acting on the gamma-butyric acid receptor of invertebrates. Such agents are described, for
25 example, in U.S. Patent No. 5,567,429, U.S. Patent No. 5,122,530, and EP 295,117. It would be well within the skill level of the practitioner to decide which individual compounds can be used in the inventive formulations.

Insect growth regulators are another class of insecticides or acaricides, which are also provided for in the inventive formulations. Compounds belonging to this group are well known to the practitioner and represent a wide range of different chemical classes. These compounds all act by interfering with the development or growth of the

- 3 -

PCT/US98/19016

WO 99/27906

.

insect pests. Insect growth regulators are described, for example, in U.S. Patent 3,748,356; U.S. patent 3,818,047; U.S. Patent 4,225,598; U.S. Patent 4,798,837; and U.S. Patent 4,751,225, as well as in EP 179,022 or U.K. 2,140,010. Again, it would be well within the skill level of the

5 practitioner to decide which individual compounds can be used in the inventive formulation.

Estrogens, progestins, and androgens refers to classes of chemical compounds which are also well known to a practitioner in this art. In fact, estrogens and progestins are among the most widely

- 10 prescribed drugs and are used, for example, alone or in combination for contraception or hormone replacement therapy in post menopausal women. Estrogens and progestins occur naturally or are prepared synthetically. This class of compounds also includes estrogens or progesterone receptor antagonists. Antiestrogens, such as tamoxifen
- 15 and clomiphene, are used to treat breast cancer and infertility. Antiprogestives are used as contraceptives and anticancer drugs, as well as to induce labor or terminate a pregnancy.

The androgens and antiandrogens structurally related to the estrogens and progestins as they are also biosynthesized from

- 20 cholesterol. These compounds are based on testosterone. Androgens are used for hypogonadism and promote muscle development. Antiandrogens are used, for example, in the management of hyperplasia and carcinoma of the prostate, acne, and male pattern baldness as well as in the inhibition of the sex drive in men who are sex
- offenders. Estrogen, progestins, and androgens are described, for example, in "Goodman & Gilman's The Pharmacological Basis of Therapeutics," 9th ed., J.G. Handman and L. Elimbird, eds., Ch. 57 to 60, pp. 1411-1485, McGraw Hill, New York (1996) or in "Principles of Medicinal Chemistry," 2nd ed., W.O. Foye, ed., Ch. 21, pp. 495-559, Lea & Febigen Philadelphic (1981).
- 30 Febiger, Philadelphia (1981).

Estrogens, progestins and androgens are also used in animal husbandry as growth promoters for food animals. It is known in the art that compounds of these classes act as growth-promoting steroids

- 4 -

PCT/US98/19016

in animals such as cattle, sheep, pigs, fowl, rabbits, etc. Delivery systems to promote the growth of animals are described, for example, in U.S. Patent 5,401,507, U.S. Patent 5,288,469, U.S. Patent 4,758,435, U.S. Patent 4,686,092, U.S. Patent 5,072,716 and U.S. Patent 5,419,910.

 $\mathbf{5}$

.

NSAIDS are well known in the art. The classes of compounds which belong to this group include salicylic acid derivatives, para-aminophenol derivatives, indole and indene acetic acids, heteroaryl acetic acids, arylpropionic acids, anthranilic acids (fenamates), enolic acids, and alkanones. NSAIDS exert their activity by

- 10 interfering with prostaglandin biosynthesis by irreversibly or reversibly inhibiting cycloxygenase. Also included are COX-2 inhibitors which act by inhibiting the COX-2 receptor. Compounds of this group possess analgesic, antipyretic and nonsteroidal anti-inflammatory properties. Compounds belonging to these classes are described, for example, in
- 15 Chapter 27 of Goodman and Gilman on pages 617 to 658 or in Ch. 22 of Foye on pages 561 to 590 as well as in U.S. Patents 3,896,145; U.S. Patent 3,337,570; U.S. Patent 3,904,682; U.S. Patent 4,009,197; U.S. Patent 4,223,299; and U.S. Patent 2,562,830, as well as the specific agents listed in The Merck Index. This invention contemplates those compounds that are oil-soluble.

These and other embodiments are disclosed or are obvious from and encompassed by the following Detailed Description of the Invention.

25 DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a long acting injectable formulation for use in human and veterinary medicine, depending on the selected specific therapeutic agent and the indication being treated. The inventive formulation comprises:

30 (a) a therapeutic agent selected from the group consisting of , e.g., insecticides, acaricides, parasiticides, growth enhancers, and oil-soluble NSAIDS,

(b) hydrogenated castor oil, and

- 5 -

15

PCT/US98/19016

(c) a hydrophobic carrier comprising:

(i) triacetin, benzyl benzoate, or ethyl oleate or a combination thereof,

(ii) acylated monoglycerides, propyl

5 dicaprylates/dicaprates and caprylic acid/capric triglycerides.

More preferred, are long-acting injectable formulations wherein

 (a) a therapeutic agent selected from the group consisting of, e.g., avermectins, milbemycins, nodulisporic acid and its
 10 derivatives, estrogens, progestins, androgens, phenylpyrazoles and COX-2 inhibitors,

(b) hydrogenated castor oil, and

(c) a hydrophobic carrier comprising:

(i) triacetin, benzyl benzoate, or ethyl oleate or a combination thereof,

(ii) acetylated monoglycerides, propyl dicaprylates/dicaprates, or caprylic/capric acid triglycerides or a combination thereof.

The formulations of the present invention considerably 20 prolong the duration of activity. By the term "acyl" Applicants mean an organic acid group in which the OH of the carboxyl group is replaced by some other substituent; i.e., RCO wherein R is, for example a C₁-C₁₀alkyl group or a carbocyclic aromatic or a heteroaromatic group. Examples of such groups include acetyl, propionyl, butyryl, isobutyryl,

- 25 and benzoyl. The term "prolonged duration of activity" means that the activity of the therapeutic agent is extended beyond the time period normally achieved when the therapeutic agent is injected into a host using a conventional, prior art carrier. As conventional injectable formulations are well known in the art, a skilled practitioner could
- 30 readily understand the meaning of this term. Generally, depending upon the agent, host, and disease state, activity can be prolonged for a period from up to 120 days to up to 180 days. Preferable time periods in which the duration of the agent is prolonged includes from 14 days to 180

- 6 -

PCT/US98/19016

days, 30 days to 150 days, 42 days to 120 days, and 60 days to 90 days. While not wishing to be bound by theory, it is believed this increase in activity is achieved because the inventive formulations significantly increase the plasma concentration in tissue for an extended period of

- 5 time by up to about 2 weeks to about 24 weeks, with time periods of up to about 6, 8, 10, 12, 16 and 20 weeks being observed. With respect to avermectins and milbemycins, the present formulations have been found to have a considerably prolonged duration against internal and external parasites over prior injectable formulation of avermectins or
- 10 milbemycins. In addition, the present formulations for avermectin and milbemycin provide significantly higher plasma levels at day 42 than prior long-acting formulations thereby producing efficacy for all relevant parasitic species.

Preferred long-acting injectable formulations comprise:

- (a) about 1.0 to about 10.0% w/v of a therapeutic agent,
- (b) about 1 to about 3% w/v of hydrogenated castor oil,

and

15

20

(c) a hydrophobic carrier comprising:

(i) about 30 to about 45% v/v of triacetin; benzyl benzoate or ethyl oleate; and

(ii) about 55 to 70% of v/v of acetylated monoglycerides, propyl dicaprylates/dicaprates, or caprylic/capric triglycerides.

Even more preferred are the above formulations wherein 25 about 1.0 to about 5.0% w/v of a therapeutic agent is present. Especially preferred are the inventive formulations wherein about 2.5 to about 5.0% w/v of a therapeutic agent is present.

Especially preferred long-acting formulation of the present invention comprises:

30

- (a) an avermectin or milbemycin compound,
- (b) hydrogenated castor oil, and
- (c) triacetin and acetylated monoglycerides.

-7-

PCT/US98/19016

In an especially preferred embodiment, the long-acting formulation comprises:

(a) about 1.0 to about 5.0% w/v of an avermectin or milbemycin compound,

5

.

about 0.5 to about 3.5% w/v of hydrogenated castor oil, (b) and

(c) about 30 to about 45% v/v of triacetin and about 55 to about 70% v/v of acetylated monoglycerides.

In a most preferred embodiment, the long-acting 10 formulation comprises:

> 3.15% w/v of ivermectin, (a)

1% w/v of hydrogenated castor oil, and (b)

(c) 40% v/v of triacetin and up to 60% v/v of acetylated monoglycerides.

15

Another aspect of the invention is to provide a method for the prevention or treatment of parasite or insect infestations in a host in need thereof for an extended period of time by administering a single dose of a long-acting injectable formulation comprising the appropriate therapeutic agent. That duration typically, for example, lasts from up to about 1 month to about six months, depending upon the agent, host and 20 indication being treated. Extensions of activity lasts from up to about 2 months to about 5 months and especially from up to 3 months to up to 4

- months are observed. A further aspect of this invention is to promote the growth in animals by administering a single long-acting formulation
- 25according to the present invention wherein the therapeutic agent is an estrogen, progestin, or androgen. Another aspect of the present invention is a method to treat inflammation, pain or fever for an extended period of time in a host in need thereof by administering a single-dose of a formulation according to the present invention wherein
- the therapeutic agents are oil-soluble NSAIDS. An especially preferred 30 aspect of the invention is to provide a method for the prevention or treatment of parasitic infestation in cattle for a minimum of 42 days which comprises administering to said cattle a single dose of a long-


- 8 -

acting injectable formulation according to the present invention where the therapeutic agent is an avermectin or milbemycin.

Therapeutic agents used in the invention formulations include all known avermectins, milbemycins, nodulisporic acid and its

- 5 derivatives, estrogens, progestins, androgens, oil-soluble NSAIDS, phenylpyrazoles, substituted pyridylmethyl compounds, and agents which act as insect growth regulators, which are compatible in the inventive formulations for their intended use. The ester and amide derivatives of these compounds, where applicable, as well as their salt
- 10 forms are also contemplated. Specific compounds which belong to these classes of therapeutic agents are well known to the practitioner of this art. Likewise, the specific disease state as well as the particular dose would be well known to the practitioner.
- Avermectins and milbemycins share the same common 16-15 membered macrocyclic lactone ring; however milbemycins do not possess the disaccharide substituent on the 13-position of the lactone ring.

While many avermectin compounds are known in the art, a representative structure of the class of compounds is as follows:



20

where the broken line indicates a single or a double bond at the 22,23positions;


 R_1 is hydrogen or hydroxy provided that R_1 is present only when the broken line indicates a single bond;

- 9 -

 R_2 is alkyl of from 1 to 6 carbon atoms or alkenyl of from 3 to 6 carbon atoms or cycloalkyl of from 3 to 8 carbon atoms;


 R_3 is hydroxy, methoxy or = NOR₅ where R_5 is hydrogen or lower alkyl; and

5 R_4 is hydrogen, hydroxy or



where R_6 is hydroxy, amino, mono-or di-lower alkylamino or lower alkanoylamino.

The preferred compounds are avermectin Bla/Blb 10 (abamectin), 22,23-dihydro avermectin Bla/Blb (ivermectin) and the 4"acetylamino-5-ketoximino derivative of avermectin Bla/Blb. Both abamectin and ivermectin are approved as broad spectrum antiparasitic agents. The structures of abamectin and ivermectin are as follows:




15 wherein for abamectin the broken line represents a double bond and R_1 is not present and for ivermectin the double bond represents a single bond and R_1 is hydrogen; and

- 10 -

PCT/US98/19016

 \mathbf{R}_2 is isopropyl or sec-butyl.

The 4"-acetylamino-5-ketoximino derivatives of avermectin Bla/Blb has the following structural formula:




5 where R_2 is isopropyl or sec-butyl.

The avermectin products are generally prepared as a mixture of at least 80% of the compound where R_2 is sec-butyl and no more than 20% of the compound where R_2 is isopropyl.


Other preferred avermectins, include ememectin, epinomectin and doramectin. Doramectin is disclosed in U.S. Patent 5,089,490 and EP 214738. This compound has the following structure:

- 11 -


-



In the present formulations, ivermectin is especially preferred. A representative structure for a milberrycin is that for milberrycin α_1 :



5 An especially preferred milbemycin is moxidectin, whose structure is as follows:



The compound is disclosed in U.S. Patent No. 5,089,490.

Insecticides contemplated by this invention are also well known in the art and such compounds include substituted pyridylmethyl derivatives and phenylpyrazoles. An especially preferred substituted pyridylmethyl derivative is imidacloprid. An especially preferred phenylpyrazole is fipronil, whose chemical name is 5-amino-3-cyano-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-trifluoromethylpyrazole. Fipronil is well known in the art as a flea and tick agent. Additional

10 insecticides included by the invention include insect growth regulators. Especially preferred insect growth regulators include diflubenzuron, lufenuron, methoprene, phenoxycarb, pyriproxyfen, and cyromazine.

Specific estrogen, progestin and androgen compounds are well known to the practitioner. Especially preferred compounds 15 belonging to this class include progesterone, estradiol benzoate and trenbolone acetate.

Oil-soluble NSAIDS are also well known to the practitioner. Classes of NSAIDS which are preferred are indole and indecene acetic acids and heteroaryl acetic acids. Especially preferred compounds

20 include indomethacin, ketorolac, caprofen, flunixin, ketoprofen, meloxicam, naproxen, and phenylbutazone.

Hydrogenated castor oil is refined, hydrogenated, and deodorized castor oil, consisting mainly of the triglyceride of

- 13 -

WO 99/27906

15

20

PCT/US98/19016

hydroxystearic acid. The hydrogenated castor oil is readily prepared using normal techniques known to those skilled in the art of preparing hydrogenated castor oils and one suitable form of hydrogenated castor oil is available commercially under the trade name "Thixcin R" from NL

- 5 Industries. While not wishing to be bound by theory, it appears that hydrogenated castor oil, being a waxy hydrophobic solid, is left at the injection site entrapping the therapeutic agent after the hydrophobic carrier has diffused from the injection site; it is this hydrophobic hydrogenated castor oil/therapeutic agent matrix that forms a "depot" of
- 10 the active material which slowly diffuses from the injection site over a prolonged period of time. The hydrogenated castor oil constitutes approximately 1% w/v of the present formulation.

The hydrophobic carrier of the present formulation comprises a mixture of

(i) triacetin, benzylbenzoate, ethyl oleate or a combination thereof; and

(ii) acylated monoglycerides, propyl dicaprylates/dicaprates, or caprylic/capric triglycerides or a combination thereof.

These compounds as well as their sources are well known in the art. For example, triacetin (glyceryl triacetate or glycerol triacetate) and acetylated monoglycerides (available under the tradename "Myvacet 9-45" from Quest International). The ratio of component (i) to component (ii) used in the present formulation is

- 25 generally from 45:55 to 30:70; preferably the ratio is approximately 40:60. In addition to the hydrogenated castor oil, the therapeutic agent and the hydrophobic carrier, the formulation can contain other inert ingredients such as antioxidants or preservatives. Antioxidant such as a propyl gallate, BHA (butylated hydroxy anisole), BHT (butylated hydroxy
- 30 toluene) monothioglycerol and the like may be added to the present formulation. The antioxidants are generally added to the formulation in amounts of from about 0.01 to about 2.0% (w/v). Preservatives such as

- 14 -

25

PCT/US98/19016

the parabens (methylparaben and/or propylparaben) are suitably used in the formulation in amounts ranging from about 0.01 to about 2.0 w/v.

The long-acting injectable formulation of the present invention may be prepared by adding a dispersion of hydrogenated castor oil in acetylated monoglycerides, propyl dicaprylates/dicaprates or caprylic/capric triglycerides to a solution comprising the therapeutic agent, and any other inert ingredients, in triacetin benzyl benzoate or ethyl oleate, and mixing the liquids until uniform. Since the long acting formulation is intended for injection, it is necessary that it be sterilized.

- 10 Heat sterilization is generally to be avoided in the situation where avermectin or milbemycin compounds are used since these compounds are unstable at autoclave temperatures. Rather, membrane sterilization is preferred in those situations with dissolved solids and gamma sterilization for the hydrogenated castor oil. The sterile hydrogenated
- 15 castor oil is dispersed in the product aseptically and then aseptically packaged.

The instant formulation is equally applicable to other compounds used for injection as long as such compounds are soluble in the mixture of the hydrogenated castor oil and hydrophobic carrier.

20 Additional compounds that can be used in this formulation are other antiparasitic agents and antibiotics, therapeutic vitamin and mineral supplements, and other agents that are assisted in their therapeutic effect by having their effects extended over a prolonged period of time. Again, such compounds would be well known to the practitioner.

The instant long-acting formulations are administered to a warm-blooded animals such as humans, cattle, sheep, pigs, cats, dogs, horses, and the like by intramuscular or subcutaneous injection. The amount of therapeutic agent depends on the individual therapeutic agent, the animal being treated, the disease state, and the severity of the

30 disease state. The determination of those factors is well within the skill level of the practitioner. Generally, such preparation normally contain about 0.0005 to about 50% w/v of therapeutic agent. Preferred formulations are those containing about 0.01 to 10% w/v of therapeutic

- 15 -

PCT/US98/19016

agent and especially preferred formulations are those containing about 2.5 to about 5% w/v of therapeutic agent. For the avermectins and milbemycins, the formulations will generally be prepared to administer from about 0.1 to about 2 mg/kg, preferably from about 0.4 to about 0.85

- 5 mg/kg and most preferably from about 0.6 to about 0.7 mg/kg of the active ingredient. At a preferred dose volume of about 1 ml to treat 50 kg of animal body weight the formulation contains from about 5 to about 50 mg of the active agent per ml of solution or about 0.5 to about 10%, w/v preferably about 2.5 to about 5% w/v. However, depending upon the
- 10 activity of the compound and the animal being treated, doses as low as about 0.3% w/v of the active ingredient are usable. For nodulisporic acid and its derivatives, a formulation containing about 0.0005 to about 5% w/v of the active compound is preferred.

The present formulation provides for an extended period of treatment. For avermectins and milbemycins a minimum of 42 days of activity against endo- and ectoparasites is obtained without causing tissue irritation. The extended period of time for the other therapeutic agents is readily determined by one skilled in the art and is determined by such factors as the therapeutic agent, disease state, host and severity

- 20 of the infection. While the previously reported avermectin formulation containing hydrogenated castor oil in triacetin did produce prolonged plasma level compared to a formulation without hydrogenated castor oil, it did not achieve a plasma level efficacious against all relevant parasitic species at the 42 day target. In contrast the present formulation using
- 25 avermectins or milbemycins surprisingly provides a significantly higher plasma at day 42 and beyond. The present formulation is also efficacious against ticks and Dermatobia hominis for up to 75 and 140 days, respectively.

The following example is provided in order that the 30 invention might be more fully understood. It is not to be construed as a limitation of the invention.

- 16 -

PCT/US98/19016

EXAMPLE 1

<u>Material</u>	<u>%</u>	\underline{Amount}
Ivermectin	3.15% w/w	17.6 gm
n-propyl gallate	0.02% w/w	0.10 gm
Thixcin R	1.0% w/w	5.0 gm
triacetin	40.0% w/w	200.0 gm
Myvacet 9-45	qs 100% w/w	qs to 500.0 gm

Triacetin was added to n-propyl gallate and ivermectin in an Erlenmyer flask and mixed until all of the n-propyl gallate dissolved. Myvacet 9-45 was placed in a non-glass beaker in a 50°C water bath, and mixed at a low speed with a dispersator mixer until the temperature of the content reached 50°C. Thixcin R was then added slowly to the vortex of the mixing Myvacet 9-45. When all the Thixcin R was added, the speed of the mixer was slowly increased to 60 rpm and mixing continued for 20 minutes. The beaker was remayed from the speet weth and

for 20 minutes. The beaker was removed from the water bath and allowed to cool to 30°C, while mixing continued at about 25 rpm. The triacetin solution was added to the Thixcin R/Myvacet 9-45 mixture and the liquids were mixed until uniform.

15

EXAMPLE 2

Material	<u>%</u>	<u>Amount/2000 L.</u>
Ivermectin triacetin hydrogenated castor oil BHT methylparaben propylparaben Myvacet 9-45	3.15% w/w 40.0% v/v 1.0% w/w 0.02 w/v 0.18% w/v 0.02% w/v qs 100% v/v	63.0 kg 800.0 L 20.0 kg 0.4 kg 3.6 kg 0.4 kg
My vacco v 40	49 100 % V/V	qs to $1200.0 \mathrm{L}$

Ivermectin, BHT, methyl and propyl paraben were 20 dissolved in 800 L of triacetin, and the solution was sterile filtered into a 2000 L tank equipped with an agitator. Myvacet 9-45 was sterile filtered into a 150 L tank capable of maintaining a batch temperature of 60°C and - 17 -

.

25

PCT/US98/19016

equipped with an agitator and with an aseptic addition of sterile powder capability. The gamma sterilized hydrogenated castor oil was dispersed in the Myvacet 9-45, and the dispersion was heated to 50°C, then transferred to the triacetin solution through a microfluidizer. The

5 liquids were mixed until uniform and then aseptically packaged in low density polyethylene containers.

EXAMPLE 3

- 10 The plasma levels of ivermectin administered once subcutaneously at a dose of 630 mcg/kg bodyweight were determined in cattle for two formulations: formulation I contains ivermectin 3.15%, npropyl gallate 0.02%, Thixcin R 1.5% and triacetin qs to 100%; formulation II has the composition given in Example 2. Ten animals
- 15 were used for formulation I and six were used for formulation II. Mean plasma levels (ng/ml) are shown in the following Table:

	Days post dosing					
<u>Formulation</u>	<u>3</u>	<u>14</u>	<u>21</u>	<u>28</u>	<u>35</u>	<u>42</u>
Ι	80	18	10	6	4	2
II	21	25	22	16	13	9

The mean plasma level for formulation II was greater than 20 3 ng/ml on day 70.

The 42-day plasma level of formulation I (2 ng/ml) is not sufficient to produce efficacy against Cooperia onocophora and Nematodirus which require an ivermectin plasma level of 3 to 4 ng/ml.

EXAMPLE 4

To facilitate the manufacture of large scale batches the following process was developed which results in a product that meets

- 18 -

.

the same release specifications as the product manufactured in Example 2. The formula is also the same as used in Example 2. Ivermectin, BHT, methyl and propyl paraben are dissolved a mixture of the triacetin and Myvacet 9-45. The solution is sterile filtered. The

5 gamma sterilized hydrogenated castor is aseptically dispersed in sterile solution using an in-line educator/homogenizer system. Such in-line system can be a Flashblend system. The product is heated and recirculated through the system until the product temperature is from 42 to 50°C. Then the product is aseptically packaged.

10

* * *

Having thus described in detail preferred embodiments of the present invention, it is to be understood that the invention defined by the appended claims is not to be limited by particular details set forth in the above description as many apparent variations thereof are possible

15 without departing from the spirit or scope thereof.

.

WHAT IS CLAIMED IS:

- 1. A long-acting injectable formulation comprising:
- (a) a therapeutic agent selected from the group
- 5 consisting of insecticides, acaricides, parasiticides, growth enhancers and oil-soluble NASIDS,
 - (b) hydrogenated castor oil, and
 - (c) a hydrophobic carrier comprising:
 - (i) triacetin, benzyl benzoate or ethyl oleate or a combination thereof; and
 - (ii) acylated monoglycerides, propyl dicaprylates/dicaprates, caprylic/capric acid triglycerides, or a combination thereof.

15

10

- 2. A long-acting injectable formulation comprising:
- (a) a therapeutic agent selected from the group consisting of avermectins, milbemycins, nodulisporic acid and its derivatives, estrogens, progestins, androgens, substituted pyridylmethyl derivatives, phenylpyrazoles, and COX-2 inhibitors,
- 20

- (b) hydrogenated castor oil, and
- (c) a hydrophobic carrier comprising:
- (i) triacetin, benzyl benzoate or ethyl oleate or a combination thereof; and
 - (ii) acetylated monoglycerides, propyl
- 25 dicaprylates/dicaprates, caprylic/capric triglycerides, or a combination thereof.

3. The long-acting injectable formulation according to claim 1 comprising

30

- (a) about 1.0 to about 10.0 w/v of a therapeutic agent;
- (b) about 0.3 to about 5% w/v of hydrogenated castor oil;
- (c) a hydrophobic carrier comprising:

(i) about 30 to about 45% v/v of triacetin; benzylbenzoate or ethyloleate; and

(ii) about 55 to 70% of v/v of acetylated monoglycerides, propyl dicaprylates/dicaprates, or caprylic/capric triglycerides.

4. The long-acting injectable formulation according to claim 2 comprising

(a) about 1.0 to about 10.0 w/v of a therapeutic agent;

(b) about 0.3 to about 5% w/v of hydrogenated castor oil;

(c) a hydrophobic carrier comprising:

(i) about 30 to about 45% v/v of triacetin; benzyl benzoate or ethyl oleate; and

(ii) about 55 to 70% of v/v of acetylated

15 monoglycerides, propyl dicaprylates/dicaprates, or caprylic/capric triglycerides.

The long-acting injectable formulation according to claim 2 wherein about 2.5 to about 5.0% w/v of a therapeutic agent is
 present.

6. The long-acting injectable formulation according to claim 2 wherein the therapeutic agent is an avermectin or a milbemycin.

25

7. The long-acting injectable formulation according to claim 6, wherein the avermectin is ivermectin, abamectin, ememectin, eprinomectin, or doramectin and the milbemycin is moxidectin.

30 8. The long-acting injectable formulation according to claim 2, wherein the therapeutic agent is an estrogen, progestin or androgen.

- 21 -

MYLAN PHARMS. INC. EXHIBIT 1002 PAGE 148

10

5

9. The long-acting injectable formulation according to claim 8, where the estrogen, progestin or androgen is estradiol benzoate, progesterone, or trenbolone acetate.

5 10. The long-acting injectable formulation according to claim 2, wherein the therapeutic agent is nodulisporic acid or its derivatives.

The long-acting injectable formulation according to
 claim 2, wherein the therapeutic agent is a substituted pyridylmethyl derivative or a phenylpyrazole.

 The long-acting injectable formulation according to claim 11, wherein the therapeutic agent is imidacloprid or fipronil.

13. The long-acting injectable formulation according to claim 2, wherein the therapeutic agent is a COX-2 inhibitor.

The long-acting injectable formulation according to
 claim 1, wherein the therapeutic agent is an oil-soluble, nonsteroidal anti-inflammatory drug.

 The long-acting injectable formulation according to claim 14, wherein the therapeutic agent is carprofen, flunixin,
 ketoprofen, meloxicam, naproxen or phenylbutazone.

16. The long-acting injectable formulation according to claim 1, wherein the therapeutic agent is an insect growth regulator.

30 17. The long-acting injectable formulation according to claim 16, wherein the therapeutic agent is diflubenzuron, lufenuron, methoprene, phenoxycarb, pyriproxyfen, and cyromazine.

- 22 -

PCT/US98/19016

18. The long-acting injectable formulation according to claim 1, which further comprises an antioxidant or a preservative.

19. The long-acting injectable formulation according to 5 claim 2 where about 1 to about 3.0 % w/v of hydrogenated caster oil is present and hydrophobic carrier comprises about 40% v/v of triacetin, benzlybenzoate or ethyloleate and about 60% v/v of acetylated monoglycerides, propyl dicaprylates/dicaprates, or caprylic/capric triglycerides.

10

20. The long-acting injectable formulation of claim 2 which comprises:

(a) about 1.0 to about 5.0% w/v of an avermectin compound,

15

(b) about 1 to about 3% w/v of hydrogenated castor oil, and

(c) about 30 to about 45% v/v of triacetin and 55 to 70% v/v of acetylated monoglycerides.

20 21. The long-acting injectable formulation of claim 2 which comprises:

(a) about 3.15% w/v of ivermectin,

(b) about 1% w/v of hydrogenated castor oil, and

(c) about 40% of triacetin and up to about 60% v/v of 25 acetylated monoglycerides.

22. The long-acting injectable formulation of claim 2 which further comprises an antioxidant.

30 23. The long acting injectable formulation of claim 2 which further comprises a preservative.

- 23 -

PCT/US98/19016

24. The long acting injectable formulation of claim 22 wherein said antioxidant is selected from n-propyl gallate, BHA, BHT and monothioglycerol.

5 25. The long-acting injectable formulation of claim 23 wherein said preservative is selected from the parabens.

26. The long-acting injectable formulation of claim 21
which further comprises an antioxidant selected from n-propyl gallate,
10 BHA, BHT and monothioglycerol.

27. The long-acting injectable formulation of claim 26 which further comprises a preservatives selected from the parabens.

- 15 28. The long acting injectable formulation of claim 21 which further comprises BHT and one or more preservatives from the parabens.
- 29. A method for the prevention or treatment of parasitic
 20 infestation in a host in need thereof, which comprises parentally
 administering a single dose of a long-acting injectable formulation of
 claim 6 to said host.
- 30. A method for the prevention or treatment of parasitic 25 infestation in a host in need thereof for a minimum of 42 days which comprises administering to said host a single dose of a long-acting injectable formulation of claim 1.

31. A method for the prevention or treatment of parasitic
 30 infestation in cattle for a minimum of 42 days which comprises
 administering to said cattle a single dose of a long-acting injectable
 formulation of claim 2.

- 24 -

PCT/US98/19016

32. A method for the prevention or treatment of parasitic infestation in cattle for a minimum of 42 days which comprises administering to said cattle a single dose of a long-acting injectable formulation of claim 21.

5

33. A method for treating or preventing insect infestation for an extended period of time in a host in need thereof which comprises parentally administering a single-dose of a long-acting injectable formulation according to claim 10 to said host.

10

34. The method according to claim 33, wherein the insects are fleas.

- 35. A method for treating or preventing insect infestation 15 for an extended period of time in a host in need thereof which comprises parenterally administering a single-dose of a long-acting injectable formulation according to claim 11 to said host.
- 36. The method according to claim 35 wherein the 20 injectable formulation as the therapeutic agent is imidacloprid or fipronil and the insects are fleas.

37. A method for promoting growth in animals which comprises administering a single does of a long-acting injectable
25 formulation according to claim 8 to said animal.

38. A method for treating inflammation, pain, or fever for an extended period of time in a host in need thereof which comprises administering a single-dose of a long-acting injectable formulation
30 according to claim 14 to a host in need thereof.

- 25 -

-	INTERNATIONAL SEARCH H	EPORT	Interr hal App	lication No		
			PCT/US 98			
a. classi IPC 6	FICATION OF SUBJECT MATTER A61K9/08 A61K47/14 A61K47/4	4 A61K31/	70 A61K	31/365		
	o International Patent Classification (IPC) or to both national classifica	tion and IPC				
	SEARCHED					
IPC 6	Minimum documentation searched (classification system followed by classification symbols) IPC 6 A61K					
	tion searched other than minimum documentation to the extent that su					
Electronic d	ata base consulted during the international search (name of data bas	e and, where practical	, search terms used)		
	ENTS CONSIDERED TO BE RELEVANT					
Category °	Citation of document, with indication, where appropriate, of the rele	vant passages		Relevant to claim No.		
Α	WO 97 11709 A (ASHMONT HOLDINGS LTD ;HARVEY COLIN MANSON (NZ)) 3 April 1997 see page 4 - page 5; examples 1-6			1–38		
A	EP 0 413 538 A (MERCK & CO INC) 20 February 1991 cited in the application see page 4 - page 5; example 1			1–38		
Α	GB 1 060 632 A (OLIN MATHISON CHEMICAL CORP.) 8 March 1967 see page 3; example 2			1-38		
A	EP 0 535 734 A (MERCK & CO INC) 1-38 7 April 1993 cited in the application see page 4 - page 5; example 1			1–38		
	_	/				
X Furth	ner documents are listed in the continuation of box C.	X Patent family	members are listed	in annex.		
° Special ca	tegories of cited documents :	T" later document pub				
consid	 "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international "B" document but published on or after the international 					
filing d	filing date A document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to					
 "O" document referring to an oral disclosure, use, exhibition or other means "O" document referring to an oral disclosure, use, exhibition or other means "O" document referring to an oral disclosure, use, exhibition or other means 						
	"P" document published prior to the international filing date but in the art. later than the priority date claimed "&" document member of the same patent family					
Date of the a	Date of the actual completion of the international search Date of mailing of the international search report					
3	3 February 1999 11/02/1999					
Name and n	nailing address of the ISA	Authorized officer				
	European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Boulois, D					

Form PCT/ISA/210 (second sheet) (July 1992)

1

INTERNATIONAL SEARCH REPORT

-

Inc. .ational application No.

	Observations where certain claims were found unsearchable (Continu	ation of item 1 of first sheet)				
	amational Search Bonort has not have established in second of an data static					
1. X	shallonal bearch hepoin has not been established in respect of certain claims under A	This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:				
 X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Remark: Although claims 29-38 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. 						
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with th an extent that no meaningful International Search can be carried out, specifically:	ne prescribed requirements to such				
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the secor					
Box II	Observations where unity of invention is lacking(Continuation of item	2 of first sheet)				
1.	As all required additional search fees were timely paid by the applicant, this Internatio searchable claims.	onal Search Report covers all				
2.	As all searchable claims could be searched without effort justifying an additional fee, of any additional fee.	this Authority did not invitepayment				
3.	As only some of the required additional search fees were timely paid by the applicant covers only those claims for which fees were paid, specifically claims Nos.:	, this International Search Report				
4.	No required additional search fees were timely paid by the applicant. Consequently, t restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	his International Search Report is				
Remark	on Protest The additional search fees were No protest accompanied the pay	accompanied by the applicant's protest. ment of additional search fees.				

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)

INTERNATIONAL SEARCH REPORT

tion) DOCUMENTS CONSIDERED TO BE RELEVANT	
Citation of document, with indication, where appropriate, of the relevant passages	Delayant to status Mi
ensities of decement, with indication, where appropriate, of the relevant passages	Relevant to claim No.
DE 196 13 972 A (BAYER AG) 16 October 1997 see page 6 - page 10; examples 1-10	1-38
US 4 330 538 A (ITIL TURAN M ET AL) 18 May 1982 see column 3 - column 4; examples 2,4A	1-38
DE 25 48 413 A (SCHERING AG) 28 April 1977 see claim 3 	1–38
	see page 6 - page 10; examples 1-10 US 4 330 538 A (ITIL TURAN M ET AL) 18 May 1982 see column 3 - column 4; examples 2,4A DE 25 48 413 A (SCHERING AG) 28 April 1977 see claim 3

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:) Confirmation No. 1199
John R. EVANS <i>et al.</i>)
Application No.: 12/285,887)) Group Art Unit: 1617
Filed: October 15, 2008) Examiner: Unassigned
FOR: FORMULATION) Date: June 4, 2009

SECOND INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Applicants wish to specifically call to the Examiner's attention in this continuing application the same circumstances as detailed in the Second Information Disclosure Statements filed September 13, 2002 and October 18, 2004 in <u>parent</u> applications, a copy of this is attached hereto for convenience. Specifically, the attached Second Information Disclosure Statement details circumstances regarding the controlled, confidential and non-commercial testing of compositions falling within the scope of the definition of "pharmaceutical formulation", as used in the present method of treatment claims, which was carried out in the United States more than one year before the filing date of the parent application in preparation for and during the testing (IND) phase of the regulatory review of such formulation by the FDA.

The present Information Disclosure Statement is being filed before the mailing date of a first Office Action, and therefore no certification under 37 CFR §1.97(e) or fee under 37 CFR §1.17(p) is required.

This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to fully comply.

Consideration by the Examiner of the circumstances detailed in the attached document is respectfully requested when taking up this continuing application for a first Action on the merits.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby

authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted, Morgan Lewis & Bockius LLP

Date: June 4, 2009 Morgan Lewis & Bockius LLP Customer No. 09629 1111 Pennsylvania Avenue, N.W. Washington, D.C. 20004 Tel. No.: 202-739-3000 /Donald Bird/

By:

Donald J. Bird Registration No. 25,323 Tel. No.: (202) 739-5320 Fax No.: (202) 739-3001

FORMULATION

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a Continuation Application of copending U.S. Patent Application No. 10/872,784, filed June 22, 2004, which claims benefit of U.S. Patent Application No. 09/756.291, filed January 9, 2001 which claims the benefit of Great Britain Application No. 0008837.7 filed April 12, 2000 and Great Britain Application No. 0000313.7, filed January 10, 2000, all of which are incorporated herein by reference in their entireties.

10 BACKGROUND OF THE INVENTION

Field of the Invention

The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound

 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol, more particularly to a formulation adapted for administration by injection containing the compound 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a nonaqueous ester solvent which is miscible in the ricinoleate vehicle.

20 Description of the Related Art

Oestrogen deprivation is fundamental to the treatment of many benign and malignant diseases of the breast and reproductive tract. In premenopausal women, this is achieved by the ablation of ovarián function through surgical, radiotherapeutic, or medical means, and, in postmenopausal women, by the use of aromatase inhibitors.

An alternative approach to oestrogen withdrawal is to antagonise oestrogens with antioestrogens. These are drugs that bind to and compete for oestrogen receptors (ER) present in the nuclei of oestrogen-responsive tissue. Conventional nonsteroidal antioestrogens, such as tamoxifen, compete efficiently for ER binding but their effectiveness is often limited by the partial agonism they display, which results in an incomplete blockade of oestrogen-mediated activity (Furr and Jordan 1984, May and Westley 1987).

The potential for nonsteroidal antioestrogens to display agonistic properties prompted the search for novel compounds that would bind ER with high affinity without activating any

of the normal transcriptional hormone responses and consequent manifestations of oestrogens.
Such molecules would be "pure" antioestrogens, clearly distinguished from tamoxifen-like
ligands and capable of eliciting complete ablation of the trophic effects of oestrogens. Such
compounds are referred to as Estrogen Receptor-Downregulators (E.R.D.). The rationale for
the design and testing of novel, pure antioestrogens has been described in: Bowler et al 1989, .

Wakeling 1990a, 1990b, 1990c. Wakeling and Bowler 1987, 1988.

Steroidal analogues of oestradiol, with an alkylsulphinyl side chain in the 7 α position, provided the first examples of compounds devoid of oestrogenic activity (Bowler et al 1989). One of these, 7α -[9-(4,4,5,5,5-pentafluoropentyl sulphinyl)nonyl]oestra-1,3,5-(10)triene-

- 3,17β-diol was selected for intensive study on the basis of its pure oestrogen antagonist activity and significantly increased antioestrogenic potency over other available antioestrogens. *In vitro* findings and early clinical experience with 7α-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3-5(10)-triene-3,17β-diol have promoted interest in the development of the drug as a therapeutic agent for oestrogen-
- 15 dependent indications such as breast cancer and certain benign gynaecological conditions.

 7α -[9-(4,4,5,5,5-Pentafluoropentylsulphinyl)nonyl]oestra-1,3-5(10)-triene-3,17 β -diol, or ICI 182,780, has been allocated the international non-proprietary name fulvestrant, which is used hereinafter. When referring to fulvestrant we include pharmaceutically-acceptable salts thereof and any possible solvates of either thereof.

20 Fulvestrant binds to ER with an affinity similar to that of oestradiol and completely blocks the growth stimulatory action of oestradiol on human breast cancer cells *in vitro*; it is more potent and more effective than tamoxifen in this respect. Fulvestrant blocks completely the uterotrophic action of oestradiol in rats, mice and monkeys, and also blocks the uterotrophic activity of tamoxifen.

25 Because fulvestrant has none of the oestrogen-like stimulatory activity that is characteristic of clinically available antioestrogens such as tamoxifen or toremifene, it may offer improved therapeutic activity characterised by more rapid, complete, or longer-lasting tumour regression; a lower incidence or rate of development of resistance to treatment; and a reduction of tumour invasiveness.

In intact adult rats, fulvestrant achieves maximum regression of the uterus at a dose which does not adversely affect bone density or lead to increased gonadotrophin secretion. If also true in humans, these findings could be of extreme importance clinically. Reduced bone

5

density limits the duration of oestrogen-ablative treatment for endometriosis. Fulvestrant does not block hypothalamic ER. Oestrogen ablation also causes or exacerbates hot flushes and other menopausal symptoms; fulvestrant will not cause such effects because it does not cross the blood-brain barrier.

European Patent Application No. 0 138 504 discloses that certain steroid derivatives are effective antioestrogenic agents. The disclosure includes information relating to the preparation of the steroid derivatives. In particular there is the disclosure within Example 35 of the compound 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-

1,3,5(10)-triene-3,17β-diol, which compound is specifically named in Claim 4. It is also
disclosed that the compounds of that invention may be provided for use in the form of a pharmaceutical composition comprising a steroid derivative of the invention together with a pharmaceutically-acceptable diluent or carrier. It is stated therein that the composition can be in a form suitable for oral or parenteral administration.

Fulvestrant shows, along with other steroidal based compounds, certain physical properties which make formulation of these compounds difficult. Fulvestrant is a particularly lipophilic molecule, even when compared with other steroidal compounds, and its aqueous solubility is extremely low at around 10 ngml⁻¹ (this is an estimate from a water/solvent mixture solute since measurements this low could not be achieved in a water only solute).

Currently there are a number of sustained release injectable steroidal formulations which have been commercialised. Commonly these formulations use oil as a solvent and wherein additional excipients may be present. Below in Table 1 are described a few commercialised sustained release injectable formulations.

In the formulations within Table 1 a number of different oils are used to solubilise the compound and additional excipients such as benzyl benzoate, benzyl alcohol and ethanol have been used. Volumes of oil needed to solubilise the steroid active ingredient are low. Extended release is achievable for periods from 1 to 8 weeks.

30

Ś
3
9
0
1
N

Table 1 - OIL BASED LONG-ACTING INTRAMUSCULAR INJECTIONS

DOSING	3 weeks	l week	< I week	15 to 30 days	8 weeks	l week	l week	1 - 2 weeks
DOSE	Iml	l or 2ml	2ml	1ml	lml	Iml	l or 2ml	l or 2ml
<u>EtOH</u>								
BZOH	0.1ml							
<u>BzBz</u>		up to 46%	*40%	45%	YES		YES	YES
0IT	Arachis	Castor	Ethyl oleate	Olive	Castor	Arachis	Castor	Castor
SOURCE	ABPI Data Sheet Comp. 1999	ABPI Data Sheet Conp.1999	Dict. Vidal 1999	Dict. Vidal 1997	ABPI Data Sheet Comp.1999	Dict. Vidal 1998	Dict. Vidal 1999	Dict. Vidal 1995
COMP'.	Organon	Schering HC	Theramax	Theramax	Schering HC	Roussel	Pharlon	Schering HC
TYPE	Androgen	Progestogen	Progestogen	Mixed	Contraceptive	Estradiol	Progestogen	Mixed
DOSE	30mg 60mg 60mg 100mg	250mgml ⁻¹	200mg 50mg 250mg	1.3mg 50mg 80mg	200mg	Smg	250mgml ^{-l}	5mgml ^{-l} 250mgml ^{-l}
STEROID	T estosterone proprionate T estosterone phenylproprionate T estosterone isocaproate T estosterone decanoate	Hydroxy progesterone hexanoate	Hydroxy progesterone enantate Progesterone α-Γocopherol	Estrapronicate Nandrolone undecanoate Hydroxyprogesterone heptanoate	Norethisterone oenanthoate	Estradiol hexahydrobenzoate	Hydroxy progesterone caproate	Estradiol 17-β-valerate Hydroxyprogesterone caproate
PRODUCT NAME	SUSTANON 100	PROLUTON DEPOT	TOCOGESTAN	TROPHOBOLENE	NORISTERAT	BENZO- GYNOËSTRYL	PROGESTERONE -RETARD	GRAVIBINAN

Z70635

- 2 -

2 weeks		
l.5ml		
45mg	2% 2%	up to 2%
75mg	20% 40%	YES
	78% 58%	YES
Arachis	Castor	Castor
Dict. Vidal	J.Pharm. Sci	(1964) 53(8) 891 J.Pharm. Sci.(1964) 53(8) 891
Negma	BMS	SMG
Androgen	Estradiol	Progestrogen
76mg	20mgml ⁻¹ 40mgml ⁻¹	250mgml ⁻¹
Trenbolone	Estradiol valerate	17-Hydroxy progesterone
PARABOLAN	DELESTROGEN	DELALUTIN

BzBz = benzylbenzoate BzOH = benzylalcohol EtOH = ethanol Dict. Vidal = Dictionnaire Vidal 5 % are w/v and * approximate as measured directly from a single sample

described which comprises 50mg of fulvestrant, 400mg of benzyl alcohol and sufficient castor oil to bring the solution to a volume of 1 ml. Manufacture at a commercial scale of a formulation as described in US 5,183,814 will be complicated by the high alcohol concentration. Therefore, there is a need to lower the alcohol concentration in fulvestrant formulations whilst preventing precipitation of fulvestrant from the formulation.

SUMMARY OF THE INVENTION

<u>The invention relates to a novel sustained release pharmaceutical formulation adapted</u> for administration by injection containing the compound

10 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol, more particularly to a formulation adapted for administration by injection containing the compound 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a nonaqueous ester solvent which is miscible in the ricinoleate vehicle.

15

5

BRIEF DESCRIPTION OF THE DRAWING

<u>Figure 1 shows the release profile *in vivo* of the four formulations from the second part of Table 4 below, and shows the effect of the fixed oil component on fulvestrant plasma profile over five days following intramuscular administration in rabbits.</u>

20

DETAILED DESCRIPTION OF THE INVENTION

Table 2 shows the solubility of fulvestrant in a number of different solvents.

Table 2 - SOLUBILITY OF FULVESTRANT

25		
	SOLVENT	SOLUBILITY
		(mgml ⁻¹ at 25°C)
	Water	0.001
	Arachis oil	0.45
	Sesame oil	0.58
	Castor oil	20
	Miglyol 810	3.06

2.72
1.25
6.15
0.80
3.79
>200
>200

As can be seen fulvestrant is significantly more soluble in castor oil than any of the other oils tested. The greater solvating ability of castor oil for steroidal compounds is known and is attributed to the high number of hydroxy groups of ricinoleic acid, which is the major 5 constituent of the fatty acids within the triglycerides present in castor oil - see (Riffkin et.al. J. Pharm. Sci., (1964), 53, 891).

However, even when using the best oil based solvent, castor oil, we have found that it is not possible to dissolve fulvestrant in an oil based solvent alone so as to achieve a high enough concentration to dose a patient in a low volume injection and achieve a therapeutically significant release rate. To achieve a therapeutically significant release rate the amount of fulvestrant needed would require the formulation volume to be large, at least 10 ml. This requires the doctor to inject an excessively large volume of formulation to administer a dose significantly high enough for human therapy.

Currently guidelines recommend that no more than 5mls of liquid is injected 15 intramuscularly in a single injection. Pharmacologically active doses required for a 1 month long acting depot formulation of fulvestrant is around 250mg. Therefore, when dissolved in just castor oil, fulvestrant would need to be administered in at least 10ml of castor oil.

The addition of organic solvents in which fulvestrant is freely soluble, and which are miscible with castor oil, may be used, such as an alcohol. With the addition of high

- 20 concentrations of an alcohol concentrations of >50mgml⁻¹ of fulvestrant in a castor oil formulation is achievable, thereby giving an injection volumes of <5ml see Table 3 below. We have surprisingly found that the introduction of a non-aqueous ester solvent which is miscible in the castor oil and an alcohol surprisingly eases the solubilisation of fulvestrant into a concentration of at least 50 mgml⁻¹ see Table 3 below. The finding is surprising since the
- 25 solubility of fulvestrant in non-aqueous ester solvents see Table 2 above is significantly

lower than the solubility of fulvestrant in an alcohol. The solubility of fulvestrant is also lower in non-aqueous ester solvents than is the solubility of fulvestrant in castor oil.

Therefore, we present as a feature of the invention a pharmaceutical formulation comprising fulvestrant (preferably fulvestrant is present at 3-10%w/v, 4-9%w/v, 4-8%w/v,

5 4-7%w/v, 4-6%w/v and most preferably at about 5%w/v) in a ricinoleate vehicle, a pharmaceutically acceptable non-aqueous ester solvent, and a pharmaceutically acceptable alcohol wherein the formulation is adapted for intramuscular administration and attaining a therapeutically significant blood plasma fulvestrant concentration for at least 2 weeks.

Another feature of the invention is a pharmaceutical formulation comprising 10 fulvestrant in which the formulation is adapted for intra-muscular injection into a human and which is capable after injection of attaining a therapeutically significant blood plasma fulvestrant concentration for at least 2 weeks.

Further features of the invention include a pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 30% or less weight of a pharmaceutically-

- 15 acceptable alcohol per volume of formulation, at least 1% weight of a pharmaceuticallyacceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation which is capable after injection of attaining a therapeutically significant blood plasma fulvestrant concentration for at least 2 weeks.
- Further features of the invention include a pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant; 35% (preferably 30% and ideally 25%) or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% (preferably at least 5% or ideally 10%) weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible within a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml⁻¹ of

fulvestrant. For the avoidance of any doubt when using the term % weight per volume of formulation for the constituents of the formulation we mean that within a unit volume of the formulation a certain percentage of the constituent by weight will be present, for example a

30 1% weight per volume formulation will contain within a 100ml volume of formulation 1g of the constituent. By way of further illustration

% of x by weight per volume of formulation	weight of x in 1ml of formulation
30%	300mg
20%	200mg
10%	100mg
5%	50mg
1%	10mg

Preferred pharmaceutical formulations of the invention are as described above 5 wherein:

1. The total volume of the formulation is 6ml, or less, and the concentration of fulvestrant is at least 45mgml⁻¹.

2. The total amount of fulvestrant in the formulation is 250mg, or more, and the total volume of the formulation is 6ml, or less.

10 3. The total amount of fulvestrant in the formulation is 250mg and the total volume of the formulation is 5-5.25ml.

It is appreciated that in the formulation an excess of formulation may be included to allow the attendant physician or care giver to be able to deliver the required dose. Therefore, when a 5ml dose is required it would be appreciated that an excess of up to 0.25ml, preferably

15 up to 0.15ml will also be present in the formulation. Typically the formulation will be presented in a vial or a prefilled syringe, preferably a prefilled syringe, containing a unit dosage of the formulation as described herein, these being further features of the invention.

Preferred concentrations of a pharmaceutically-acceptable alcohol present in any of the above formulations are; at least 3%w/v, at least 5%w/v, at least 7%w/v, at least 10% w/v, at

- 20 least 11% w/v, at least 12% w/v, at least 13% w/v, at least 14% w/v, at least 15% w/v and, preferably, at least 16% w/v. Preferred maximal concentrations of pharmaceutically-acceptable alcohol present in the formulation are ;28% w/v or less, 22% w/v or less and 20% w/v or less.. Preferred ranges of pharmaceutically-acceptable alcohol present in any of the above formulations are selected from any minimum or maximum value described above and
- 25 preferably are; 3-35%w/v, 4-35%w/v, 5-35%w/v, 5-32%w/v, 7-32%w/v, 10-30%w/v, 12-28%w/v, 15-25%w/v, 17-23%w/v, 18-22%w/v and ideally 19-21%w/v.

The pharmaceutically-acceptable alcohol may consist of one alcohol or a mixture of two or more alcohols, preferably a mixture of two alcohols. Preferred pharmaceutically-acceptable alcohols for parenteral administration are ethanol, benzyl alcohol or a mixture of both ethanol and benzyl alcohol, preferably the ethanol and benzyl alcohol are present in the formulation in the same w/v amounts. Preferably the formulation alcohol contains 10% w/v ethanol and 10% w/v benzyl alcohol.

The pharmaceutically-acceptable non-aqueous ester solvent may consist of one or a mixture of two or more pharmaceutically-acceptable non-aqueous ester solvents, preferably just one. A preferred pharmaceutically-acceptable non-aqueous ester solvent for parenteral administration is selected from benzyl benzoate, ethyl oleate, isopropyl myristate, isopropyl palmitate or a mixture of any thereof.

The ricinoleate vehicle should preferably be present in the formulation in a proportion of at least 30% weight per volume of the formulation, ideally at least 40% or at least 50% weight per volume of formulation.

15 It will be understood by the skilled person that the pharmaceutically-acceptable alcohol will be of a quality such that it will meet pharmacopoeial standards (such as are described in the US, British, European and Japanese pharmacopoeias) and as such will contain some water and possibly other organic solvents, for example ethanol in the US Pharmacopeia contains not less than 94.9% by volume and not more than 96.0% by volume of ethanol when 20 measured at 15.56°C. Dehydrated alcohol in the US Pharmacopeia contains not less than

99.5% ethanol by volume when measured at 15.56°C.

Preferred concentrations of the pharmaceutically-acceptable non-aqueous ester solvent present in any of the above formulations are; at least 5% w/v, at least 8% w/v, at least 10% w/v, at least 11% w/v, at least 12% w/v, at least 13% w/v, at least 15% w/v, at least 16% w/v,

- at least 17% w/v, at least 18% w/v, at least 19% w/v and at least 20% w/v. Preferred maximal concentrations of the pharmaceutically-acceptable non-aqueous ester solvent are; 60% w/v or less, 50%w/v or less, 45% w/v or less, 40% w/v or less, 35% w/v or less, 30% w/v or less and 25% w/v or less. A preferred concentration is 15% w/v. Preferred ranges of pharmaceutically-acceptable non-aqueous ester solvent present in any of the above formulations are selected
- 30 from any minimum or maximum value described above and preferably are; 5-60%w/v, 7-55%w/v, 8-50%w/v, 10-50%w/v, 10-45%w/v, 10-40%w/v, 10-35%w/v, 10-30%w/v, 10-

25%w/v, 12-25%w/v, 12-22%w/v, 12-20%w/v, 12-18%w/v, 13-17%w/v and ideally 14-16%w/v. Preferably the ester solvent is benzyl benzoate, most preferably at about 15%w/v.

It will be understood by the skilled person that the pharmaceutically-acceptable nonaqueous ester solvent will be of a quality that it will meet pharmacopoeial standards (such as 5 described in the US, British, European and Japanese pharmacopoeias).

Preferred combinations of pharmaceutically-acceptable alcohol and pharmaceuticallyacceptable non-aqueous ester solvent in the formulation are set out below:

Pharmaceutically-acceptable	Pharmaceutically-acceptable non-aqueous
alcohol(%w/v)	ester (%w/v)
10-30	5-60, 7-55, 8-50, 10-50, 10-45, 10-40, 10-35, 10-
	30, 10-25, 12-25, 12-22, 12-20, 12-18, 13-17 and
	ideally 14-16.
17-23	5-60, 7-55, 8-50, 10-50, 10-45, 10-40, 10-35, 10-
	30, 10-25, 12-25, 12-22, 12-20, 12-18, 13-17 and
	ideally 14-16.
3-35, 4-35, 5-35, 5-32, 7-32, 10-30, 12-	10-35
28, 15-25, 17-23, 18-22 and ideally 19-	· · · · · · · · · · · · · · · · · · ·
3-35, 4-35, 5-35, 5-32, 7-32, 10-30, 12-	12-18
28, 15-25, 17-23, 18-22 and ideally 19-	
21.	
ethanol and benzyl alcohol, most	benzyl benzoate, most preferably at about 15%
preferably each at about 10%	

10 By the use of the term ricinoleate vehicle we mean an oil which has as a proportion (at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% w/v) of its composition as triglycerides of ricinoleic acid. The ricinoleate vehicle may be a synthetic oil or conveniently is castor oil, ideally of pharmacopoeial standards, as described above.

We have surprisingly found that the above formulations of the invention provide, after 15 intra-muscular injection, satisfactory release of fulvestrant over an extended period of time.

This finding is indeed surprising for the following reasons.

1. Previously tested by the applicants have been intra-muscular injections of fulvestrant in the form of an aqueous suspension. We have found extensive local tissue irritation at the injection site as well as a poor release profile. It is believed that the tissue irritation/inflammation was due to the presence of fulvestrant in the form of solid particles.

5 The release profile appeared to be determined by the extent of inflammation/irritation present at the injection site and this was variable and difficult to control. Also the fulvestrant release rate was not sufficiently high to be clinically significant.

Our findings from studies using ¹⁴C labelled benzyl alcohol show that it dissipates rapidly from the injection site and is removed from the body within 24 hours of administration.

It would be expected that ethanol will dissipate at least as quickly, if not more rapidly, from the injection site.

It is known that benzyl benzoate is metabolised by conjugation to glycine to form hippuric acid by the human liver and excreted into the urine - Martindale: The Extra 15 Pharmacopoeia 32nd edition page 1103, and, therefore, it is unlikely that benzyl benzoate, when used, is present at the injection site during the whole of the extended release period.

We have found that despite the rapid elimination of the additional solubilising excipients, i.e. the alcohol and pharmaceutically-acceptable non-aqueous ester solvent, from the formulation vehicle and the site of injection after injection of the formulation, extended release at therapeutically significant levels of fulvestrant over an extended period can still achieved by the formulation of the invention.

By use of the term "therapeutically significant levels" we mean that blood plasma concentrations of at least 2.5 ngml⁻¹, ideally at least 3 ngml⁻¹, at least 8.5 ngml⁻¹, and up to 12 ngml⁻¹ of fulvestrant are achieved in the patient. Preferably blood plasma levels should be less than 15 ngml⁻¹.

By use of the term "extended release" we mean at least two weeks, at least three weeks, and, preferably at least four weeks of continuous release of fulvestrant is achieved. In a preferred feature extended release is achieved for 36 days. Preferably extended release of fulvestrant is for at least 2- 5 weeks and more preferably for the following periods (weeks) 30 2.5-5, 2.5-4, 3-4, 3.5-4 and most preferably for at least about 4 weeks.

- 12 -

It will be understood that the attendant physician may wish to administer the intramuscular injection as a divided dose, i.e. a 5ml formulation is sequentially administered in two separate injections of 2.5ml, this is a further feature of the invention

Simply solubilising fulvestrant in an oil based liquid formulation is not predictive of a 5 good release profile or lack of precipitation of drug after injection at the injection site.

Table 3 shows the solubility of fulvestrant in a castor oil vehicle additionally containing alcohols ethanol and benzyl alcohol with or without benzyl benzoate. The results clearly show the positive effect of benzyl benzoate on fulvestrant solubility in castor oil, despite fulvestrant having a lower solubility in benzyl benzoate than in either alcohol or castor 10 oil.

Z70635

Table 3

- 14 -

Table 3 - EFFECT OF BENZYL BENZOATE ON FULVESTRANT SOLUBILITY IN CASTOR OIL AT 25°C

MYLAN PHARMS. INC. EXHIBIT 1002 PAGE 171

Ś

Table 4

The following Table 4 shows the solubility of fulvestrant in a range of oil based formulations which contain the same amounts of alcohol and benzyl benzoate but in which the oil is changed. The data also shows solubility of fulvestrant after removal of the alcohols.

	Fulvestrant Solubility mg ml ⁻¹ @ 25°C			
Formulation ^(a)	Complete vehicle	Vehicle minus alcohols		
Castor oil based	81.2	12.6		
Miglyol 812-N based	86.8	1.7		
Sesame seed/Castor oil (1:1) based	70.1	4.4		
Sesame seed oil based	45.7	0.7		
Arachis oil based	40.2	< 0.2		

5 Solubility comparisons of fulvestrant in oil based formulations with and without alcohols

(a) Complete Vehicle Formulations comprised ethanol [96%](10%), benzyl alcohol (10%) and benzyl benzoate
 (15%) made to volume with the stated oil. Excess fulvestrant was added to each solvent mixture and solubility determined.

30					Days			
	Formulation ^a	2	3	4	7	10	30	51
35	Formulation F1 castor oil based	0	0	0	0	0	0	0
	Formulation F2 Miglyol 812-N based	++ p	+++	+++	+++	+++	++	0
40	Formulation F3 sesame seed oil/castor oil based	+ ^c	++	++	+++	++	+	+

Effect of formulation on precipitation of fulvestrant at the injection site

0, +, ++, +++ = Degree of precipitation (None detected, Mild, Moderate, Severe)

45 ^a Formulations comprised fulvestrant (5%), ethanol [96%] (10%), benzyl alcohol (10%) and benzyl benzoate

(15%) made to volume with the stated oil.

^b Mainly large needle shaped crystals

^c Small needles and/or sheafs of crystals

Precipitation of fulvestrant and the release profile was determined with the above formulations in an *in vivo* rabbit study.

Figure 1 shows the release profile *in vivo* of the four formulations from the second part of Table 4 and shows the effect of the fixed oil component on fulvestrant plasma profile over
five days following intramuscular administration in rabbits (data normalised to 50mg per 3kg; mean given; number of animals per timepoint = 8, plasma samples assayed for fulvestrant content using lc-ms/ms detection following solvent extraction). As can be seen the castor oil formulation showed a particularly even release profile with no evidence of precipitation of fulvestrant at the injection site.

10 Therefore we present as a further feature of the invention an extended release pharmaceutical formulation adapted for intramuscular injection comprising fulvestrant; 35% (preferably 30% or ideally 25%) or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% (preferably at least 5% or ideally 10%) weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per

15 volume of formulation and sufficient amount of a ricinoleate vehicle, taking into account the addition of any further optional pharmaceutically-acceptable excipients, so as to prepare a formulation of at least 45mgml⁻¹ of fulvestrant.

A further feature of the invention is a pharmaceutical formulation adapted for intramuscular injection, as defined above, for use in medical therapy.

- A further feature of the invention is a method of treating a benign or malignant diseases of the breast or reproductive tract, preferably treating breast cancer, by administration to a human in need of such treatment by intramuscular injection an extended release ricinoleate vehicle based pharmaceutical formulation comprising at least 45mgml⁻¹ of fulvestrant; 35% (preferably 30% or ideally 25%) or less weight of a pharmaceutically-
- 25 acceptable alcohol per volume of formulation, at least 1% (preferably at least 5% or ideally 10%) weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation.

Preferably 5ml of the intramuscular injection is administered.

A further feature of the invention is use of fulvestrant in the preparation of a 30 pharmaceutical formulation as describe hereinabove, for the treatment of a benign or malignant disease of the breast or reproductive tract, preferably treating breast cancer.

- 16 -

Additional excipients commonly used in the formulation field including, for example, an antioxidant preservative, a colorant or a surfactant may be used. A preferred optional excipient is a surfactant.

As described above fulvestrant is useful in the treatment of oestrogen-dependent 5 indications such as breast cancer and gynaecological conditions, such as endometriosis.

In addition to fulvestrant another similar type of molecule is currently under clinical investigation. SH-646 (11 β -fluoro- 7 α -(14,14,15,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl)estra-1,3,5(10)-triene-3,17 β -diol) is also putatively a compound with the same mode of action as fulvestrant and has a very similar chemical

10 structure. It is believed that the compound will also share with fulvestrant similar physical properties and therefore the current invention will also have application with this compound.

A further feature of the invention is a pharmaceutical formulation adapted for intra-muscular injection comprising 11 β -fluoro- 7 α -(14,14,15,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl)estra-1,3,5(10)-triene-3,17 β -diol; 35% or less weight of a

15 pharmaceutically-acceptable alcohol per volume of formulation, at least 1% weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible within a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml⁻¹ of 11β-fluoro- 7α -(14,14,15,15,15-pentafluoro-6methyl-10-thia-6-azapentadecyl)estra-1,3,5(10)-triene-3,17β-diol.

20

Further features of the invention are those as described above but in which SH-646 is substituted for fulvestrant.

Formulation Example

Fulvestrant is mixed with alcohol and benzyl alcohol, stirring until completely dissolved. Benzyl benzoate is added and the solution is made to final weight with castor oil and stirred, (for convenience weight is used rather than volume by using the weight to volume ratio). The bulk solution is overlaid with Nitrogen. The solution is sterilised by filtration using one or two filters of 0.2µm porosity. The sterile filtrate is kept under a nitrogen overlay as it is filled under aseptic conditions into washed and depyrogenised, sterile primary containers, for example vials or pre-filled syringes. An overage is included in the primary

5

pack to facilitate removal of the dose volume. The primary packs are overlaid with sterile nitrogen, before aseptically sealing.

See also process flow diagram below


Quantities of each component of the formulation is chosen according to the required formulation specification, examples are described above. For example quantities are added of each component to prepare a formulation which contains 10% weight per volume of benzyl alcohol

10 10% weight per volume of ethanol

15% weight per volume of benzyl benzoate

250mg of fulvestrant for each 5ml of finished formulation

and the remaining amount as castor oil



References

1. Bowler J, Lilley TJ, Pittam JD, Wakeling AE. Novel steroidal pure antioestrogens. Steroids 989; 5471-99.

5 2. Wakeling AE. Novel pure antioestrogens: mode of action and therapeutic prospects. American New York Academy Science 1990a; 595: 348-56.

3. Wakeling AE. Steroidal pure antioestrogens. In Lippman M, Dickson R, editors. Regulatory mechanisms in breast cancer. Boston: Kluwer Academic, 1990b: 239-57.

10

4. Wakeling AE. Therapeutic potential of pure antioestrogens in the treatment of breast cancer. Journal Steroid Biochemistry 1990c; 37: 771-5.

5. Wakeling AE, Bowler J. Steroidal pure antioestrogens. Journal Endocrinology 1987; 112:15 R7-10.

6. Wakeling AE, Bowler J. Biology and mode of action of pure antioestrogens. Journal Steroid Biochemistry 1988; 3: 141-7.

Claims

 A pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 30% or less weight of a pharmaceutically-acceptable alcohol per volume of
 formulation, at least 1% weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation which is capable after injection of attaining a therapeutically significant blood plasma fulvestrant concentration of at least 2.5ngml⁻¹ for at least 2 weeks.

10 2. A pharmaceutical formulation as claimed in claim 1 wherein the blood plasma fulvestrant concentration is attained for at least 4 weeks.

3. A pharmaceutical formulation as claimed in claim 1 wherein the blood plasma fulvestrant concentration is attained for 2 to 5 weeks.

15 4. A pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 30% or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml⁻¹ of fulvestrant.

20

5. A pharmaceutical formulation as claimed in claim 1 to 4 which contains 25% w/v or less of a pharmaceutically-acceptable alcohol.

6. A pharmaceutical formulation as claimed in claim 5 which contains 20% w/v or less of 25 a pharmaceutically-acceptable alcohol.

7. A pharmaceutical formulation as claimed in any claim from 1 to 6 which contains 60% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

30 8. A pharmaceutical formulation as claimed in claim 7 which contains 50%w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

9. A pharmaceutical formulation as claimed in claim 7 which contains 45% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

5 10. A pharmaceutical formulation as claimed in claim 7 which contains 40% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

11. A pharmaceutical formulation as claimed in claim 7 which contains 35% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

10

12. A pharmaceutical formulation as claimed in claim 7 which contains 30% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.

A pharmaceutical formulation as claimed in claim 7 which contains 25% w/v or less
 of a pharmaceutically-acceptable non-aqueous ester solvent.

14. A pharmaceutical formulation as claimed in any claim from 1 to 13 wherein the pharmaceutically-acceptable alcohol is a mixture of ethanol and benzyl alcohol.

20 15. A pharmaceutical formulation as claimed in any claim from 1 to 14 wherein the pharmaceutically-acceptable non-aqueous ester solvent is selected from benzyl benzoate, ethyl oleate, isopropyl myristate, isopropyl palmitate or a mixture of any thereof.

A pharmaceutical formulation as claimed in any claim from 1 to 15 wherein the
 pharmaceutically-acceptable non-aqueous ester solvent is benzyl benzoate.

17. A pharmaceutical formulation as claimed in any claim from 1 to 16 wherein the total volume of the formulation is 6ml, or less, and the concentration of fulvestrant is at least 45mgml⁻¹.

30

18. A pharmaceutical formulation as claimed in any claim from 1 to 13 wherein the total amount of fulvestrant in the formulation is 250mg, or more, and the total volume of the formulation is 6ml, or less.

5 19. A pharmaceutical formulation as claimed in claim 18 wherein the total amount of fulvestrant in the formulation is 250mg and the total volume of the formulation is 5 to 5.25ml.

20. A pharmaceutical formulation as claimed in any of claims 1-19 wherein the pharmaceutically-acceptable alcohol is a mixture of 10% weight of ethanol per volume of
10 formulation, 10% weight of benzyl alcohol per volume of formulation and 15% weight of
benzyl benzoate per volume of formulation and the ricinoleate vehicle is castor oil.

21. A method of treating a benign or malignant diseases of the breast or reproductive tract by administration to a human in need of such treatment by intramuscular a pharmaceutical
15 formulation as claimed in claims 1 to 19.

22. A method as claimed in claim 21 for treating breast cancer.

A syringe or vial containing a pharmaceutical formulation as defined in claim 20.

ABSTRACT


TITLE: Formulation

ABSTRACT OF THE DISCLOSURE

5 The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound

 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol, more particularly to a formulation adapted for administration by injection containing the compound 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol in

10 solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a nonaqueous ester solvent which is miscible in the ricinoleate vehicle.





PTO/SB/06 (07-06)

Approved for use through 1/31/2007. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

											OMB control number.	
P	ATENT APPL		for Form P		N RECORD	A	Application or Docket Number 12/285,887			ing Date 15/2008	To be Mailed	
APPLICATION AS FILED – PART I										OTHER THAN		
_			(Column ⁻	,	Column 2)		SMALL		OR			
	FOR		NUMBER FI	LED NUM	MBER EXTRA		RATE (\$)	FEE (\$)		RATE (\$)	FEE (\$)	
	BASIC FEE (37 CFR 1.16(a), (b),	or (c))	N/A	N/A			N/A			N/A		
	SEARCH FEE (37 CFR 1.16(k), (i), (i), (i), (i), (i), (i), (i), (i	or (m))	N/A		N/A		N/A			N/A		
	EXAMINATION FE (37 CFR 1.16(o), (p),		N/A		N/A		N/A			N/A		
	TAL CLAIMS CFR 1.16(i))		mir	nus 20 = *			X \$ =		OR	X \$ =		
	EPENDENT CLAIM CFR 1.16(h))	S	m	inus 3 = *			X \$ =			X\$ =		
	APPLICATION SIZE (37 CFR 1.16(s))	FEE is ad	eets of pap \$250 (\$125 ditional 50 s	ation and drawing er, the applicatio for small entity) sheets or fractior a)(1)(G) and 37	n size fee due for each n thereof. See							
	MULTIPLE DEPEN	IDENT CLAIM I	PRESENT (3	7 CFR 1.16(j))								
* If i	he difference in colu	umn 1 is less th	an zero, ente	er "0" in column 2.			TOTAL			TOTAL		
APPLICATION AS AMENDED – PART II (Column 1) (Column 2) (Column 3)				SMAL	L ENTITY	OR		ER THAN ALL ENTITY				
AMENDMENT	10/15/2008	CLAIMS REMAINING AFTER AMENDMEN	г	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE (\$)	ADDITIONAL FEE (\$)		RATE (\$)	ADDITIONAL FEE (\$)	
IME	Total (37 CFR 1.16(i))	* 23	Minus	** 23	= 0		X \$ =		OR	X \$52=	0	
IN I	Independent (37 CFR 1.16(h))	* 2	Minus	***3	= 0		X \$ =		OR	X \$220=	0	
AMI	Application Si	ize Fee (37 CFF	R 1.16(s))									
`		NTATION OF MUL	TIPLE DEPEN	DENT CLAIM (37 CFI	R 1.16(j))				OR			
							TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	0	
		(Column 1)		(Column 2)	(Column 3)				-			
Г	06/04/2009	CLAIMS REMAINING AFTER AMENDMEN		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE (\$)	ADDITIONAL FEE (\$)		RATE (\$)	ADDITIONAL FEE (\$)	
EN	Total (37 CFR 1.16(i))	* 23	Minus	** 23	= 0		X \$ =		OR	X \$52 =	0	
AMENDMENT	Independent (37 CFR 1.16(h))	* 2	Minus	*** 3	= 0		X \$ =		OR	X \$220 =	0	
EN	Application Si	ize Fee (37 CFF	R 1.16(s))	1.16(s))								
AN		NTATION OF MUL	TIPLE DEPEN	DENT CLAIM (37 CFI	R 1.16(j))				OR			
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	0		
** If *** I The This (FEE											

preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.** *If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

	Electronic Ack	knowledgement Receipt			
	EFS ID:	5447464			
	Application Number:	12285887			
	International Application Number:				
	Confirmation Number:	1199			
Adjustme 06/05/2(05 FC:12	nt date: 06/10/2009 MTEKLEMI 09 INTEFSW 00000215 500310 12285887 01 440.00 CR				
	Title of Invention:	Formulation			
	First Named Inventor/Applicant Name:	John R. Evans			
	Customer Number:	09629			
	Filer:	Donald J. Bird			
	Filer Authorized By:				
:	Attorney Docket Number:	056291-5004-02			
	Receipt Date:	04-JUN-2009			
	Filing Date:	15-OCT-2008			
	Time Stamp:	14:01:06			
	Application Type:	Utility under 35 USC 111(a)			

Payment information:

Submitted with Payment	yes		
Payment Type	Deposit Account		
Payment was successfully received in RAM	\$5544		
RAM confirmation Number	215		
Deposit Account 500310			
Authorized User			
The Director of the USPTO is hereby authorized to	charge indicated fees and credit any overpayment as follows:		
Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)			
Charge any Additional Fees required under 37 C	.F.R. Section 1.17 (Patent application and reexamination processing fees)		

	United State	<u>s Patent</u>	and Tradema	UNITED STA United State: Address: COMMI P.O. Box	a, Virginia 22313-1450
APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS IND CLAIMS
12/285,887	10/15/2008	1617	2754	056291-5004-02	23 2
					CONFIRMATION NO. 1199
9629				UPDATE	D FILING RECEIPT
MORGAN LEV	VIS & BOCKIU	S LLP			
1111 PENNSY	LVANIA AVEN	IUE NW			
WASHINGTO	N, DC 20004				*000000036411369*

Date Mailed: 06/17/2009

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections

Applicant(s)

John R. Evans, Macclesfield, UNITED KINGDOM; Rosalind U. Grundy, Macclesfield, UNITED KINGDOM;

Power of Attorney: None

Domestic Priority data as claimed by applicant

This application is a CON of 10/872,784 06/22/2004 PAT 7,456,160

Foreign Applications

UNITED KINGDOM 0008837.7 04/12/2000 UNITED KINGDOM 0000313.7 01/10/2000

If Required, Foreign Filing License Granted: 11/03/2008

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 12/285,887**

Projected Publication Date: 09/24/2009

Non-Publication Request: No

Early Publication Request: No

Title

Formulation

Preliminary Class

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

<u>GRANTED</u>

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as

page 2 of 3

set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

page 3 of 3

UNITED ST	ATES PATENT AND TRADEMA	UNITED STA' United States Address: COMMI PO. Box I	a, Virginia 22313-1450
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
12/285,887	10/15/2008	John R. Evans	056291-5004-02
9629		WITHDRA	CONFIRMATION NO. 1199 WAL NOTICE
MORGAN LEWIS & BOC 1111 PENNSYLVANIA AV WASHINGTON, DC 2000	VENUE NW		C000000037186366*
			Date Mailed: 08/03/2009

Letter Regarding a New Notice and/or the Status of the Application

If a new notice or Filing Receipt is enclosed, applicant may disregard the previous notice mailed on 11/04/2008. The time period for reply runs from the mail date of the new notice. Within the time period for reply, applicant is required to file a reply in compliance with the requirements set forth in the new notice to avoid abandonment of the application.

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. <u>https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html</u>

For more information about EFS-Web please call the USPTO Electronic Business Center at **1-866-217-9197** or visit our website at <u>http://www.uspto.gov/ebc.</u>

If the reply is not filed electronically via EFS-Web, the reply must be accompanied by a copy of the new notice.

If the Office previously granted a petition to withdraw the holding of abandonment or a petition to revive under 37 CFR 1.137, the status of the application has been returned to pending status.

/tnguyen/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

UNITED ST	ates Patent and Tradema	UNITED STA' United States Address: COMMI P.O. Box 1	, Virginia 22313-1450	
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE	
12/285,887	10/15/2008	John R. Evans	056291-5004-02	
9629 MORGAN LEWIS & BOC			CONFIRMATION NO. 1199 WAL NOTICE	
1111 PENNSYLVANIA A WASHINGTON, DC 2000		*OC000000037186358* Date Mailed: 08/03/20		

Letter Regarding a New Notice and/or the Status of the Application

If a new notice or Filing Receipt is enclosed, applicant may disregard the previous notice mailed on 06/17/2009. The time period for reply runs from the mail date of the new notice. Within the time period for reply, applicant is required to file a reply in compliance with the requirements set forth in the new notice to avoid abandonment of the application.

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. <u>https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html</u>

For more information about EFS-Web please call the USPTO Electronic Business Center at **1-866-217-9197** or visit our website at <u>http://www.uspto.gov/ebc.</u>

If the reply is not filed electronically via EFS-Web, the reply must be accompanied by a copy of the new notice.

If the Office previously granted a petition to withdraw the holding of abandonment or a petition to revive under 37 CFR 1.137, the status of the application has been returned to pending status.

/tnguyen/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

	United State	<u>s Patent</u>	and Tradema	UNITED STAT United States Address: COMMIS P.O. Bax I	Virginia 22313-1450
APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS IND CLAIMS
12/285,887	10/15/2008	1617	2754	056291-5004-02	23 2
					CONFIRMATION NO. 1199
9629				FILING R	ECEIPT
MORGAN LEV	VIS & BOCKIU	S LLP			
1111 PENNSY	LVANIA AVEN	IUE NW			OC000000037186523*
WASHINGTON	N, DC 20004			7	OC0000003/186523*
WASHINGTO	N, DC 20004				

Date Mailed: 08/03/2009

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections

Applicant(s)

John R. Evans, Macclesfield, UNITED KINGDOM; Rosalind U. Grundy, Macclesfield, UNITED KINGDOM;

Power of Attorney: None

Domestic Priority data as claimed by applicant

This application is a CON of 10/872,784 06/22/2004 PAT 7,456,160

Foreign Applications

UNITED KINGDOM 0008837.7 04/12/2000 UNITED KINGDOM 0000313.7 01/10/2000

If Required, Foreign Filing License Granted: 11/03/2008

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 12/285,887**

Projected Publication Date: None.

Non-Publication Request: No

Early Publication Request: No

Title

Formulation

Preliminary Class

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

<u>GRANTED</u>

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as

page 2 of 3

set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

page 3 of 3

UNITED ST	ates Patent and Trademai	UNITED STA' United States Address: COMMI P.O. Box I	a, Virginia 22313-1450
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
12/285,887	10/15/2008	John R. Evans	056291-5004-02
			CONFIRMATION NO. 1199
9629		FORMALI	TIES LETTER
MORGAN LEWIS & BOC	KIUS LLP		
1111 PENNSYLVANIA AV WASHINGTON, DC 2000			C000000037186524*
			Date Mailed: 08/03/2009

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Filing Date Granted

An application number and filing date have been accorded to this application. The application is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given TWO MONTHS from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

The required item(s) identified below must be timely submitted to avoid abandonment:

- A substitute specification in compliance with 37 CFR 1.52, 1.121(b)(3), and 1.125, is required. The substitute specification must be submitted with markings and be accompanied by a clean version (without markings) as set forth in 37 CFR 1.125(c) and a statement that the substitute specification contains no new matter (see 37 CFR 1.125(b)). The specification, claims, and/or abstract page(s) submitted is not acceptable and cannot be scanned or properly stored because:
 - The specification contains drawings or flow diagrams (37 CFR 1.58(a)) on page(s) 19. Drawings or flow diagrams cannot be embedded in the specification and should be submitted separately in accordance with 37 CFR 1.84. (Both a substitute specification in compliance with 37 CFR 1.125 and new drawings in compliance with 37 CFR 1.84 and 1.121(d) are required).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

Replies should be mailed to:

Mail Stop Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. <u>https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html</u>

For more information about EFS-Web please call the USPTO Electronic Business Center at **1-866-217-9197** or visit our website at <u>http://www.uspto.gov/ebc.</u>

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

/tnguyen/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

page 2 of 2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:) Confirmation No. 1199
John R. EVANS <i>et al.</i>	
Application No.: 12/285,887) Group Art Unit: 1617
Filed: October 15, 2008) Prior Examiner: Unassigned
FOR: FORMULATION)) Date: March 3, 2010

STATEMENT ACCOMPANYING SUBSTITUTE SPECIFICATION

In response to the Notice to File Corrected Application Papers, attached are a clean copy and a marked up copy of the second substitute specification in which the flow diagram on page 19 has been removed and resubmitted as Figure 2. The attached copies of the substitute specification do not include prohibited new matter. In particular, referring to the "marked up" copy:

- At page 19, the flow diagram was deleted to create a new formal Figure 2.
- At page 6, "Brief Description" of the new Figure 2 was inserted.
- At page 18, the "below" reference was changed to refer to "Figure 2."

By:


• Figure 1 was modified to designate "1/2" at the top

If there are any additional fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 50-0310. If a fee is required for an extension of time under 37 C.F.R. §1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Respectfully Submitted, Morgan Lewis & Bockius LLP

Date: March 3, 2010 Morgan Lewis & Bockius LLP Customer No. 09629 1111 Pennsylvania Avenue, N.W. Washington, D.C. 20004 Tel. No.: 202-739-3000 /Donald Bird/ Donald J. Bird Registration No.25,323 Tel. No.: (202) 739-5320 Fax No.: (202) 739-3001

DB1/63063958.1



1/2

Figure 1

FLOW DIAGRAM OF MANUFACTURING




Figure 2

Electronic Patent Application Fee Transmittal							
Application Number:	122	285887					
Filing Date:	15-	Oct-2008					
Title of Invention:		Formulation					
First Named Inventor/Applicant Name:	Joł	n R. Evans					
Filer:	Do	nald J. Bird					
Attorney Docket Number:	056291-5004-02						
Filed as Large Entity							
Utility under 35 USC 111(a) Filing Fees							
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)		
Basic Filing:							
Pages:							
Claims:							
Miscellaneous-Filing:							
Petition:							
Patent-Appeals-and-Interference:							
Post-Allowance-and-Post-Issuance:							
Extension-of-Time:							
Extension - 5 months with \$0 paid		1255	1	2350	2350		

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Miscellaneous:				
	Tot	al in USD) (\$)	2350

Electronic Ac	Electronic Acknowledgement Receipt					
EFS ID:	7135227					
Application Number:	12285887					
International Application Number:						
Confirmation Number:	1199					
Title of Invention:	Formulation					
First Named Inventor/Applicant Name:	John R. Evans					
Customer Number:	09629					
Filer:	Donald J. Bird					
Filer Authorized By:						
Attorney Docket Number:	056291-5004-02					
Receipt Date:	03-MAR-2010					
Filing Date:	15-OCT-2008					
Time Stamp:	17:40:20					
Application Type:	Utility under 35 USC 111(a)					

Payment information:

Submitted with Payment yes					
Payment Type	Deposit Account				
Payment was successfully received in RAM	ed in RAM \$2350				
RAM confirmation Number	confirmation Number 4396				
Deposit Account	500310				
Authorized User					
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:					
Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)					
Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)					

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)		
	056291-5004-	217584		24			
1		SubstituteSpecification-Clean pdf		yes	21		
	Multip	art Description/PDF files in .	zip description				
	Document Des	scription	Start	E	nd		
	Specificat	ion	1	20			
	Abstrac	t	21	21			
Warnings:			· · ·				
Information:							
2	Specification	056291-5004- SubstituteSpecification-	184205	no	22		
		Marked.pdf	44acc667ccfffa425dc7c9d0f3e2455b24d19 2da				
Warnings:							
Information:							
3 Miscellaneous Incoming Letter	056291-5004- StatementAccomSubstituteSpe	91194	no	1			
		cification.pdf	a21304a1693605cb782d50e3929611c7bd5 4f64d				
Warnings:							
Information:							
4	Drawings-only black and white line	Figure1.pdf	50623	no	1		
drawings			8f7fdc8fb2fb09a76e666027ded6c1d066e6 56e6				
Warnings:		·	· · · · ·	<u> </u>			
Information:							
5	Drawings-only black and white line	Figure2.pdf	56407		1		
drawings			3050fd5f0cdb31d94da5f8cb7e1225c57d59 bbbc		·		
Warnings:							
Information:							
6 Fee Works	Fee Worksheet (PTO-875)	fee-info.pdf	29814	no	2		
-			237e4bf3c55936644445d0c482604308e86 a54b9		-		
Warnings:							
Information:							

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Application No. 12/285,887

Second Substitute Specification

Clean Version

FORMULATION

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a Continuation Application of copending U.S. Patent Application 5 No. 10/872,784, filed June 22, 2004, which claims benefit of U.S. Patent Application No. 09/756,291, filed January 9, 2001 which claims the benefit of Great Britain Application No. 0008837.7 filed April 12, 2000 and Great Britain Application No. 0000313.7, filed January 10, 2000, all of which are incorporated herein by reference in their entireties.

10 BACKGROUND OF THE INVENTION

Field of the Invention

The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound

 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol.

15

Description of the Related Art

Oestrogen deprivation is fundamental to the treatment of many benign and malignant diseases of the breast and reproductive tract. In premenopausal women, this is achieved by the ablation of ovarian function through surgical, radiotherapeutic, or medical means, and, in 20 postmenopausal women, by the use of aromatase inhibitors.

An alternative approach to oestrogen withdrawal is to antagonise oestrogens with antioestrogens. These are drugs that bind to and compete for oestrogen receptors (ER) present in the nuclei of oestrogen-responsive tissue. Conventional nonsteroidal antioestrogens, such as tamoxifen, compete efficiently for ER binding but their effectiveness

25 is often limited by the partial agonism they display, which results in an incomplete blockade of oestrogen-mediated activity (Furr and Jordan 1984, May and Westley 1987).

The potential for nonsteroidal antioestrogens to display agonistic properties prompted the search for novel compounds that would bind ER with high affinity without activating any of the normal transcriptional hormone responses and consequent manifestations of oestrogens.

30 Such molecules would be "pure" antioestrogens, clearly distinguished from tamoxifen-like ligands and capable of eliciting complete ablation of the trophic effects of oestrogens. Such compounds are referred to as Estrogen Receptor-Downregulators (E.R.D.). The rationale for

the design and testing of novel, pure antioestrogens has been described in: Bowler et al 1989, Wakeling 1990a, 1990b, 1990c. Wakeling and Bowler 1987, 1988.

Steroidal analogues of oestradiol, with an alkylsulphinyl side chain in the 7α position, provided the first examples of compounds devoid of oestrogenic activity (Bowler et al 1989).

- 5 One of these, 7α -[9-(4,4,5,5,5-pentafluoropentyl sulphinyl)nonyl]oestra-1,3,5-(10)triene-3,17 β -diol was selected for intensive study on the basis of its pure oestrogen antagonist activity and significantly increased antioestrogenic potency over other available antioestrogens. *In vitro* findings and early clinical experience with 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3-5(10)-triene-3,17 β -diol have
- 10 promoted interest in the development of the drug as a therapeutic agent for oestrogendependent indications such as breast cancer and certain benign gynaecological conditions.

7α-[9-(4,4,5,5,5-Pentafluoropentylsulphinyl)nonyl]oestra-1,3-5(10)-triene-3,17β-diol, or ICI 182,780, has been allocated the international non-proprietary name fulvestrant, which is used hereinafter. When referring to fulvestrant we include pharmaceutically-acceptable
15 salts thereof and any possible solvates of either thereof.

Fulvestrant binds to ER with an affinity similar to that of oestradiol and completely blocks the growth stimulatory action of oestradiol on human breast cancer cells *in vitro*; it is more potent and more effective than tamoxifen in this respect. Fulvestrant blocks completely the uterotrophic action of oestradiol in rats, mice and monkeys, and also blocks the uterotrophic activity of tamoxifen.

Because fulvestrant has none of the oestrogen-like stimulatory activity that is characteristic of clinically available antioestrogens such as tamoxifen or toremifene, it may offer improved therapeutic activity characterised by more rapid, complete, or longer-lasting tumour regression; a lower incidence or rate of development of resistance to treatment; and a 25 reduction of tumour invasiveness.

In intact adult rats, fulvestrant achieves maximum regression of the uterus at a dose which does not adversely affect bone density or lead to increased gonadotrophin secretion. If also true in humans, these findings could be of extreme importance clinically. Reduced bone density limits the duration of oestrogen-ablative treatment for endometriosis. Fulvestrant does

30 not block hypothalamic ER. Oestrogen ablation also causes or exacerbates hot flushes and other menopausal symptoms; fulvestrant will not cause such effects because it does not cross the blood-brain barrier.

MYLAN PHARMS. INC. EXHIBIT 1002 PAGE 205

- 2 -

European Patent Application No. 0 138 504 discloses that certain steroid derivatives are effective antioestrogenic agents. The disclosure includes information relating to the preparation of the steroid derivatives. In particular there is the disclosure within Example 35 of the compound 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-

- 5 1,3,5(10)-triene-3,17β-diol, which compound is specifically named in Claim 4. It is also disclosed that the compounds of that invention may be provided for use in the form of a pharmaceutical composition comprising a steroid derivative of the invention together with a pharmaceutically-acceptable diluent or carrier. It is stated therein that the composition can be in a form suitable for oral or parenteral administration.
- 10 Fulvestrant shows, along with other steroidal based compounds, certain physical properties which make formulation of these compounds difficult. Fulvestrant is a particularly lipophilic molecule, even when compared with other steroidal compounds, and its aqueous solubility is extremely low at around 10 ngml⁻¹ (this is an estimate from a water/solvent mixture solute since measurements this low could not be achieved in a water only solute).
- 15 Currently there are a number of sustained release injectable steroidal formulations which have been commercialised. Commonly these formulations use oil as a solvent and wherein additional excipients may be present. Below in Table 1 are described a few commercialised sustained release injectable formulations.
- In the formulations within Table 1 a number of different oils are used to solubilise the compound and additional excipients such as benzyl benzoate, benzyl alcohol and ethanol have been used. Volumes of oil needed to solubilise the steroid active ingredient are low. Extended release is achievable for periods from 1 to 8 weeks.

25

MYLAN PHARMS. INC. EXHIBIT 1002 PAGE 206

- 3 -

Table 1 - OIL BASED LONG-ACTING INTRAMUSCULAR INJECTIONS

PRODUCT NAME	<u>STEROID</u>	<u>DOSE</u>	<u>TYPE</u>	<u>COMP'.</u>	<u>SOURCE</u>	<u>OIL</u>	<u>BzBz</u>	<u>BzOH</u>	<u>EtO</u> <u>H</u>	<u>DOSE</u>	<u>DOSING</u>
SUSTANON 100	Testosterone proprionate Testosterone phenylproprionate Testosterone isocaproate	30mg 60mg 60mg	Androgen	Organon	ABPI Data Sheet Comp.1999	Arachis		0.1ml	Π	1ml	3 weeks
PROLUTON DEPOT	Testosterone decanoate Hydroxy progesterone hexanoate	100mg 250mgml ⁻¹	Progestogen	Schering HC	ABPI Data Sheet Comp.1999	Castor	up to 46%			1 or 2ml	1 week
TOCOGESTAN	Hydroxy progesterone enantate Progesterone	200mg 50mg 250mg	Progestogen	Theramax	Dict. Vidal 1999	Ethyl oleate	*40%			2ml	< 1week
TROPHOBOLENE	α-Tocopherol Estrapronicate Nandrolone undecanoate Hydroxyprogesterone heptanoate	230mg 1.3mg 50mg 80mg	Mixed	Theramax	Dict. Vidal 1997	Olive	45%			1ml	15 to 30 days
NORISTERAT	Norethisterone oenanthoate	200mg	Contraceptive	Schering HC	ABPI Data Sheet Comp.1999	Castor	YES			1ml	8 weeks
BENZO- GYNOESTRYL	Estradiol hexahydrobenzoate	5mg	Estradiol	Roussel	Dict. Vidal 1998	Arachis				1ml	1 week
PROGESTERONE -RETARD	Hydroxy progesterone caproate	250mgml ⁻¹	Progestogen	Pharlon	Dict. Vidal 1999	Castor	YES			1 or 2ml	1 week
GRAVIBINAN	Estradiol 17-β-valerate Hydroxyprogesterone caproate	5mgml ⁻¹ 250mgml ⁻¹	Mixed	Schering HC	Dict. Vidal 1995	Castor	YES			1 or 2ml	1 - 2 weeks

PARABOLAN	Trenbolone	76mg	Androgen	Negma	Dict. Vidal 1997	Arachis		75mg	45mg	1.5ml	2 weeks
DELESTROGEN	Estradiol valerate	20mgml ⁻¹ 40mgml ⁻¹	Estradiol	BMS	J.Pharm. Sci (1964) 53(8) 891	Castor	78% 58%	20% 40%	2% 2%		
DELALUTIN	17-Hydroxy progesterone	250mgml ⁻¹	Progestrogen	DMS	J.Pharm. Sci.(1964) 53(8) 891	Castor	YES	YES	up to 2%		

BzBz = benzylbenzoateBzOH = benzylalcoholEtOH = ethanolDict. Vidal = Dictionnaire Vidal5% are w/v and * approximate as measured directly from a single sample

described which comprises 50mg of fulvestrant, 400mg of benzyl alcohol and sufficient castor oil to bring the solution to a volume of 1 ml. Manufacture at a commercial scale of a formulation as described in US 5,183,814 will be complicated by the high alcohol concentration. Therefore, there is a need to lower the alcohol concentration in fulvestrant

5 formulations whilst preventing precipitation of fulvestrant from the formulation.

SUMMARY OF THE INVENTION

The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound

10 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol, more particularly to a formulation adapted for administration by injection containing the compound 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a nonaqueous ester solvent which is miscible in the ricinoleate vehicle.

15

25

BRIEF DESCRIPTION OF THE DRAWING

Figure 1 shows the release profile *in vivo* of the four formulations from the second part of Table 4 below, and shows the effect of the fixed oil component on fulvestrant plasma profile over five days following intramuscular administration in rabbits.

20 Figure 2 shows a process flow diagram associated with the Formulation Example.

DETAILED DESCRIPTION OF THE INVENTION

Table 2 shows the solubility of fulvestrant in a number of different solvents.

Table 2 - SOLUBILITY OF FULVESTRANT

SOLVENT	SOLUBILITY
	(mgml ⁻¹ at 25°C)
Water	0.001
Arachis oil	0.45
Sesame oil	0.58
Castor oil	20

MYLAN PHARMS. INC. EXHIBIT 1002 PAGE 209

- 6 -

Miglyol 810	3.06
Miglyol 812	2.72
Ethyl oleate	1.25
Benzyl benzoate	6.15
Isopropyl myristate	0.80
Span 85 (surfactant)	3.79
Ethanol	>200
Benzyl Alcohol	>200

As can be seen fulvestrant is significantly more soluble in castor oil than any of the other oils tested. The greater solvating ability of castor oil for steroidal compounds is known and is attributed to the high number of hydroxy groups of ricinoleic acid, which is the major 5 constituent of the fatty acids within the triglycerides present in castor oil - see (Riffkin et.al.

J. Pharm. Sci., (1964), 53, 891).

However, even when using the best oil based solvent, castor oil, we have found that it is not possible to dissolve fulvestrant in an oil based solvent alone so as to achieve a high enough concentration to dose a patient in a low volume injection and achieve a

10 therapeutically significant release rate. To achieve a therapeutically significant release rate the amount of fulvestrant needed would require the formulation volume to be large, at least 10 ml. This requires the doctor to inject an excessively large volume of formulation to administer a dose significantly high enough for human therapy.

Currently guidelines recommend that no more than 5mls of liquid is injected

15 intramuscularly in a single injection. Pharmacologically active doses required for a 1 month long acting depot formulation of fulvestrant is around 250mg. Therefore, when dissolved in just castor oil, fulvestrant would need to be administered in at least 10ml of castor oil.

The addition of organic solvents in which fulvestrant is freely soluble, and which are miscible with castor oil, may be used, such as an alcohol. With the addition of high

20 concentrations of an alcohol concentrations of >50mgml⁻¹ of fulvestrant in a castor oil formulation is achievable, thereby giving an injection volumes of <5ml - see Table 3 below. We have surprisingly found that the introduction of a non-aqueous ester solvent which is miscible in the castor oil and an alcohol surprisingly eases the solubilisation of fulvestrant into a concentration of at least 50 mgml⁻¹ - see Table 3 below. The finding is surprising since

Z70635

the solubility of fulvestrant in non-aqueous ester solvents - see Table 2 above - is significantly lower than the solubility of fulvestrant in an alcohol. The solubility of fulvestrant is also lower in non-aqueous ester solvents than is the solubility of fulvestrant in castor oil.

Therefore, we present as a feature of the invention a pharmaceutical formulation 5 comprising fulvestrant (preferably fulvestrant is present at 3-10%w/v, 4-9%w/v, 4-8%w/v, 4-7%w/v, 4-6%w/v and most preferably at about 5%w/v) in a ricinoleate vehicle, a pharmaceutically acceptable non-aqueous ester solvent, and a pharmaceutically acceptable alcohol wherein the formulation is adapted for intramuscular administration and attaining a therapeutically significant blood plasma fulvestrant concentration for at least 2 weeks.

10 Another feature of the invention is a pharmaceutical formulation comprising fulvestrant in which the formulation is adapted for intra-muscular injection into a human and which is capable after injection of attaining a therapeutically significant blood plasma fulvestrant concentration for at least 2 weeks.

Further features of the invention include a pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 30% or less weight of a pharmaceuticallyacceptable alcohol per volume of formulation, at least 1% weight of a pharmaceuticallyacceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation which is capable after injection of attaining a therapeutically significant blood plasma 20 fulvestrant concentration for at least 2 weeks.

Further features of the invention include a pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant; 35% (preferably 30% and ideally 25%) or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% (preferably at least 5% or ideally 10%) weight of a pharmaceutically-acceptable non-aqueous 25 ester solvent miscible within a ricinoleate vehicle per volume of formulation and a sufficient

amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml⁻¹ of fulvestrant.

For the avoidance of any doubt when using the term % weight per volume of formulation for the constituents of the formulation we mean that within a unit volume of the formulation a certain percentage of the constituent by weight will be present, for example a 1% weight per volume formulation will contain within a 100ml volume of formulation 1g of the constituent. By way of further illustration

MYLAN PHARMS. INC. EXHIBIT 1002 PAGE 211

- 8 -

% of x by weight per volume of formulation	weight of x in 1ml of formulation
30%	300mg
20%	200mg
10%	100mg
5%	50mg
1%	10mg

Preferred pharmaceutical formulations of the invention are as described above 5 wherein:

1. The total volume of the formulation is 6ml, or less, and the concentration of fulvestrant is at least 45mgml⁻¹.

2. The total amount of fulvestrant in the formulation is 250mg, or more, and the total volume of the formulation is 6ml, or less.

10 3. The total amount of fulvestrant in the formulation is 250mg and the total volume of the formulation is 5-5.25ml.

It is appreciated that in the formulation an excess of formulation may be included to allow the attendant physician or care giver to be able to deliver the required dose. Therefore, when a 5ml dose is required it would be appreciated that an excess of up to 0.25ml, preferably

15 up to 0.15ml will also be present in the formulation. Typically the formulation will be presented in a vial or a prefilled syringe, preferably a prefilled syringe, containing a unit dosage of the formulation as described herein, these being further features of the invention.

Preferred concentrations of a pharmaceutically-acceptable alcohol present in any of the above formulations are; at least 3%w/v, at least 5%w/v, at least 7%w/v, at least 10% w/v,

- 20 at least 11% w/v, at least 12% w/v, at least 13% w/v, at least 14% w/v, at least 15% w/v and, preferably, at least 16% w/v. Preferred maximal concentrations of pharmaceutically-acceptable alcohol present in the formulation are ;28% w/v or less, 22% w/v or less and 20% w/v or less. Preferred ranges of pharmaceutically-acceptable alcohol present in any of the above formulations are selected from any minimum or maximum value described above and
- 25 preferably are; 3-35%w/v, 4-35%w/v, 5-35%w/v, 5-32%w/v, 7-32%w/v, 10-30%w/v, 12-28%w/v, 15-25%w/v, 17-23%w/v, 18-22%w/v and ideally 19-21%w/v.

The pharmaceutically-acceptable alcohol may consist of one alcohol or a mixture of two or more alcohols, preferably a mixture of two alcohols. Preferred pharmaceuticallyacceptable alcohols for parenteral administration are ethanol, benzyl alcohol or a mixture of both ethanol and benzyl alcohol, preferably the ethanol and benzyl alcohol are present in the

5 formulation in the same w/v amounts. Preferably the formulation alcohol contains 10% w/v ethanol and 10% w/v benzyl alcohol.

The pharmaceutically-acceptable non-aqueous ester solvent may consist of one or a mixture of two or more pharmaceutically-acceptable non-aqueous ester solvents, preferably just one. A preferred pharmaceutically-acceptable non-aqueous ester solvent for parenteral administration is selected from benzyl benzoate, ethyl oleate, isopropyl myristate, isopropyl palmitate or a mixture of any thereof.

The ricinoleate vehicle should preferably be present in the formulation in a proportion of at least 30% weight per volume of the formulation, ideally at least 40% or at least 50% weight per volume of formulation.

15 It will be understood by the skilled person that the pharmaceutically-acceptable alcohol will be of a quality such that it will meet pharmacopoeial standards (such as are described in the US, British, European and Japanese pharmacopoeias) and as such will contain some water and possibly other organic solvents, for example ethanol in the US Pharmacopeia contains not less than 94.9% by volume and not more than 96.0% by volume of 20 ethanol when measured at 15.56°C. Dehydrated alcohol in the US Pharmacopeia contains not

less than 99.5% ethanol by volume when measured at 15.56°C.

Preferred concentrations of the pharmaceutically-acceptable non-aqueous ester solvent present in any of the above formulations are; at least 5% w/v, at least 8% w/v, at least 10% w/v, at least 11% w/v, at least 12% w/v, at least 13% w/v, at least 15% w/v, at least 16% w/v,

25 at least 17% w/v, at least 18% w/v, at least 19% w/v and at least 20% w/v. Preferred maximal concentrations of the pharmaceutically-acceptable non-aqueous ester solvent are; 60% w/v or less, 50%w/v or less, 45% w/v or less, 40% w/v or less, 35% w/v or less, 30% w/v or less and 25% w/v or less. A preferred concentration is 15% w/v. Preferred ranges of pharmaceutically-acceptable non-aqueous ester solvent present in any of the above formulations are selected

30 from any minimum or maximum value described above and preferably are; 5-60%w/v, 7-55%w/v, 8-50%w/v, 10-50%w/v, 10-45%w/v, 10-40%w/v, 10-35%w/v, 10-30%w/v, 10-

25%w/v, 12-25%w/v, 12-22%w/v, 12-20%w/v, 12-18%w/v, 13-17%w/v and ideally 14-

16%w/v. Preferably the ester solvent is benzyl benzoate, most preferably at about 15%w/v.

It will be understood by the skilled person that the pharmaceutically-acceptable nonaqueous ester solvent will be of a quality that it will meet pharmacopoeial standards (such as 5 described in the US, British, European and Japanese pharmacopoeias).

Preferred combinations of pharmaceutically-acceptable alcohol and pharmaceuticallyacceptable non-aqueous ester solvent in the formulation are set out below:

Pharmaceutically-acceptable	Pharmaceutically-acceptable non-aqueous
alcohol(%w/v)	ester (%w/v)
10-30	5-60, 7-55, 8-50, 10-50, 10-45, 10-40, 10-35, 10-
	30, 10-25, 12-25, 12-22, 12-20, 12-18, 13-17 and
	ideally 14-16.
17-23	5-60, 7-55, 8-50, 10-50, 10-45, 10-40, 10-35, 10-
	30, 10-25, 12-25, 12-22, 12-20, 12-18, 13-17 and
	ideally 14-16.
3-35, 4-35, 5-35, 5-32, 7-32, 10-30, 12-	10-35
28, 15-25, 17-23, 18-22 and ideally 19-	
3-35, 4-35, 5-35, 5-32, 7-32, 10-30, 12-	12-18
28, 15-25, 17-23, 18-22 and ideally 19-	
21.	
ethanol and benzyl alcohol, most	benzyl benzoate, most preferably at about 15%
preferably each at about 10%	

By the use of the term ricinoleate vehicle we mean an oil which has as a proportion (at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% w/v) of its composition as triglycerides of ricinoleic acid. The ricinoleate vehicle may be a synthetic oil or conveniently is castor oil, ideally of pharmacopoeial standards, as described above.

We have surprisingly found that the above formulations of the invention provide, after intra-muscular injection, satisfactory release of fulvestrant over an extended period of time. This finding is indeed surprising for the following reasons.

1. Previously tested by the applicants have been intra-muscular injections of fulvestrant in the form of an aqueous suspension. We have found extensive local tissue irritation at the

injection site as well as a poor release profile. It is believed that the tissueirritation/inflammation was due to the presence of fulvestrant in the form of solid particles.The release profile appeared to be determined by the extent of inflammation/irritation presentat the injection site and this was variable and difficult to control. Also the fulvestrant releaserate was not sufficiently high to be clinically significant.

2. Our findings from studies using ¹⁴C labelled benzyl alcohol show that it dissipates rapidly from the injection site and is removed from the body within 24 hours of administration.

It would be expected that ethanol will dissipate at least as quickly, if not more rapidly, 10 from the injection site.

It is known that benzyl benzoate is metabolised by conjugation to glycine to form hippuric acid by the human liver and excreted into the urine - Martindale: The Extra Pharmacopoeia 32nd edition page 1103, and, therefore, it is unlikely that benzyl benzoate, when used, is present at the injection site during the whole of the extended release period.

15 We have found that despite the rapid elimination of the additional solubilising excipients, i.e. the alcohol and pharmaceutically-acceptable non-aqueous ester solvent, from the formulation vehicle and the site of injection after injection of the formulation, extended release at therapeutically significant levels of fulvestrant over an extended period can still achieved by the formulation of the invention.

By use of the term "therapeutically significant levels" we mean that blood plasma concentrations of at least 2.5 ngml⁻¹, ideally at least 3 ngml⁻¹, at least 8.5 ngml⁻¹, and up to 12 ngml⁻¹ of fulvestrant are achieved in the patient. Preferably blood plasma levels should be less than 15 ngml⁻¹.

By use of the term "extended release" we mean at least two weeks, at least three 25 weeks, and, preferably at least four weeks of continuous release of fulvestrant is achieved. In a preferred feature extended release is achieved for 36 days. Preferably extended release of fulvestrant is for at least 2- 5 weeks and more preferably for the following periods (weeks) 2.5-5, 2.5-4, 3-4, 3.5-4 and most preferably for at least about 4 weeks.

It will be understood that the attendant physician may wish to administer the intramuscular injection as a divided dose, i.e. a 5ml formulation is sequentially administered in two separate injections of 2.5ml, this is a further feature of the invention

Simply solubilising fulvestrant in an oil based liquid formulation is not predictive of a good release profile or lack of precipitation of drug after injection at the injection site.

Table 3 shows the solubility of fulvestrant in a castor oil vehicle additionally containing alcohols ethanol and benzyl alcohol with or without benzyl benzoate. The results

⁵ clearly show the positive effect of benzyl benzoate on fulvestrant solubility in castor oil, despite fulvestrant having a lower solubility in benzyl benzoate than in either alcohol or castor oil.

10

Table 3

Table 3 - EFFECT OF BENZYL BENZOATE ON FULVESTRANT SOLUBILITY IN CASTOR OIL AT 25°C

				% w/v				
Ethanol	5	5	10	10	10	10	15	15
(96%)								
Benzyl	5	5	5	5	10	10	15	15
Alcohol								
Benzyl		15		15		15		15
Benzoate								
Castor Oil	to 100	to100	to 100					
Fulvestrant	27	36	46	54	45	65	76	102
Solubility								
$[mgml^{-1}]$								

5

The following Table 4 shows the solubility of fulvestrant in a range of oil based formulations which contain the same amounts of alcohol and benzyl benzoate but in which the oil is changed. The data also shows solubility of fulvestrant after removal of the alcohols.

Table 4

1			···· +1 ~ 2500
10		Fulvestrant Solul	oility mg ml ⁻¹ @ 25°C
	Formulation ^(a)	Complete vehicle	Vehicle minus alcohols
	Castor oil based	81.2	12.6
15	Miglyol 812-N based	86.8	1.7
	Sesame seed/Castor oil (1:1) based	70.1	4.4
20	Sesame seed oil based	45.7	0.7
20	Arachis oil based	40.2	< 0.2

5 Solubility comparisons of fulvestrant in oil based formulations with and without alcohols

(a) Complete Vehicle Formulations comprised ethanol [96%](10%), benzyl alcohol (10%) and benzyl benzoate
 (15%) made to volume with the stated oil. Excess fulvestrant was added to each solvent mixture and solubility determined.

30					Days			
	Formulation ^a	2	3	4	7	10	30	51
35	Formulation F1 castor oil based	0	0	0	0	0	0	0
	Formulation F2 Miglyol 812-N based	++ ^b	+++	+++	+++	+++	++	0
40	Formulation F3 sesame seed oil/castor oil based	+ ^c	++	++	+++	++	+	+

Effect of formulation on precipitation of fulvestrant at the injection site

 $\overline{0, +, ++, +++}$ = Degree of precipitation (None detected, Mild, Moderate, Severe)

45 ^a Formulations comprised fulvestrant (5%), ethanol [96%] (10%), benzyl alcohol (10%) and benzyl benzoate (15%) made to volume with the stated oil.

^b Mainly large needle shaped crystals

^c Small needles and/or sheafs of crystals

Precipitation of fulvestrant and the release profile was determined with the above formulations in an *in vivo* rabbit study.

Figure 1 shows the release profile *in vivo* of the four formulations from the second part of Table 4 and shows the effect of the fixed oil component on fulvestrant plasma profile

- 5 over five days following intramuscular administration in rabbits (data normalised to 50mg per 3kg; mean given; number of animals per timepoint = 8, plasma samples assayed for fulvestrant content using lc-ms/ms detection following solvent extraction). As can be seen the castor oil formulation showed a particularly even release profile with no evidence of precipitation of fulvestrant at the injection site.
- 10 Therefore we present as a further feature of the invention an extended release pharmaceutical formulation adapted for intramuscular injection comprising fulvestrant; 35% (preferably 30% or ideally 25%) or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% (preferably at least 5% or ideally 10%) weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per
- 15 volume of formulation and sufficient amount of a ricinoleate vehicle, taking into account the addition of any further optional pharmaceutically-acceptable excipients, so as to prepare a formulation of at least 45mgml⁻¹ of fulvestrant.

A further feature of the invention is a pharmaceutical formulation adapted for intramuscular injection, as defined above, for use in medical therapy.

- A further feature of the invention is a method of treating a benign or malignant diseases of the breast or reproductive tract, preferably treating breast cancer, by administration to a human in need of such treatment by intramuscular injection an extended release ricinoleate vehicle based pharmaceutical formulation comprising at least 45mgml⁻¹ of fulvestrant; 35% (preferably 30% or ideally 25%) or less weight of a pharmaceutically-
- 25 acceptable alcohol per volume of formulation, at least 1% (preferably at least 5% or ideally 10%) weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation.

Preferably 5ml of the intramuscular injection is administered.

A further feature of the invention is use of fulvestrant in the preparation of a pharmaceutical formulation as describe hereinabove, for the treatment of a benign or malignant disease of the breast or reproductive tract, preferably treating breast cancer.

MYLAN PHARMS. INC. EXHIBIT 1002 PAGE 219

- 16 -

Additional excipients commonly used in the formulation field including, for example, an antioxidant preservative, a colorant or a surfactant may be used. A preferred optional excipient is a surfactant.

As described above fulvestrant is useful in the treatment of oestrogen-dependent 5 indications such as breast cancer and gynaecological conditions, such as endometriosis.

In addition to fulvestrant another similar type of molecule is currently under clinical investigation. SH-646 (11 β -fluoro- 7 α -(14,14,15,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl)estra-1,3,5(10)-triene-3,17 β -diol) is also putatively a

10 structure. It is believed that the compound will also share with fulvestrant similar physical properties and therefore the current invention will also have application with this compound.

compound with the same mode of action as fulvestrant and has a very similar chemical

A further feature of the invention is a pharmaceutical formulation adapted for intra-muscular injection comprising 11 β -fluoro- 7 α -(14,14,15,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl)estra-1,3,5(10)-triene-3,17 β -diol; 35% or less weight of a

- 15 pharmaceutically-acceptable alcohol per volume of formulation, at least 1% weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible within a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml⁻¹ of 11β-fluoro- 7α -(14,14,15,15,15-pentafluoro-6methyl-10-thia-6-azapentadecyl)estra-1,3,5(10)-triene-3,17β-diol.
- 20 Further features of the invention are those as described above but in which SH-646 is substituted for fulvestrant.

Formulation Example

- 25 Fulvestrant is mixed with alcohol and benzyl alcohol, stirring until completely dissolved. Benzyl benzoate is added and the solution is made to final weight with castor oil and stirred, (for convenience weight is used rather than volume by using the weight to volume ratio). The bulk solution is overlaid with Nitrogen. The solution is sterilised by filtration using one or two filters of 0.2µm porosity. The sterile filtrate is kept under a nitrogen overlay
- 30 as it is filled under aseptic conditions into washed and depyrogenised, sterile primary containers, for example vials or pre-filled syringes. An overage is included in the primary

pack to facilitate removal of the dose volume. The primary packs are overlaid with sterile nitrogen, before aseptically sealing.

See also process flow diagram of Figure 2.

5

Quantities of each component of the formulation is chosen according to the required formulation specification, examples are described above. For example quantities are added of each component to prepare a formulation which contains 10% weight per volume of benzyl alcohol

10 10% weight per volume of ethanol
15% weight per volume of benzyl benzoate
250mg of fulvestrant for each 5ml of finished formulation
and the remaining amount as castor oil

15

- 18 -

References

1. Bowler J, Lilley TJ, Pittam JD, Wakeling AE. Novel steroidal pure antioestrogens. Steroids 989; 5471-99.

5 2. Wakeling AE. Novel pure antioestrogens: mode of action and therapeutic prospects.American New York Academy Science 1990a; 595: 348-56.

3. Wakeling AE. Steroidal pure antioestrogens. In Lippman M, Dickson R, editors. Regulatory mechanisms in breast cancer. Boston: Kluwer Academic, 1990b: 239-57.

10

4. Wakeling AE. Therapeutic potential of pure antioestrogens in the treatment of breast cancer. Journal Steroid Biochemistry 1990c; 37: 771-5.

5. Wakeling AE, Bowler J. Steroidal pure antioestrogens. Journal Endocrinology 1987; 112:15 R7-10.

6. Wakeling AE, Bowler J. Biology and mode of action of pure antioestrogens. Journal Steroid Biochemistry 1988; 3: 141-7.

ABSTRACT OF THE DISCLOSURE

The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound

5 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol, more particularly to a formulation adapted for administration by injection containing the compound 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a nonaqueous ester solvent which is miscible in the ricinoleate vehicle.

10

Application No. 12/285,887

Second Substitute Specification

Marked Version

FORMULATION

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a Continuation Application of copending U.S. Patent Application 5 No. 10/872,784, filed June 22, 2004, which claims benefit of U.S. Patent Application No. 09/756,291, filed January 9, 2001 which claims the benefit of Great Britain Application No. 0008837.7 filed April 12, 2000 and Great Britain Application No. 0000313.7, filed January 10, 2000, all of which are incorporated herein by reference in their entireties.

10 BACKGROUND OF THE INVENTION

Field of the Invention

The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound

 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol.

15

Description of the Related Art

Oestrogen deprivation is fundamental to the treatment of many benign and malignant diseases of the breast and reproductive tract. In premenopausal women, this is achieved by the ablation of ovarian function through surgical, radiotherapeutic, or medical means, and, in 20 postmenopausal women, by the use of aromatase inhibitors.

An alternative approach to oestrogen withdrawal is to antagonise oestrogens with antioestrogens. These are drugs that bind to and compete for oestrogen receptors (ER) present in the nuclei of oestrogen-responsive tissue. Conventional nonsteroidal antioestrogens, such as tamoxifen, compete efficiently for ER binding but their effectiveness

25 is often limited by the partial agonism they display, which results in an incomplete blockade of oestrogen-mediated activity (Furr and Jordan 1984, May and Westley 1987).

The potential for nonsteroidal antioestrogens to display agonistic properties prompted the search for novel compounds that would bind ER with high affinity without activating any of the normal transcriptional hormone responses and consequent manifestations of oestrogens.

30 Such molecules would be "pure" antioestrogens, clearly distinguished from tamoxifen-like ligands and capable of eliciting complete ablation of the trophic effects of oestrogens. Such compounds are referred to as Estrogen Receptor-Downregulators (E.R.D.). The rationale for

the design and testing of novel, pure antioestrogens has been described in: Bowler et al 1989, Wakeling 1990a, 1990b, 1990c. Wakeling and Bowler 1987, 1988.

Steroidal analogues of oestradiol, with an alkylsulphinyl side chain in the 7α position, provided the first examples of compounds devoid of oestrogenic activity (Bowler et al 1989).

- 5 One of these, 7α -[9-(4,4,5,5,5-pentafluoropentyl sulphinyl)nonyl]oestra-1,3,5-(10)triene-3,17 β -diol was selected for intensive study on the basis of its pure oestrogen antagonist activity and significantly increased antioestrogenic potency over other available antioestrogens. *In vitro* findings and early clinical experience with 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3-5(10)-triene-3,17 β -diol have
- 10 promoted interest in the development of the drug as a therapeutic agent for oestrogendependent indications such as breast cancer and certain benign gynaecological conditions.

7α-[9-(4,4,5,5,5-Pentafluoropentylsulphinyl)nonyl]oestra-1,3-5(10)-triene-3,17β-diol, or ICI 182,780, has been allocated the international non-proprietary name fulvestrant, which is used hereinafter. When referring to fulvestrant we include pharmaceutically-acceptable
15 salts thereof and any possible solvates of either thereof.

Fulvestrant binds to ER with an affinity similar to that of oestradiol and completely blocks the growth stimulatory action of oestradiol on human breast cancer cells *in vitro*; it is more potent and more effective than tamoxifen in this respect. Fulvestrant blocks completely the uterotrophic action of oestradiol in rats, mice and monkeys, and also blocks the uterotrophic activity of tamoxifen.

Because fulvestrant has none of the oestrogen-like stimulatory activity that is characteristic of clinically available antioestrogens such as tamoxifen or toremifene, it may offer improved therapeutic activity characterised by more rapid, complete, or longer-lasting tumour regression; a lower incidence or rate of development of resistance to treatment; and a 25 reduction of tumour invasiveness.

In intact adult rats, fulvestrant achieves maximum regression of the uterus at a dose which does not adversely affect bone density or lead to increased gonadotrophin secretion. If also true in humans, these findings could be of extreme importance clinically. Reduced bone density limits the duration of oestrogen-ablative treatment for endometriosis. Fulvestrant does

30 not block hypothalamic ER. Oestrogen ablation also causes or exacerbates hot flushes and other menopausal symptoms; fulvestrant will not cause such effects because it does not cross the blood-brain barrier.

MYLAN PHARMS. INC. EXHIBIT 1002 PAGE 226

- 2 -

European Patent Application No. 0 138 504 discloses that certain steroid derivatives are effective antioestrogenic agents. The disclosure includes information relating to the preparation of the steroid derivatives. In particular there is the disclosure within Example 35 of the compound 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-

- 5 1,3,5(10)-triene-3,17β-diol, which compound is specifically named in Claim 4. It is also disclosed that the compounds of that invention may be provided for use in the form of a pharmaceutical composition comprising a steroid derivative of the invention together with a pharmaceutically-acceptable diluent or carrier. It is stated therein that the composition can be in a form suitable for oral or parenteral administration.
- 10 Fulvestrant shows, along with other steroidal based compounds, certain physical properties which make formulation of these compounds difficult. Fulvestrant is a particularly lipophilic molecule, even when compared with other steroidal compounds, and its aqueous solubility is extremely low at around 10 ngml⁻¹ (this is an estimate from a water/solvent mixture solute since measurements this low could not be achieved in a water only solute).
- 15 Currently there are a number of sustained release injectable steroidal formulations which have been commercialised. Commonly these formulations use oil as a solvent and wherein additional excipients may be present. Below in Table 1 are described a few commercialised sustained release injectable formulations.
- In the formulations within Table 1 a number of different oils are used to solubilise the compound and additional excipients such as benzyl benzoate, benzyl alcohol and ethanol have been used. Volumes of oil needed to solubilise the steroid active ingredient are low. Extended release is achievable for periods from 1 to 8 weeks.

25

MYLAN PHARMS. INC. EXHIBIT 1002 PAGE 227

- 3 -

Table 1 - OIL BASED LONG-ACTING INTRAMUSCULAR INJECTIONS

PRODUCT NAME	<u>STEROID</u>	<u>DOSE</u>	<u>TYPE</u>	<u>COMP'.</u>	<u>SOURCE</u>	<u>OIL</u>	<u>BzBz</u>	<u>BzOH</u>	<u>EtO</u> <u>H</u>	<u>DOSE</u>	<u>DOSING</u>
SUSTANON 100	Testosterone proprionate Testosterone phenylproprionate Testosterone isocaproate	30mg 60mg	Androgen	Organon	ABPI Data Sheet Comp.1999	Arachis		0.1ml	Π	1ml	3 weeks
PROLUTON DEPOT	Testosterone decanoate Hydroxy progesterone hexanoate	100mg 250mgml ⁻¹	Progestogen	Schering HC	ABPI Data Sheet Comp.1999	Castor	up to 46%			1 or 2ml	1 week
TOCOGESTAN	Hydroxy progesterone enantate Progesterone	200mg 50mg 250mg	Progestogen	Theramax	Dict. Vidal 1999	Ethyl oleate	*40%			2ml	< 1week
TROPHOBOLENE	α-Tocopherol Estrapronicate Nandrolone undecanoate Hydroxyprogesterone heptanoate	230mg 1.3mg 50mg 80mg	Mixed	Theramax	Dict. Vidal 1997	Olive	45%			lml	15 to 30 days
NORISTERAT	Norethisterone oenanthoate	200mg	Contraceptive	Schering HC	ABPI Data Sheet Comp.1999	Castor	YES			1ml	8 weeks
BENZO- GYNOESTRYL	Estradiol hexahydrobenzoate	5mg	Estradiol	Roussel	Dict. Vidal 1998	Arachis				1ml	1 week
PROGESTERONE -RETARD	Hydroxy progesterone caproate	250mgml ⁻¹	Progestogen	Pharlon	Dict. Vidal 1999	Castor	YES			1 or 2ml	1 week
GRAVIBINAN	Estradiol 17-β-valerate Hydroxyprogesterone caproate	5mgml ⁻¹ 250mgml ⁻¹	Mixed	Schering HC	Dict. Vidal 1995	Castor	YES			1 or 2ml	1 - 2 weeks

PARABOLAN	Trenbolone	76mg	Androgen	Negma	Dict. Vidal 1997	Arachis		75mg	45mg	1.5ml	2 weeks
DELESTROGEN	Estradiol valerate	20mgml ⁻¹ 40mgml ⁻¹	Estradiol	BMS	J.Pharm. Sci (1964) 53(8) 891	Castor	78% 58%	20% 40%	2% 2%		
DELALUTIN	17-Hydroxy progesterone	250mgml ⁻¹	Progestrogen	DMS	J.Pharm. Sci.(1964) 53(8) 891	Castor	YES	YES	up to 2%		

BzBz = benzylbenzoateBzOH = benzylalcoholEtOH = ethanolDict. Vidal = Dictionnaire Vidal5% are w/v and * approximate as measured directly from a single sample

described which comprises 50mg of fulvestrant, 400mg of benzyl alcohol and sufficient castor oil to bring the solution to a volume of 1 ml. Manufacture at a commercial scale of a formulation as described in US 5,183,814 will be complicated by the high alcohol concentration. Therefore, there is a need to lower the alcohol concentration in fulvestrant

5 formulations whilst preventing precipitation of fulvestrant from the formulation.

SUMMARY OF THE INVENTION

The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound

10 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol, more particularly to a formulation adapted for administration by injection containing the compound 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a nonaqueous ester solvent which is miscible in the ricinoleate vehicle.

15

BRIEF DESCRIPTION OF THE DRAWING

Figure 1 shows the release profile *in vivo* of the four formulations from the second part of Table 4 below, and shows the effect of the fixed oil component on fulvestrant plasma profile over five days following intramuscular administration in rabbits.

20

Figure 2 shows a process flow diagram associated with the Formulation Example.

DETAILED DESCRIPTION OF THE INVENTION

Table 2 shows the solubility of fulvestrant in a number of different solvents.

2	5
4	2

Table 2 - SOLUBILITY OF FULVESTRANT

SOLVENT	SOLUBILITY
	(mgml ⁻¹ at 25°C)
Water	0.001
Arachis oil	0.45
Sesame oil	0.58
Castor oil	20

Miglyol 810	3.06
Miglyol 812	2.72
Ethyl oleate	1.25
Benzyl benzoate	6.15
Isopropyl myristate	0.80
Span 85 (surfactant)	3.79
Ethanol	>200
Benzyl Alcohol	>200

As can be seen fulvestrant is significantly more soluble in castor oil than any of the other oils tested. The greater solvating ability of castor oil for steroidal compounds is known and is attributed to the high number of hydroxy groups of ricinoleic acid, which is the major 5 constituent of the fatty acids within the triglycerides present in castor oil - see (Riffkin et.al.

J. Pharm. Sci., (1964), 53, 891).

However, even when using the best oil based solvent, castor oil, we have found that it is not possible to dissolve fulvestrant in an oil based solvent alone so as to achieve a high enough concentration to dose a patient in a low volume injection and achieve a

10 therapeutically significant release rate. To achieve a therapeutically significant release rate the amount of fulvestrant needed would require the formulation volume to be large, at least 10 ml. This requires the doctor to inject an excessively large volume of formulation to administer a dose significantly high enough for human therapy.

Currently guidelines recommend that no more than 5mls of liquid is injected

15 intramuscularly in a single injection. Pharmacologically active doses required for a 1 month long acting depot formulation of fulvestrant is around 250mg. Therefore, when dissolved in just castor oil, fulvestrant would need to be administered in at least 10ml of castor oil.

The addition of organic solvents in which fulvestrant is freely soluble, and which are miscible with castor oil, may be used, such as an alcohol. With the addition of high

20 concentrations of an alcohol concentrations of >50mgml⁻¹ of fulvestrant in a castor oil formulation is achievable, thereby giving an injection volumes of <5ml - see Table 3 below. We have surprisingly found that the introduction of a non-aqueous ester solvent which is miscible in the castor oil and an alcohol surprisingly eases the solubilisation of fulvestrant into a concentration of at least 50 mgml⁻¹ - see Table 3 below. The finding is surprising since

the solubility of fulvestrant in non-aqueous ester solvents - see Table 2 above - is significantly lower than the solubility of fulvestrant in an alcohol. The solubility of fulvestrant is also lower in non-aqueous ester solvents than is the solubility of fulvestrant in castor oil.

Therefore, we present as a feature of the invention a pharmaceutical formulation 5 comprising fulvestrant (preferably fulvestrant is present at 3-10%w/v, 4-9%w/v, 4-8%w/v, 4-7%w/v, 4-6%w/v and most preferably at about 5%w/v) in a ricinoleate vehicle, a pharmaceutically acceptable non-aqueous ester solvent, and a pharmaceutically acceptable alcohol wherein the formulation is adapted for intramuscular administration and attaining a therapeutically significant blood plasma fulvestrant concentration for at least 2 weeks.

10 Another feature of the invention is a pharmaceutical formulation comprising fulvestrant in which the formulation is adapted for intra-muscular injection into a human and which is capable after injection of attaining a therapeutically significant blood plasma fulvestrant concentration for at least 2 weeks.

Further features of the invention include a pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 30% or less weight of a pharmaceuticallyacceptable alcohol per volume of formulation, at least 1% weight of a pharmaceuticallyacceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation which is capable after injection of attaining a therapeutically significant blood plasma 20 fulvestrant concentration for at least 2 weeks.

Further features of the invention include a pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant; 35% (preferably 30% and ideally 25%) or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% (preferably at least 5% or ideally 10%) weight of a pharmaceutically-acceptable non-aqueous 25 ester solvent miscible within a ricinoleate vehicle per volume of formulation and a sufficient

amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml⁻¹ of fulvestrant.

For the avoidance of any doubt when using the term % weight per volume of formulation for the constituents of the formulation we mean that within a unit volume of the formulation a certain percentage of the constituent by weight will be present, for example a 1% weight per volume formulation will contain within a 100ml volume of formulation 1g of the constituent. By way of further illustration

MYLAN PHARMS. INC. EXHIBIT 1002 PAGE 232

- 8 -

% of x by weight per volume of formulation	weight of x in 1ml of formulation
30%	300mg
20%	200mg
10%	100mg
5%	50mg
1%	10mg

Preferred pharmaceutical formulations of the invention are as described above 5 wherein:

1. The total volume of the formulation is 6ml, or less, and the concentration of fulvestrant is at least 45mgml⁻¹.

2. The total amount of fulvestrant in the formulation is 250mg, or more, and the total volume of the formulation is 6ml, or less.

10 3. The total amount of fulvestrant in the formulation is 250mg and the total volume of the formulation is 5-5.25ml.

It is appreciated that in the formulation an excess of formulation may be included to allow the attendant physician or care giver to be able to deliver the required dose. Therefore, when a 5ml dose is required it would be appreciated that an excess of up to 0.25ml, preferably

15 up to 0.15ml will also be present in the formulation. Typically the formulation will be presented in a vial or a prefilled syringe, preferably a prefilled syringe, containing a unit dosage of the formulation as described herein, these being further features of the invention.

Preferred concentrations of a pharmaceutically-acceptable alcohol present in any of the above formulations are; at least 3%w/v, at least 5%w/v, at least 7%w/v, at least 10% w/v,

- 20 at least 11% w/v, at least 12% w/v, at least 13% w/v, at least 14% w/v, at least 15% w/v and, preferably, at least 16% w/v. Preferred maximal concentrations of pharmaceutically-acceptable alcohol present in the formulation are ;28% w/v or less, 22% w/v or less and 20% w/v or less. Preferred ranges of pharmaceutically-acceptable alcohol present in any of the above formulations are selected from any minimum or maximum value described above and
- 25 preferably are; 3-35%w/v, 4-35%w/v, 5-35%w/v, 5-32%w/v, 7-32%w/v, 10-30%w/v, 12-28%w/v, 15-25%w/v, 17-23%w/v, 18-22%w/v and ideally 19-21%w/v.

The pharmaceutically-acceptable alcohol may consist of one alcohol or a mixture of two or more alcohols, preferably a mixture of two alcohols. Preferred pharmaceuticallyacceptable alcohols for parenteral administration are ethanol, benzyl alcohol or a mixture of both ethanol and benzyl alcohol, preferably the ethanol and benzyl alcohol are present in the

5 formulation in the same w/v amounts. Preferably the formulation alcohol contains 10% w/v ethanol and 10% w/v benzyl alcohol.

The pharmaceutically-acceptable non-aqueous ester solvent may consist of one or a mixture of two or more pharmaceutically-acceptable non-aqueous ester solvents, preferably just one. A preferred pharmaceutically-acceptable non-aqueous ester solvent for parenteral administration is selected from benzyl benzoate, ethyl oleate, isopropyl myristate, isopropyl palmitate or a mixture of any thereof.

The ricinoleate vehicle should preferably be present in the formulation in a proportion of at least 30% weight per volume of the formulation, ideally at least 40% or at least 50% weight per volume of formulation.

15 It will be understood by the skilled person that the pharmaceutically-acceptable alcohol will be of a quality such that it will meet pharmacopoeial standards (such as are described in the US, British, European and Japanese pharmacopoeias) and as such will contain some water and possibly other organic solvents, for example ethanol in the US Pharmacopeia contains not less than 94.9% by volume and not more than 96.0% by volume of 20 ethanol when measured at 15.56°C. Dehydrated alcohol in the US Pharmacopeia contains not

less than 99.5% ethanol by volume when measured at 15.56°C.

Preferred concentrations of the pharmaceutically-acceptable non-aqueous ester solvent present in any of the above formulations are; at least 5% w/v, at least 8% w/v, at least 10% w/v, at least 11% w/v, at least 12% w/v, at least 13% w/v, at least 15% w/v, at least 16% w/v,

25 at least 17% w/v, at least 18% w/v, at least 19% w/v and at least 20% w/v. Preferred maximal concentrations of the pharmaceutically-acceptable non-aqueous ester solvent are; 60% w/v or less, 50%w/v or less, 45% w/v or less, 40% w/v or less, 35% w/v or less, 30% w/v or less and 25% w/v or less. A preferred concentration is 15% w/v. Preferred ranges of pharmaceutically-acceptable non-aqueous ester solvent present in any of the above formulations are selected

30 from any minimum or maximum value described above and preferably are; 5-60%w/v, 7-55%w/v, 8-50%w/v, 10-50%w/v, 10-45%w/v, 10-40%w/v, 10-35%w/v, 10-30%w/v, 10-

25%w/v, 12-25%w/v, 12-22%w/v, 12-20%w/v, 12-18%w/v, 13-17%w/v and ideally 14-

16%w/v. Preferably the ester solvent is benzyl benzoate, most preferably at about 15%w/v.

It will be understood by the skilled person that the pharmaceutically-acceptable nonaqueous ester solvent will be of a quality that it will meet pharmacopoeial standards (such as 5 described in the US, British, European and Japanese pharmacopoeias).

Preferred combinations of pharmaceutically-acceptable alcohol and pharmaceuticallyacceptable non-aqueous ester solvent in the formulation are set out below:

Pharmaceutically-acceptable	Pharmaceutically-acceptable non-aqueous
alcohol(%w/v)	ester (%w/v)
10-30	5-60, 7-55, 8-50, 10-50, 10-45, 10-40, 10-35, 10-
	30, 10-25, 12-25, 12-22, 12-20, 12-18, 13-17 and
	ideally 14-16.
17-23	5-60, 7-55, 8-50, 10-50, 10-45, 10-40, 10-35, 10-
	30, 10-25, 12-25, 12-22, 12-20, 12-18, 13-17 and
	ideally 14-16.
3-35, 4-35, 5-35, 5-32, 7-32, 10-30, 12-	10-35
28, 15-25, 17-23, 18-22 and ideally 19-	
3-35, 4-35, 5-35, 5-32, 7-32, 10-30, 12-	12-18
28, 15-25, 17-23, 18-22 and ideally 19-	
21.	
ethanol and benzyl alcohol, most	benzyl benzoate, most preferably at about 15%
preferably each at about 10%	

By the use of the term ricinoleate vehicle we mean an oil which has as a proportion (at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% w/v) of its composition as triglycerides of ricinoleic acid. The ricinoleate vehicle may be a synthetic oil or conveniently is castor oil, ideally of pharmacopoeial standards, as described above.

We have surprisingly found that the above formulations of the invention provide, after intra-muscular injection, satisfactory release of fulvestrant over an extended period of time. This finding is indeed surprising for the following reasons.

1. Previously tested by the applicants have been intra-muscular injections of fulvestrant in the form of an aqueous suspension. We have found extensive local tissue irritation at the

injection site as well as a poor release profile. It is believed that the tissueirritation/inflammation was due to the presence of fulvestrant in the form of solid particles.The release profile appeared to be determined by the extent of inflammation/irritation presentat the injection site and this was variable and difficult to control. Also the fulvestrant releaserate was not sufficiently high to be clinically significant.

2. Our findings from studies using ¹⁴C labelled benzyl alcohol show that it dissipates rapidly from the injection site and is removed from the body within 24 hours of administration.

It would be expected that ethanol will dissipate at least as quickly, if not more rapidly, 10 from the injection site.

It is known that benzyl benzoate is metabolised by conjugation to glycine to form hippuric acid by the human liver and excreted into the urine - Martindale: The Extra Pharmacopoeia 32nd edition page 1103, and, therefore, it is unlikely that benzyl benzoate, when used, is present at the injection site during the whole of the extended release period.

15 We have found that despite the rapid elimination of the additional solubilising excipients, i.e. the alcohol and pharmaceutically-acceptable non-aqueous ester solvent, from the formulation vehicle and the site of injection after injection of the formulation, extended release at therapeutically significant levels of fulvestrant over an extended period can still achieved by the formulation of the invention.

By use of the term "therapeutically significant levels" we mean that blood plasma concentrations of at least 2.5 ngml⁻¹, ideally at least 3 ngml⁻¹, at least 8.5 ngml⁻¹, and up to 12 ngml⁻¹ of fulvestrant are achieved in the patient. Preferably blood plasma levels should be less than 15 ngml⁻¹.

By use of the term "extended release" we mean at least two weeks, at least three 25 weeks, and, preferably at least four weeks of continuous release of fulvestrant is achieved. In a preferred feature extended release is achieved for 36 days. Preferably extended release of fulvestrant is for at least 2- 5 weeks and more preferably for the following periods (weeks) 2.5-5, 2.5-4, 3-4, 3.5-4 and most preferably for at least about 4 weeks.

It will be understood that the attendant physician may wish to administer the intramuscular injection as a divided dose, i.e. a 5ml formulation is sequentially administered in two separate injections of 2.5ml, this is a further feature of the invention

Simply solubilising fulvestrant in an oil based liquid formulation is not predictive of a good release profile or lack of precipitation of drug after injection at the injection site.

Table 3 shows the solubility of fulvestrant in a castor oil vehicle additionally containing alcohols ethanol and benzyl alcohol with or without benzyl benzoate. The results

⁵ clearly show the positive effect of benzyl benzoate on fulvestrant solubility in castor oil, despite fulvestrant having a lower solubility in benzyl benzoate than in either alcohol or castor oil.

10

Table 3

- 14 -

Table 3 - EFFECT OF BENZYL BENZOATE ON FULVESTRANT SOLUBILITY IN CASTOR OIL AT 25°C

				% w/v				
Ethanol	5	5	10	10	10	10	15	15
(96%)								
Benzyl	5	5	5	5	10	10	15	15
Alcohol								
Benzyl		15		15		15		15
Benzoate								
Castor Oil	to 100	to100	to 100					
Fulvestrant	27	36	46	54	45	65	76	102
Solubility								
$[mgml^{-1}]$								

5

The following Table 4 shows the solubility of fulvestrant in a range of oil based formulations which contain the same amounts of alcohol and benzyl benzoate but in which the oil is changed. The data also shows solubility of fulvestrant after removal of the alcohols.

Table 4

10		Fulvestrant Solul	bility mg ml ⁻¹ @ 25°C
10	Formulation ^(a)	ulation ^(a) Complete vehicle	
	Castor oil based	81.2	12.6
15	Miglyol 812-N based	86.8	1.7
	Sesame seed/Castor oil (1:1) based	70.1	4.4
20	Sesame seed oil based	45.7	0.7
20	Arachis oil based	40.2	< 0.2

5 Solubility comparisons of fulvestrant in oil based formulations with and without alcohols

(a) Complete Vehicle Formulations comprised ethanol [96%](10%), benzyl alcohol (10%) and benzyl benzoate
 (15%) made to volume with the stated oil. Excess fulvestrant was added to each solvent mixture and solubility determined.

30					Days				
	Formulation ^a	2	3	4	7	10	30	51	
35	Formulation F1 castor oil based	0	0	0	0	0	0	0	
	Formulation F2 Miglyol 812-N based	++ ^b	+++	+++	+++	+++	++	0	
40	Formulation F3 sesame seed oil/castor oil based	+ ^c	++	++	+++	++	+	+	

Effect of formulation on precipitation of fulvestrant at the injection site

 $\overline{0, +, ++, +++}$ = Degree of precipitation (None detected, Mild, Moderate, Severe)

45 ^a Formulations comprised fulvestrant (5%), ethanol [96%] (10%), benzyl alcohol (10%) and benzyl benzoate (15%) made to volume with the stated oil.

^b Mainly large needle shaped crystals

^c Small needles and/or sheafs of crystals

Precipitation of fulvestrant and the release profile was determined with the above formulations in an *in vivo* rabbit study.

Figure 1 shows the release profile *in vivo* of the four formulations from the second part of Table 4 and shows the effect of the fixed oil component on fulvestrant plasma profile

- 5 over five days following intramuscular administration in rabbits (data normalised to 50mg per 3kg; mean given; number of animals per timepoint = 8, plasma samples assayed for fulvestrant content using lc-ms/ms detection following solvent extraction). As can be seen the castor oil formulation showed a particularly even release profile with no evidence of precipitation of fulvestrant at the injection site.
- 10 Therefore we present as a further feature of the invention an extended release pharmaceutical formulation adapted for intramuscular injection comprising fulvestrant; 35% (preferably 30% or ideally 25%) or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% (preferably at least 5% or ideally 10%) weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per
- 15 volume of formulation and sufficient amount of a ricinoleate vehicle, taking into account the addition of any further optional pharmaceutically-acceptable excipients, so as to prepare a formulation of at least 45mgml⁻¹ of fulvestrant.

A further feature of the invention is a pharmaceutical formulation adapted for intramuscular injection, as defined above, for use in medical therapy.

- A further feature of the invention is a method of treating a benign or malignant diseases of the breast or reproductive tract, preferably treating breast cancer, by administration to a human in need of such treatment by intramuscular injection an extended release ricinoleate vehicle based pharmaceutical formulation comprising at least 45mgml⁻¹ of fulvestrant; 35% (preferably 30% or ideally 25%) or less weight of a pharmaceutically-
- 25 acceptable alcohol per volume of formulation, at least 1% (preferably at least 5% or ideally 10%) weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation.

Preferably 5ml of the intramuscular injection is administered.

A further feature of the invention is use of fulvestrant in the preparation of a pharmaceutical formulation as describe hereinabove, for the treatment of a benign or malignant disease of the breast or reproductive tract, preferably treating breast cancer.

Additional excipients commonly used in the formulation field including, for example, an antioxidant preservative, a colorant or a surfactant may be used. A preferred optional excipient is a surfactant.

As described above fulvestrant is useful in the treatment of oestrogen-dependent 5 indications such as breast cancer and gynaecological conditions, such as endometriosis.

In addition to fulvestrant another similar type of molecule is currently under clinical investigation. SH-646 (11 β -fluoro- 7 α -(14,14,15,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl)estra-1,3,5(10)-triene-3,17 β -diol) is also putatively a

10 structure. It is believed that the compound will also share with fulvestrant similar physical properties and therefore the current invention will also have application with this compound.

compound with the same mode of action as fulvestrant and has a very similar chemical

A further feature of the invention is a pharmaceutical formulation adapted for intra-muscular injection comprising 11 β -fluoro- 7 α -(14,14,15,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl)estra-1,3,5(10)-triene-3,17 β -diol; 35% or less weight of a

- 15 pharmaceutically-acceptable alcohol per volume of formulation, at least 1% weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible within a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml⁻¹ of 11β-fluoro- 7α -(14,14,15,15,15-pentafluoro-6methyl-10-thia-6-azapentadecyl)estra-1,3,5(10)-triene-3,17β-diol.
- 20 Further features of the invention are those as described above but in which SH-646 is substituted for fulvestrant.

Formulation Example

- 25 Fulvestrant is mixed with alcohol and benzyl alcohol, stirring until completely dissolved. Benzyl benzoate is added and the solution is made to final weight with castor oil and stirred, (for convenience weight is used rather than volume by using the weight to volume ratio). The bulk solution is overlaid with Nitrogen. The solution is sterilised by filtration using one or two filters of 0.2μm porosity. The sterile filtrate is kept under a nitrogen overlay
- 30 as it is filled under aseptic conditions into washed and depyrogenised, sterile primary containers, for example vials or pre-filled syringes. An overage is included in the primary


5

pack to facilitate removal of the dose volume. The primary packs are overlaid with sterile nitrogen, before aseptically sealing.

See also process flow diagram-below of Figure 2.

Quantities of each component of the formulation is chosen according to the required formulation specification, examples are described above. For example quantities are added of each component to prepare a formulation which contains 10% weight per volume of benzyl alcohol

10 10% weight per volume of ethanol
15% weight per volume of benzyl benzoate
250mg of fulvestrant for each 5ml of finished formulation
and the remaining amount as castor oil



References

1. Bowler J, Lilley TJ, Pittam JD, Wakeling AE. Novel steroidal pure antioestrogens. Steroids 989; 5471-99.

5 2. Wakeling AE. Novel pure antioestrogens: mode of action and therapeutic prospects. American New York Academy Science 1990a; 595: 348-56.

3. Wakeling AE. Steroidal pure antioestrogens. In Lippman M, Dickson R, editors. Regulatory mechanisms in breast cancer. Boston: Kluwer Academic, 1990b: 239-57.

10

4. Wakeling AE. Therapeutic potential of pure antioestrogens in the treatment of breast cancer. Journal Steroid Biochemistry 1990c; 37: 771-5.

5. Wakeling AE, Bowler J. Steroidal pure antioestrogens. Journal Endocrinology 1987; 112:15 R7-10.

6. Wakeling AE, Bowler J. Biology and mode of action of pure antioestrogens. Journal Steroid Biochemistry 1988; 3: 141-7.

ABSTRACT OF THE DISCLOSURE

The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound

5 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol, more particularly to a formulation adapted for administration by injection containing the compound 7α -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 β -diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a nonaqueous ester solvent which is miscible in the ricinoleate vehicle.

10

UNITED STATES PATENT AND TRADEMARK OFFICE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS PO. Box 1450 Alexandria, Virginia 22313-1450 www.uspic.gov							
APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS IND CLAIMS		
12/285,887	10/15/2008	1617	2754	056291-5004-02	23 2		
				CONFIRMATION NO. 1199			
9629				UPDATE	D FILING RECEIPT		
MORGAN LEV	VIS & BOCKIU	S LLP					
1111 PENNSY		IUE NW					
WASHINGTON, DC 20004 *0C00000040521967*							

Date Mailed: 03/11/2010

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections

Applicant(s)

John R. Evans, Macclesfield, UNITED KINGDOM; Rosalind U. Grundy, Macclesfield, UNITED KINGDOM;

Power of Attorney: None

Domestic Priority data as claimed by applicant

This application is a CON of 10/872,784 06/22/2004 PAT 7,456,160

Foreign Applications

UNITED KINGDOM 0008837.7 04/12/2000 UNITED KINGDOM 0000313.7 01/10/2000

If Required, Foreign Filing License Granted: 11/03/2008

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 12/285,887**

Projected Publication Date: 06/17/2010

Non-Publication Request: No

Early Publication Request: No

page 1 of 3

Title

Formulation

Preliminary Class

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

<u>GRANTED</u>

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as

page 2 of 3

set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

page 3 of 3

UNITED ST	ates Patent and Trademai	UNITED STA' United States Address: COMMIS PO. Box I	i, Virginia 22313-1450	
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE	
12/285,887	10/15/2008	John R. Evans	056291-5004-02	
			CONFIRMATION NO. 1199	
9629		PUBLICATION NOTICE		
MORGAN LEWIS & BOCI 1111 PENNSYLVANIA AV WASHINGTON, DC 2000	/ENUE NW		DC000000042144085*	

Title:Formulation

Publication No.US-2010-0152149-A1 Publication Date:06/17/2010

NOTICE OF PUBLICATION OF APPLICATION

The above-identified application will be electronically published as a patent application publication pursuant to 37 CFR 1.211, et seq. The patent application publication number and publication date are set forth above.

The publication may be accessed through the USPTO's publically available Searchable Databases via the Internet at www.uspto.gov. The direct link to access the publication is currently http://www.uspto.gov/patft/.

The publication process established by the Office does not provide for mailing a copy of the publication to applicant. A copy of the publication may be obtained from the Office upon payment of the appropriate fee set forth in 37 CFR 1.19(a)(1). Orders for copies of patent application publications are handled by the USPTO's Office of Public Records. The Office of Public Records can be reached by telephone at (703) 308-9726 or (800) 972-6382, by facsimile at (703) 305-8759, by mail addressed to the United States Patent and Trademark Office, Office of Public Records, Alexandria, VA 22313-1450 or via the Internet.

In addition, information on the status of the application, including the mailing date of Office actions and the dates of receipt of correspondence filed in the Office, may also be accessed via the Internet through the Patent Electronic Business Center at www.uspto.gov using the public side of the Patent Application Information and Retrieval (PAIR) system. The direct link to access this status information is currently http://pair.uspto.gov/. Prior to publication, such status information is confidential and may only be obtained by applicant using the private side of PAIR.

Further assistance in electronically accessing the publication, or about PAIR, is available by calling the Patent Electronic Business Center at 1-866-217-9197.

page 1 of 1

Office of Data Managment, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

	'ED STATES PATEN'	United States Patent and Address: COMMISSIONER F P.O. Box 1450	Alexandria, Virginia 22313-1450		
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
12/285,887	10/15/2008	John R. Evans	056291-5004-02	1199	
· · ·	7590 12/21/2010 WIS & BOCKIUS LLP	EXAMINER			
	LVANIA AVENUE NV	HUI, SAN MING R			
wASHINGTO.	N, DC 20004	ART UNIT	PAPER NUMBER		
			1628		
			MAIL DATE	DELIVERY MODE	
			12/21/2010	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)					
	12/285,887	EVANS ET AL.					
Office Action Summary	Examiner	Art Unit					
	San-ming Hui	1628					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
 A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>3</u> MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). 							
Status							
1) Responsive to communication(s) filed on							
	action is non-final.						
3) Since this application is in condition for allowa		secution as to the merits is					
closed in accordance with the practice under <i>B</i>	1						
Disposition of Claims							
4) Claim(s) <u>1-23</u> is/are pending in the application							
4a) Of the above claim(s) is/are withdra	wh from consideration.						
5) Claim(s) is/are allowed.							
6) Claim(s) <u>1-23</u> is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) are subject to restriction and/o	r election requirement.						
Application Papers							
9) The specification is objected to by the Examine	r.						
10) The drawing(s) filed on is/are: a) acc		Examiner.					
Applicant may not request that any objection to the							
Replacement drawing sheet(s) including the correct							
11) The oath or declaration is objected to by the E>							
Priority under 35 U.S.C. § 119							
12) 🔀 Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a)⊠ All b) Some * c) None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No. <u>10/872784</u> .							
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s)							
1) Notice of References Cited (PTO-892)	4) 🔲 Interview Summary	(PTO-413)					
2) DNotice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	ate					
3) X Information Disclosure Statement(s) (PTO/SB/08)	5) Notice of Informal P	atent Application					
Paper No(s)/Mail Date <u>9/4/09</u> . U.S. Patent and Trademark Office	6) 🛄 Other:						
	ction Summary Pa	urt of Paper No./Mail Date 20101219					

Application/Control Number: 12/285,887 Art Unit: 1628

DETAILED ACTION

This is a continuation of US 10/872,784, filed 6/22/2004, now patent 7,456,160,

which is a continuation of US 09/756,291, filed 1/9/2001, now patent 6,774,122. The

instant application also claims the benefit of UNITED KINGDOM 0000313.7, filed

01/10/2000 and UNITED KINGDOM 0008837.7, filed 04/12/2000.

Claims 1-23 are pending.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all

obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148

USPQ 459 (1966), that are applied for establishing a background for determining

obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1-23 are rejected under 35 U.S.C. 103(a) as being unpatentable over

Dukes (EP 0 346 014) in view of Lehmann et al. (US Patent Re. 28,690), GB 1 569 286

(herein after referred as '286), Osborne et al., Journal of National Cancer Institute,

1995;87(10):746-750, and Remington (Remington's Pharmaceutical Sciences, 18th ed., 1990, page 219), all of the references are of record in the parent application.

Dukes teaches antiestrogen agents, including fulvestrant, are useful in treating postmenopausal symptoms such as urogenital atrophy affecting the vagina (See page 3, lines 56-page 4, line 1; also page 7, line 28-29). Dukes teaches that antiestrogen agent, including fulvestrant, may be used in a dosage of 50mg to 5g in vehicle comprising castor oil and benzyl alcohol (See page 7, line 20-24).

Dukes does not expressly teach the dosage of fulvestrant to be 45mg. Dukes does not expressly teach the employment of benzyl benzoate, in the percent amount of 60% w/v or less, or 50% w/v or less, or 45% w/v or less, 40% w/v or less, or 35% w/v or less, or 30% w/v or less, 25% w/v or less, or 10-25% w/v, or 12-18% w/v, as part of the vehicle herein. Dukes does not expressly teach the total amount of the fulvestrant-containing composition administered. Dukes does not expressly teach weight amount of castor oil and benzyl alcohol. Dukes does not expressly teach the employment of ethanol as part of the vehicle herein. Dukes does not expressly teach the dosage of fulvestrant to be 250mg. Dukes does not expressly teach the plasma concentration of fulvestrant herein.

Lehmann et al. teaches that benzyl benzoate and castor oil are well-known solvent useful as conventional carriers for steroids (See col. 1, line 21-26).

'286 teaches an intramuscular injection of testosterone derivative containing castor oil/benzoate in a ratio of 6:4 (See page 1, line 17).

Osborne et al. teaches fulvestrant as useful in treating human breast cancer (See pages 747-748, Result Section).

Remington teaches that ethanol is one of the most commonly used solvents in pharmaceutical industry (See page 219).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to employ benzyl benzoate, ethanol, castor oil, and benzyl alcohol, in the herein claimed weight percent, with fulvestrant in the dosage herein, in a method of treating postmenopausal symptoms such as urogenital atrophy in the vagina.

One of ordinary skill in the art would have been motivated to employ benzyl benzoate, ethanol, castor oil, and benzyl alcohol, in the herein claimed weight percent, with fulvestrant, in the dosage herein, in a method of treating postmenopausal symptoms such as urogenital atrophy or treating breast cancer because fulvestrant is known to be useful in treating urogenital atrophy, a benign disease of the female reproductive tract in the vagina and breast cancer. Castor oil and benzyl alcohol are known to be effective as vehicle for fulvestrant. Ethanol is a commonly used pharmaceutical solvent. Benzyl benozate is known to be effective as solvent for steroidal compounds. Since fulvestrant is a estrogen derivative, benzyl benzoate would be reasonably expected to be useful as a solvent for fulvestrant. Therefore, combining one or more agents, which are known to be useful as commonly used solvents, such as benzyl benzoate, ethanol, castor oil, and benzyl alcohol, together and incorporated such combination with an estrogen derivatives, fulvestrant, would be reasonably expected to be useful as a pharmaceutical composition. Furthermore, employing such

fulvestrant-containing composition to treat urogenital atrophy in vagina would be reasonably expected to be effective. Moreover, the optimization of result effect parameters (e.g., amount of excipients, dosage range, and dosing regimens) is obvious as being within the skill of the artisan, absent evidence to the contrary.

One of ordinary skill in the art would have been motivated to maintain the plasma concentration of fulvestrant herein because maintaining the therapeutic plasma level of the active compounds would be considered obvious as being within the purview of the skilled artisan, absent evidence to the contrary. Furthermore, the fulvestrant composition is known to be administered through injection, therefore, putting the composition into a syringe for delivering the fulvestrant composition would be considered obvious.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29

USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 21-22 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-9 of U.S. Patent No. 6,774,122 ('122). Although the conflicting claims are not identical, they are not patentably distinct from each other because '122 teaches the method of treating hormonal dependent benign or malignant disease of reproductive tract by employing the herein claimed composition.

Claims 21-22 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-12 of U.S. Patent No. 7,456,160 ('160). Although the conflicting claims are not identical, they are not patentably distinct

from each other because '160 teaches the method of treating hormonal dependent benign or malignant disease of reproductive tract by employing the herein claimed composition.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to San-ming Hui whose telephone number is (571) 272-0626. The examiner can normally be reached on Mon - Fri from 9:00 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brandon Fetterolf can be reached on (571) 272-2919. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

> San-ming Hui Primary Examiner Art Unit 1628

/San-ming Hui/ Primary Examiner, Art Unit 1628

	Application/Control No.	Applicant(s)/Patent Under Reexamination
Index of Claims	12285887	EVANS ET AL.
*1228588	Examiner	Art Unit
1220300	San-ming Hui	1628
7*		

✓	Rejected	-	Cancelled	Ν	Non-Elected		Α	Appeal
=	Allowed	÷	Restricted	I	Interference		0	Objected

Claims	renumbered	in the same order a	as presented by applicant		🗌 СРА	🗆 т.С) . 🗆	R.1.47	
CL	AIM	DATE							
Final	Original	12/19/2010							
	1	✓							
	2	✓							
	3	✓							
	4	√							
	5	✓							
	6	✓							
	7	✓							
	8	✓							
	9	✓							
	10	✓							
	11	✓							
	12	√							
	13	✓							
	14	✓							
	15	✓							
	16	✓							
	17	✓							
	18	✓							
	19	✓							
	20	✓							
	21	✓							
	22	✓							
	23	√							

Part of Paper No. : 20101219

	Application/Control No.	Applicant(s)/Patent Under Reexamination
Search Notes	12285887	EVANS ET AL.
*1228588	Examiner	Art Unit
	San-ming Hui	1628
7*		

SEARCHED							
Class	Subclass	Date	Examiner				
514	177, 178	12/19/10	SH				

SEARCH NOTES		
Search Notes	Date	Examiner
EAST and inventor search in PALM	12/19/10	SH

	INTERFERENCE SEAF	RCH	
Class	Subclass	Date	Examiner



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 1199

SERIAL NUM 12/285,88		FILING or 371(c) DATE 10/15/2008		L ASS 514	GRC	DUP ART 1628	UNIT	UNIT ATTORNEY DO NO. 056291-5004	
		RULE							
APPLICANTS John R. Evans, Macclesfield, UNITED KINGDOM; Rosalind U. Grundy, Macclesfield, UNITED KINGDOM;									
** CONTINUING DATA ***********************************									
UNITED	** FOREIGN APPLICATIONS ************************************								
	** IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** 11/03/2008								
Foreign Priority claime 35 USC 119(a-d) cond		Ves No Ves No		STATE OR COUNTRY		EETS WINGS	TOT. CLAI		INDEPENDENT CLAIMS
									2
1111 PE	MORGAN LEWIS & BOCKIUS LLP 1111 PENNSYLVANIA AVENUE NW WASHINGTON, DC 20004								
TITLE									
Formulati	ion								
		Authority has been give to charge/cre				□ 1.16 F □ 1.17 F	`	•	ing Ext. of time)
		for following				🖵 1.18 F	- ees (lss	sue)	
						D Other			
						Credi	t		

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	76861	castor adj oil	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L2	310	fulvestrant and (castor adj oil)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L3	2043	oil and fulvestrant	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L4	2	"4659516".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L5	6	"346014".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L6	13851	(benzyl adj benzoate) or (phenylmethyl adj benzoate)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L7	1744228	solvent	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L8	7012	((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33

file:///Cl/Documents%20and%20Settings/SHui/My%20Docu...887/EASTSearchHistory.12285887_AccessibleVersion.htm (1 of 7)12/19/10 10:49:56 PM

L9	4	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent) same (estrogen or estradiol or estrone)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L10	7	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent) same (testosterone)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L11	13	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent) same (steroid)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L12	1562	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent) and (steroid)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L13	2	"6774122".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L14	910	514/177.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L15	1322	514/178.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L16	1979621	castor oil	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L17	76861	castor adj oil	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33

file:///Cl/Documents%20and%20Settings/SHui/My%20Docu...887/EASTSearchHistory.12285887_AccessibleVersion.htm (2 of 7)12/19/10 10:49:56 PM

L18	310	fulvestrant and	US-PGPUB;	OR	ON	2010/12/19
		(castor adj oil)	USPAT; EPO; JPO; DERWENT; IBM_TDB			22:33
L19	2043	oil and fulvestrant	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L20	13851	(benzyl adj benzoate) or (phenylmethyl adj benzoate)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L21	1744228	solvent	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L22	7012	((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L23	7	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent) same (testosterone)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L24	13	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent) same (steroid)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L25	1562	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent) and (steroid)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L26	76861	castor adj oil	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33

file:///Cl/Documents%20and%20Settings/SHui/My%20Docu...887/EASTSearchHistory.12285887_AccessibleVersion.htm (3 of 7)12/19/10 10:49:56 PM

L27	4282	((benzyl adj benzoate) or (phenylmethyl adj benzoate)) and (castor adj oil)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L28	2482	((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same (castor adj oil)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L29	1306	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same (castor adj oil)) same solvent	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L30	3	((((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same (castor adj oil)) same solvent) same steroid	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L31	2692	fulvestrant	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L32	2692	fulvestrant	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L33	76861	castor adj oil	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L34	310	fulvestrant and (castor adj oil)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L35	2043	oil and fulvestrant	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33

file:///Cl/Documents%20and%20Settings/SHui/My%20Docu...887/EASTSearchHistory.12285887_AccessibleVersion.htm (4 of 7)12/19/10 10:49:56 PM

L36	2	"4659516".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L37	6	"346014".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L38	13851	(benzyl adj benzoate) or (phenylmethyl adj benzoate)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L39	1744228	solvent	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L40	7012	((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L41	4	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent) same (estrogen or estradiol or estrone)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L42	7	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent) same (testosterone)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L43	13	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent) same (steroid)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L44	1562	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent) and (steroid)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33

file:///Cl/Documents%20and%20Settings/SHui/My%20Docu...887/EASTSearchHistory.12285887_AccessibleVersion.htm (5 of 7)12/19/10 10:49:56 PM

L45	76861	castor adj oil	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L46	4282	((benzyl adj benzoate) or (phenylmethyl adj benzoate)) and (castor adj oil)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L47	2482	((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same (castor adj oil)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L48	1306	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same (castor adj oil)) same solvent	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L49	3	((((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same (castor adj oil)) same solvent) same steroid	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L50	2692	fulvestrant	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L51	81494	breast adj cancer	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L52	1783	breast adj cancer and fulvestrant	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L53	281	breast adj cancer same fulvestrant	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33

file:///Cl/Documents%20and%20Settings/SHui/My%20Docu...887/EASTSearchHistory.12285887_AccessibleVersion.htm (6 of 7)12/19/10 10:49:56 PM

L54	1131	cancer same fulvestrant	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:33
L55	2	"7456160".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:38
L56	2	"6,774,122".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2010/12/19 22:38

EAST Search History (Interference)

< This search history is empty>

12/19/10 10:49:53 PM C:\ Documents and Settings\ SHui\ My Documents\ EAST\ Workspaces\ 12-285887.wsp

INFOR	MA	FION DISCLOSU	RE CITATION	Attorney Docket No 056291-5004-02		А	application No. 12/285,887		
	(U	se several sheets if nece	essary)	Applicants: John R. EVANS et al.					
		PTO Form 1449 June 4, 2009		Filing Date: October 15,	2008	Group	9 Art Unit: 1617		
			U.S. PA	TENT DOCUMENTS					
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date		
	1.	US 3,164,520	January 5, 1965						
	2.	US 4,212,863	July 15, 1980	Cornelius	_				
	3.	US 4,388,307	June 14, 1983	Cavanak					
			FOREIGN	PATENT DOCUMENTS					
		Document No.	Date	Country	Class	Sub-Class	Translation		
	4.	EP 0310542A1	April 5, 1989	EPO			Yes		
		OTHER DO	OCUMENTS (Inclu	ding Author, Title, Date, Per	tinent Pa	ges, etc.)			
	5.	P.K. Gupta and G.A. E 11 & 17 Interpharm Pr		ble Drug Development:Techn lo (1999)	iques to Re	educe Pain a	nd Irritation. Chapters		
	6.	P.V. Lopatin, V. P. Sat solutions. <i>Pharm. Cher</i>		a and L. M. Yakimenko. Use (2)	of nonaque	eous solvents	to prepare injection		
	7.	S. Nema, R.J. Washku 51:166-71 (1997)	hn, and R.J. Brendel.	. Excipients and their use in injectable products. PDA J. Pharm. Sci. Technol.					
	8.	Physicians' Desk Refer NJ (1973)	rence (27th edition).	1277-1278, 1350-1354, 1391-	1392 Med	ical Economi	ics Company, Oradell,		
	9.	M. F. Powell, T. Nguy Technol. 52 :238–311 [Compendium of excipients for ded] (1998)	parenteral	formulations	s. PDA J. Pharm. Sci.		
	10.	R. G. Strickley. Parent J. Pharm. Sci. Technol		small molecule therapeutics m	arketed in	the United S	tates (1999) -Part I. PDA		
	11.	R. G. Strickley. Parent PDA J. Pharm. Sci. Te		small molecule therapeutics m	arketed in	the United S	tates (1999) - Part II		
	12.	R. G. Strickley. Parent PDA J. Pharm. Sci. Te		small molecule therapeutics m 2000)	arketed in	the United S	tates (1999) - Part III.		
	13.	Y.C. J. Wang and R. R Parenteral Drug Assoc		excipients and pH's for parent	eral produ	cts used in th	e United States. J.		
Examiner	/	San Ming Hui/	Date (Considered 12	/19/2010				
Examiner:	Initia	l if reference considered	d, whether or not cita	tion is in conformance with M	IPEP 609:	draw line thr	ough citation if not in		
				with next communication to app			~		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.H./ DB1/63065447.1

INFOR	RMAT	TION DISCLOSU	RE CITATION		Attorney Docket No. 056291-5004-02		Application No. 12/285,887		
	(Us	e several sheets if nece	essary)	Ap	plicants: John R. EVAN	S et al.			
	PTO Form 1449 June 4, 2009			F	iling Date: October 15, 2	2008	Group Art Unit: 1617		
			TEN	T DOCUMENTS					
Initial		Document No.	Date		Name	Class	Sub-Class	Filing Date	
	1.	2,822,316	February 4, 1958	3	Richter et al.				
	2.	2,983,649	May 9, 1961		Ercoli et al.				
	3.	3,541,209	November 17, 197		Neumann et al.				
	4.	RE 28,690	January 20, 1976	5	Lehmann et al.				
	5.	4,048,309	September 13, 197		Chen et al.				
	6.	4,048,310	September 13, 197	77	Chen et al.				
	7.	4,659,516	April 21, 1987		Bowler et al.				
	8.	4,888,331	December 19, 198		Elger et al.				
	9.	5,095,129	March 10, 1992		Ottow et al.				
	10.	5,183,814	February 2, 1993		Dukes				
	11.	5,484,801	January 16, 1996		Al-Razzak et al.				
	12.	5,733,902	March 31, 1998		Schneider				
	13.	5,929,030	July 27, 1999		Hamied et al.				
	14. 20010006963 July 5, 2001			Lachnit-Fixson et al.					
			FODEICN	DAT	ENT DOCUMENTS				
		Document No.	Date	PAL	<u>ENT DOCUMENTS</u> Country	Class	Sub-Class	Translation	
	15.	EP 0138504	Apr., 1985		EP		Sub-Class		
	16.	EP 0346014	Dec., 1989		EP		+ +		
	17.	EP 0819431	Mar., 1999		EP		+ +		
	18.	EP 0905143	Mar., 1999		EP		+ +		
	19.	FR 6241	Sep., 1968		France			Abstract	
	20.	GB 817241	Jul., 1959		GB			11001100	
	21.	GB 1126892	Sep., 1968		GB				
	22.	GB 1207571	Oct., 1970		GB				
	23.	GB 1569286	Jun., 1980		GB				
	24.	JP 43-27327	Nov., 1992		Japan				
	25.	JP 09-208496	Dec., 1997		Japan		1	Abstract	
	26.	JP 10-203982	Apr., 1998		Japan				
	27.	JP 10-152438	Jun., 1998		Japan			Abstract	
	28.	JP 11-501649	Feb., 1999		Japan				
	29.	JP 11-158200	Jun., 1999		Japan				
	30.	SU 549118	Mar., 1977		Soviet Union			Abstract	
	31.	SU 676284	Jul., 1979		Soviet Union			Abstract	
	32.	WO 95/12383	May., 1995		WIPO			Abstract	
		OTHED D		JP		(l., / D			
		UTHER D	NUMENTS (Includ	uing A	Author, Title, Date, Per	unent Pa	ges, etc.)		
Examiner			Date C	oneid	lered				
			Date C	JUIISIC					
Examiner	: Initial	if reference considere	d, whether or not cita	tion i	s in conformance with M	PEP 609:	draw line thr	ough citation if not in	
					ext communication to app			J	
			* *		**				

DB1/630 AP21 REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.H./

INFOR	RMA	FION DISCLOSU	RE CITATION		Attorney Docket No 056291-5004-02		А	pplication No. 12/285,887		
	(U	se several sheets if nece	essary)	Applicants: John R. EVANS et al.						
	PTO Form 1449 June 4, 2009			F	Filing Date: October 15, 2008 Group Art Unit: 16					
			U.S. PA	TENT DOCUMENTS						
Initial		Document No.	Date		Name	Class	Sub-Class	Filing Date		
			FOREIGN	PAT	ENT DOCUMENTS	-				
		Document No.	Date		Country	Class	Sub-Class	Translation		
	33.	WO 96/19997	Jul., 1996		WIPO			Abstract		
	34.	WO 97/21440	Jun., 1997		WIPO					
	35.	WO 97/37653	Oct., 1997		WIPO			Abstract		
	36.	WO 97/40823	Nov., 1997		WIPO					
	37.	WO 98/11902	Mar., 1998		WIPO			Abstract		
	38.	WO 99/27906	Jun., 1999		WIPO					
	39.	ZA 681014	Feb., 1968		South Africa					
	40.	ZA 682530	Apr., 1968		South Africa					
		OTHER DO	CUMENTS (Includ	lina	Author, Title, Date, Pe	rtinant Pa	gos oto)			
	41.				in Injektionen", Pharm,			(2) np. 781 787		
	42.				aproate:with Chemica					
	-2.	And Metabolism, 1955			aproate with Chemica	IIY I UIC I I	ogesterone,	J. Chin. Endocrinoi.		
	43.	Dukes et al "Antiuter	otrophic effects of pu	ire ar	ntioestrogen. ICI 182,780) the ut	erus in ovarie	ctomized monkeys" L		
	151	Endocrinology, 1992,			110003105011 101 102,700	, ine ut		etomized monitojs , s.		
	44.				e antioestrogen ICI 182,	780qu	antitative mag	gnetic resonance		
		imaging"; J. Endocrino				1	c c	~		
	45.	Howell et al., "Pharma	cokinetics, pharmacc	ologie	cal and anti-tumour effec	ts of the s	pecific anti-o	estrogen ICI 182780 in		
					urnal of Cancer, 1996, V			-		
	46.	Howell et al., "Respon	se to a specific antioe	estrog	gen (ICI 182780) in tame	oxifen-resi	stant breast c	ancer", The Lancet,		
		Jan. 7, 1995, pp. 29-30								
	47.			r inje	ections of testosterone es	ter in oil v	ehicle", Hum	an Reproduction, vol.		
		10, no. 4, pp, 869-865,	1995							
	48.	Martindale, 32nd Ed.,	"Alcohol", Pharmace	utica	al Press, 1999, pp. 1099-	1101				
	49.				Alcohol"; Pharmaceutic			2-1104		
	50.				harmaceutical Press, 199					
	51.				pate Used as a Vehicle fo	or Antiand	rogens on the	Adrenal Cortex",		
		Archives of Andrology								
	52.				Pure Steroidal Antiestrog					
					Cancer, May 1995, Vol.					
	53.	U		one C	Caproate in Threatened A	bortion",	Current Thera	apeutic Research, Vol.		
	54	4, No. 6, June, 1962, p			D)		.	1		
	54.			· •	po-Provera) vs Wom		letastatic End	ometrial		
	55				Cancer Society, 1980, pp.	208-272				
	55.	Remington's Pharmace	suitear Sciences, 18th	ı ea.,	1990, p. 219					
Examiner	I	1	Date C	onsi	dered					
Examine				/01131						
Examiner	: Initia	al if reference considered	d, whether or not cita	tion	is in conformance with N	APEP 609	draw line the	rough citation if not in		
					ext communication to ap					

DB1/630 APPLI REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.H./

INFOR	INFORMATION DISCLOSURE CITATION				Attorney Docket No. 056291-5004-02		А	pplication No. 12/285,887
	(U	se several sheets if nece	essary)	Ap	plicants: John R. EVAN	NS <i>et al</i> .		
		PTO Form 1449 June 4, 2009		F	iling Date: October 15,	2008	Group	o Art Unit: 1617
	U.S. PA				T DOCUMENTS			
Initial		Document No.	Date		Name	Class	Sub-Class	Filing Date
			FOREIGN	РАТ	ENT DOCUMENTS			
		Document No.	Date		Country	Class	Sub-Class	Translation
		OTHER DC	CUMENTS (Inclue	ding /	Author, Title, Date, Per	tinent Pa	ges. etc.)	
	56.	Riffkin et al., "Castor (Dil as a Vehicle for F	Parent	eral Administration of S	teroid Hor	mones", Jour	rnal of Pharmaceutical
		Sciences, Vol. 53, No.	8, August 1964, pp.	891-8	395	•		
	57.				multicentre study compa CI 182,780 with tamoxi			
		breast cancer prior to s	urgery"; Abstract 28	,22n	l Annual San Antonio B	reast Canc	er Symposiu	m: Dec. 8-11, 1999,
		San Antonio, Breast Ca	ancer Research and T	Freatr	nent 1999; 57 (1; special	issue); p.	31	
	58.				II82,780 Exacerbates Iso No. 1, 2000, pp. 112-118		ury in Femal	e Mouse", Journal of
	59.	Vidal, Le Dictionnaire,				•		
	60.	Vidal, Le Dictionnaire	, "Gravibinan", 1995	, pp 6	660-661			
	61.	Vidal, Le Dictionnaire,						
	62. 63.	Vidal, Le Dictionnaire,			p. 1706-1707 ogen with Clinical Poter	atial" Can	aan Dagaanah	1001 Vol 51 m
	05.	3867-3873	tent specific Pure Af	mesu	ogen with Chinical Poter	mai , Can	cer Research	i, 1991, Vol. 51, pp.
	64.				gtailed MonkeyTreate 1. 43, No. 3, 1993, pp. 24		Novel Pure	Antiestrogen, ICI
	65.	"Pharmaceutical dosag Lachman, 1992	e forms: Parenteral r	nedic	ations, Volume 1", 2nd e	edition, ed	ited by Avis,	Lieberman and
Examiner		/San Ming Hui/	Date C	Consic	lered 12/1	9/2010		
	: Initia	l if reference considered			s in conformance with M		draw line th	rough citation if not in
conforman	ice and	not considered. Include	e copy of this form w	vith ne	ext communication to ap	plicant.		

DB1/630 APPLI REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.H./

PATENT Attorney Docket No. 11285.0056-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
John R. Evans et al.)) Group Art Unit: 1628
Application No.: 12/285,887)) Examiner: HUI, San Ming R.
Filed: October 15, 2008	
For: FORMULATION) Confirmation No.: 1199
)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

REVOCATION OF POWER OF ATTORNEY STATEMENT UNDER 37 C.F.R. § 3.73(b) AND GRANT OF NEW POWER OF ATTORNEY

The undersigned, a representative authorized to sign on behalf of the assignee owning all of the interest in this patent application, hereby revokes all previous powers of attorney or authorization of agent granted in this application before the date of execution hereof.

As required by 37 C.F.R. § 3.73(b), the undersigned verifies that AstraZeneca AB is the assignee of the entire right, title, and interest in the patent application identified above by virtue of an assignment from the inventors recorded in parent Application No. 10/872,784 in the U.S. Patent and Trademark Office at Reel 015906, Frame 0402.

The undersigned representative of the Assignee hereby grants its power of attorney to the patent practitioners associated with **FINNEGAN**, **HENDERSON**,

FARABOW, GARRETT & DUNNER, L.L.P., Customer Number 22,852, to prosecute

this application and to transact all business in the Patent and Trademark Office connected therewith, and to receive the Letters Patent.

Please send all future correspondence concerning this application to Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., Customer No. 22,852.

Ву:	D.C.C.
Name:	DR ALLEN F GILES
Title:	AUTHORISED REPRESENTATIVE
	Name:

AstraZeneca AB

Electronic A	cknowledgement Receipt
EFS ID:	10182478
Application Number:	12285887
International Application Number:	
Confirmation Number:	1199
Title of Invention:	Formulation
First Named Inventor/Applicant Name:	John R. Evans
Customer Number:	09629
Filer:	Carlos M. Tellez
Filer Authorized By:	
Attorney Docket Number:	056291-5004-02
Receipt Date:	27-MAY-2011
Filing Date:	15-OCT-2008
Time Stamp:	13:09:13
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with F	Payment		no					
File Listing:								
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)			
1	Power of Attorney		ecuted_power_11285-0056.	36929	no	2		
	rower of Attorney		pdf	1df66963cd97026c75078f395b2ba7dac73 a9f6a	no	2		
Warnings:								
Information:								

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMAR		RK OFFICE UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS PO. Box 1450 Alexandrix, Virginia 22313-1450 www.uspto.gov	
APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
12/285,887	10/15/2008	John R. Evans	11285.0056-00000
			CONFIRMATION NO. 1199
22852		POA ACCEPTANCE LETTER	
FINNEGAN, HENDERSO LLP 901 NEW YORK AVENUI WASHINGTON, DC 2000			OC000000048042566"
			Date Mailed: 06/07/2011

NOTICE OF ACCEPTANCE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 05/27/2011.

The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the above address as provided by 37 CFR 1.33.

/snguyen/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

page 1 of 1

PATENT Attorney Docket No. 11285.0056-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

John R. Evans et al.

Application No.: 12/285,887

Filed: October 15, 2008

For: FORMULATION

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Group Art Unit: 1628 Examiner: HUI, San Ming R. Confirmation No.: 1199 VIA EFS-WEB

Sir:

RESPONSE AND AMENDMENT UNDER 37 C.F.R. § 1.111 AND PETITION FOR EXTENSION OF TIME

In reply to the non-final Office Action mailed December 21, 2010 ("Office Action"), and pursuant to 37 C.F.R. § 1.111, Applicants hereby respectfully request reconsideration of this application in view of the following amendments and remarks. Applicants hereby petition for a three-month extension of time to respond to the Office Action. The requisite fee is being paid concurrently with this Response.

Amendments to the Claims are reflected in the listing of claims, which starts on page 2 of this paper. **Remarks** follow the amendment sections of this paper and start on page 9.

AMENDMENTS TO THE CLAIMS

Please add new claims 24-53. Please also cancel claims 1-23 without prejudice or disclaimer. This listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-23 (Cancelled)

24. (New) A method for treating a hormonal dependent benign or malignant disease of the breast or reproductive tract comprising administering intramuscularly to a human in need of such treatment a formulation comprising:

at least 45 mgml⁻¹ of fulvestrant;

a mixture of from 17 – 23% w/v of ethanol and benzyl alcohol;

12 - 18% w/v of benzyl benzoate; and

a sufficient amount of castor oil vehicle;

wherein the method achieves a therapeutically significant blood plasma fulvestrant concentration of at least 2.5 ngml⁻¹ for at least two weeks.

- 25. (New) The method of claim 24, wherein the ethanol and benzyl alcohol are present in the same weight/volume amounts.
- 26. (New) The method of claim 24, wherein the therapeutically significant blood plasma fulvestrant concentration is at least 8.5 ngml⁻¹.
- 27. (New) The method of claim 24, wherein the hormonal dependent benign or malignant disease of the breast or reproductive tract is breast cancer.

- 2 -

- 28. (New) The method of claim 24, wherein the therapeutically significant blood plasma fulvestrant concentration is attained for at least 4 weeks.
- 29. (New) The method of claim 24, wherein the method comprises administering intramuscularly to a human in need of such treatment 5 mL of the formulation.
- 30. (New) The method of claim 24, wherein the method further comprises once monthly administration of the formulation.
- 31. (New) The method of claim 24, wherein the formulation comprises:
 about 50 mgml⁻¹ of fulvestrant;
 about 10% w/v of ethanol;
 about 10% w/v of benzyl alcohol; and

about 15% w/v of benzyl benzoate;

wherein the therapeutically significant blood plasma fulvestrant concentration is at least 8.5 ngml⁻¹.

- 32. (New) The method of claim 31, wherein the hormonal dependent benign or malignant disease of the breast or reproductive tract is breast cancer.
- 33. (New) The method of claim 32, wherein the therapeutically significant blood plasma fulvestrant concentration is attained for at least 4 weeks.
- 34. (New) The method of claim 33, wherein the method comprises administering intramuscularly to a human in need of such treatment 5 mL of the formulation.

- 3 -

- 35. (New) The method of claim 34, wherein the method further comprises once monthly administration of the formulation.
- 36. (New) A method for treating a hormonal dependent benign or malignant disease of the breast or reproductive tract comprising administering intramuscularly to a human in need of such treatment a formulation consisting essentially of:

at least 45 mgml⁻¹ of fulvestrant;

a mixture of from 17 – 23% w/v of ethanol and benzyl alcohol;

12 - 18% w/v of benzyl benzoate; and

a sufficient amount of castor oil vehicle;

wherein the method achieves a therapeutically significant blood plasma fulvestrant concentration of at least 2.5 ngml⁻¹ for at least two weeks.

- 37. (New) The method of claim 36, wherein the ethanol and benzyl alcohol are present in the same weight/volume amounts.
- 38. (New) The method of claim 36, wherein the therapeutically significant blood plasma fulvestrant concentration is at least 8.5 ngml⁻¹.
- 39. (New) The method of claim 36, wherein the hormonal dependent benign or malignant disease of the breast or reproductive tract is breast cancer.
- 40. (New) The method of claim 36, wherein the therapeutically significant blood plasma fulvestrant concentration is attained for at least 4 weeks.

- 4 -

- 41. (New) The method of claim 36, wherein the method comprises administering intramuscularly to a human in need of such treatment 5 mL of the formulation.
- 42. (New) The method of claim 36, wherein the method further comprises once monthly administration of the formulation.
- 43. (New) The method of claim 36, wherein the formulation consists essentially of:
 about 50 mgml⁻¹ of fulvestrant;

about 10% w/v of ethanol;

about 10% w/v of benzyl alcohol; and

about 15% w/v of benzyl benzoate;

wherein the therapeutically significant blood plasma fulvestrant concentration is at least 8.5 ngml⁻¹.

- 44. (New) The method of claim 43, wherein the hormonal dependent benign or malignant disease of the breast or reproductive tract is breast cancer.
- 45. (New) The method of claim 44, wherein the therapeutically significant blood plasma fulvestrant concentration is attained for at least 4 weeks.
- 46. (New) The method of claim 45, wherein the method comprises administering intramuscularly to a human in need of such treatment 5 mL of the formulation.
- 47. (New) The method of claim 46, wherein the method further comprises once monthly administration of the formulation.

- 5 -

48. (New) A method for treating a hormonal dependent benign or malignant disease of the breast or reproductive tract comprising administering intramuscularly to a human in need of such treatment 5 – 5.25 mL of a formulation comprising:

4 - 6% w/v of fulvestrant;

a mixture of from 17 – 23% w/v of ethanol and benzyl alcohol;

12 - 18% w/v of benzyl benzoate; and

a sufficient amount of castor oil vehicle;

wherein the method achieves a therapeutically significant blood plasma fulvestrant concentration of at least 2.5 ngml⁻¹ for at least two weeks.

49. (New) A method for treating a hormonal dependent benign or malignant disease of the breast or reproductive tract comprising monthly intramuscular administration to a human in need of such treatment of a formulation comprising:

4 - 6% w/v of fulvestrant;

a mixture of from 17 - 23% w/v of ethanol and benzyl alcohol;

12 - 18% w/v of benzyl benzoate; and

a sufficient amount of castor oil vehicle;

wherein the method achieves a therapeutically significant blood plasma fulvestrant concentration of at least 2.5 ngml⁻¹ for at least two weeks.

50. (New) A method for treating a hormonal dependent benign or malignant disease of the breast or reproductive tract comprising monthly intramuscular administration to a human in need of such treatment of a formulation comprising:

4 - 6% w/v of fulvestrant;

- 6 -

Application No.: 12/285,887 Attorney Docket No.: 11285.0056-00000

a mixture of from 17 – 23% w/v of ethanol and benzyl alcohol;

12 - 18% w/v of benzyl benzoate; and

a sufficient amount of castor oil vehicle;

wherein the formulation is administered in a divided dose; and wherein the method achieves a therapeutically significant blood plasma fulvestrant concentration of at least 2.5 ngml⁻¹ for at least two weeks.

51. (New) A method for treating a hormonal dependent benign or malignant disease of the breast or reproductive tract comprising administering intramuscularly to a human in need of such treatment 5 – 5.25 mL of a formulation consisting essentially of:

4 - 6% w/v of fulvestrant;

a mixture of from 17 – 23% w/v of ethanol and benzyl alcohol;

12 - 18% w/v of benzyl benzoate; and

a sufficient amount of castor oil vehicle;

wherein the method achieves a therapeutically significant blood plasma fulvestrant concentration of at least 2.5 ngml⁻¹ for at least two weeks.

52. (New) A method for treating a hormonal dependent benign or malignant disease of the breast or reproductive tract comprising monthly intramuscular administration to a human in need of such treatment of a formulation consisting essentially of:

4 - 6% w/v of fulvestrant;

a mixture of from 17 – 23% w/v of ethanol and benzyl alcohol;

- 7 -

12 - 18% w/v of benzyl benzoate; and

a sufficient amount of castor oil vehicle;

wherein the method achieves a therapeutically significant blood plasma fulvestrant concentration of at least 2.5 ngml⁻¹ for at least two weeks.

53. (New) A method for treating a hormonal dependent benign or malignant disease of the breast or reproductive tract comprising monthly intramuscular administration to a human in need of such treatment of a formulation consisting essentially of:

4 - 6% w/v of fulvestrant;

a mixture of from 17 – 23% w/v of ethanol and benzyl alcohol;

12 - 18% w/v of benzyl benzoate; and

a sufficient amount of castor oil vehicle;

wherein the formulation is administered in a divided dose; and

wherein the method achieves a therapeutically significant blood plasma

fulvestrant concentration of at least 2.5 ngml⁻¹ for at least two weeks.

- 8 -

REMARKS

I. Status of the claims and amendments

Upon entry of the instant amendments, claims 24-53 will be pending in this application. Claims 1-23 are being cancelled in this Response without prejudice or disclaimer. New claims 24-53 are being added in this Response. Claims 24-35 and 48-50 are directed to methods for treating a hormonal dependent benign or malignant disease of the breast or reproductive tract comprising administering intramuscularly to a human in need of such treatment a formulation *comprising* various components. Claims 36-47 and 51-53 are identical to claims 24-35 and 48-50 except that the phrase "formulation *consisting essentially of*" replaces the phrase "formulation *comprising*" the various components.

New claim 24 finds support, for example, in original claim 21. The recitation in claim 24 regarding "at least 45 mg ml⁻¹ of fulvestrant" finds support, for example, in the specification at $\P [0028]$.¹ The recitation regarding "a mixture of from 17 – 23% w/v of ethanol and benzyl alcohol" finds support, for example, in the specification at $\P [0035]$, [0036], and [0042]. The recitation regarding "12 - 18% w/v of benzyl benzoate" finds support, for example, in the specification at $\P [0027]$. The recitation at $\P [0027]$. The recitation regarding "a therapeutically significant blood

¹ Unless otherwise specified, all citations to the instant specification refer to the pagination from the published application US 2010/0152149.

plasma fulvestrant concentration of at least 2.5 $ngml^{-1}$ for at least two weeks" finds support, for example, in the specification at ¶¶ [0027] and [0051].

New claim 25 finds support, for example, in the specification at ¶ [0036]. New claim 26 finds support, for example, in the specification at ¶ [0051]. New claim 27 finds support, for example, in the specification at ¶ [0064]. New claim 28 finds support, for example, in the specification at ¶ [0052]. New claim 29 finds support, for example, in the specification at ¶ [0052]. New claim 30 finds support, for example, in the specification at ¶ [0063]. New claim 30 finds support, for example, in the specification at ¶ [0023]. New claim 31 finds support, for example, in the specification at ¶ [0051] and the "Formulation Example" (*e.g.*, ¶¶ [0072] to [0076]). New claim 32 finds support, for example, in the specification at ¶ [0052]. New claim 34 finds support, for example, in the specification at ¶ [0063]. New claim 35 finds support, for example, in the specification at ¶ [0063]. New claim 35 finds support, for example, in the specification at ¶ [0063]. New claim 35 finds support, for example, in the specification at ¶ [0063]. New claim 35 finds support, for example, in the specification at ¶ [0063]. New claim 35 finds support, for example, in the specification at ¶ [0063]. New claim 35 finds support, for example, in the specification at ¶ [0063]. New claim 35 finds support, for example, in the specification at ¶ [0063]. New claim 35 finds support, for example, in the specification at ¶ [0063]. New claim 35 finds support, for example, in the specification at ¶ [0063]. New claim 35 finds support, for example, in the specification at ¶ [0023].

Claims 48-50 share various limitations with claim 24, for which support has been identified above. The recitation in **claim 48** regarding administration of "5 – 5.25 mL" of formulation finds support, for example, in the specification at ¶ [0034]. The recitation in **claim 48** regarding "4 - 6% w/v of fulvestrant" finds support, for example, in the specification at ¶ [0025]. The recitation in **claim 49** regarding "monthly intramuscular administration" finds support, for example, in the specification at ¶ [0023]. The recitation in **claim 50** regarding "the formulation [being] administered in a divided dose" finds support, for example, in the specification at ¶ [0053].

Because **claims 36-47 and 51-53** are identical to claims 24-35 and 48-50 except for the transitional phrase ("consisting essentially of" instead of "comprising"), the same

- 10 -

disclosure from the instant specification cited above for claims 24-35 and 48-50 provides support for claims 36-47 and 51-53. The instant amendments do not add new matter.

II. Rejection under 35 U.S.C. § 103

The Office rejected claims 1-23 under 35 U.S.C. § 103(a) as being unpatentable over European Patent Specification No. EP 0 346 014 ("*Dukes*") in view of US Reissue Patent No. 28,690 ("*Lehmann*"), Great Britain Patent Specification No. GB 1 569 286 ("GB 1 569 286"), Osborne et al., Journal of National Cancer Institute, 87(10):746-750 (1995) ("*Osborne*"), and Remington's Pharmaceutical Sciences, 18th ed., p. 219 (1990) ("*Remington*").

Applicants cancelled claims 1-23 in the instant Response. Thus, this rejection is now moot. However, in an effort to advance prosecution, and to the extent that the Office is considering applying the arguments from the outstanding obviousness rejection to the newly added claims, Applicants will address the rejections in the Office Action below.

According to the Office, *Dukes* teaches that "antiestrogen agents, including fulvestrant, are useful in treating postmenopausal symptoms such as urogenital atrophy affecting the vagina." Office Action at 3. The Office further argues that *Dukes* "teaches that antiestrogen agent, including fulvestrant, may be used in a dosage of 50mg to 5g in vehicle comprising castor oil and benzyl alcohol." *Id.* The Office acknowledges, however, that among other deficiencies, *Dukes* "does not expressly teach the employment of benzyl benzoate . . . as part of the vehicle herein." *Id.*

- 11 -

In an attempt to cure the shortcomings in Dukes, the Office cites Lehmann as

teaching "that benzyl benzoate and castor oil are well-known solvent useful as

conventional carriers for steroids." Office Action at 3. In the Office's view GB 1 569 286

"teaches an intramuscular injection of testosterone derivative containing castor

oil/benzoate in a ratio of 6:4" (id.); Osborne "teaches fulvestrant as useful in treating

human breast cancer" (id. at 4); and Remington teaches "that ethanol is one of the most

commonly used solvents in pharmaceutical industry" (id.).

The Office concludes that:

One of ordinary skill in the art would have been motivated to employ benzyl benzoate, ethanol, castor oil, and benzyl alcohol, in the herein claimed weight percent, with fulvestrant, in the dosage herein, in a method of treating postmenopausal symptoms such as urogenital atrophy or treating breast cancer because fulvestrant is known to be useful in treating urogenital atrophy, a benign disease of the female reproductive tract in the vagina and breast cancer.

Office Action at 4. According to the Office:

[C]ombining one or more agents, which are known to be useful as commonly used solvents, such as benzyl benzoate, ethanol, castor oil, and benzyl alcohol, together and incorporated such combination with an estrogen derivatives, fulvestrant, would be reasonably expected to be useful in formulating a pharmaceutical composition.

Office Action at 4. The Office further argues that "the optimization of result

effect[ive] parameters (e.g., amount of excipients, dosage range, and dosing

regimens) is obvious as being within the skill of the artisan, absent evidence to

the contrary." Id. at 5. Applicants respectfully traverse this rejection.

- 12 -

II.A One of ordinary skill in the art would not have combined the cited references in the manner proposed in the rejection

The Office relies on *Dukes* to argue that formulations comprising fulvestrant "in a dosage of 50mg to 5g in vehicle comprising castor oil and benzyl alcohol" were known in the art. Office Action at 3. The Office then states that one of ordinary skill in the art would have added ethanol and benzyl benzoate to *Dukes* formulation to arrive at the formulation recited in the claims. *Id.* The Office, however, provides no explanation for why one of ordinary skill in the art would have modified *Dukes* formulation in the proposed manner. As will be explained below, one of ordinary skill in the art would not have modified *Dukes* formulation. Because fulvestrant is difficult to formulate, one of ordinary skill in the art would not have prepared a formulation in which fulvestrant was expected to have a lower solubility than that in the initial formulation. *See, e.g.*, specification at ¶ [0014].

The passage from *Dukes* cited by the Office as disclosing fulvestrant formulations indicates that when administering a pure antiestrogen by periodic intramuscular injection, an oily solution of the pure antiestrogen "containing arachis or castor oil [and] an alcohol such as benzyl alcohol" is preferred. *Dukes* at 7, II. 19-23. *Dukes* also discloses two different formulations of fulvestrant in its working examples. Example 1 from *Dukes* discloses fulvestrant "in a mixture of propylene glycol: ethanol: water: poloxamer 407." *Dukes* at 8, II. 35-37. Example 2 discloses a formulation "contain[ing] 50 mg of [fulvestrant], 400 mg of benzyl alcohol and sufficient castor oil to

- 13 -

bring the solution to a volume of 1 ml" ("*Dukes* castor oil formulation"). *Dukes* at 9, II. 21-23.

No explanation for why one of ordinary skill in the art would have modified the *Dukes* castor oil formulation in any way is set forth in the Office Action. The Office seems to imply that one of ordinary skill in the art would have added ethanol and benzyl benzoate to *Dukes* castor oil formulation simply because ethanol and benzyl benzoate were "known to be useful as commonly used solvents." Office Action at 3. The focus in an obviousness rejection, however, is not on what one of ordinary skill in the art would have done, but rather "on what a person of ordinary skill in the pertinent art would have known at the time of the invention, and on what such a person *would have reasonably expected to have been able to do* in view of that knowledge." M.P.E.P. § 2141.II (emphasis added).

In this regard, one of ordinary skill in the art attempting to improve any of the *Dukes* formulations would have determined the solubility of fulvestrant in any test solvent before adding the solvent to the formulation. See, for example, Table 2 of the instant application, which reports solubility of fulvestrant in castor oil, benzyl alcohol, ethanol, and benzyl benzoate. According to Table 2, the solubility of fulvestrant in benzyl benzoate is 6.15 mgml⁻¹, whereas the corresponding solubility in benzyl alcohol is >200 mgml⁻¹. Thus, based on solubility data, one of ordinary skill in the art would have realized that fulvestrant is more than one order of magnitude more soluble in benzyl alcohol than in benzyl benzoate. Therefore, incorporating benzyl benzoate into *Dukes* castor oil formulation at the expense of reducing the concentration of benzyl alcohol, as would be required to arrive at the formulation recited in the instant claims

- 14 -

starting from *Dukes* disclosure, would have been expected to *decrease* the solubility of fulvestrant in the resulting formulation. None of the references cited by the Office suggests otherwise. As mentioned before, decreasing the solubility of fulvestrant in a given formulation would exacerbate the problem of finding a suitable formulation for fulvestrant.

Thus, none of the cited references would have suggested to one of ordinary skill in the art the modification of any of *Dukes* formulations by the addition of benzyl benzoate. For at least this reason, the Office has not made a *prima facie* case of obviousness and Applicants respectfully request that this rejection be withdrawn.

II.B The Office has not made the necessary factual findings to support a conclusion of obviousness

By arguing that one of ordinary skill in the art would have added ethanol and benzyl benzoate to *Dukes* castor oil formulation simply because the additional solvents were known in the art (Office Action at 3), the Office seems to be basing the rejection in a "combination of prior art elements" rationale. *See, e.g.*, M.P.E.P. § 2143.A. However, an obviousness rejection under this rationale requires, among other requisites: (1) "a finding that . . . each element [in the combination] merely performs the same function as it does separately" and (2) "a finding that one of ordinary skill in the art would have recognized that the results of the combination were predictable." *Id.* The Office has not met either of these requirements.

First, the Office has not shown that the solvents proposed to be added to *Dukes* castor oil formulation, ethanol and benzyl benzoate, would have performed the same function in the resulting formulation as they performed separately. As explained in the

- 15 -

previous section, the addition of benzyl benzoate to a given fulvestrant formulation would have been expected to reduce the solubility of fulvestrant in the original formulation. Table 3 in the instant specification compares the solubility of fulvestrant in various formulations comprising ethanol, benzyl alcohol, and castor oil in the presence and absence of benzyl benzoate. In each case, the solubility of fulvestrant in the solution containing benzyl benzoate *increased* compared to the solubility of fulvestrant in the corresponding formulation without benzyl benzoate. *Id*. The trend shown in Table 3 demonstrates that benzyl benzoate is *not* "perform[ing] the same function as it does separately."

Second, because the addition of benzyl benzoate does not decrease the solubility of fulvestrant in the resulting formulation, as would have been expected, the Office cannot find that "one of ordinary skill in the art would have recognized that the results of the combination were predictable."

Even under an "obvious to try" rationale, the Office needs to show that "one of ordinary skill in the art could have pursued the known potential solutions *with a reasonable expectation of success.*" M.P.E.P. § 2143.E. In the instant case, as shown in Section II.A above, one of ordinary skill in the art could not have expected that adding benzyl benzoate to *Dukes* castor oil formulation, while decreasing the amount of benzyl alcohol as would be required to arrive at the formulation recited in the instant claims, would have resulted in a suitable fulvestrant formulation.

For the foregoing reasons, the Office has not met its burden of proving a *prima facie* case of obviousness. Accordingly, Applicants respectfully request that this rejection be withdrawn.

- 16 -

Application No.: 12/285,887 Attorney Docket No.: 11285.0056-00000

III. Double Patenting Rejection

The Office rejected claims 21-22 under the nonstatutory obviousness-type double patenting doctrine as being unpatentable over: (a) claims 1-9 of U.S. Patent No. 6,774,122 and (b) claims 1-12 of U.S. Patent No. 7,456,160.

Because Applicants cancelled claims 21 and 22 in this Response, this rejection is now moot. Accordingly, Applicants respectfully request that this rejection be withdrawn.

IV. Conclusion

In view of the foregoing amendments and remarks, Applicants respectfully request reconsideration of this application and the timely allowance of the pending claims.

Please grant any extensions of time required to enter this response and charge any required fees not included with this Response to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: June 20, 2011

Bv:

Carlos M. Téllez Reg. No. 48,638 (202) 408-4123

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
John R. Evans et al.)) Group Art Unit: 1628
Application No.: 12/285,887)) Examiner: HUI, San Ming R.
Filed: October 15, 2008)) Confirmation No.: 1199
For: FORMULATION))) VIA EFS-WEB
Commission on few Datasta	

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

A. Documents Listed in the Attached SB/08 Form

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants brings to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

B. Teva's Paragraph IV Letter Dated November 25, 2009

The undersigned wishes to make of record the following information. Teva Parenteral Medicines, Inc., ("Teva") filed Abbreviated New Drug Application ("ANDA") No. 200479 with the FDA seeking approval of a generic 50 mg/mL Fulvestrant injection. In connection with ANDA No. 200479, Teva sent a letter to AstraZeneca Pharmaceuticals LP dated November 25, 2009, ("Teva's Letter") concerning U.S. Patent Nos. 6,774,122 and 7,456,160 ("the '122 and '160 patents").

The instant application claims the benefit of priority from each of the '122 and '160 patents. Teva's Letter alleges that the '122 and '160 patents are obvious in light of, *inter alia*, Howell *et al.* (cited in the Information Disclosure Statement filed on June 4, 2009) and McLeskey *et al.* (cited in this Information Disclosure Statement).

All documents cited in Teva's Letter are listed in the table below. To the extent Teva's Letter provided a pinpoint citation for any of the documents, the citation is also provided below. Otherwise, the phrase "generally" appears when Teva's Letter referred to the disclosure in the given document without a citation.

References cited in Teva's Paragraph IV Letter Dated November 25, 2009, Concerning AstraZeneca's U.S. Patent Nos. 6,774,122 and 7,456,160					
Reference Citation					
U.S. Patent No. 5,183,814 to Dukes et al., and its	Generally;				
"European cognate," European Patent Application	Col. 3, I. 66 - Col. 4, I. 4;				
No. EP 0 346 014	Col. 6, II. 20-26;				
	Col. 9, II. 15-25;				
	Example 3, col. 11, ll. 1-11				

- 2 -

References cited in Teva's Paragraph IV Letter Dated November 25, 2009, Concerning AstraZeneca's U.S. Patent Nos. 6,774,122 and 7,456,160					
Reference	Citation				
U.S. Patent No.4,659,516 to Bowler et al. (and	Generally				
European Patent Application No. EP 0 138 504, which					
was termed an "equivalent" of U.S. Patent					
No.4,659,516 in Teva's Letter)					
European Patent Application No. EP 0 346 014, which	Generally				
was termed the "European cognate" of U.S. Patent					
No. 5,183,814 in Teva's Letter					
Howell et al., "Pharmacokinetics, Pharmacological,	Generally;				
and Anti-tumour Effects of the Specific Anti-oestrogen	300; 301; 302; 303; 305				
ICI 182780 in Women with Advanced Breast Cancer,"	Figure 2;				
Brit J. Cancer 74:300-308 (1996).					
McLeskey et al., "Tamoxifen-Resistant Fibroblast	Generally;				
Growth Factor-Transfected MCF-7 Cells are Cross-	698				
Resistant In Vivo to the Antiestrogen ICI 182,780 and					
Two Aromatase Inhibitors," Clin. Cancer Res. 4:697-					
711 (1998).					
Wakeling et al., "A Potent Specific Pure Antiestrogen	Generally;				
with Clinical. Potential," Cancer Res., 51:3867-73	3869				
(1991).					
U.S. Patent No. 4,212,863	Col. 1, II. 30-32				
P.K. Gupta and GA. Brazeau (eds), Injectable Drug	405				
Development: Techniques to Reduce Pain and	418				
Irritation. Chapters 11 & 17 Interpharm Press, Denver,					
Colorado (1999).					

AstraZeneca Pharmaceuticals LP and other AstraZeneca related corporate entities brought suit against Teva and other Teva related corporate entities charging

them with infringement of the '122 and '160 patents. The suit was filed on January 7, 2010 in the U.S. District Court for the District of Delaware and was assigned Civil Action No. 10-18-JAP.

Subsequently, Teva withdrew ANDA No. 200479 and is no longer seeking approval of a generic 50 mg/mL Fulvestrant injection from the FDA. Civil Action No. 10-18-JAP was dismissed without prejudice on June 15, 2011.

Unless already of record, all documents cited in the preceding table are being submitted to the Office in the attached SB/08 form.

<u>C. Documents from the prosecution of European Patent Applications</u> <u>member of the same family as the instant application</u>

Applicants submitted documents from the opposition against European Patent Application No. 01900186.6 with the Information Disclosure Statement filed June 4, 2009. Applicants now supplement that submission with documents submitted after the June 4, 2009, Information Disclosure Statement. Applicants are also enclosing the search reports from European Patent Application Nos. 10180667.7 and 10180661.0. European Patent Application Nos. 01900186.6, 10180667.7, and 10180661.0 are European members of the same patent family as the instant application.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the documents listed in the attached SB/08 form or in the table above are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and Applicant determines that the cited documents do not constitute "prior

- 4 -

art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement not included herein, please charge the fee to Deposit Account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: June 20, 2011

By: Carlos M. Téllez

Reg. No. 48,638 (202) 408-4123

				C		
				Application Number	12/285,887	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	IRE	Filing Date	October 15, 2008			
		First Named Inventor	John R. EVANS			
••••				Art Unit	1628	
	(Use as many sheets	as necessary)	-	Examiner Name	San Ming R. Hui	
Sheet	1	of	1	Attorney Docket Number	11285.0056-00000	

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Cite Document Number	issue or	Name of Patentee or	Pages, Columns, Lines, Where		
	Publication Date MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear		
US-			· · · · · · · · · · · · · · · · · · ·		
US-	1	· · · · · · · · · · · · · · · · · · ·			
US-					
			·		
US-		,			
US-					
-	ite Document Number o. ¹ Number-Kind Code ² (if know US- US- US- US-	ite o. ¹ Issue or Publication Date MM-DD-YYYY US- US- US- US- US- US- US- US-	Interpretation Document Number Issue or Publication Date MM-DD-YYYY Name of Patentee or Applicant of Cited Document US- US-		

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

	FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶			

		NONPATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
	1	McLeskey et al., "Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors," Clin. Cancer Res., 4:697-711 (1998).	
	2	JRF Robertson, et al., "Fulvestrant: pharmacokinetics and pharmacology," British Journal of Cancer, 90(1):S7-S10 (2004).	
	3	John F. R. Robertson, "Fulvestrant (Faslodex®)how to make a good drug better," The Oncologist, 12:774-784 (2007).	
	4	Search Report for European Patent Application No. 10180667.7 dated November 23, 2010.	·
	5	Search Report for European Patent Application No. 10180661.0 dated January 19, 2011.	
	6	Documents from the Opposition against European Patent Application No. 01900186.6 from April 21, 2009 to September 7, 2009.	

Evention		
Examiner	Date	
O'una d	Date	
Signature	Considered	
	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Electronic Patent Application Fee Transmittal					
Application Number:	12285887				
Filing Date:	15-	Oct-2008			
Title of Invention:	For	Formulation			
First Named Inventor/Applicant Name:	John R. Evans				
Filer:	Carlos M. Tellez/Delia Herring				
Attorney Docket Number: 11285.0056-00000					
Filed as Large Entity					
Utility under 35 USC 111(a) Filing Fees					
Description		Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:					
Pages:					
Claims:					
Miscellaneous-Filing:					
Petition:					
Patent-Appeals-and-Interference:					
Post-Allowance-and-Post-Issuance:					
Extension-of-Time:					
Extension - 3 months with \$0 paid		1253	1	1110	1110

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Miscellaneous:				
Submission- Information Disclosure Stmt	1806	1	180	180
	Total in USD (\$)			1290

Electronic A	Electronic Acknowledgement Receipt					
EFS ID:	10343633					
Application Number:	12285887					
International Application Number:						
Confirmation Number:	1199					
Title of Invention:	Formulation					
First Named Inventor/Applicant Name:	John R. Evans					
Customer Number:	22852					
Filer:	Carlos M. Tellez					
Filer Authorized By:						
Attorney Docket Number:	11285.0056-00000					
Receipt Date:	20-JUN-2011					
Filing Date:	15-OCT-2008					
Time Stamp:	16:59:43					
Application Type:	Utility under 35 USC 111(a)					

Payment information:

Submitted wi	th Payment	yes	yes				
Payment Type	e	Credit Card					
Payment was successfully received in RAM \$1290							
RAM confirma	ation Number	4028					
Deposit Acco	unt						
Authorized User							
File Listin	g:						
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)		

1		11285-0056-0000020- JUN-2011	587464	Vor	17						
		ResponseandAmendment.pdf	f0c060149d0e3c9cfe78972c101304eb349e 299b	yes	17						
	Mul	tipart Description/PDF files in .	zip description								
	Document I	Description	Start	End							
	Amendment/Req. Reconside	ration-After Non-Final Reject	1	1							
	Clai	ims	2		8						
	Applicant Arguments/Rema	rks Made in an Amendment	9	1	17						
Warnings:											
Information:											
2		11285-0056-0000020-	73727	yes	6						
-		JUN-2011IDSandSB08.pdf	27bc537a476efc3075103da02bd9fdf7b275 1a2f	yes	0						
	Multipart Description/PDF files in .zip description										
	Document I	Description	Start	End							
	Transmit	tal Letter	1								
	Information Disclosure Sta	atement (IDS) Form (SB08)	6		6						
Warnings:											
Information:											
3	Non Patent Literature	11285-0056-0000020- JUN-2011MCLESKEY.pdf	552191	no	15						
			83120								
Warnings:											
Information:											
		11225 2256 2222 22	110217								
4	Non Patent Literature	11285-0056-0000020- JUN-2011	118217	no	4						
4	Non Patent Literature		118217 85e15a34de0ba428157506d8e148b124bc e26f17	no	4						
4 Warnings:	Non Patent Literature	JUN-2011	85e15a34de0ba428157506d8e148b124bc	no	4						
Warnings:	Non Patent Literature	JUN-2011	85e15a34de0ba428157506d8e148b124bc	no	4						
Warnings: Information:	Non Patent Literature Non Patent Literature	JUN-2011 JFRRobertsonFulvestraint.pdf 11285-0056-0000020-	85e15a34de0ba428157506d8e148b124bc	no	4						
Warnings:		JUN-2011 JFRRobertsonFulvestraint.pdf	85e15a34de0ba428157506d8e148b124bc e26f17								
Warnings: Information: 5 Warnings:		JUN-2011 JFRRobertsonFulvestraint.pdf 11285-0056-0000020- JUN-2011JohnFRRobertson.	85e15a34de0ba428157506d8e148b124bc e26f17 291690 41898efd490c024a52c360ac37be99c0082								
Warnings: Information: 5 Warnings:		JUN-2011 JFRRobertsonFulvestraint.pdf 11285-0056-0000020- JUN-2011JohnFRRobertson.	85e15a34de0ba428157506d8e148b124bc e26f17 291690 41898efd490c024a52c360ac37be99c0082								
Warnings: Information:		JUN-2011 JFRRobertsonFulvestraint.pdf 11285-0056-0000020- JUN-2011JohnFRRobertson.	85e15a34de0ba428157506d8e148b124bc e26f17 291690 41898efd490c024a52c360ac37be99c0082								

Information:					
7	Foreign Reference	11285-0056-0000020- JUN-2011ISR10180661-0.pdf	66093 549156ea24a6e5820e5b114f514966558a0 1342b	no	5
Warnings:		•			
Information:					
8	Non Patent Literature	11285-0056-0000020- JUN-2011	697437	no	51
		DocumentsfromOpposition.pdf	fcc44c176cbe2b76f5ea85a1b1162d8d5e30 0552		
Warnings:		·			
Information					
9	Fee Worksheet (SB06)	fee-info.pdf	31886	no	2
			ff9996e9130d928a675262ef7a75a7e64bc1 1611		-
Warnings:					
Information:					
		Total Files Size (in bytes)	: 24	84611	
characterized Post Card, as <u>New Applica</u> If a new appl 1.53(b)-(d) at Acknowledg <u>National Star</u> If a timely su U.S.C. 371 ar national sta <u>c</u> <u>New Internat</u> If a new inter	ledgement Receipt evidences receip d by the applicant, and including pa described in MPEP 503. tions Under 35 U.S.C. 111 ication is being filed and the applica nd MPEP 506), a Filing Receipt (37 C ement Receipt will establish the filin ge of an International Application u bmission to enter the national stage of other applicable requirements a l ge submission under 35 U.S.C. 371 w tional Application Filed with the US rnational application is being filed a onal filing date (see PCT Article 11 an	age counts, where applicable. ation includes the necessary of FR 1.54) will be issued in due ng date of the application. <u>nder 35 U.S.C. 371</u> e of an international applicati Form PCT/DO/EO/903 indicati vill be issued in addition to the <u>PTO as a Receiving Office</u> and the international applicat	It serves as evidence components for a filin course and the date s on is compliant with t ng acceptance of the e Filing Receipt, in due ion includes the neces	of receipt s g date (see hown on thi the conditio application e course. ssary compo	imilar to a 37 CFR is ons of 35 as a onents for
	ternational Filing Date (Form PCT/R urity, and the date shown on this Ac on.				

	Under the Pa	perwork Reduc	tion Act of 19	95, no persons are	e required to respor			nd Trademark Off	ce; U.S	. DEPARTME	PTO/SB/06 (07-06) 007. OMB 0651-0032 NT OF COMMERCE OMB control number.
P	ATENT APPL		FEE DET		N RECORD	A		Docket Number 5,887		ing Date 15/2008	To be Mailed
	A	PPLICATIO	N AS FILE (Column ⁻		(Column 2)		SMALL		OR		HER THAN
	FOR		NUMBER FI	_ED NU	MBER EXTRA		RATE (\$)	FEE (\$)		RATE (\$)	FEE (\$)
	BASIC FEE (37 CFR 1.16(a), (b), (or (c))	N/A		N/A		N/A			N/A	
	SEARCH FEE (37 CFR 1.16(k), (i), c		N/A		N/A	1	N/A			N/A	
	EXAMINATION FE (37 CFR 1.16(o), (p), (E	N/A		N/A		N/A			N/A	
	TOTAL CLAIMS (37 CFR 1.16(i))			nus 20 = *			X \$ =		OR	X \$ =	
IND	EPENDENT CLAIM CFR 1.16(h))	S	inus 3 = *		1	X \$ =			X \$ =		
	APPLICATION SIZE 37 CFR 1.16(s)) MULTIPLE DEPEN	FEE is ac 35	neets of pap \$250 (\$125 dditional 50 5 U.S.C. 41(ation and drawin er, the applicatio for small entity) sheets or fractio a)(1)(G) and 37 7 CFR 1.16(j))	on size fee due for each n thereof. See						
* If t	he difference in colu	umn 1 is less th	nan zero, ente	er "0" in column 2.			TOTAL			TOTAL	
	APPI	LICATION A		DED — PART II (Column 2)	(Column 3)	_	SMAL	L ENTITY	OR		ER THAN ALL ENTITY
NT	06/20/2011	CLAIMS REMAINING AFTER AMENDMEN		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE (\$)	ADDITIONAL FEE (\$)		RATE (\$)	ADDITIONAL FEE (\$)
ME	Total (37 CFR 1.16(i))	* 30	Minus	** 23	= 7		X \$ =		OR	X \$52=	364
AMENDMENT	Independent (37 CFR 1.16(h))	* 8	Minus	***3	= 5		X \$ =		OR	X \$220=	1100
AMI	Application Si	ize Fee (37 CF	R 1.16(s))								
		NTATION OF MU	LTIPLE DEPEN	DENT CLAIM (37 CF	R 1.16(j))				OR		
							TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	1464
		(Column 1))	(Column 2)	(Column 3)						
⊢		CLAIMS REMAINING AFTER AMENDMEN		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE (\$)	ADDITIONAL FEE (\$)		RATE (\$)	ADDITIONAL FEE (\$)
ENDMENT	Total (37 CFR 1.16(i))	*	Minus	**	=		X \$ =		OR	X \$ =	
DN	Independent (37 CFR 1.16(h))	*	Minus	***	=		X \$ =		OR	X \$ =	
Z	Application Si	ize Fee (37 CF	R 1.16(s))								

FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))

AME

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to In scollection of information is required by 37 GFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 GFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

TOTAL

ADD'L

FEE

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

MYLAN PHARMS. INC. EXHIBIT 1002 PAGE 306

OR

OR

Legal Instrument Examiner:

/NICHELE PETERSON/

TOTAL

ADD'L

FEE

Document code: WFEE

United States Patent and Trademark Office Sales Receipt for Accounting Date: 06/29/2011

NPETERSO SALE #00000001 Mailroom Dt: 06/20/2011 060916 12285887 01 FC : 1201 1,100.00 DA

	<u>'ed States Patent a</u>	AND TRADEMARK OFFICE	UNITED STATES DEPAR United States Patent and Address: COMMISSIONER F P.O. Box 1450 Alexandria, Virginia 22. www.uspto.gov	FOR PATENTS
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/285,887	10/15/2008	John R. Evans	11285.0056-00000	1199
	7590 09/16/2011	V, GARRETT & DUNNER	EXAM	IINER
LLP		, OARRELL & DONNER	HUI, SAN	N MING R
	RK AVENUE, NW N, DC 20001-4413		ART UNIT	PAPER NUMBER
			1628	
			MAIL DATE	DELIVERY MODE
			09/16/2011	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)							
	12/285,887	EVANS ET AL.							
Office Action Summary	Examiner	Art Unit							
	SAN-MING HUI	1628							
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address							
 A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING D/ Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period v Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). 	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin vill apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).							
Status									
1) Responsive to communication(s) filed on <u>20 Ju</u>	ine 2011.								
	action is non-final.								
3) An election was made by the applicant in resp	onse to a restriction requirement	set forth during the interview on							
; the restriction requirement and election	have been incorporated into this	action.							
4) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.									
Disposition of Claims	,,,,,,,,,,,,.								
 5) Claim(s) <u>24-53</u> is/are pending in the application 5a) Of the above claim(s) is/are withdraw 6) Claim(s) is/are allowed. 7) Claim(s) <u>24-53</u> is/are rejected. 8) Claim(s) is/are objected to. 9) Claim(s) are subject to restriction and/o 	wn from consideration.								
Application Papers									
10) The specification is objected to by the Examine	r.								
11) The drawing(s) filed on is/are: a) acc	epted or b) 🗌 objected to by the I	Examiner.							
Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correct									
12) The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.							
Priority under 35 U.S.C. § 119									
 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 									
Attachment(s)									
1) 🔀 Notice of References Cited (PTO-892)	4) 🔲 Interview Summary								
2) D Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da 5)								
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	6) Other:								
U.S. Patent and Trademark Office PTOL-326 (Rev. 03-11) Office Ac	tion Summary Pa	art of Paper No./Mail Date 20110906							

DETAILED ACTION

This is a continuation of US 10/872,784, filed 6/22/2004, now patent 7,456,160, which is a continuation of US 09/756,291, filed 1/9/2001, now patent 6,774,122. The instant application also claims the benefit of UNITED KINGDOM 0000313.7, filed 01/10/2000 and UNITED KINGDOM 0008837.7, filed 04/12/2000.

Applicant's amendments filed 6/20/2011 have been entered. Claims 24-53 are pending.

The outstanding rejection under 35 USC 103(a) is withdrawn due to the cancellation of the claims.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422

F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 24-53 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-9 of U.S. Patent No. 6,774,122 ('122). Although the conflicting claims are not identical, they are not patentably distinct from each other because '122 teaches the method of treating hormonal dependent benign or malignant disease of reproductive tract by employing the herein claimed composition. The ratio of the solvents and the excipients are within the range taught in '122. The optimization of result effect parameters (e.g., dosing regimen, weight ratio of the actives and the excipients) is obvious as being within the skill of the artisan. The optimization of known effective amounts of known active agents to be administered, is considered well in the competence level of an ordinary skilled artisan in pharmaceutical science, involving merely routine skill in the art. It has been held that it is within the skill in the art to select optimal parameters, such as amounts of ingredients, in a composition

in order to achieve a beneficial effect. See *In re Boesch*, 205 USPQ 215 (CCPA 1980). It is also noted that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." *In re Aller*, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955).

Claims 24-53 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-12 of U.S. Patent No. 7,456,160 (160). Although the conflicting claims are not identical, they are not patentably distinct from each other because '160 teaches the method of treating hormonal dependent benign or malignant disease of reproductive tract by employing the herein claimed composition. The ratio of the solvents and the excipients are within the range taught in '160. The optimization of result effect parameters (e.g., dosing regimen, weight ratio of the actives and the excipients) is obvious as being within the skill of the artisan. The optimization of known effective amounts of known active agents to be administered, is considered well in the competence level of an ordinary skilled artisan in pharmaceutical science, involving merely routine skill in the art. It has been held that it is within the skill in the art to select optimal parameters, such as amounts of ingredients, in a composition in order to achieve a beneficial effect. See In re Boesch, 205 USPQ 215 (CCPA 1980). It is also noted that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 24-53 are rejected under 35 U.S.C. 103(a) as being unpatentable over McKeskey et al., from IDS filed 6/20/2011 in view of Dukes (EP 0 346 014), Osborne et al., Journal of National Cancer Institute, 1995;87(20):746-750, and the abstract of Wakeling et al., The Journal of Steroid Biochemistry and Molecular Biology, 1992;43(1-3):173-177.

McKeskey et al. teaches a studies employing subcutaneous injection of fulvestrant to nude mice. The fulvestrant formulation contains 50mg/ml in a vehicle of 10% ethanol, 15% benzyl benzoate, 10% benzyl alcohol brought to volume with castor oil (see page 698, col. 2, Drugs section).

McKeskey et al. does not expressly teach the use of fulvestrant in treating hormonal dependent diseases of breast. It does not expressly teach the dosing regimen to be once a month, intramuscular administration, or the volume administered. McKeskey et al. does not expressly teach the herein claimed serum concentration of fulvestrant.

Dukes teaches antiestrogen agents, including fulvestrant, are useful in treating postmenopausal symptoms such as urogenital atrophy affecting the vagina (See page 3, lines 56-page 4, line 1; also page 7, line 28-29). Dukes teaches that antiestrogen

agent, including fulvestrant, via intramuscular route of administration may be used in a dosage of 50mg to 5g in vehicle comprising castor oil and benzyl alcohol (See page 7, line 20-24).

Osborne et al. teaches fulvestrant as useful in treating human breast cancer (See pages 747-748, Result Section).

Wakeling et al. teaches the administration of fulvestrant (ICI 182780) demonstrating the antiestrogenic effect for over a 1 month period (see the abstract).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to employ fulvestrant in McKeskey's, in the herein claimed dosing regimen and dosage, for treating hormonal dependent diseases such as breast cancer and postmenopausal symptoms.

One of ordinary skill in the art would have been motivated to employ fulvestrant in McKeskey's, in the herein claimed dosing regimen and dosage, for treating hormonal dependent diseases such as breast cancer and postmenopausal symptoms. It is known in the art that fulvestrant as being useful in treating hormonal dependent disease. It is also known in the art that fulvestrant can be administered intramuscularly and its antitumor effect can last for more than 1 month. Employing McKeskey's formulation of fulvestrant for intramuscular administration would be seen as obvious since administering a relative large volume of fulvestrant (5ml) would not be appropriate for subcutaneous administration. The examiner notes that in McKeskey's study, only 0.1ml was injected via subcutaneous administration. Furthermore, the optimization of result effect parameters (e.g., dosing regimen, weight ratio of the actives and the excipients) is

obvious as being within the skill of the artisan. The optimization of known effective amounts of known active agents to be administered, is considered well in the competence level of an ordinary skilled artisan in pharmaceutical science, involving merely routine skill in the art. It has been held that it is within the skill in the art to select optimal parameters, such as amounts of ingredients, in a composition in order to achieve a beneficial effect. See *In re Boesch*, 205 USPQ 215 (CCPA 1980). It is also noted that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." *In re Aller*, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955).

The examiner notes that the herein claimed serum concentration is considered to be an inherent effect of the formulation of fulvestrant.

Response to Arguments

Applicant's arguments with respect to claims 24-53 have been considered but are moot in view of the new ground(s) of rejection.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not

mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAN-MING HUI whose telephone number is (571)272-0626. The examiner can normally be reached on Mon - Fri from 9:00 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brandon Fetterolf can be reached on (571) 272-2919. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

San-ming Hui

> Primary Examiner Art Unit 1628

/San-ming Hui/ Primary Examiner, Art Unit 1628

Notice of References Cited	Application/Control No. 12/285,887	Applicant(s)/Pater Reexamination EVANS ET AL.	nt Under
Notice of helefences offed	Examiner	Art Unit	_
	SAN-MING HUI	1628	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	в	US-			
	С	US-			
	D	US-			
	Е	US-			
	F	US-			
	G	US-			
	н	US-			
	1	US-			
	J	US-			
	к	US-			
	L	US-			
	м	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	Ν					
	0					
	Ρ					
	α					
	R					
	s					
	Т					

NON-PATENT DOCUMENTS

	NON'I ATENT DOCOMENTS										
*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)									
	U	The abstract of Wakeling et al., The Journal of Steroid Biochemistry and Molecular Biology, 1992;43:1-3:173-177									
	v										
	w										
	x										

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

U.S. Patent and Trademark Office PTO-892 (Rev. 01-2001)

Notice of References Cited

Part of Paper No. 20110906

In	dex of (Nain	16		oplication/	/Cont	trol N	lo.	F	Applicant(s)/Patent Under Reexamination EVANS ET AL.				
				.	285887									
				E E	aminer				4	Art Un	it			
				Sa	an-ming Hu	ii			1	628				
✓ F	Rejected		-	Can	Cancelled		N Non-El		Elec	ected		Α	Appeal	
=	= Allowed ÷			Res	tricted		Ι	Interf	erer	ice		0	Obje	ected
Claims	renumbered	in the s	ame o	rder as pr	esented by a	applica	ant			PA] т.с).	R.1.47
CL	AIM							DATE						
Final	Original	12/19/2	010 0	9/06/2011										
	1	✓												
	2	✓												
	3	~												
	4	✓												
	5	✓												
	6	✓												
	7	✓ ✓												
	8	✓ ✓												
	9 10	v v												
	11	v √												
	12	√												
	13	✓												
	14	✓												
	15	√												
	16	√												
	17	✓												
	18	~												
	19	~												
	20	✓												
	21	✓												
	22	✓ ✓												
	23	· ·		√										
	24 25			× ✓										
	25			 ✓		1								
	20													
	28			✓										
	29			√										
	30			~										
	31			\checkmark										
	32			\checkmark										
	33			√										
	34			\checkmark										
	35			\checkmark										
	36			\checkmark										

U.S. Patent and Trademark Office

Part of Paper No. :

	Index of Claims					Application/Control No.					Applicant(s)/Patent Under Reexamination					
	Inc	lex of (Claim	าร	1	12285887				EVAN	S ET	AL.				
					 E	Examiner				Art Ur	nit					
					S	San-ming Hu	i			1628						
✓	✓ Rejected -			Ca	ancelled		N	Non-Ele	ected		A	Арр	peal			
= Allowed ÷				Re	stricted		Ι	Interfer	ence		0	Objected				
	Claims r	enumbered	in the s	ame	order as	presented by a	pplica	ant		СРА	C] т.с). 🗆	R.1.47		
	CLA	M							DATE							
Fi	inal	Original	12/19/2	010	09/06/201	11										
		37			✓											
		38			√											
		39			√											
		40			√											
		41			\checkmark											
		42			√											
		43			√											
		44			✓											
		45			\checkmark											
		46			~											
		47			~											
		48			~											
		49			~											
		50			~											
		51			~											
		52			√											
		53			√											

Part of Paper No. :

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	82307	castor adj oil	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	ON	2011/09/06 18:58	
L2	387	fulvestrant and (castor adj oil)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L3	2488	oil and fulvestrant	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L4	3	"4659516".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	ON	2011/09/06 18:58	
L5	7	"346014".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L6	15161	(benzyl adj benzoate) or (phenylmethyl adj benzoate)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L7	1829323	solvent	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L8	7808	((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L9	4	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent) same (estrogen or estradiol or estrone)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L10	7	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent) same (testosterone)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L11	13	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent) same (steroid)	US-PGPUB; OR USPAT; EPO; JPO; DERWENT; IBM_TDB		ON	2011/09/06 18:58
L12	1810	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent) and (steroid)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58

file:///Cl/Users/shui/Documents/e-Red%20Folder/12285887/EASTSearchHistory.12285887_AccessibleVersion.htm[9/6/2011 7:04:43 PM]
MYLAN PHARMS. INC. EXHIBIT 1002 PAGE 321

L13	2	"6774122".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM TDB	OR	ON	2011/09/06 18:58
L14	951	514/177.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L15	1378	514/178.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L16	2093489	castor oil	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L17	82307	castor adj oil	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L18	387	fulvestrant and (castor adj oil)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L19	2488	oil and fulvestrant	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L20	15161	(benzyl adj benzoate) or (phenylmethyl adj benzoate)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L21	1829323	solvent	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L22	7808	((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L23	7	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent) same (testosterone)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L24	13	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent) same (steroid)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L25	1810	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent) and (steroid)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L26	82307	castor adj oil	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L27	4762	((benzyl adj benzoate) or (phenylmethyl adj benzoate)) and (castor adj oil)	US-PGPUB; USPAT; EPO; JPO; DERWENT;	OR	ON	2011/09/06 18:58

	<u> </u>		IBM_TDB	<u></u>		<u></u>
	2718	((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same (castor adj oil)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L29	1411	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same (castor adj oil)) same solvent	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L30	3	((((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same (castor adj oil)) same solvent) same steroid	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L31	3264	fulvestrant	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L32	3264	fulvestrant	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L33	82307	castor adj oil	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L34	387	fulvestrant and (castor adj oil)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L35	2488	oil and fulvestrant	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L36	3	"4659516".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L37	7	"346014".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L38	15161	(benzyl adj benzoate) or (phenylmethyl adj benzoate)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L39	1829323	solvent	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L40	7808	((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L41	4	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent) same (estrogen or estradiol or estrone)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L42	7	(((benzyl adj benzoate) or	US-PGPUB;	OR	ON	2011/09/06

		(phenylmethyl adj benzoate)) same solvent) same (testosterone)	USPAT; EPO; JPO; DERWENT; IBM_TDB			18:58
L43	13	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent) same (steroid)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L44	1810	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same solvent) and (steroid)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L45	82307	castor adj oil	US-PGPUB; USPAT; EPO; JPO; DERWENT; I.BM_TDB	OR	ON	2011/09/06 18:58
L46	4762	((benzyl adj benzoate) or (phenylmethyl adj benzoate)) and (castor adj oil)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L47	2718	((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same (castor adj oil)	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L48	1411	(((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same (castor adj oil)) same solvent	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L49	3	((((benzyl adj benzoate) or (phenylmethyl adj benzoate)) same (castor adj oil)) same solvent) same steroid	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L50	3264	fulvestrant	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L51	90122	breast adj cancer	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L52	2211	breast adj cancer and fulvestrant	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L53	342	breast adj cancer same fulvestrant	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L54	1407	cancer same fulvestrant	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L55	2	"7456160".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58
L56	2	"6,774,122".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2011/09/06 18:58

file:///Cl/Users/shui/Documents/e-Red%20Folder/12285887/EASTSearchHistory.12285887_AccessibleVersion.htm[9/6/2011 7:04:43 PM]
MYLAN PHARMS. INC. EXHIBIT 1002 PAGE 324

EAST Search History (Interference)

< This search history is empty>

9/6/2011 7:04:28 PM C:\ Users\ shui\ Documents\ EAST\ Workspaces\ 12-285887.wsp

	Application/Control No.	Applicant(s)/Patent Under Reexamination
Search Notes	12285887	EVANS ET AL.
	Examiner	Art Unit
	San-ming Hui	1628

SEARCHED			
Class	Subclass	Date	Examiner
514	177, 178	12/19/10	SH
514	177, 178	9/6/11	SH

SEARCH NOTES		
Search Notes	Date	Examiner
EAST and inventor search in PALM	12/19/10	SH
update search in EAST and inventor search in PALM	9/6/11	SH

	INTERFERENCE SEARCH	ł	
Class	Subclass	Date	Examiner

Г

Г

٦

٦

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL			Appli	cation Number:	12/285,887	Confirmation Number: 1199		
			Filing	Filing Date: October 15, 2008				
			First	First Named Inventor: John E. EVANS				
			Grou	p Art Unit: 1628		· · · · · · · · · · · · · · · · · · ·		
Co	mmi		er for Patents	S	Exan	niner: HUI, San	Ming R.	
		ox 14 dria, '	50 VA 22313-14	450	Attor	ney Docket Num	ber: 11285.0056	-00000
Th	is is	a Re	equest for Co	ontinued Examination (RCE) und	er 37 C	.F.R. § 1.114 of	the above-identi	fied application.
				xamination (RCE) practice under 37 / design application.	7 C.F.R	. § 1.114 does no	ot apply to any uti	lity or plant application filed prior
1.	<u>an</u> otł	d am herwi	endments e ise. If applic	ed under 37 C.F.R. § 1.114: <u>Note:</u> nclosed with the RCE will be ent cant does not wish to have any p of such amendment.	ered in	the order in wh	ich they were file	ed unless applicant instructs
	a.			submitted. If a final Office action is as a submission even if this box is			Iments filed after	the final Office action may be
		i.		Consider the arguments in the A			f previously filed	on
		ii.		Other				
	b. с.		DO NOT EN Enclosed su	NTER the amendment(s) previously	/ filed or	n	An alternate subr	nission is attached.
	U.						⊠ Inform	nation Disclosure Statement
		i. ii.	\boxtimes	Amendment/Reply Affidavit(s)/Declaration(s)		iii. iv.	_	Terminal Disclaimer
 Miscellaneous a. Suspension of action on the above-mentioned application is requested under 37 C.F.R. § 1.103(c) for a period of 								
		_		of action on the above-mentioned	applica	tion is requested	under 37 C.F.R.	§ 1.103(c) for a period of
	a.	_	Suspension months. (P	eriod of suspension shall not excee	ed 3 mo	nths; fee under 3		
		_	Suspension months. (P		ed 3 mo	nths; fee under 3		
3.	a.		Suspension months. (P	eriod of suspension shall not excee	ed 3 mo	nths; fee under 3		
3.	a. b. Fe	es	Suspension months. (P Other	eriod of suspension shall not excee	ed 3 mo	nths; fee under 3		
3.	a. b. Fe	es	Suspension months. (P Other	eriod of suspension shall not excee	ed 3 mo	nths; fee under 3		
3.	a. b. Fe	es	Suspension months. (P Other The filing fe	eriod of suspension shall not excee e is calculated as follows:	ed 3 mo	nths; fee under 3	37 C.F.R. § 1.17(i	
3.	a. b. Fe	es i.	Suspension months. (P Other The filing fe	eriod of suspension shall not excee e is calculated as follows: \$930.00 RCE fee required under	ed 3 mo 37 C.F (one (1)	nths; fee under 3	37 C.F.R. § 1.17(i	
3.	a. b. Fe	es i. i.	Suspension months. (P Other The filing fe ⊠ ⊠	eriod of suspension shall not excee e is calculated as follows: \$930.00 RCE fee required under Petition for extension of time for (ed 3 mo 37 C.F (one (1) 60.00)	nths; fee under 3	37 C.F.R. § 1.17(i	
3.	a. b. Fea	□ es i. ii. iii.	Suspension months. (P Other The filing fe ⊠ ⊠ Payment in	eriod of suspension shall not excee e is calculated as follows: \$930.00 RCE fee required under Petition for extension of time for (Other <u>Terminal Disclaimer (\$1</u> the amount of <u>\$1,240.00</u> enclosed issioner is authorized to charge any	ed 3 mo 37 C.F (one (1) 60.00)	nths; fee under 3 .R. § 1.17(e) Months) <u>\$150.0</u>	0 0 0 0 0 0) required.)
3.	a. b. Fea a. b.	es i. ii.	Suspension months. (P Other The filing fe ⊠ ⊠ Payment in The Commi	eriod of suspension shall not excee e is calculated as follows: \$930.00 RCE fee required under Petition for extension of time for (Other <u>Terminal Disclaimer (\$1</u> the amount of <u>\$1,240.00</u> enclosed issioner is authorized to charge any	ed 3 mo 37 C.F (one (1) 60.00) v deficie	nths; fee under 3 .R. § 1.17(e) Months) <u>\$150.0</u> 	97 C.F.R. § 1.17(i)) required.)
	a. b. Fe a. b. c.	□ es i. ii. ⊠ ⊠	Suspension months. (P Other The filing fe ⊠ ⊠ Payment in The Commi	eriod of suspension shall not excee e is calculated as follows: \$930.00 RCE fee required under Petition for extension of time for (Other <u>Terminal Disclaimer (\$1</u> the amount of <u>\$1,240.00</u> enclosed issioner is authorized to charge any 0.06-0916.	37 C.F (one (1) 60.00) v deficie	nths; fee under 3 .R. § 1.17(e) Months) <u>\$150.0</u> 	87 C.F.R. § 1.17(i) 0 1 fees, or credit ar nt Required) required.)
Na	a. b. Fea a. b. c. me:	es i. ii. M Carlo	Suspension months. (P Other The filing fe X Payment in The Commi Account No	eriod of suspension shall not excee e is calculated as follows: \$930.00 RCE fee required under Petition for extension of time for (Other <u>Terminal Disclaimer (\$1</u> the amount of <u>\$1,240.00</u> enclosed issioner is authorized to charge any 0.06-0916. Signature of Applica	37 C.F (one (1) 60.00) v deficie	nths; fee under 3 .R. § 1.17(e) Months) <u>\$150.0</u> encies in the filing	87 C.F.R. § 1.17(i) 0 1 fees, or credit ar nt Required) required.)
Na	a. b. Fea a. b. c. me:	es i. ii. M Carlo	Suspension months. (P Other The filing fe X Payment in The Commi Account No	eriod of suspension shall not excee e is calculated as follows: \$930.00 RCE fee required under Petition for extension of time for (Other <u>Terminal Disclaimer (\$1</u> the amount of <u>\$1,240.00</u> enclosed issioner is authorized to charge any 0.06-0916. Signature of Applica (202) 408-400 arabow, Garrett & Dunner, L.L.P.	37 C.F (one (1) 60.00) v deficie	nths; fee under 3 .R. § 1.17(e) Months) <u>\$150.0</u> encies in the filing	87 C.F.R. § 1.17(i) 0 1 fees, or credit ar 1 nt Required 18) required.)
Na	a. b. Fea a. b. c. me:	es i. ii. M Carlo	Suspension months. (P Other The filing fe X Payment in The Commi Account No os M. Téllez	eriod of suspension shall not excee e is calculated as follows: \$930.00 RCE fee required under Petition for extension of time for (Other <u>Terminal Disclaimer (\$1</u> the amount of <u>\$1,240.00</u> enclosed issioner is authorized to charge any 0.06-0916. Signature of Applica (202) 408-400 arabow, Garrett & Dunner, L.L.P.	ed 3 mo 37 C.F (one (1) 60.00) v deficie ant, Att	nths; fee under 3 .R. § 1.17(e) Months) <u>\$150.0</u> encies in the filing torney, or Age Reg. No.: 48,63	87 C.F.R. § 1.17(i) 0 1 fees, or credit ar 1 nt Required 18) required.)
Na Fin Sig	a. b. Fea a. b. c. me: mega	es i. ii. iii. Carlo Carlo an, H	Suspension months. (P Other The filing fe ⊠ ⊠ Payment in The Commi Account No os M. Téllez lenderson, Fa Carlos M. Tél	eriod of suspension shall not excee e is calculated as follows: \$930.00 RCE fee required under Petition for extension of time for (Other <u>Terminal Disclaimer (\$1</u> the amount of <u>\$1,240.00</u> enclosed issioner is authorized to charge any 0.06-0916. Signature of Applica (202) 408-400 arabow, Garrett & Dunner, L.L.P.	ad 3 mo 37 C.F (one (1) 60.00) v deficie ant, Att 00 of Mailin tates Posl	nths; fee under 3 .R. § 1.17(e) Months) <u>\$150.0</u> encies in the filing torney, or Age Reg. No.: 48,63 Date: January g or Transmission tal Service as first classical	87 C.F.R. § 1.17(i) 0 1 fees, or credit ar nt Required 88 17, 2012 ss mail in an envelope) required.) ny overpayments to Deposit
Na Fin Sig	a. b. Fea a. b. c. me: mes gnatu	es i. ii. iii. Carlo Carlo an, H	Suspension months. (P Other The filing fe ⊠ ⊠ Payment in The Commi Account No os M. Téllez lenderson, Fa Carlos M. Tél	eriod of suspension shall not excee e is calculated as follows: \$930.00 RCE fee required under Petition for extension of time for (Other <u>Terminal Disclaimer (\$1</u> the amount of <u>\$1,240.00</u> enclosed issioner is authorized to charge any 0.06-0916. Signature of Applica (202) 408-400 arabow, Garrett & Dunner, L.L.P. lez/ <u>Certificate</u> ondence is being deposited with the United Si	ad 3 mo 37 C.F (one (1) 60.00) v deficie ant, Att 00 of Mailin tates Posl	nths; fee under 3 .R. § 1.17(e) Months) <u>\$150.0</u> encies in the filing torney, or Age Reg. No.: 48,63 Date: January g or Transmission tal Service as first classical	87 C.F.R. § 1.17(i) 0 1 fees, or credit ar nt Required 88 17, 2012 ss mail in an envelope) required.) ny overpayments to Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: John R. Evans et al. Application No.: 12/285,887 Filed: October 15, 2008 For: FORMULATION

) Group Art Unit: 1628) Examiner: HUI, San Ming R.) Confirmation No.: 1199)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

VIA EFS-WEB

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicant brings to the attention of the Examiner the listed documents on the attached listing. This Information Disclosure Statement is being filed before the mailing date of a first Office Action after the filing of a

Request for Continued Examination in the above-referenced application.

Copies of the listed foreign and non-patent literature documents are attached.

Copies of the U.S. patent publications are not enclosed.

Documents from the prosecution of European Patent Applications members of the same family as the instant application

Applicants had submitted documents in previous Information Disclosure Statements from the prosecution histories of European Patent Application Nos. 01900186.6 (EP 1 250 138), 10180667.7 (EP 2 266 573), and 10180661.0 (EP 2 286 818), which are European members of the same patent family as the instant application. Applicants now supplement those submissions with documents made of

record in those European applications after the previous Information Disclosure Statement was filed.

Applicants respectfully request that the Examiner consider the listed documents and indicate they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

By:

Dated: January 17, 2012

Carlos M. Téllez Reg. No. 48,638 (202) 408-4123

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
John R. Evans et al.) Group Art Unit: 1628
Application No.: 12/285,887) Examiner: HUI, San Ming R.
Filed: October 15, 2008) Confirmation No.: 1199
For: FORMULATION)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

TERMINAL DISCLAIMER

Assignee, AstraZeneca AB, duly organized under the laws of Sweden and having its principal place of business at S-151 85 Sodertalje, Sweden, represents that is the assignee of the entire right, title, and interest in and to the above-identified application, Application No. 12/285,887 ("the '887 application"), filed on October 15, 2008, entitled "Formulation," in the names of John R. EVANS, and Rosalind U. GRUDY, as indicated by the assignment duly recorded in the United States Patent and Trademark Office for U.S. Application No. 10/872,784 ("the '784 application"), now U.S. Patent No. 7,456,160 (the '887 application being a Continuation of the '784 application) at Reel 015906, Frame 0402 on October 14, 2004.

Assignee, AstraZeneca AB, further represents that it is the assignee of the entire right, title, and interest in and to U.S. Patent Nos. 6,774,122, and 7,456,160 as indicated by the assignments duly recorded in the United States Patent and Trademark Office at

Reel 011635, Frame 0063 on March 27, 2001, and Reel 015906, Frame 0402 on October 18, 2004, respectively.

To obviate a double patenting rejection, Assignee hereby disclaims, except as provided below, the terminal part of the statutory term of any patents granted on the instant application that would extend beyond the expiration date of the full statutory term, as presently shortened by any terminal disclaimer, of prior U.S. Patent Nos. 7,456,160 and 6,774,122. Assignee hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors, or assigns.

In making the above disclaimer, Assignee does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term of the prior patents, as presently shortened by any terminal disclaimer, in the event that the prior patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or in part, is terminally disclaimed under 37 C.F.R. § 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated before the expiration of its full statutory term as presently shortened by any terminal disclaimer.

In accordance with the fee schedule in 37 C.F.R. § 1.20(d), the required fee of \$160.00 is being filed with this disclaimer.

- 2 -

If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to Deposit Account No. 06-0916.

The undersigned is authorized to act on behalf of assignee AstraZeneca AB.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,

Dated: 12th January 2012

By: Signature Name: ALLEN FRANK GILLS

Title: AUTHORISCO JENATORY

Assignee: AstraZeneca AB

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

))VIA EFS-WEB
For: FORMULATION) Mail Stop RCE
Filed: October 15, 2008) Confirmation No.: 1199
Application No.: 12/285,887) Examiner: HUI, San Ming R.
John R. Evans et al.) Group Art Unit: 1628
In re Application of:)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

RESPONSE TO OFFICE ACTION, SUBMISSION UNDER 37 C.F.R. § 1.114, AND PETITION FOR EXTENSION OF TIME

In reply to the Final Office Action mailed September 16, 2011 ("Office Action"), Applicants respectfully request reconsideration of the claimed invention in view of the following amendments and remarks. This paper fulfills the requirements of a submission under 37 C.F.R. § 1.114, and is filed together with a Request for Continued Examination (RCE).

Applicants hereby petition for a one-month extension of time to respond to the Office Action, extending the period for response to January 16, 2012. The requisite extension-of-time fee is being paid concurrently with this filing.

Amendments to the Claims are reflected in the listing of claims, which starts on page 2 of this paper. **Remarks** follow the amendment sections of this paper and start on page 7.

REMARKS

I. Status of the claims and amendments

Upon entry of the instant amendments, claims 24, 26, 27, 29, 30, 32, 34-36, 38, 39, 41, 42, 44, 46, 47, and 54-57 will be pending in this application. Claims 25, 28, 31, 33, 37, 40, 43, 45, and 48-53 are cancelled in this Response without prejudice or disclaimer. New claims 54-57 are added in this Response and find support, for example, in the specification at ¶ [0053].¹

Applicants amended claim 24 to recite a formulation comprising "about 50 mgml-1 of fulvestrant; about 10% w/v of ethanol; about 10% w/v of benzyl alcohol; and about 15% w/v of benzyl benzoate." Support for this amendment can be found, for example, in the specification at ¶¶ [0072]-[0075]. Applicants also amended claim 24 to recite that the method achieves a therapeutically significant blood plasma fulvestrant concentration "for at least four weeks." Support for this amendment can be found, for example, in the specification at ¶ [0052]. Applicants amended claim 36 in a similar manner to claim 24, with support in the same portions of the specification as the amendments to claim 24 mentioned above. Applicants amended claims 32, 34, 44, and 46 to change their dependency because the claim from which each depended has been cancelled in this Response. None of the claim amendments introduce new matter.

Claims 24, 26, 27, 29, 30, 32, 34, 35, 54 and 55 are directed to methods for treating a hormonal dependent benign or malignant disease of the breast or

¹ Unless otherwise specified, all citations to the instant specification refer to the pagination in the published application, US 2010/0152149.

reproductive tract comprising administering intramuscularly to a human in need of such treatment a formulation *comprising* various components. Claims 36, 38, 39, 41, 42, 44, 46, 47, 56, and 57 are identical to claims 24, 26, 27, 29, 30, 32, 34, 35, 54 and 55 except that the phrase "formulation *consisting essentially of*" replaces the phrase "formulation *comprising*" the various components.

II. Statement of Substance of Interview under 37 C.F.R. § 1.133(b)

Applicants would like to thank Examiner San Ming Hui for granting a personal interview to Applicants on August 4, 2011. Applicants present this Statement of Substance of Interview in connection with that interview conducted between Examiner San Ming Hui, the undersigned, Dr. Paul R. Gellert (AstraZeneca Pharmaceuticals), and Mr. Allen F. Giles (AstraZeneca Pharmaceuticals).

During the interview, the undersigned and the Examiner discussed the then pending claims 24-53 and the disclosures of the following references: a) Howell et al., "Pharmacokinetics, Pharmacological, and Anti-tumour Effects of the Specific Anti-Estrogen ICI 182780 in Women with Advanced Breast Cancer," *Brit J. Cancer* 74:300-308 (1996), b) European Patent Application No. EP 0 346 014, and McLeskey et al., "Tamoxifen-Resistant Fibroblast Growth Factor-Transfected MCF-7 Cells are Cross-Resistant In Vivo to the Antiestrogen ICI 182,780 and Two Aromatase Inhibitors," *Clin. Cancer Res.* 4:697-711 (1998).

At the interview, the undersigned also mentioned the status of the lawsuit between AstraZeneca Pharmaceuticals and Teva Parenteral Medicines concerning a generic product containing 50 mg/ml of fulvestrant, which was also mentioned in the Information Disclosure Statement filed on June 20, 2011.

- 8 -

No agreement was reached and the Examiner indicated he would consider the information presented at the interview in the preparation of the next Office Action.

III. Double Patenting Rejection

The Office rejected claims 24-53 under the nonstatutory obviousness-type double patenting doctrine as being unpatentable over: (a) claims 1-9 of U.S. Patent No. 6,774,122 ("the '122 patent") and (b) claims 1-12 of U.S. Patent No. 7,456,160 ("the '160 patent").

With the sole purpose of expediting prosecution, Applicants submit a Terminal Disclaimer concurrently with this Response, which shows common ownership of the instant application and the '122 and '160 patents and should obviate this rejection. Accordingly, Applicants respectfully request that this rejection be withdrawn.

The filing of the Terminal Disclaimer is not an admission of the alleged obviousness of the instant claims in light of the claims in the '122 and '160 patents. *See*, *e.g.*, M.P.E.P. § 804.02.II; *Quad Environmental Technologies, Corp. v. Union Sanitary District*, 946 F.2d 870, 874 (Fed. Cir. 1991).

IV. Errors in the specification

Applicants would like to remind the Office of certain errors appearing in the instant specification. Applicants mentioned those errors in the Declaration Under 35 U.S.C §1.132 of Dr. Paul Gellert filed on August 2008 ("the Gellert Declaration"), in the parent application (Application No. 10/872,784). Applicants listed the Gellert Declaration Declaration in an Information Disclosure Statement being filed concurrently with this Response.

- 9 -

V. Rejections under 35 U.S.C. 103(a)

The Office rejected claims 24-53 under 35 U.S.C. 103(a) as being unpatentable over McLeskey et al., *Clinical Cancel Research* 4:697-711 (1998) ("*McLeskey*"); in view of European Patent Specification No. EP 0 346 014, which names Michael Dukes as inventor ("*Dukes*"); Osborne et al., *Journal of National Cancer Institute*, 87(20):746-750 (1995) ("*Osborne*"); and the abstract of Wakeling et al., "ICI 182,780, *J. Steroid Biochemistry and Molecular Biology*, 43(1-3):173-177 (1992) ("*Wakeling*"). Office Action at 5.

According to the Office, *McLeskey* teaches "a stud[y] employing subcutaneous injection of fulvestrant to nude mice" and a "fulvestrant formulation contain[ing] 50mg/ml in a vehicle of 10% ethanol, 15% benzyl benzoate, 10% benzyl alcohol brought to volume with castor oil." *Id.* The Office acknowledges that *McLeskey* does not expressly teach "the use of fulvestrant in treating hormonal dependent diseases of breast", "the dosing regimen to be once a month, intramuscular administration", "the volume administered", or "the herein claimed serum concentration of fulvestrant." *Id.*

In the Office's view, *Dukes* teaches that "antiestrogen agent[s], including fulvestrant, via intramuscular route of administration may be used in a dosage of 50mg to 5g in vehicle comprising castor oil and benzyl alcohol." *Id.* at 5-6.

The Office cites *Osborne* as teaching that fulvestrant is "useful in treating human breast cancer" (*id.* at 6) and *Wakeling* as teaching that "the administration of fulvestrant (ICI 182780) demonstrat[es] the antiestrogenic effect for over a 1 month period." *Id.*

According to the Office "[i]t would have been obvious to one of ordinary skill in the art at the time the invention was made to employ fulvestrant in [*McLeskey*], in the

- 10 -

herein claimed dosing regimen and dosage, for treating hormonal dependent diseases such as breast cancer and postmenopausal symptoms" because it is "known in the art that fulvestrant can be administered intramuscularly and its antitumor effect can last for more than 1 month." *Id.*

The Office argues that "[e]mploying *McLeskey's* formulation of fulvestrant for intramuscular administration would be seen as obvious since administering a relative large volume of fulvestrant (5ml) would not be appropriate for subcutaneous administration." *Id.* The Office further argues that "the optimization of result effect[ive] parameters (e.g., dosing regimen, weight ratio of the actives and the excipients) is obvious as being within the skill of the artisan." *Id.* Applicants respectfully traverse this rejection.

A. Declaration of Dr. Ronald J. Sawchuk

In support of Applicants' statements regarding the state of the art and how one of ordinary skill in the art would have understood the references cited in the Office Action prior to the earliest priority date for the instant application (January 10, 2000), Applicants submit concurrently with this Response a declaration by Dr. Ronald J. Sawchuk ("Sawchuk Decl.").

B. The Office has not made the necessary factual findings to support a conclusion of obviousness

Applicants understand that the Office's rejection is based on at least the following two implicit assumptions: 1) that a person of ordinary skill in the art ("POSITA") would have chosen the fulvestrant composition disclosed in *McLeskey*, from among all other known compositions in which fulvestrant had been dissolved, for the development of a

- 11 -

method of treating the diseases recited in the claims, and 2) that the POSITA would have had a reasonable expectation that such a composition would have been successful in those methods. Applicants respectfully submit that the Office has not provided support for those assumptions.

Applicants respectfully remind the Office that the focus in an obviousness rejection is not on what one of ordinary skill in the art *could have done*, but rather "on what a person of ordinary skill in the pertinent art would have known at the time of the invention, and on what such a person *would have reasonably expected to have been able to do* in view of that knowledge. M.P.E.P. § 2141.II (emphasis added). Thus, two of the relevant questions in this rejection are: (1) whether the knowledge in the art would have suggested to a POSITA that *McLeskey's* composition had some advantages over other known fulvestrant compositions such that it would have been assuming that a POSITA would have selected the fulvestrant *McLeskey's* composition for the development of a method of human treatment, and (2) even assuming that a POSITA would have selected the fulvestrant *McLeskey's* composition for the development of a method of the relevant *McLeskey's* composition for the development of a method of the knowledge in the art prior to January 10, 2000, one of ordinary skill in the art would have been successful in a method of treating as recited in the instant claims.

Specifically, regarding the second question, even after *KSR*, an obviousness rejection in which the Office argues that the claimed invention would have been the result of a combination of references requires that the Office show that one of ordinary skill in the art would have had a reasonable expectation of success when combining the references. M.P.E.P. § 2143.02; *see also* M.P.E.P. § 2143.A (addressing the

- 12 -

requirements for a "combination of prior art elements" rationale). As will be explained below, a critical review and analysis of the state of the art at the time the instant application was filed leads to the conclusion that no such expectation existed.

Applicants will explain and discuss below the following *independent* reasons supporting withdrawal of the instant obviousness rejection:

- McLeskey would not have suggested to a POSITA the specific %w/v composition recited in the claims;
- (2) None of the cited references would have provided a POSITA with information to select the fulvestrant composition disclosed in *McLeskey* over other known fulvestrant compositions;
- (3) The POSITA would not have had a reasonable expectation that the *McLeskey* composition would have been successful in such a method. Applicants present two independent arguments to support a lack of expectation of success:
 - a. One of ordinary skill in the art would have understood that results from subcutaneous administration, such as those in *McLeskey*, cannot be extrapolated to intramuscular administration and, thus, a POSITA would not have a had an expectation as to whether the fulvestrant composition from *McLeskey* would have been effective for intramuscular delivery of fulvestrant.
 - Numerous variables affect the efficacy of an intramuscular formulation, among them the identity and proportion of each of its cosolvents, and a POSITA understands that the resulting variability precludes a POSITA from having an expectation a priori that a given formulation would be

- 13 -

successful in a given method of treatment until actual suitable in vivo experiments are performed.

1. <u>Independent Reason 1. McLeskey would not have suggested</u> to a POSITA the specific %w/v composition recited in the claims

McLeskey discloses two fulvestrant compositions. One composition was prepared by dissolving powdered drug in 100% ethanol and then spiking it into warmed peanut oil to give a final concentration of 50 mg/ml ("the *McLeskey* peanut oil composition"). *McLeskey* at 698, col. 2, under "Drugs"; Sawchuk Decl. at ¶ 16. The second composition is a 50 mg/ml fulvestrant composition "in a vehicle of 10% ethanol, 15% benzyl benzoate, 10% benzyl alcohol, brought to volume with castor-oil" ("the *McLeskey* castor oil composition"). *Id.* The Office only refers to the *McLeskey* castor oil composition in the Office Action. Office Action at 5.

McLeskey does not specify whether the percentages in the *McLeskey* castor oil composition are in weight/volume units (%w/v, as recited in the instant claims) or in volume/volume units (%v/v). Sawchuk Decl. at ¶ 16. Dr. Sawchuk states that "[i]In a liquid composition, when a solute or cosolvent is a liquid, it is often convenient to express its concentration as a volume percent, i.e., % v/v." *Id.* at ¶ 17.

Dr. Sawchuk provides various examples of references in which the concentration of liquid components in a composition is reported in terms of %v/v values, whereas the concentration of solid solutes is reported in terms of %w/v. *Id.* at ¶¶ 18-20. Dr. Sawchuk concludes that "[b]ecause all of the components of the vehicle disclosed in *McLeskey* are liquids, one of ordinary skill in the art would have concluded that the

- 14 -

composition was described in terms of volume/volume percent units (% v/v)." *Id.* at \P 21.

Based on that information, Dr. Sawchuk states that "one of ordinary skill in the art would have concluded that the *McLeskey* castor oil composition on page 698 was reported in % v/v units and referred to a composition containing 10% \underline{v} /v ethanol, 15% \underline{v} /v benzyl benzoate, and 10% \underline{v} /v benzyl alcohol in a castor oil vehicle. *Id.* at ¶ 22. This composition *is different* from a composition containing 10% \underline{w} /v ethanol, 15% \underline{w} /v benzyl benzoate, and 10% \underline{w} /v benzyl alcohol in a castor oil vehicle. *Id.* at ¶ 22. This composition *is different* from a composition containing 10% \underline{w} /v ethanol, 15% \underline{w} /v benzyl benzoate, and 10% \underline{w} /v benzyl alcohol in a castor oil vehicle. *Id.* The units of the fulvestrant composition recited in the instant claims are %w/v.

Dr. Sawchuk converted the %v/v values that *McLeskey* would have suggested to a POSITA into %w/v values, which would allow a direct comparison between the *McLeskey* castor oil composition and the composition recited in the instant claims. *Id.* at ¶¶ 23-27. Table 1 below shows the results of the calculation, with Column E having the final concentration values in %w/v units for each component in the *McLeskey* castor oil composition. *Id.* at ¶ 27.

	Α	В	C	D	E
Component	% v/v	Volume (ml)	Density (g/ml)	Weight (g)	% w/v
Ethanol	10	10	0.808	8.08	8.1
Benzyl Benzoate	15	15	1.118	16.77	16.8
Benzyl Alcohol	10	10	1.04156	10.42	10.4

Table 1. Information for 100 ml of the fulvestrant McLeskey castor oil composition

According to Dr. Sawchuk, a POSITA "reading *McLeskey* would have concluded that *McLeskey* described a composition containing about **8.1% w/v** ethanol, about

- 15 -

10.4% w/v benzyl alcohol, and about **16.8 % w/v** benzyl benzoate in a castor oil vehicle." *Id.* at ¶ 29. Therefore, *McLeskey would not have suggested the fulvestrant composition recited in the claims comprising about* **10% w/v** *of ethanol; about* **10% w/v** *of benzyl alcohol; and about* **15% w/v** *of benzyl benzoate.*

In Dr. Sawchuk's opinion, none of the references cited in the Office Action contain any disclosure "that would have suggested to one of ordinary skill in the art the modification of a composition containing about 8.1% w/v ethanol, about 16.8 % w/v benzyl benzoate, and about 10.4% w/v benzyl alcohol (i.e., the *McLeskey* castor oil composition) in an attempt to produce a composition as recited in the claims containing about 10% w/v ethanol, about 15% w/v benzyl benzoate, and about 10% v/v benzyl alcohol". *Id.* at ¶ 30.

For at least this reason, the cited references, either alone or in combination, fail to meet all of the limitations of the claims, and Applicants respectfully request that this rejection be withdrawn.

2. <u>Independent Reason 2.</u> The Office has not shown that a <u>POSITA would have selected the *McLeskey* castor oil</u> <u>composition for the development of a method of treating</u> <u>involving intramuscular administration as instantly claimed</u>

Applicants remind the Office that "[o]bviousness requires more than a mere showing that the prior art includes separate references covering each separate limitation in a claim under examination." *Unigene Laboratories, Inc. v. Apotex, Inc.*, No. 2010-1006, slip op. at 13 (Fed. Cir. Aug. 25, 2011) (internal citations omitted). Indeed, the Federal Circuit explained that:

[O]bviousness requires the additional showing that a person of ordinary skill at the time of the invention *would have selected and combined those prior art elements* in the normal course of research and development to yield the claimed invention.

Id. (internal citations omitted, italics added). Thus, in the instant rejection, the Office needs to identify reasons why a POSITA would have: a) selected and then b) combined the elements the Office argues are disclosed in the cited references. For example, the Office needs to explain why a POSITA would have selected the *McLeskey* castor oil composition (comprising ethanol, benzyl alcohol, and benzyl benzoate), from among the known fulvestrant formulations at the time of filing, to develop a method of treatment as instantly claimed.

Dr. Sawchuk explains that *McLeskey* provides no information that would have suggested to a POSITA the desirability of any of its two fulvestrant compositions over other known fulvestrant formulations. Sawchuk Decl. at \P 31. For example,

Dr. Sawchuk points out that antitumor treatment with fulvestrant was ineffective in the *McLeskey* experiments. *Id.* at ¶ 33. In addition, with respect to the two formulations disclosed in *McLeskey*, Dr. Sawchuk highlights that *McLeskey* "did not provide any experimental data that would have allowed one of ordinary skill in the art to compare any aspect of the performance of the two fulvestrant compositions for the treatment of cancerous tumors." *Id.* at ¶ 31.

Therefore, in Dr. Sawchuk's opinion, "because of the lack of fulvestrant efficacy and the absence of pharmacokinetic data in *McLeskey*, one of ordinary skill in the art would have been unable to conclude whether either of the two fulvestrant *McLeskey* compositions (peanut oil or castor oil) was able to deliver a dose of fulvestrant that had

- 17 -

an antitumor therapeutic effect in the mice when administered subcutaneously." *Id.* at ¶ 35.

In light of those circumstances, Dr. Sawchuk concludes that "*McLeskey* provides no information that would have led one of ordinary skill in the art to have a preference for either the peanut oil or the castor oil fulvestrant compositions over the other one, or even a preference for one of the two *McLeskey* fulvestrant compositions over other fulvestrant compositions known in the art prior to January 10, 2000." *Id.* at ¶ 36.

Regarding fulvestrant compositions known in the art different from the *McLeskey* castor oil composition, Dr. Sawchuk lists various compositions disclosed in the references cited by the Office. *Id.* at ¶¶ 37-39. Among those formulations, Dr. Sawchuk mentions fulvestrant in an oil suspension (*Wakeling*), fulvestrant in a castor oil composition (*Osborne*), fulvestrant in a mixture of propylene glycol:ethanol:water:poloxamer 407 (*Dukes*), and fulvestrant in 400 mg of benzyl alcohol and sufficient castor oil to bring the solution to a volume of 1 ml (*Dukes*), in addition to the peanut oil fulvestrant composition from *McLeskey*. Sawchuk Decl. at ¶ 37-39.

Therefore, Dr. Sawchuk concludes, "one of ordinary skill in the art had other choices besides the *McLeskey* castor oil composition with respect to potential fulvestrant formulations that could have been further investigated for the development of a method of treating humans with intramuscular fulvestrant." *Id.* at ¶ 40. However, in Dr. Sawchuk' opinion, "none of the references cited in the Office Action provides any information that would have guided one of ordinary skill in the art to select the *McLeskey* castor oil composition, over any of the other fulvestrant compositions

- 18 -

mentioned above," for the potential development of a method of treatment as recited in the instant claims. *Id.*

In this regard, the Federal Circuit has explained that:

When a field is unreduced by direction of the prior art, and when prior art gives no indication of which parameters were critical or no direction as to which of many possible choices is likely to be successful, an invention is not obvious to try.

Unigene, slip op. at 15 (internal citation omitted).

In this case, the Office has not explained how the cited art directs a POSITA to select the *McLeskey* castor oil composition from among all other known fulvestrant compositions to develop a method as claimed. Indeed, according to Dr. Sawchuk, "none of the references cited by the Examiner provides any guidance as to the relevant factors to consider when selecting a formulation for the potential development of a method of treatment as recited in the instant claims." Sawchuk Decl. at ¶ 41.

Nonetheless, in Dr. Sawchuk's opinion, and judging solely on the basis of efficacy, "the *McLeskey* castor oil composition would have been among the least favored compositions to select for further development from among the fulvestrant compositions discussed above because one of ordinary skill in the art would not have been able to conclude from the information in *McLeskey* whether fulvestrant, using that composition, was sufficiently bioavailable to have an antitumor effect." *Id.* Rather, according to Dr. Sawchuk and based on only efficacy, "the fulvestrant oil suspension from *Wakeling* would have been among the most favored formulations to select for

- 19 -

formulation, when given as a single injection, showed a therapeutic antitumor effect in mice for over a one-month period." *Id.*

Accordingly, at least because the Office has failed to explain why a POSITA would have selected the *McLeskey* castor oil composition from among those fulvestrant compositions known in the art at the time of filing to develop a method of treatment as claimed, the Office has not made a prima facie case of obviousness. Thus, Applicants respectfully request that this rejection be withdrawn.

3. <u>One of ordinary skill in the art would not have had an</u> <u>expectation that the formulation disclosed in *McLeskey*, <u>administered subcutaneously to mice, would have been</u> <u>successful for intramuscular administration as instantly</u> <u>recited</u></u>

The POSITA would not have had a reasonable expectation that the *McLeskey* castor oil composition would have been effective to administer fulvestrant intramuscularly to achieve a therapeutic effect for at least four weeks, as instantly recited. Two independent reasons are set forth below supporting a lack of expectation of success for the combination of the references cited by the Office.

a) <u>Independent Reason 3. A POSITA would not have had</u> an expectation that the results from subcutaneous injection in <u>McLeskey</u> would have been applicable to the intramuscular administration of fulvestrant

One of ordinary skill in the art would have understood that results from subcutaneous administration, such as those reported in *McLeskey*, cannot be extrapolated to intramuscular administration. Sawchuk Decl. at ¶ 42. In Dr. Sawchuk's view, "one of ordinary skill in the art would not have had an expectation as to whether the *McLeskey* castor oil composition would have had a therapeutic effect when

- 20 -

administered intramuscularly before actually performing suitable in vivo experiments." Id.

Dr. Sawchuk cites a few examples in which comparison of the results from subcutaneous administration yielded significant differences with respect to those from intramuscular administration. For example, a study of administration of probenecid in ewes showed that administration of the same dose of probenecid, a drug which may be used to prolong the half-life of some antibiotics in animals, resulted in significant differences in absorption and bioavailability of the drug when administered subcutaneously or intramuscularly. Guerrini V.H., Filippich L.J., English P.B., Schneider J., Cao G.R. and Bourne D.W.A., "Pharmacokinetics of probenecid in sheep", *J Vet Pharmacol Ther.* 8(2):128-35 (1985) (*"Guerrini"*); Sawchuk Decl. at ¶ 44.

Dr. Sawchuk comments that in *Guerrini* the intramuscular dose was absorbed more rapidly and more completely than the subcutaneous dose, whereas the subcutaneous administration resulted in a "higher and more prolonged plasma probenecid concentration". Sawchuk Decl. at ¶ 46. Due to the overall characteristics associated with subcutaneous administration, *Guerrini* reports that such a mode of administration is preferred over intramuscular administration under the conditions of its study. *Id.* at 46. Dr. Sawchuk concludes that "*this is an example where subcutaneous administration achieves a certain desired result but where intramuscular administration does not accomplish the same result.*" *Id.* (italics added).

In contrast to the pharmacokinetic profiles observed in *Guerrini*, in another study, subcutaneous administration of clindamycin, an antibiotic, resulted in faster absorption compared to intramuscular injection. Lavy E, Ziv G, Shem-Tov M, Glickman A, Dey A.,

- 21 -

"Pharmacokinetics of clindamycin HCl administered intravenously, intramuscularly and subcutaneously to dogs", *J Vet Pharmacol Ther*. 22(4):261-5 (1999) ("*Lavy*"); Sawchuk Decl. at ¶ 47. Nevertheless, the pharmacokinetic profiles in *Lavy* were such that subcutaneous administration maintained a therapeutic plasma concentration for a longer period of time than intramuscular administration. Sawchuk Decl. at ¶ 49. Based on the results from *Lavy*, Dr. Sawchuk concludes that in that case, "one of ordinary skill in the art would not have been able to rely on data from subcutaneous administration to predict results of intramuscular administration because intramuscular administration would not have produced the same level of long-term efficacy achieved by subcutaneous administration." *Id.* (italics added).

In yet another study highlighting the lack of correlation between subcutaneous and intramuscular administration, Dr. Sawchuk gives an example where, in contrast to the results from *Lavy*, the absorption of the drug was more rapid and complete following intramuscular dosing than after subcutaneous injection. Ismail M., "Disposition kinetics of difloxacin after intravenous, intramuscular and subcutaneous administration in calves", *Vet Res Commun.*, 31(4):467-76 (2007) (*"Ismail"*); Sawchuk Decl. at ¶ 50. Dr. Sawchuk states that for the purposes in *Ismail*, the intramuscular administration was preferred to subcutaneous administration. Sawchuk Decl. at ¶ 52. Dr. Sawchuk explains that "[i]n this case, contrary to the two examples above, the intramuscular administration was considered to be associated with greater clinical efficacy." *Id.*

Dr. Sawchuk summarizes that "[t]hese three examples above show that there are significant differences in the rate and extent of absorption of a drug given by the intramuscular and subcutaneous route, even when given to the same animals in a

- 22 -

crossover study." *Id.* at ¶ 53. Dr. Sawchuk concludes that "[a]s a result, it cannot be predicted a priori whether intramuscular or subcutaneous dosing will result in more rapid and/or complete drug absorption, as examples of both cases are found in the scientific literature." *Id.* Dr. Sawchuk further explains that the examples above "*underscore the fact that efficacy of a given drug administered by a given route of dosing (e.g., intramuscular) cannot be known until appropriate comparative studies are performed in a suitable animal model." <i>Id.* at ¶ 54 (emphasis added). Dr. Sawchuk indicates that "[f]or some drugs, the desired effect might be achieved following a particular route of dosing, but for other drugs it might not," which underlies the lack of expectation that results from subcutaneous administration could be indicative of results obtained from intramuscular administration. *Id.*

With respect to the specific results from *McLeskey*, Dr. Sawchuk concludes that "one of ordinary skill in the art having the very limited experimental subcutaneous data from *McLeskey* would not have had an expectation that the intramuscular administration of fulvestrant using the *McLeskey* castor oil composition would have been effective following intramuscular administration, such as in the method described in the claims." *Id.* at ¶ 55.

For at least this additional reason, the instant claims are not obvious in light of the cited references and Applicants respectfully request that this rejection be withdrawn.

- 23 -

b) <u>Independent Reason 4.</u> Numerous variables affect the efficacy of an intramuscular formulation (e.g.,. identity and proportion of cosolvents) and a POSITA would have understood that the resulting variability precludes a POSITA from having an expectation a priori that a given formulation would be successful in a given method of treatment until actual suitable in vivo experiments are performed

Dr. Sawchuk explains that "[t]ypically, during the development of an intramuscular dosage form for administration of a drug in humans, one would have carried out, among other tasks, formulation studies to determine suitable compositions in which the drug of interest is dissolved, as well as initial intramuscular dosing experiments in animals (e.g., mice, rabbits, and/or dogs) under various conditions (e.g., different compositions, different solvents, varying the proportion of the components of the composition, different drug concentrations, etc.) in order to gain an understanding of the pharmacokinetics of fulvestrant before attempting human administration." Sawchuk Decl. at ¶ 58

Dr. Sawchuk highlights that by its very nature, the "existence of this generalized approach highlights the lack of expectation of success with respect to the extrapolation of the *McLeskey* disclosure of subcutaneous administration to mice, lacking any pharmacokinetic information, to human intramuscular administration." *Id.*

With respect to formulation studies, Dr. Sawchuk cites to the Gellert Declaration as disclosing the importance of performing additional formulation studies in order to attempt to minimize potential side effects arising from the presence of co-solvents. *Id.* at ¶ 59-61.

- 24 -

Dr. Sawchuk explains, however, that "[r]egardless of how high or low the cosolvent concentrations are in a given formulation, the preparation of formulations in which a drug such as fulvestrant can be solubilized is not sufficient to ensure the desired therapeutic effect when such formulation is administered in vivo." *Id.* at ¶ 62. Dr. Sawchuk cites to the instant specification as warning that "[s]imply solubilising fulvestrant in an oil based liquid formulation is not predictive of a good release profile or lack of precipitation of drug after injection at the injection site." *Id.* (citing the specification at ¶ [0054]). Thus, Dr. Sawchuk concludes that "suitable experiments are needed to determine the pharmacokinetic performance of any candidate formulation(s)." *Id.*

According to Dr. Sawchuk, as part of that process to develop methods of human treatment, and in order to discriminate among the various formulations in development, "pharmacokinetic data could be used to characterize important variables" in the process of developing a suitable method of treatment. In the case of "drugs that are difficult to formulate, such as fulvestrant, the pharmacokinetic data could be useful to investigate the most promising formulation for the desired route of administration." *Id.* at ¶ 63 (internal quotations omitted).

Dr. Sawchuk indicates that in a study testing seven different 100 mg/ml fulvestrant formulations intramuscularly in rabbits, the resulting pharmacokinetic data showed variability dependent on the proportion of the components in the formulations. *Id.* at **¶** 64 (citing data in PCT Application Publication No. WO 03/006064 ("WO 03/006064")). All of the fulvestrant formulations tested contained ethanol, benzyl alcohol, and benzyl benzoate in a castor oil vehicle, which are the same components of

- 25 -

the fulvestrant composition recited in the claims, but with different proportions for each component. *Id.*

Dr. Sawchuk explains that according to WO 03/006064, "[p]lasma levels were more variable than Control over the first 30 days following intramuscular administration of fulvestrant." *Id.* at **¶** 65 (internal quotations omitted). Based on differences observed in the pharmacokinetic profiles, the formulations were divided into two groups, Group A, which "demonstrates "rapid release early time points, corresponding to formulations containing lower benzyl benzoate and low castor oil concentrations, while Group B shows a lower release, flatter profile corresponding to formulations containing lower benzyl benzoate and higher castor oil concentrations." *Id.* (internal quotations omitted).

Summarizing the results in WO 03/006064, Dr. Sawchuk states that "higher benzyl benzoate concentrations in the formulation resulted in a more rapid initial release of fulvestrant, whereas lower benzyl benzoate concentrations resulted in a lower initial release, and a flatter plasma level profile." *Id.* at ¶ 66. Dr. Sawchuk concludes that "[d]epending on the overall objective of the administration of fulvestrant, some of the fulvestrant formulations tested in WO 03/006064's study would be more desirable than others for that given purpose and, based on the relevant pharmacokinetic profiles, one of ordinary skill in the art would be able to select one of those fulvestrant formulations for further development and/or testing." *Id.*

Nonetheless, Dr. Sawchuk explains that "one of ordinary skill in the art would not have been able to determine whether a given fulvestrant formulation injected intramuscularly as in WO 03/006064 would have had the desired pharmacokinetic profile until such in vivo pharmacokinetic studies were carried out." *Id.* at ¶ 67

- 26 -

Based on the differences in pharmacokinetic profiles from WO 03/006064, Dr. Sawchuk reiterates that "one of ordinary skill in the art knowing only the composition of a given formulation administered subcutaneously, but having no pharmacokinetic data from its intramuscular administration, would have had no expectation, one way or another, that the formulation would be effective when administered intramuscularly in a given method of treatment." *Id.* at ¶ 68.

In particular, with respect to the disclosure in *McLeskey*, Dr. Sawchuk indicates that "one of ordinary skill in the art would not have had a reasonable expectation that the *McLeskey* castor oil composition would have been effective when given as an intramuscular injection, such as in the method of treatment recited in the claims" *Id.* at ¶ 69.

Thus, for this additional independent reason, the instant claims are not obvious over the references cited and Applicants respectfully request that this rejection be withdrawn.

VI. Conclusion

In view of the foregoing amendments and remarks, Applicants respectfully request reconsideration of this application and the timely allowance of the pending claims.

- 27 -

Please grant any extensions of time required to enter this response and charge

any required fees not included with this Response to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

By:_

Dated: January 17, 2012

Carlos M. Téllez Reg. No. 48,638 (202) 408-4123

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
John R. Evans et al.)) Group Art Unit: 1628
Application No.: 12/285,887)) Examiner: HUI, San Ming R.
Filed: October 15, 2008)) Confirmation No.: 1199
For: FORMULATION)) VIA EFS-WEB
O maria di an an fan Data ata	

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

DECLARATION UNDER 37 C.F.R. § 1.132 OF RONALD J. SAWCHUK

I, Ronald J. Sawchuk, declare as follows:

Qualifications

1. My academic background and work experience are summarized in my curriculum vitae, which is attached as **Exhibit 1**.

2. Currently, I am a Professor of Pharmaceutics, Emeritus, and Morse Alumni Distinguished Teaching Professor. I am also the Director of the Bioanalytic and Pharmacokinetic Services Laboratory at the University of Minnesota.

3. I obtained a Bachelor of Science Degree in Pharmacy in 1963 from the University of Toronto. I also received a Masters of Science Degree in Pharmaceutics from the University of Toronto in 1966 and completed a Doctoral Degree (Ph. D.) in Pharmaceutical Chemistry (pharmacokinetics emphasis) at the University of California, San Francisco in 1972.

4. I joined the University of Minnesota in 1971 as an Instructor in Pharmaceutics, and served from 1972 to 1977 as an Assistant Professor of Pharmaceutics, from 1977 to 1983 as an Associate Professor of Pharmaceutics, and as a full Professor of Pharmaceutics from 1983 until my retirement in July of 2010.

5. At the University of Minnesota, I served as a member of the graduate programs in Pharmaceutics, Neurosciences, and Experimental and Clinical Pharmacology. From 1983 to 1989 and 1991 to 1994 I was the Director of Graduate Studies in Pharmaceutics at the University. From 1998 to 1999 I served as the Head of the Department of Pharmaceutics at the University of Minnesota.

Also, from 1982 to 1995, I served as Director of the Clinical
 Pharmacokinetics Laboratory at the College of Pharmacy at the University of
 Minnesota.

7. During my career, I received several honors, scholarships and awards, including the Weaver Medal of Honor in 2001, the Meritorious Manuscript Award from the American Association of Pharmaceutical Scientists in 1999 and the Hallie Bruce Memorial Lecture Award in 1996. In 2007, I received the American Pharmacists Association (APhA) Research Achievement Award in the Basic Pharmaceutical Sciences.

8. I am a member of numerous scientific and clinical societies. I am a Fellow of the American Association of Pharmaceutical Scientists and of the American Association for the Advancement of Science. I have been a member of the International Society of Anti-infective Pharmacology and the International Society for the Study of

- 2 -

Xenobiotics (ISSX). I recently served as a member-at-large on the American Association of Pharmaceutical Scientists (AAPS) Executive Council.

9. I have served on the editorial boards of scientific journals such as the Journal of Pharmaceutical Sciences and the Saudi Pharmaceutical Journal. I am currently on the Editorial Board of the AAPS Journal, and on the ISSX Journal, Xenobiotica. I have also served on numerous advisory committees and review panels.

10. I have participated in multiple research projects focused in the areas of preclinical and clinical pharmacokinetics, both publicly and privately funded. I am a named author on over 100 refereed scientific publications, in addition to several book chapters, a book that I co-edited on drug bioavailability, and over 170 abstracts which have been presented at scientific meetings. I have also given hundreds of invited lectures.

11. I have significant experience in the areas of pharmaceutical research, pharmacokinetics, and drug development. Therefore, I believe that I am qualified to render the opinions set forth in this declaration.

12. I have read the Office Action dated September 16, 2011 ("Office Action"), which is attached as **Exhibit 2**. Among other rejections, I understand that the Office Action rejects the claims pending in the captioned application as unpatentable over the following references:

McLeskey et al., "Tamoxifen-resistant fibroblast growth factor-transfected
 MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and

- 3 -

two aromatase inhibitors", *Clinical Cancel Research* 4:697-711 (1998) ("*McLeskey*", attached hereto as **Exhibit 3**);

- b. European Patent Specification No. EP 0 346 014, which names Michael
 Dukes as inventor ("*Dukes*", attached hereto as **Exhibit 4**);
- c. Osborne et al., "Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer", *J. National Cancer Institute*, 87(20):746-750 (1995) ("*Osborne*", attached hereto as **Exhibit 5**); and
- d. the abstract of Wakeling et al., "ICI 182,780, a new antioestrogen with clinical potential", *J. Steroid Biochemistry & Molecular Biology*, 43(1-3):173-177 (1992) ("*Wakeling*", attached hereto as Exhibit 6);

13. I have read the instant application ("the '887 application"), which I believe corresponds to U.S. Application Publication No. US 2010/0152149 (attached hereto as **Exhibit 7**.)

14. I attach hereto **Exhibit 8**, which I believe is a copy of the pending claims in the '887 application with proposed amendments. I understand the claims in **Exhibit 8** will be filed in the Patent and Trademark Office as part of the response to the Office Action.

15. I understand that the earliest priority date for the '887 application is January 10, 2000. In the paragraphs below, I will refer to the state of the art in the areas of pharmaceutical research, pharmacokinetics, and drug development prior to January 10, 2000. I will also explain how a person of ordinary skill in that art at that time

- 4 -

would have understood the references cited in the Office Action and how such a person would have interpreted certain experimental results related to various fulvestrant formulations.

Disclosure in *McLeskey* regarding the castor oil fulvestrant composition

16. *McLeskey* discloses two fulvestrant compositions. One composition was prepared by dissolving powdered drug in 100% ethanol and then spiking it into warmed peanut oil to give a final concentration of 50 mg/ml ("the *McLeskey* peanut oil composition"). *McLeskey* at 698, col. 2, under "Drugs". The second composition is a 50 mg/ml fulvestrant composition "in a vehicle of 10% ethanol, 15% benzyl benzoate, 10% benzyl alcohol, brought to volume with castor oil" ("the *McLeskey* castor oil composition"). *Id. McLeskey* does not specify whether the percentages in the castor oil composition are in weight/volume units (% w/v, as recited in the claims of the '887 application) or in volume/volume units (% v/v).

17. In a liquid composition, when a solute or cosolvent is a liquid, it is often convenient to express its concentration as a volume percent, i.e., % v/v. For the reasons that follow, I believe one of ordinary skill in the art would have concluded the *McLeskey* castor oil composition was described in volume/volume units (% v/v).

18. For example, U.S. Patent No. 3,164,520 ("the '520 patent", attached as **Exhibit 9**) entitled "Injectable Steroid Compositions Containing at least 75% Benzyl Benzoate" discloses the preparation of parenteral injections of steroid drugs in formulations containing benzyl benzoate, and often also containing castor oil or sesame oil. *See, e.g.*, the working examples. The '520 patent states: "The amount of benzyl

- 5 -

benzoate which may be employed in the compositions of this invention while still yielding satisfactory results has been found to range from about 75% to 100% by volume of the pharmaceutical vehicle employed." The '520 patent at col. 2, II. 10-14. In addition, each of the four claims of the '520 patent refers to a parenteral steroid formulation in a pharmaceutical vehicle or pharmaceutical carrier wherein at least 75% by volume of said vehicle is benzyl benzoate.

19. Raymond Huber, the named inventor of the '520 patent, is a co-author of a similar publication in which parenteral formulations of steroid hormones in castor oil are described. Riffkin, C., Huber, R., and Keysser, C.H., "Castor oil as a vehicle for parenteral administration of steroid hormones", J Pharm Sci, 53(8): 891-95 (1964) ("*Riffkin*", attached as **Exhibit 10**). *Riffkin* lists the compositions of various vehicles prepared in Tables IV to VI, which reference liquid components and their proportions in the overall composition in terms of percentage units ("%"). Although *Riffkin* does not specifically state that those compositions are % v/v, one would understand them to be % v/v because *Riffkin* refers to the concentrations of the solid solutes (the steroids) in terms of w/v, (e.g., mg./ml.), whereas the concentrations of the liquid components are simply reported in terms of "%" units. See, e.g., Tables V and VI. One would reasonably assume that, had Riffkin intended the concentration of the liquid components to be in terms of % w/v units, *Riffkin* would have explicitly indicated that fact, as it did for the solid components. Footnote 4 is another example of the use of the above nomenclature. Footnote 4 refers to the concentration of estradiol valerate in the injectable formulations, in terms of "mg./ml.", but refers to a "%" value for the liquids—

- 6 -

castor oil, benzyl benzoate, and benzyl alcohol. Therefore, one would conclude that the composition of the solvents in *Riffkin's* vehicles is expressed as % v/v.

20. Other publications also describe the composition of injectable formulations comprising liquid solvents or co-solvents on a "by volume" basis. For example, a published review tabulates various excipients included in the formulation of injectable products marketed in the Unites States. Neema, S, Washkuhn, R.J., and Brendel, R.J., "Excipients and their use in injectable products", *PDA J Pharm Sci Tech*, 51(4):166-171 (1997)("*Neema*", attached as **Exhibit 11**). *Neema* lists liquid solvents, co-solvents, and solubilizing agents, and identifies commercial products in which the content of such liquid agents is described on a % v/v basis (e.g., benzyl benzoate, 20% v/v; PEG 40 castor oil, 11.5% v/v; sorbitol, 50% v/v). *See*, *e.g.*, Tables I and II.

21. Considering the above examples, and because all of the components of the vehicle disclosed in *McLeskey* are liquids, one of ordinary skill in the art would have concluded that the composition was described in terms of volume/volume percent units (% v/v).

22. Therefore, one of ordinary skill in the art would have concluded that the *McLeskey* castor oil composition on page 698 was reported in % v/v units and referred to a composition containing 10% \underline{v} /v ethanol, 15% \underline{v} /v benzyl benzoate, and 10% \underline{v} /v benzyl alcohol in a castor oil vehicle. This composition *is different* from a composition containing 10% \underline{w} /v benzyl benzoate, and 10% \underline{w} /v benzyl alcohol in a castor oil vehicle. This composition *is different* from a composition containing 10% \underline{w} /v benzyl benzoate, and 10% \underline{w} /v benzyl alcohol in a castor oil vehicle.

-7-

23. It is possible to convert % v/v values for a given component in a liquid composition into % w/v values by calculating the weight of the corresponding volume of that component in the composition. As a first approximation, the weight of the component can be calculated by multiplying the volume of the component by its density.

24. In order to facilitate this calculation, I assumed the preparation of 100 ml of the *McLeskey* castor oil composition and reported the associated volume and weight values in Table 1 below, using densities reported or calculated at 25°C. The resulting % w/v values are independent of the choice of a particular volume of the *McLeskey* castor oil composition for this calculation. However, a volume of 100 ml of the castor oil composition was selected for simplicity to show the corresponding volumes and weights. The differences between % v/v and % w/v compositions for each of the three components can be seen by comparing the values in Columns A and E. It should be noted that although these compositions are identical, they are described differently; in Column A, the composition is described on a percentage "by volume" (% v/v) basis, and in Column E, the composition is described on a percentage "by weight" (% w/v) basis.

- 8 -

	Α	В	С	D	E
Component	% v/v	Volume (ml)	Density (mg/ml)	Weight (g)	% w/v
Ethanol	10	10	0.808	8.08	8.1
Benzyl Benzoate	15	15	1.118	16.77	16.8
Benzyl Alcohol	10	10	1.04156	10.42	10.4

Table 1. Information for 100 ml of the fulvestrant *McLeskey* castor oil composition¹

25. In Table 1, <u>Column A</u> represents the concentration of each component in the *McLeskey* castor oil composition in % \underline{v} /v units (i.e., as one of ordinary skill in the art in would have understood the *McLeskey* disclosure). <u>Column B</u> represents the volume in milliliters (ml) of each component necessary to prepare 100 ml of the *McLeskey* castor oil composition.

26. <u>Column C</u> represents the density of each component in g/ml at 25°C,

reported or calculated from published relative density data from the Merck Index,

Exhibit 12. The Merck Index reports specific gravity values for liquid substances as the ratio of the density of the substance at a given temperature relative to the density of water at a reference temperature. **Exhibit 12** at p. xiv (entry for "d"). Regarding the benzyl benzoate and benzyl alcohol values, their densities were reported at 25°C and

¹ *McLeskey* does not indicate whether the ethanol used in its castor oil fulvestrant composition is dehydrated ethanol or the binary azeotropic ethanol composition containing about 96% ethanol by volume (see entry no. 3806 for ethanol in the Merck Index, 12th Ed., Merck & Co., Inc. (1996) at pp. 641-642 ("the Merck Index", relevant copies attached as **Exhibit 8**)). The value in Table 1 for the density of ethanol corresponds to the density of the azeotropic ethanol composition. The density of dehydrated ethanol is 0.789 mg/ml at 20°C (**Exhibit 8**), which would produce an even lower w/v% value for ethanol than that reported in Table 1.

the density of water was reported at 4°C (**Exhibit 12** at entries no. 1159, 1162; pp. 189-190). Because the density of water at 3.98°C is 1.0000 g/ml (**Exhibit 12** at entry 10175; p. 1715), the values reported in the Merck Index for benzyl benzoate and benzyl alcohol were used in Table 1 as the corresponding densities in mg/ml (considering that 3.98°C is 4°C for purposes of this calculation). For ethanol, the Merck Index reports a specific gravity of 0.810 at 25°C with respect to the density of water at 25°C (**Exhibit 12** at entry no. 3806; p. 642). Thus, to obtain the density of ethanol (the binary azeotrope) at 25°C, I multiplied the density of water at 25°C, 0.997 mg/ml (**Exhibit 12** at entry no. 10175; p. 1715), by the specific gravity reported in the Merck Index (0.810) to produce a value of 0.808 mg/ml for the density of ethanol at 25°C.

27. <u>Column D</u> represents the weight of each component, obtained by multiplying the volume of each component (Column B) by its density (Column C). <u>Column E</u> represents the concentration of each component in the *McLeskey* castor oil composition in w/v% units, which is the weight of each component (Column D) in 100 ml of solution (the total volume of the composition) after rounding the value to a single decimal place.

28. Accordingly, based on the values in Table 1, a composition containing 10% v/v ethanol, 15% v/v benzyl benzoate, and 10% v/v benzyl alcohol translates into a composition containing about 8.1% w/v ethanol, about 16.8 % w/v benzyl benzoate, and about 10.4% w/v benzyl alcohol.

29. Thus, one of ordinary skill in the art reading *McLeskey* would have concluded that *McLeskey* described a composition containing about 8.1% w/v ethanol,

- 10 -

about 16.8 % w/v benzyl benzoate, and about 10.4% w/v benzyl alcohol in a castor oil vehicle.

30. Neither *McLeskey* nor any of the references cited in the Office Action contain any disclosure that would have suggested to one of ordinary skill in the art the modification of a composition containing about 8.1% w/v ethanol, about 16.8 % w/v benzyl benzoate, and about 10.4% w/v benzyl alcohol (i.e., the *McLeskey* castor oil composition) in an attempt to produce a composition as recited in the claims containing about 10% w/v ethanol, about 15% w/v benzyl benzoate, and about 10% w/v benzyl alcohol.

Disclosure in McLeskey regarding administration of fulvestrant compositions

31. As mentioned above, *McLeskey* disclosed two different fulvestrant compositions, the peanut oil composition and the castor oil composition. *McLeskey* at 698. *McLeskey*, however, did not provide any experimental data that would have allowed one of ordinary skill in the art to compare any aspect of the performance of the two fulvestrant compositions for the treatment of cancerous tumors. Therefore, *McLeskey* provided no information that would have suggested to one of ordinary skill in the art the desirability of either of its fulvestrant compositions over other known fulvestrant formulations.

32. *McLeskey* did not disclose plasma or blood levels of fulvestrant in mice after subcutaneous administration of either the peanut oil or the castor oil compositions. Thus, no information regarding the rate and/or extent of absorption of fulvestrant from

- 11 -

the subcutaneous injection site is available to one of ordinary skill in the art for either composition.

33. *McLeskey* concluded that treatment with fulvestrant (ICI 182,780), using either of the disclosed compositions was not effective in that it "did not slow estrogen-independent growth or prevent metastasis of tumors produced by FGF-transfected MCF-7 cells in ovariectomized nude mice." *McLeskey* at Abstract. Thus, one of ordinary skill in the art would not have been informed about the usefulness of either fulvestrant formulation when administered subcutaneously to a mouse for the treatment of cancerous tumors.

34. *McLeskey* also reports that fulvestrant "retained activity" based on the results from injecting fulvestrant into "reproductively intact female mice for two weeks . . . at the same doses used in the above experiment" and the uteri subsequently harvested from those mice "weighed less than those from control mice and exhibited a complete lack of endometrial glandular structures (data not shown)." *Id.* at ¶ bridging 701-702. Unfortunately, *McLeskey* does not specify which of the two fulvestrant formulations, if any, (the peanut oil composition or the castor oil composition), was used in these experiments. *McLeskey* does not disclose the route of administration (subcutaneous, intramuscular, intraperitoneal, etc.) for the injection of fulvestrant into those "reproductively intact female mice." Thus, one of ordinary skill in the art reading *McLeskey* cannot draw any conclusions regarding the extent to which fulvestrant administered subcutaneously became absorbed, if at all, when using the peanut oil or the castor oil compositions.

- 12 -

35. Indeed, because of the lack of fulvestrant efficacy and the absence of pharmacokinetic data in *McLeskey*, one of ordinary skill in the art would have been unable to conclude whether either of the two fulvestrant *McLeskey* compositions (peanut oil or castor oil) was able to deliver a dose of fulvestrant that had an antitumor therapeutic effect in the mice when administered subcutaneously, nor any insight about fulvestrant absorption characteristics (rate and extent) when administered via the *intramuscular route* in any species, including humans.

36. Thus, *McLeskey* provides no information that would have led one of ordinary skill in the art to have a preference for either the peanut oil or the castor oil fulvestrant compositions over the other one, or even a preference for one of the two *McLeskey* fulvestrant compositions over other fulvestrant compositions known in the art prior to January 10, 2000.

37. While I have not performed a search for fulvestrant compositions known in the art prior to January 10, 2000, I note that some of the references cited by the Examiner in the Office Action do disclose other fulvestrant compositions. For example, *Osborne* discloses experiments in which a composition of fulvestrant "in castor oil" was injected subcutaneously to female nude mice. *Osborne* (**Exhibit 5**) at 747, col. 1. Based on the positive results of those experiments, *Osborne* concludes that fulvestrant "is a more effective estrogen antagonist than tamoxifen in the MCF-7 tumor cell/nude mouse model system." *Osborne* at Abstract.

38. The fulvestrant composition in *Wakeling* is described as having fulvestrant "in oil suspension" for parenteral administration to mice. *Wakeling* (**Exhibit 6**) at

- 13 -

Abstract. *Wakeling* reports that, "over a 1 month period, a single injection of [fulvestrant] in oil suspension achieved effects comparable with those of daily tamoxifen treatment." *Id.*

39. *Dukes* discloses two different fulvestrant compositions for intramuscular injection, one containing fulvestrant dissolved "in a mixture of propylene glycol: ethanol: water: poloxamer 407" administered daily by intramuscular injection to rats. *Dukes* (**Exhibit 4**) at Example 2, p. 8. The second composition contained 50 mg of fulvestrant, "400 mg of benzyl alcohol and sufficient castor oil to bring the solution to a volume of 1 ml." *Id.* at Example 3, p. 9. For each composition, *Dukes* reports that "at all doses tested the compound [fulvestrant] selectively inhibits the action of the animals' endogenous oestrogen on their uteri." *Id.* at Examples 2 & 3, pp. 8-9.

40. Thus, it is clear that one of ordinary skill in the art had other choices besides the *McLeskey* castor oil composition with respect to potential fulvestrant formulations that could have been further investigated for the development of a method of treating humans with intramuscular fulvestrant. However, none of the references cited in the Office Action provides any information that would have guided one of ordinary skill in the art to select the *McLeskey* castor oil composition, over any of the other fulvestrant compositions mentioned above, for the potential development of such a method of treatment.

41. Moreover, none of the references cited by the Examiner provides any guidance as to the relevant factors to consider when selecting a formulation for the potential development of a method of treatment as recited in the instant claims.

- 14 -

However, judging solely on the basis of efficacy, the *McLeskey* castor oil composition would have been among the least favored compositions to select for further development from the fulvestrant compositions discussed above because the *McLeskey* experiments were ineffective and one of ordinary skill in the art would not have been able to conclude from the information in *McLeskey* whether fulvestrant, using that composition, was sufficiently bioavailable to have an antitumor effect. In this regard, and considering only efficacy, the fulvestrant oil suspension from *Wakeling* would have been among the most favored formulations to select for further development from among those discussed above because at least that formulation, when given as a single injection, showed a therapeutic antitumor effect in mice for over a one-month period.

Lack of disclosure in *McLeskey* regarding intramuscular efficacy of either fulvestrant composition disclosed therein

42. The mode of administration of a drug (e.g., oral, intramuscular, subcutaneous, etc.) and the dose administered affects the release profile of the drug. One of ordinary skill in the art would have understood that results from subcutaneous administration in general, and including those reported in *McLeskey*, cannot be extrapolated to intramuscular administration. As a result, one of ordinary skill in the art would not have had an expectation as to whether the *McLeskey* castor oil composition would have had a therapeutic effect when administered intramuscularly before actually performing suitable *in vivo* experiments.

43. There is abundant evidence in the scientific literature that the intramuscular and subcutaneous administration of a drug to the same animal or human

- 15 -

may produce very different plasma level curves, and therefore very different pharmacologic effects. These effects include the desired effects (efficacy) and those that are not desired (adverse events, or side effects). If a drug is poorly absorbed from the injected site, (e.g., too slowly, or to only a modest extent) the drug may show no effects whatsoever.

44. For example, a study in sheep using probenecid, a drug which may be used to prolong the half-life of some antibiotics in animals, demonstrates significant differences in the absorption of intramuscular and subcutaneous injections of probenecid. Guerrini V.H., Filippich L.J., English P.B., Schneider J., Cao G.R. and Bourne D.W.A., "Pharmacokinetics of probenecid in sheep", *J Vet Pharmacol Ther.* 8(2):128-35 (1985) ("*Guerrini*", attached as **Exhibit 13**).

45. Those investigators administered probenecid to ewes in doses of 1 gram by both intramuscular and subcutaneous injection. *Guerrini* at 129. The study shows that the absorption of probenecid is more rapid and complete following intramuscular injection, compared to subcutaneous injection. *Id.* at Abstract. *Guerrini* reports that the bioavailability of the intramuscular dose was 135% of that of the subcutaneous dose (corresponding to an average bioavailability of 46% for intramuscular injection compared with an average bioavailability of 34% for subcutaneous injection). *Id.* The subcutaneous dose was also absorbed more slowly, with average plasma levels of the drug peaking at 1.5 hr, compared to 0.67 hr for the intramuscular dose. *Id.* at 131. Because of this slower absorption following subcutaneous dosing, probenecid plasma concentrations remained higher after 2 hours when the drug was administered

- 16 -

subcutaneously than when it was administered intramuscularly. *Id.* at 135. Consistent with these observations, the rate constant for absorption for the intramuscular dose was 41% greater than for the subcutaneous dose (5.45 vs. 3.87 hr⁻¹). *Id.* at 133.

46. In this case, despite the overall higher bioavailability of intramuscular probenecid, the "higher and more prolonged plasma probenecid concentration" following subcutaneous administration resulted in "similar plasma concentrations to those found in man after oral administration." *Id.* at 135. *Guerrini* concludes that "[t]he s.c. [subcutaneous] administration of probenecid in animals is preferred [to intramuscular administration] because muscle damage is avoided and it provided useful plasma concentrations." *Id.* Thus, this is an example where subcutaneous administration does not accomplish the same result.

47. Another study shows that, contrary to the pharmacokinetic profiles observed in *Guerrini*, subcutaneous administration resulted in faster absorption compared to intramuscular injection. Lavy E, Ziv G, Shem-Tov M, Glickman A, Dey A., "Pharmacokinetics of clindamycin HCI administered intravenously, intramuscularly and subcutaneously to dogs", *J Vet Pharmacol Ther.* 22(4):261-5 (1999) (*"Lavy*", attached as **Exhibit 14**).

48. *Lavy* reports that when a 10 mg/kg dose of clindamycin HCl, an antibioitic, was given subcutaneously to dogs, the average maximum blood serum concentration (Cmax) of clindamycin was 20.8 μg/ml, and the time when this maximum occurred (Tmax) averaged 46.7 min. *Lavy* at Table 3. When the same dose was given

- 17 -

intramuscularly to the same animals, the corresponding values for Cmax and Tmax were 4.4 μ g/ml and 73 min, exhibiting a very much slower rate of absorption. *Id.* In addition, the exposure of the dogs to clindamycin, assessed through an analysis of the plasma serum area under the curve (AUC) was 2.9 times greater for the subcutaneous dose than for the intramuscular dose. *Id.* This means that the bioavailability of the subcutaneous dose of this drug is 2.9 times that of the intramuscular dose.

49. Based on the differences in pharmacokinetic profiles for subcutaneous and intramuscular administration, *Lavy* concludes that "it appears from the present study that the s.c. [subcutaneous] route is superior to the i.m. [intramuscular] in practical terms by permitting a longer treatment interval." *Id.* at 265. This is another example in which subcutaneous administration is able to fulfill certain design criteria (maintain a therapeutic plasma concentration for a longer period of time) better than intramuscular administration. Therefore, under these circumstances, one of ordinary skill in the art would not have been able to rely on data from subcutaneous administration to predict results of intramuscular administration because intramuscular administration would not have produced the same level of long-term efficacy achieved by subcutaneous administration.

50. There are other reports in the literature that show that, in contrast to the results from *Lavy*, the absorption of a drug is more rapid and complete following intramuscular dosing than after subcutaneous injection. For example, when the fluoroquinolone antimicrobial agent difloxacin was given by these routes to the same calves in a crossover study, the rates of absorption differed greatly, with intramuscular

- 18 -

injection showing higher and earlier peak plasma concentrations, confirming much more rapid absorption. Ismail M., "Disposition kinetics of difloxacin after intravenous, intramuscular and subcutaneous administration in calves", *Vet Res Commun.*, 31(4):467-76 (2007) ("*Ismail*", attached as **Exhibit 15**).

51. After intramuscular and subcutaneous dosing, maximum plasma concentrations (Cmax) of 3.38 and 2.18 μ g/ml were observed after (Tmax) 1.22 and 3.7 hr, respectively. *Ismail* at Abstract. The time for half of the dose to be absorbed when given by intramuscular injection was only 0.38 hr, whereas the corresponding time for absorption of the subcutaneously injected dose was 2.1 hr, over 5 times as long. *Id.* at 473.

52. Under the conditions of its study, *Ismail* concludes that "the doses of difloxacin used in this study are likely to involve better pharmacodynamic characteristics that are associated with greater clinical efficacy following i.m. [intramuscular] administration than following s.c. [subcutaneous] administration." *Id.* at Abstract. In this case, contrary to the two examples above, the intramuscular administration was considered to be associated with greater clinical efficacy.

53. These three examples above show that there are significant differences in the rate and extent of absorption of a drug given by the intramuscular and subcutaneous route, even when given to the same animals in a crossover study. As a result, it cannot be predicted a priori whether intramuscular or subcutaneous dosing will result in more rapid and/or complete drug absorption, as examples of both cases are found in the scientific literature.

- 19 -